Form 10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if a smaller reporting company)

Smaller reporting company

0001193125-15-052611.txt : 20150219 0001193125-15-052611.hdr.sgml : 20150219 20150218150755 ACCESSION NUMBER: 0001193125-15-052611 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20141231 FILED AS OF DATE: 20150218 DATE AS OF CHANGE: 20150218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUNLINK HEALTH SYSTEMS INC CENTRAL INDEX KEY: 0000096793 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 310621189 STATE OF INCORPORATION: OH FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-12607 FILM NUMBER: 15627580 BUSINESS ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 BUSINESS PHONE: 7709337000 MAIL ADDRESS: STREET 1: 900 CIRCLE 75 PARKWAY STREET 2: SUITE 1120 CITY: ATLANTA STATE: GA ZIP: 30339 FORMER COMPANY: FORMER CONFORMED NAME: KRUG INTERNATIONAL CORP DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: TECHNOLOGY INC DATE OF NAME CHANGE: 19860803 FORMER COMPANY: FORMER CONFORMED NAME: COMANCO INDUSTRIES INC DATE OF NAME CHANGE: 19710719 10-Q 1 d834962d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2014

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 1-12607

SUNLINK HEALTH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Ohio

31-0621189

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

900 Circle 75 Parkway, Suite 1120, Atlanta, Georgia 30339

(Address of principal executive offices) (Zip Code)

(770) 933-7000

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter during the preceding 12 months (of for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

The number of Common Shares, without par value, outstanding as of February 17, 2015 was 9,443,408.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)


	December 31, 2014 (unaudited)			June 30, 2014
ASSETS
Current Assets:
Cash and cash equivalents	$	3,971		$	3,587
Receivables—net		11,115			9,850
Inventory		4,047			3,757
Deferred income tax asset		2,319			2,978
Due from third party payors		2,672			2,786
Current assets held for sale		0			270
Prepaid expense and other assets		3,536			2,547

Total current assets		27,660			25,775
Property, plant and equipment, at cost		54,307			53,466
Less accumulated depreciation		31,484			30,389

Property, plant and equipment—net		22,823			23,077
Noncurrent Assets:
Intangible assets—net		2,908			2,979
Goodwill		461			461
Deferred income tax asset		4,436			4,432
Noncurrent assets held for sale		0			6,111
Other noncurrent assets		1,550			1,012

Total noncurrent assets		9,355			14,995

TOTAL ASSETS	$	59,838		$	63,847

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	5,433		$	4,530
Current maturities of long-term debt		866			561
Accrued payroll and related taxes		4,097			4,186
Income tax payable		139			73
Current liabilities held for sale		0			4,842
Other accrued expenses		2,072			2,314

Total current liabilities		12,607			16,506
Long-Term Liabilities
Long-term debt		11,579			11,948
Noncurrent liability for professional liability risks		964			1,268
Other noncurrent liabilities		786			807

Total long-term liabilities		13,329			14,023
Commitment and Contingencies
Shareholders’ Equity
Preferred Shares, authorized and unissued, 2,000 shares		0			0
Common Shares, without par value:
Issued and outstanding, 9,444 shares at December 31, 2014 and at June 30, 2014		4,722			4,722
Additional paid-in capital		13,464			13,444
Retained earnings		16,050			15,486
Accumulated other comprehensive loss		(334	)		(334	)

Total Shareholders’ Equity		33,902			33,318

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	59,838		$	63,847

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

AND COMPREHENSIVE EARNINGS (LOSS)

(in thousands, except per share amounts)

(unaudited)


	Three Months Ended December 31,						Six Months Ended December 31,
	2014			2013			2014			2013
Operating revenues (net of contractual allowances)	$	25,108		$	26,111		$	49,717		$	50,197
Less provision for bad debts of Healthcare Facilities Segment		1,982			2,231			4,215			4,288

Net revenues		23,126			23,880			45,502			45,909
Costs and Expenses
Cost of goods sold		5,456			6,485			10,072			10,760
Salaries, wages and benefits		10,589			10,722			21,406			21,514
Provision for bad debts of Specialty Pharmacy Segment		123			42			123			95
Supplies		2,034			2,054			4,140			3,982
Purchased services		1,025			1,350			2,202			2,595
Other operating expenses		1,968			3,030			4,340			5,973
Rent and lease expense		329			358			677			713
Insurance settlement		(1,000	)		0			(1,000	)		0
EHR incentive payments		0			(1,215	)		0			(1,215	)
Depreciation and amortization		580			763			1,215			1,537

Operating Profit (Loss)		2,022			291			2,327			(45	)
Other Expense:
Interest expense—net		(234	)		(238	)		(464	)		(480	)

Earnings (Loss) from Continuing Operations before income taxes		1,788			53			1,863			(525	)
Income Tax Expense (Benefit)		799			(297	)		985			(95	)

Earnings (Loss) from Continuing Operations		989			350			878			(430	)
Loss from Discontinued Operations, net of tax		(12	)		(123	)		(314	)		(501	)

Net Earnings (Loss)		977			227			564			(931	)
Other comprehensive income		0			0			0			0

Comprehensive Earnings (Loss)	$	977		$	227		$	564		$	(931	)

Earnings (Loss) Per Share:
Continuing Operations:
Basic	$	0.10		$	0.04		$	0.09		$	(0.05	)

Diluted	$	0.10		$	0.04		$	0.09		$	(0.05	)

Discontinued Operations:
Basic	$	(0.00	)	$	(0.01	)	$	(0.03	)	$	(0.05	)

Diluted	$	(0.00	)	$	(0.01	)	$	(0.03	)	$	(0.05	)

Net Earnings (Loss):
Basic	$	0.10		$	0.02		$	0.06		$	(0.10	)

Diluted	$	0.10		$	0.02		$	0.06		$	(0.10	)

Weighted-Average Common Shares Outstanding:
Basic		9,443			9,443			9,443			9,443

Diluted		9,497			9,446			9,478			9,443

SUNLINK HEALTH SYSTEMS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)


	Six Months Ended
	December 31,
	2014			2013
Net Cash Provided by (Used in) Operating Activities	$	(52	)	$	3,545
Cash Flows from Investing Activities:
Proceeds from sale of Fulton		6,090			—
Net change in cash in escrow		—			(160	)
Expenditures for property, plant and equipment—continuing operations		(737	)		(768	)
Expenditures for property, plant and equipment—discontinued operations		(11	)		(83	)

Net Cash Provided by (Used in) Investing Activities		5,342			(1,011	)
Cash Flows from Financing Activities:
Payments on long-term debt—continuing operation		(239	)		(409	)
Payments on long-term debt—discontinued operations		(4,842	)		(61	)
Proceeds from long-term debt		175			—

Net Cash Used in Financing Activities		(4,906	)		(470	)

Net increase in Cash and Cash Equivalents		384			2,064
Cash and Cash Equivalents Beginning of Period		3,587			2,497

Cash and Cash Equivalents End of Period	$	3,971		$	4,561

Supplement Disclosure of Cash Flow Information:
Cash Paid (Received) for:
Interest	$	562		$	575

Income taxes	$	29		$	(1,629	)

See notes to condensed consolidated financial statements.

SUNLINK HEALTH SYSTEMS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND SIX MONTHS ENDED DECEMBER 31, 2014

(all dollar amounts in thousands except per share amounts)

(unaudited)

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2014 and for the three and six month periods ended December 31, 2014 and 2013 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:

•

The Healthcare Facilities Segment is composed of three operational areas:

•

Three community hospital subsidiaries in two states with a total of 183 licensed beds;

•

Two nursing homes with a total of 166 licensed beds, each of which is located adjacent to, or in close proximity with a corresponding SunLink community hospital; and

•

A healthcare facility which is currently vacant except for two medical offices which are rented.

•

The Specialty Pharmacy Segment is composed of four operational areas:

•

Retail pharmacy products and services, all of which are conducted in rural markets;

•

Institutional pharmacy services;

•

Specialty pharmacy services; and

•

Durable medical equipment.

SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy business since April 2008. The Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of SunLink ScriptsRx, LLC.

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013			2014			2013
Net Revenues:
Fulton Hospital	$	3,321		$	3,184		$	6,730		$	6,733
Dexter Hospital		90			418			131			513
Memorial of Adel		69			2			53			(4	)

	$	3,480		$	3,604		$	6,914		$	7,242

Earnings (loss) before income taxes:
Fulton Hospital	$	(449	)	$	(549	)	$	(897	)	$	(1,147	)
Dexter Hospital		532			410			570			482
Memorial of Adel		56			(1	)		32			(12	)
Life sciences and engineering		(30	)		(40	)		(64	)		(79	)

Earnings (Loss) before income taxes		109			(180	)		(359	)		(756	)

Loss on Sale
Fulton Hospital		(191	)		—			(191	)		—

Loss on Sale		(191	)		—			(191	)		—

Income tax expense (benefit)		(70	)		(57	)		(236	)		(255	)

Loss from discontinued operations	$	(12	)	$	(123	)	$	(314	)	$	(501	)

Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of December 31, 2014 and June 30, 2014 and for the three and six month periods ended December 31, 2014 and 2013. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. A loss of $191 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the RDA loan.

Fulton RDA Loan—SunLink, Fulton and HealthMont LLC (“HLLC”), the direct parent of HOM closed on a $5,000 Loan Agreement dated as of March 16, 2012 (the “Fulton RDA Loan”) with a bank. The Fulton RDA Loan was repaid in full on December 31, 2014 concurrent with the sale of Fulton.

Dexter Hospital—On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). The assets of Dexter consisted of a leased 50-bed acute care hospital and related clinics, equipment, and home health services in Dexter, Missouri. Subsequent to the sale, Dexter managed the hospital and related businesses for Southeast Health Center of Stoddard County, LLC through a transition period ended June 30, 2013. Dexter retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology and substantially all liabilities of the hospital as of December 31, 2012. Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013.

Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense

and related tax benefit or expense is reflected in the results of operations for this segment for the three and six months ended December 31, 2014 and 2013. The components of pension expense for the three and six months ended December 31, 2014 and 2013, respectively, were as follows:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013						2013
Interest Cost	$	16		$	15		$	33		$	30
Expected return on assets		(7	)		(7	)		(15	)		(14	)
Amortization of prior service cost		23			32			48			63

Net pension expense	$	32		$	40		$	66		$	79

SunLink contributed $56 to the plan in the three and six months ended December 31, 2014.

Note 4. – Shareholders’ Equity

Stock-Based Compensation

For the three months ended December 31, 2014 and 2013, the Company recognized $48 and $15, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2014 and 2013, the Company recognized $21 and $31, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 90,000 and 0 share options granted under the 2005 Equity Incentive Plan during the six months ended December 31, 2014 and 2013, respectively. There were 0 and 21,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2014 and 2013, respectively.

Note 5. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues before provision for doubtful accounts by payor were as follows for the three and six months ended December 31, 2014 and 2013:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013			2014			2013
Healthcare Facilities Segment:
Medicare	$	6,685		$	6,516		$	13,963		$	13,623
Medicaid		3,602			3,524			6,971			6,844
Self-pay		2,002			2,453			3,990			4,705
Managed Care & Other Insurance		4,189			4,156			8,514			8,572
Other		43			45			96			98

Revenues before provision for doubtful accounts		16,521			16,694			33,534			33,842
Provision for doubtful accounts		(1,982	)		(2,231	)		(4,215	)		(4,288	)

Healthcare Facilities Segment Net Revenues		14,539			14,463			29,319			29,554
Specialty Pharmacy Segment Net Revenues		8,430			9,326			15,884			16,168
Other Revenues		157			91			299			187

Total Net Revenues	$	23,126		$	23,880		$	45,502		$	45,909

The net revenues of the Specialty Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Specialty Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:


	December 31,			June 30,
	2014			2014
Accounts receivable (net of contractual allowances)	$	18,394		$	16,753
Less allowance for doubtful accounts		(7,279	)		(6,903	)

Patient accounts receivable—net	$	11,115		$	9,850

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and six months ended December 31, 2014:


	Healthcare			Specialty
Three Months Ended December 31, 2014:	Facilities			Pharmacy			Total
Balance at October 1, 2014	$	7,117		$	213		$	7,330
Additions recognized as a reduction to revenues		3,016			80			3,096
Accounts written off, net of recoveries		(3,078	)		(69	)		(3,147	)

Balance at December 31, 2014	$	7,055		$	224		$	7,279


	Healthcare			Specialty
Six Months Ended December 31, 2014:	Facilities			Pharmacy			Total
Balance at July 1, 2014	$	6,649		$	254		$	6,903
Additions recognized as a reduction to revenues		6,251			80			6,331
Accounts written off, net of recoveries		(5,845	)		(110	)		(5,955	)

Balance at December 31, 2014	$	7,055		$	224		$	7,279


	Healthcare			Specialty
Three Months Ended December 31, 2013:	Facilities			Pharmacy			Total
Balance at October 1, 2013	$	7,317		$	482		$	7,799
Additions recognized as a reduction to revenues		2,899			42			2,941
Accounts written off, net of recoveries		(3,456	)		(45	)		(3,501	)

Balance at December 31, 2013	$	6,760		$	479		$	7,239


	Healthcare			Specialty
Six Months Ended December 31, 2013:	Facilities			Pharmacy			Total
Balance at July 1, 2013	$	7,286		$	475		$	7,761
Additions recognized as a reduction to revenues		5,617			95			5,712
Accounts written off, net of recoveries		(6,143	)		(91	)		(6,234	)

Balance at December 31, 2013	$	6,760		$	479		$	7,239

Net revenues included increase (decrease) of ($297) and $302 for the three months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($297) and $506 for the six months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports.

Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives

Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services.

For the three and six months ended December 31, 2014, the Company reported no EHR incentive payments. For the three and six months ended December 31, 2013, the Company reported a net $1,215 gain for Medicare and Medicaid EHR incentive payments which were for successful Medicaid attestation by the three hospitals and also adjustments calculated at the time of filing Medicare cost reports for the preceding fiscal year.

Note 7. – Goodwill and Intangible Assets

SunLink’s Specialty Pharmacy Segment has goodwill and intangible assets related to its Carmichael acquisition.

Goodwill consists of the following:


	December 31,		June 30,
	2014		2014
Specialty Pharmacy Segment	$	461	$	461

Intangibles consist of the following, net of amortization:


	December 31,			June 30,
	2014			2014
Specialty Pharmacy Segment
Trade Name		2,000			2,000
Customer Relationships		1,089			1,089
Medicare License		769			769

		3,858			3,858
Accumulated Amortization		(950	)		(879	)

Total	$	2,908		$	2,979

The trade name intangible asset under the Specialty Pharmacy Segment is a non-amortizing intangible asset.

Amortization expense was $36 and $35 for both the three months ended December 31, 2014 and 2013, respectively, and $71 and $70 for the six months ended December 31, 2014 and 2013, respectively.

Note 8. – Long-Term Debt

Long-term debt consisted of the following:


	December 31,			June 30,
	2014			2014
Trace RDA Loan	$	8,405		$	8,624
SHPP RDA Loan		2,013			2,033
Carmichael Notes		1,852			1,852
Other		175			—

Total		12,445			12,509
Less current maturities		(866	)		(561	)

	$	11,579		$	11,948

Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (formerly known as SunLink Healthcare, LLC) (“MedCare”), a wholly owned subsidiary of the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.

The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at December 31, 2014). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds were used to repay a portion of the Company’s senior debt under the Term Loan under the then outstanding Credit Facility. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs.

The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ending December 31, 2014, $875; (b) for the quarter ended March 31, 2015, $750; (c) for the quarter ending June 30, 2015, $625; and (d) thereafter, $500. The Trace Working Capital Loan expires July 2, 2015. It is subject to annual renewal at the discretion of the lender. At December 31, 2014, there were no outstanding borrowings under the Trace Working Capital Loan.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require our SHCH subsidiary to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge coverage, and funded debt to EBITDA, all as defined in the Trace RDA Loan. If SHCH is unable to remain in compliance with the financial covenants, SHCH would cease to have a right to draw on the revolving working capital loan (of which $0 was drawn at December 31, 2014 and June 30, 2014).

SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at December 31, 2014). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and MedCare.

Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Purchase Note”). On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue promissory notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note (the “PIK Notes”). The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note (the “Carmichael Note” dated April 22, 2014 for the remaining balance payable of $1,852. The Carmichael Note is payable in one interest only payment of $75 due on October 22, 2014 and five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company.

Note 9. – Insurance settlement

In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the three and six months ended December 31, 2014 for this settlement.

Note 10. – Income Taxes

Income tax expense of $799 ($643 federal tax expense and $156 state tax expense) and income tax benefit of $297 ($328 federal tax expense and $31 state tax expense) was recorded for the three months ended December 31, 2014 and 2013, respectively. Income tax expense of $985 ($863 federal tax expense and $122 state tax expense) and income tax benefit of $95 ($78 federal tax benefit and $17 state tax benefit) was recorded for the six months ended December 31, 2014 and 2013, respectively.

At December 31, 2014, the Company had $5,190 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At December 31, 2014, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,755. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized.

Note 11. – Commitments and Contingencies

Litigation—A settlement was reached on November 3, 2014 relating to litigation as a result of sellers failure to close on the sale of approximately 24.74 acres of real property located in Gilmer County, Georgia purchased by a subsidiary of the Company. In satisfaction of the Company’s claims against the sellers, a five year promissory note in the principal amount of $600 was issued to Castlemark Properties, LLC, (“Castlemark”) one of the Company’s subsidiaries. The note is secured by a mortgage on the real property. Castlemark will have a right to immediate payment of the note if the property is sold prior to maturity. If the owner does not sell the property prior to maturity and does not pay the note in full at maturity or deed the property to Castlemark, then Castlemark will have a right to foreclose the mortgage and take title to the property. The litigation was dismissed by joint stipulation on or about November 12, 2014. As a result of this settlement the Company recorded pre-tax income of $500, the estimated fair value of the real property, which is the most probable value of the judgment in the quarter ended December 31, 2014. The promissory note is included in long-term assets in the December 31, 2014 balance sheet.

SunLink and its subsidiaries are a party to various medical malpractice and other claims and litigation incidental to its business, for which it is not currently possible to determine the ultimate liability, if any. Based on an evaluation of information currently available and consultation with legal counsel, management believes that resolution of such claims and litigation is not likely to but could have a material adverse effect on the financial position, cash flows, or results of operations of the Company. The Company expenses legal costs as they are incurred.

Sale of Hospital Facilities—The Company has sold three hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and substantial liabilities. – See Note 3 Discontinued Operations.

Office of Inspector General Investigation— In March 2013, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the

outpatient psychiatric service provider, including financial arrangements. SHCD is continuing to cooperate with the government with respect to an ongoing document production, as well as conducting a joint medical necessity review of a sampling of medical records. We cannot at this time estimate what, if any, impact these matters and any results from these matters could have on our business, financial position, operating results or cash flows.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2014 were as follows:


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	866	$	858	$	712
2 years		775		333		708
3 years		1,951		200		650
4 years		601		74		508
5+ years		8,252		22		3,104

	$	12,445	$	1,487	$	5,682

At December 31, 2014, SunLink had a guarantee agreement with one physician. A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period (normally three years) or be liable to repay all or a portion of the guarantee received. The physician’s liability for any guarantee repayment due to non-compliance with the provisions of a guarantee agreement generally is collateralized by the physician’s patient accounts receivable and/or a promissory note from the physician. All potential payments payable under this one guarantee have been paid as of December 31, 2014. SunLink expensed $16 and $33 on physician guarantees and recruiting for the three months ended December 31, 2014 and 2013, respectively. SunLink expensed $31 and $67 on physician guarantees and recruiting for the six months ended December 31, 2014 and 2013, respectively.

Note 12. – Related Party Transactions

A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $91 and $159 for legal services to these law firms in the three months ended December 31, 2014 and 2013, respectively. The Company has expensed an aggregate of $190 and $319 for legal services to these law firms in the six months ended December 31, 2014 and 2013, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2014 and June 30, 2014 is $113 and $115, respectively, of amounts payable to these law firms.

Note 13. – Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Specialty Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of December 31, 2014 and 2013 and for the three and six months then ended is as follows:


	Healthcare		Specialty		Corporate
	Facilities		Pharmacy		and Other			Total
Three months ended December 31, 2014
Net revenues from external customers	$	14,539	$	8,430	$	158		$	23,126
Operating profit (loss)		2,596		80		(654	)		2,022
Depreciation and amortization		360		177		43			580
Assets		33,843		12,165		13,830			59,838
Expenditures for property, plant and equipment		48		271		0			319
Six months ended December 31, 2014
Net revenues from external customers	$	29,319	$	15,884	$	299		$	45,502
Operating profit (loss)		3,374		219		(1,266	)		2,327
Depreciation and amortization		720		345		150			1,215
Assets		33,843		12,165		13,830			59,838
Expenditures for property, plant and equipment		132		574		31			737
Three months ended December 31, 2013
Net revenues from external customers	$	14,463	$	9,326	$	91		$	23,880
Operating profit (loss)		1,287		229		(1,225	)		291
Depreciation and amortization		370		171		222			763
Assets		38,225		11,517		18,782			68,524
Expenditures for property, plant and equipment		161		104		141			406
Six months ended December 31, 2013
Net revenues from external customers	$	29,554	$	16,168	$	187		$	45,909
Operating profit (loss)		2,116		135		(2,296	)		(45	)
Depreciation and amortization		769		337		431			1,537
Assets		38,225		11,517		18,782			68,524
Expenditures for property, plant and equipment		294		283		191			768

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(Dollars in thousands, except per share and admissions data)

Forward-Looking Statements

This Quarterly Report and the documents that are incorporated by reference in this Quarterly Report contain certain forward-looking statements within the meaning of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue.” These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to:

General Business Conditions

•

general economic and business conditions in the U.S., both nationwide and in the states in which we operate;

•

increases in uninsured and/or underinsured patients due to unemployment or other conditions, higher deductibles and co-insurance, terms of health insurance coverage resulting in higher bad debt amounts;

•

the competitive nature of the U.S. community hospital, nursing home, homecare and specialty pharmacy businesses;

•

demographic changes in areas where we operate;

•

the availability of cash or borrowings to fund working capital, renovations, replacements, expansions and capital improvements at existing healthcare and specialty pharmacy facilities and for acquisitions and replacement of such facilities;

•

changes in accounting principles generally accepted in the U.S.; and,

•

fluctuations in the market value of equity securities including SunLink common shares;

Operational Factors

•

inability to operate profitably in one or more segments of the healthcare business;

•

the availability of, and our ability to attract and retain, sufficient qualified staff physicians, management, nurses, pharmacists and staff personnel for our operations;

•

timeliness and amount of reimbursement payments received under government programs;

•

the ability or inability to obtain external financing for working capital included under lending agreements;

•

changes in interest rates under debt agreements

•

the ability or inability to refinance former or existing indebtedness and potential defaults under existing indebtedness;

•

restrictions imposed by existing or future debt agreements;

•

the cost and availability of insurance coverage including professional liability (e.g., medical malpractice) and general liability insurance;

•

the efforts of insurers, healthcare providers, government payors and others to contain healthcare costs;

•

the impact on hospital services of the treatment of patients in lower acuity healthcare settings, whether with drug therapy or in alternative healthcare settings, such as surgery centers or urgent care centers;

•

changes in medical and other technology;

•

risks of changes in estimates of self insurance claims and reserves;

•

changes in prices of materials and services utilized in our Healthcare Facilities and Specialty Pharmacy Segments;

•

changes in wages as a result of inflation or competition for management, physician, nursing, pharmacy and staff positions;

•

changes in the amount and risk of collectability of accounts receivable, including deductibles and co-pay amounts;

•

the functionality or costs with respect to our information systems for our Healthcare Facilities and Specialty Pharmacy Segments and our corporate office, including both software and hardware; and

•

the availability of and competition from alternative drugs or treatments provided by our Specialty Pharmacy Segment;

Liabilities, Claims, Obligations and Other Matters

•

claims under leases, guarantees and other obligations relating to discontinued operations, including sold facilities, retained or acquired subsidiaries and former subsidiaries;

•

potential adverse consequences of known and unknown government investigations;

•

claims for product and environmental liabilities from continuing and discontinued operations;

•

professional, general and other claims which may be asserted against us; and,

•

natural disasters and weather-related events such as earthquakes, hurricanes, flooding, snow, ice and wind damage and population evacuations affecting areas in which we operate.

Regulation and Governmental Activity

•

existing and proposed governmental budgetary constraints;

•

Federal and state insurance exchanges and their rules on reimbursement terms;

•

the decision by states in which we operate hospitals (Georgia, Mississippi, Missouri) to not expand Medicaid;

•

the regulatory environment for our businesses, including state certificate of need laws and regulations, pharmacy licensing laws and regulations, rules and judicial cases relating thereto;

•

anticipated adverse changes in the levels and terms of government (including Medicare, Medicaid and other programs) and private reimbursement for SunLink’s healthcare services including the payment arrangements and terms of managed care agreements; EHR reimbursement and indigent care reimbursements (Medicare Upper Payment Limit “UPL” and Disproportionate Share Hospital “DSH” adjustments);

•

changes in or failure to comply with Federal, state or local laws and regulations affecting our Healthcare Facilities and Specialty Pharmacy Segments; and,

•

the possible enactment of additional Federal healthcare reform laws or reform laws in states where our subsidiaries operate hospital and pharmacy facilities (including Medicaid waivers, bundled payments, accountable care and similar organizations, competitive bidding, and other reforms).

Dispositions, Acquisitions, and Renovation Related Matters

•

the ability to dispose of underperforming facilities;

•

the availability and terms of capital to fund acquisitions, improvements, renovations or replacement facilities; and

•

competition in the market for acquisitions of hospitals and healthcare businesses.

The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect SunLink in an adverse manner.

You should read this Quarterly Report completely and with the understanding that actual future results may be materially different from what we expect. You are cautioned not to unduly rely on forward-looking statements when evaluating the information presented in this Quarterly Report or our other disclosures because current plans, anticipated actions, and future financial conditions and results may differ from those expressed in any forward-looking statements made by or on behalf of SunLink.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to an mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and the risk factors set forth elsewhere in this report and in our Annual Report on Form 10-K.

Business Strategy: Operations, Dispositions and Acquisitions

SunLink’s business strategy is to focus its efforts on improving internal operations of its existing healthcare facilities and its pharmacy business. We also consider from time to time potential healthcare facility acquisitions, development and dispositions, including but not limited to hospitals, physician clinics, ambulatory surgery centers, nursing, long-term care and assisted living homes, medical office buildings and pharmacy businesses. We consider dispositions of facilities or operations based on a variety of factors including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, corporate strategy and other corporate objectives.

Our efforts over the last two years have been more focused on the disposition of hospital facilities than on acquisitions due to our financial position and need to reduce our leverage and interest expense, the changing nature of certain of our subsidiary hospital markets resulting in, among other things, substantial additional competition, and pressure from Federal and state programs (e.g., Medicare and Medicaid) and private payors to reduce reimbursement for medical services. In July 2012, we sold our Adel, Georgia hospital and its related nursing home; in December 2012, we sold our Dexter, Missouri hospital and its related home health agency; and in December 2014, we our sold our Fulton, Missouri hospital. We currently have engaged advisors to advise us on and to assist us with the possible sale of one other hospital facility. As a result of the sale of these three hospitals and the improved operations of the remaining three hospitals and the Specialty Pharmacy Segment, the Company has reduced its debt from $29,021 at June 30, 2012 to $12,445 at December 31, 2014, and has increased its working capital by approximately $16,000 over the same two and a half year period.

Even though the Company’s financial position has improved, we believe our ability to compete for acquisitions is still limited. However, during the last fiscal year, we have evaluated certain rural and exurban hospitals, pharmacy operations and healthcare facilities and businesses which were for sale, monitored other selected acquisition targets which we believed might become available for sale, and considered the feasibility of developing healthcare facilities on property we own as well as on property that may be for sale. Although we have no current plans to do so, from time to time we may consider the acquisition of other complementary based healthcare businesses, outside of our existing business segments, which are or may become available for acquisition.

At its Board of Directors meeting on February 9, 2015, the Board discussed extensively the Company’s future and strategic alternatives. No action was taken on future and strategic alternatives other than the Board determined that the Company should not pursue its previously announced going private strategy at this time.

Critical Accounting Estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect reported amounts and related disclosures. We consider an accounting estimate to be critical if:

•

it requires assumptions to be made that were uncertain at the time the estimate was made; and

• changes in the estimate or different estimates that could have been made could have a material impact on our consolidated results of operations or financial condition.

Our critical accounting estimates are more fully described in our 2014 Annual Report on Form 10-K and continue to include the following areas:

•

Receivables – net and provision for doubtful accounts;

•

Revenue recognition / Net Patient Service Revenues;

•

Goodwill, intangible assets and accounting for business combinations;

•

Professional and general liability claims

•

Accounting for income taxes; and

•

Electronic Health Record incentives

Financial Summary

The results of continuing operations shown in the financial summary below are for our two business segments, Healthcare Facilities and Specialty Pharmacy.


	Three Months Ended									Six Months Ended
	December 31,									December 31,
	2014			2013			% Change			2014			2013			% Change
Net Revenues - Healthcare Facilities	$	14,539		$	14,463			0.5	%	$	29,319		$	29,554			(0.8	)%
Net Revenues - Specialty Pharmacy		8,430			9,326			(9.6	)%		15,884			16,168			(1.8	)%
Other Revenues		157			91			72.5	%		299			187			59.9	%

Total Net Revenues		23,126			23,880			3.2	%		45,502			45,909			(0.9	)%
Costs and expenses		(21,104	)		(23,589	)		10.5	%		(43,175	)		(45,954	)		(6.0	)%

Operating profit (loss)		2,022			291			594.8	%		2,327			(45	)		NA
Interest expense - net		(234	)		(238	)		(1.7	)%		(464	)		(480	)		(3.3	)%

Earning (Loss) from continuing operations before income taxes	$	1,788		$	53			3273.6	%	$	1,863		$	(525	)		NA

Healthcare Facilities Segment:
Admissions		660			646			2	%		1,292			1,233			5	%
Equivalent admissions		1,787			1,958			(9	)%		3,736			4,013			(7	)%
Surgeries		410			418			(2	)%		828			859			(4	)%
Revenue per equivalent admission	$	8,135		$	7,387			10	%	$	7,848		$	7,318			7	%

Equivalent admissions – Equivalent admissions is used by management (and certain investors) as a general measure of combined inpatient and outpatient volume for our hospital operations. Equivalent admissions are computed by multiplying admissions (inpatient volume) by the sum of gross inpatient revenues and gross outpatient revenues and dividing the result by gross inpatient revenues. The equivalent admissions computation is intended to relate outpatient revenues to the volume measure (admissions) used to measure inpatient volume to result in a general approximation of combined inpatient and outpatient volume (equivalent admissions).

Results of Operations

Healthcare Facilities Segment Net Revenues

The following table sets forth the percentage of net patient revenues from major payors for the Healthcare Facilities Segment for the periods indicated:


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013			2014			2013
Source:
Medicare		40.5	%		39.0	%		41.8	%		41.3	%
Medicaid		21.8	%		21.1	%		20.8	%		19.9	%
Managed Care Insurance & Other		25.4	%		24.9	%		25.5	%		24.7	%
Self-pay		12.3	%		15.0	%		11.9	%		14.1	%

		100.0	%		100.0	%		100.0	%		100.0	%

Healthcare Facilities net revenues included increase (decrease) of ($297) and $302 for the three months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($297) and $506 for the six months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports.

Medicare and Medicaid net revenues as a percentage of net revenues were up slightly for the three and six months ended December 31, 2014 compared to the prior year periods. Self-pay net revenues decreased primarily due to the closing of the emergency room in one of our hospitals in September 2014.

Specialty Pharmacy Segment Net Revenues

Specialty Pharmacy net revenues for the three months ended December 31, 2014 were $8,430 a decrease of $896, or 9.6%, from $9,326 for the three months ended December 31, 2013. Specialty Pharmacy net revenues for the six months ended December 31, 2014 were $15,884, a decrease of $284, or 1.8%, from $16,168 for the six months ended December 31, 2013. The decrease was a result of decreased Louisiana Medicaid revenues including sales of one product which is primarily sold to patients with Louisiana Medicaid coverage. Medicaid has restricted both the number of eligible customers and the number of approved purchases of this drug. Durable medical equipment and related products sales increased during the quarter ended December 31, 2014 compared to the prior year.

Healthcare Facilities Segment Cost and Expenses

Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $11,953 and $13,176 for the three months ended December 31, 2014 and 2013, respectively. Costs and expenses for our Healthcare Facilities Segment, including depreciation and amortization, were $25,945 and $27,438 for the six months ended December 31, 2014 and 2013, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013			2014			2013
Salaries, wages and benefits		56.5	%		59.9	%		57.1	%		58.4	%
Supplies		12.8	%		13.8	%		12.9	%		13.1	%
Purchased services		8.2	%		9.6	%		8.4	%		9.2	%
EHR incentive payments		0	%		-8.4	%		0	%		-4.1	%
Other operating expenses		12.9	%		15.1	%		12.5	%		14.9	%
Rent and lease expense		2.3	%		2.4	%		2.3	%		2.4	%
Depreciation and amortization expense		2.2	%		2.3	%		2.2	%		2.6	%

Salaries, wages and benefits decreased as a percentage of net revenue in the three and six months ended December 31, 2014 due to decreased employee medical claims incurred as compared to the three and six months ended December 31, 2013.

Other operating expenses decreased as a percentage of net revenues for the three and six months ended December 31, 2014 compared to the comparable prior year periods due to decreased insurance expense as a result of lower professional and general liability claims incurred in the three and six months ended December 31, 2014.

Specialty Pharmacy Segment Cost and Expenses

Cost and expenses for our Specialty Pharmacy Segment, including depreciation and amortization, were $8,350 and $9,097 for the three months ended December 31, 2014 and 2013, respectively. Cost and expenses for our Specialty Pharmacy Segment, including depreciation and amortization, were $15,665 and $16,033 for the six months ended December 31, 2014 and 2013, respectively.


	Cost and Expenses
	as a % of Net Revenues
	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013			2014			2013
Cost of goods sold		64.7	%		69.5	%		63.4	%		66.6	%
Salaries, wages and benefits		22.8	%		17.9	%		23.4	%		21.1	%
Provision for bad debts		0.9	%		0.5	%		0.5	%		0.6	%
Supplies		0.4	%		0.6	%		0.4	%		0.6	%
Purchased services		3.7	%		3.7	%		4.1	%		3.9	%
Other operating expenses		3.7	%		2.9	%		3.8	%		3.4	%
Rent and lease expense		0.8	%		0.8	%		0.9	%		0.9	%
Depreciation and amortization expense		2.1	%		1.9	%		2.2	%		2.1	%

Cost of goods sold as a percent of net revenues decreased in the three and six month periods ended December 31, 2014 as compared to the comparable periods of the prior year due to the current period sales product mix. Sales of one high sales volume product with a higher than average cost of goods sold decreased approximately 40%, based on units sold for the three and six months compared to the comparable periods last year.

Salaries, wages and benefits as a percent of net revenues increased in the six month period ended December 31, 2014 as compared to the comparable period of the prior year due to the increased staffing requirements related to the net growth in the institutional pharmacy business as seven new institutional supply contracts have been added this fiscal year.

Insurance settlement

In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the three and six months ended December 31, 2014 for this settlement.

Operating Profit and Loss

SunLink had an operating profit of $2,022 and $291 for the three months ended December 31, 2014 and 2013, respectively. SunLink had an operating profit of $2,327 for the six months ended December 31, 2014 and an operating loss of $45 for the six months ended December 31, 2013. The increased operating profit for the three and six months ended December 31, 2014 compared to the prior year period resulted from the decrease in professional and general liability claims, reduced provision for bad debts and the $1,000 insurance settlement, somewhat offset by negative cost reports settlements in the current year compared to positive cost report settlements last year.

Interest Expense

Interest expense was $234 and $238 for the three months ended December 31, 2014 and 2013, respectively and $464 and $480 for the six months ended December 31, 2014 and 2013, respectively.

Income Taxes

Earnings (Loss) After Taxes

Earnings from continuing operations were $989 ($0.10 per fully diluted share) for the three months ended December 31, 2014 compared to earnings from continuing operations of $350 ($0.04 per fully diluted share) for the three months ended December 31, 2013. Earnings from continuing operations were $878 ($0.08 per fully diluted share) for the six months ended December 31, 2014 compared to a loss from continuing operations of $430 ($0.05 loss per fully diluted share) for the six months ended December 31, 2013. The increased earnings for the three and six months ended December 31, 2014 resulted from the increased operating profit as compared to the comparable prior year period.

Loss from discontinued operations of $12 for the three months ended December 31, 2014 resulted from pre-tax earnings from businesses sold in prior years of $558 (primarily recognition of Medicare EHR incentive payments received for the fiscal year ended June 30, 2014), offset by the loss from operations of $449 of Fulton and the loss on sale of Fulton of $191. Tax benefit for discontinued operations for the three months ended December 31, 2014 was $70. The loss from discontinued operations for the six months ended December 31, 2014 of $314 resulted from a pre-tax earnings from businesses sold in prior years of $538, offset by the loss from operations of $897 for Fulton and the loss on sale of Fulton of $191. Tax benefit for discontinued operations for the six months ended December 31, 2013 was $236.

Loss from discontinued operations of $123 for the three months ended December 31, 2013 resulted from earnings from businesses sold in prior years, offset by the loss from operations of $549 for Fulton. Tax benefit for discontinued operations for the three months ended December 31, 2013 was $57. The loss from discontinued operations for the six months ended December 31, 2013 of $501 resulted from a pre-tax earnings from businesses sold in prior fiscal years of $391, offset by the Fulton loss from operations of $1,147. Tax benefit for discontinued operations for the six months ended December 31, 2013 was $255.

Net earnings for the three months ended December 31, 2014 were $977 ($0.10 earnings per fully diluted share) compared to net earnings of $227 ($0.02 earnings per fully diluted share) for the three months ended December 31, 2013. Net earnings for the six months ended December 31, 2014 were $564 ($0.06 loss per fully diluted share) compared to a net loss of $931 ($0.10 loss per fully diluted share) for the six months ended December 31, 2013.

Adjusted earnings before income taxes, interest, depreciation and amortization

Earnings before income taxes, interest, depreciation and amortization (“EBITDA”) represent the sum of income before income taxes, interest, depreciation and amortization. We understand that certain industry analysts and investors generally consider EBITDA to be one measure of the liquidity of a company, and it is presented to assist analysts and investors in analyzing the ability of a company to generate cash, service debt and meet capital requirements. We believe increased EBITDA is an indicator of improved ability to service existing debt and to satisfy capital requirements. EBITDA, however, is not a measure of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income as a measure of operating performance or to cash liquidity. Because EBITDA is not a measure determined in accordance with accounting principles generally accepted in the United States of America and is thus susceptible to varying calculations, EBITDA, as presented, may not be comparable to other similarly titled measures of other corporations. Where we adjust EBITDA for non-cash charges we refer to such measurement as “Adjusted EBITDA”, which we report on a company wide basis. Non-cash adjustments in Adjusted EBITDA are not intended to be identified or characterized in any respect as “non-recurring, infrequent or unusual,” if we believe such charge is reasonably likely to recur within two years, or if there was a similar charge (or gain) within the prior two years. Where we report Adjusted EBITDA, we typically also report Healthcare Facilities Segment Adjusted EBITDA and Specialty Pharmacy Segment Adjusted EBITDA which is the EBITDA for the applicable segments without any allocation of corporate overhead, which we report as a separate line item, without gains on sales of businesses and without any allocation of the non-cash adjustments, which we also report as a separate line item in Adjusted EBITDA. Net cash used in operations for the three and six months ended December 31, 2014 and 2013, respectively, is shown below.


	Three Months Ended						Six Months Ended
	December 31,						December 31,
	2014			2013			2014			2013
Healthcare Facilities Adjusted EBITDA	$	2,956		$	1,657		$	4,094		$	2,885
Specialty Pharmacy Adjusted EBITDA		257			400			564			472
Corporate overhead costs		(611	)		(1,003	)		(1,116	)		(1,865	)
Taxes and interest expense		(1,033	)		59			(1,449	)		(575	)
Other non-cash expenses and net change in operating assets and liabilities		(576	)		46			(2,145	)		2,628

Net cash provided by (Used in) operations	$	993		$	1,159		$	(52	)	$	3,545

Liquidity and Capital Resources

Overview

Our primary sources of liquidity are cash on hand and one facility-based revolving loan facility of $750, which has limited availability due to facility cash on hand restrictions. Currently, the Company’s ability to raise capital (debt or equity) in the public or private markets on what it considers acceptable terms is uncertain. We are nevertheless actively seeking options to obtain financing for the Company’s liquidity needs.

Although two of the Company’s subsidiaries have been able to borrow money through facility based mortgages, each of which is guaranteed by the Company, utilizing USDA Rural Development Authority guaranties, (individually, an “RDA Loan” and collectively, the “RDA Loans”), and, in the case of our Trace hospital subsidiary, obtain a working revolving capital loan facility of $750, the Company and its subsidiaries currently are funding its working capital needs primarily from cash from operations and from the sale of additional assets. See “Subsidiary Loans” below.

Although operations of the Company’s Healthcare Facilities and Specialty Pharmacy segments have improved in fiscal 2015, the Company believes its hospital facilities and its specialty pharmacy business continue to underperform. The Company has incurred losses from continuing operations in five of the last ten fiscal quarters through the quarter ending December 31, 2014.

In light of the current underperformance of the Company’s hospital facilities and its specialty pharmacy business, the Company has engaged advisors to evaluate and conduct the possible sale of one hospital facility. There can be no assurance that the sale will occur or that, if a sale occurs, it will be at a price that results in a gain or net proceeds after transaction costs, taxes and outstanding debt. The Company may need to use a portion of the net proceeds, if any, from future asset sales to fund its working capital needs if its remaining hospitals and its specialty pharmacy segment are not, at that time, providing sufficient cash flow to fund working capital.

Subject to the risks and uncertainties discussed herein, we believe we have adequate financing and liquidity to support our current level of operations through the next twelve months.

Subsidiary Loans

Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (formerly known as SunLink Healthcare, LLC) (“MedCare”), a wholly owned subsidiary or the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.

SHPP RDA Loan - On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

Contractual Obligations, Commitments and Contingencies


Payments due in:	Long-Term Debt		Operating Leases		Interest on Outstanding Debt
1 year	$	866	$	858	$	712
2 years		775		333		708
3 years		1,951		200		650
4 years		601		74		508
5+ years		8,252		22		3,104

	$	12,445	$	1,487	$	5,682

At December 31, 2014, we had outstanding long-term debt of $12,444 of which $8,405 was incurred under the Trace RDA Loan, $2,013 was incurred under the SHPP RDA Loan, $1,851 was incurred under the Carmichael Notes, and $175 was related to other debt.

Discontinued Operations

Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of December 31, 2014 and June 30, 2014 and for the three and six month periods ended December 31, 2014 and 2013. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. Loss of $191 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the RDA loan.

Dexter Hospital - On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). The assets of Dexter consisted of a leased 50-bed acute care hospital and related clinics, equipment, and home health services in Dexter, Missouri. Subsequent to the sale, Dexter managed the hospital and related businesses for Southeast Health Center of Stoddard County, LLC through a transition period ended June 30, 2013. Dexter retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology and substantially all liabilities of the hospital as of December 31, 2012. Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013.

Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially of all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013.

Related Party Transactions

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We have not entered into any transactions using derivative financial instruments or derivative commodity instruments and believe that our exposure to market risk associated with other financial instruments (such as investments and borrowings) and interest rate risk is not material.

ITEM 4. CONTROLS AND PROCEDURES

We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to process, summarize and disclose this information within the time periods specified in the rules of the SEC.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer initially concluded that, as of the end of such period, our disclosure controls and procedures were effective in providing reasonable assurances that information required to be disclosed by the Company in the reports filed or submitted under the Exchange Act are recorded, processed, summarized and reported in a timely manner. However, subsequent to such quarter end and evaluation, our management in response to correspondence from the SEC with respect to our annual report for the year ended June 30, 2014 re-examined the effectiveness of our disclosure controls and procedures and concluded that our controls during the quarter ended December 31, 2014 were not effective as of December 31, 2014 based on management’s failure to include a complete report on internal controls over financial reporting as required under Item 308(a) of Regulation S-K in prior filings with the SEC. Accordingly, subsequent to the end of the period covered by this report, the Company implemented procedures in the preparation and filing of its periodic reports which it believes will remediate for future periods such material weakness in internal controls.

Except for the changes subsequent to the end of the quarter as described above, there were no changes during the quarter ended June 30, 2014, or in the other periods referred to above, in our internal control over financial reporting or in other factors that materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II. OTHER INFORMATION

Items required under Part II not specifically shown below are not applicable.

ITEM 1. LEGAL PROCEEDINGS

Office of Inspector General Investigation

In March 2013, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD is continuing to cooperate with the government with respect to an ongoing document production, as well as conducting a joint medical necessity review of a sampling of medical records. We cannot at this time estimate what, if any, impact these matters and any results from these matters could have on our business, financial position, operating results or cash flows.

ITEM 1A. RISK FACTORS

Risk Factors Relating to an Investment in SunLink

Information regarding risk factors appears in “MD&A – Forward-Looking Statements,” in Part I – Item 2 of this Form 10-Q and in “MD&A -Risks Factors Relating to an Investment in SunLink” in Part I – Item 1A of the Company’s Annual Report on Form 10-K for the year ended June 30, 2013. While we believe there have been no material changes from the risk factors previously disclosed in such Annual Report except as set forth herein, you should carefully consider, in addition to the other information set forth in this report, the risk factors discussed in our Annual Report which could materially affect our business, financial condition or future results. Such risk factors are expressly incorporated herein by reference. The risks described in our Annual Report are not the only risks facing our Company. In addition to risks and uncertainties inherent in forward looking statements contained in this Report on Form 10-Q, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. Whenever we refer to “SunLink,” “Company”, “we,” “our,” or “us” in this Item 1A, we mean SunLink Health Systems, Inc. and its subsidiaries, unless the context suggests otherwise.

ITEM 6. EXHIBITS


Exhibits:

31.1		Chief Executive Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

31.2		Chief Financial Officer’s Certification Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.

32.1		Chief Executive Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Chief Financial Officer’s Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from the Company’s quarterly report on Form 10-Q for the three months ended December 31, 2014, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of December 31, 2014 (unaudited) and June 30, 2014, (ii) Condensed Consolidated Statements of Operations for the three months ended December 31, 2014 and 2013 (unaudited), (iii) Condensed Consolidated Statements of Cash Flows, for the three months ended December 31, 2014 and 2013 (unaudited), and (iv) Notes to Condensed Consolidated Financial Statements (unaudited), tagged as blocks of text.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, SunLink Health Systems, Inc. has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


SunLink Health Systems, Inc.

By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

Dated: February 18, 2015

EX-31.1 2 d834962dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION

I, Robert M. Thornton, Jr., the Chief Executive Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended December 31, 2014 (the “report”);

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of December 31, 2014 (the “Evaluation Date”), based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


February 18, 2015		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		SunLink Health Systems, Inc.
		Chief Executive Officer

EX-31.2 3 d834962dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION

I, Mark J. Stockslager, the Chief Financial Officer of SunLink Health Systems, Inc. (the “registrant”), certify that:

(1) I have reviewed this quarterly report on Form 10-Q of the registrant for the period ended December 31, 2014 (the “report”);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


February 18, 2015		/s/ Mark J. Stockslager
		Mark J. Stockslager
		SunLink Health Systems, Inc.
		Chief Financial Officer

EX-32.1 4 d834962dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended December 31, 2014, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Robert M. Thornton, Jr., Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Robert M. Thornton, Jr.
		Robert M. Thornton, Jr.
		Chief Executive Officer

February 18, 2015

EX-32.2 5 d834962dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

SUNLINK HEALTH SYSTEMS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of SunLink Health Systems, Inc. (the “Company”) on Form 10-Q for the quarterly period ended December 31, 2014, as filed with the United States Securities and Exchange Commission on the date hereof (the “Report”), I, Mark J. Stockslager, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


By:		/s/ Mark J. Stockslager
		Mark J. Stockslager
		Chief Financial Officer

February 18, 2015

EX-101.INS 6 ssy-20141231.xml XBRL INSTANCE DOCUMENT

2100000

9443408

0.08

3000000

5000000

7799000

7317000

482000

7239000

68524000

4561000

38225000

11517000

18782000

6760000

479000

7330000

7117000

213000

9444000

2000000

24.74

2000000

33902000

2072000

175000

31484000

12607000

139000

13329000

4722000

-334000

5433000

16050000

866000

13464000

786000

11579000

59838000

4097000

12445000

7279000

59838000

3971000

461000

22823000

11115000

3536000

4436000

18394000

54307000

9355000

59838000

6755000

2319000

4047000

5190000

2672000

2908000

1550000

27660000

964000

775000

1951000

12445000

601000

866000

8252000

333000

200000

1487000

74000

858000

22000

708000

650000

5682000

508000

712000

3104000

33843000

12165000

13830000

1255000

7055000

950000

224000

461000

3858000

2908000

1089000

2000000

769000

113000

8405000

875000

0.80

0.0525

2013000

0.08

1852000

600000

750000

9975000

1000000

7761000

2497000

7286000

475000

9444000

2000000

33318000

2314000

30389000

4842000

16506000

73000

14023000

4722000

-334000

4530000

15486000

561000

13444000

807000

11948000

63847000

4186000

12509000

6903000

3587000

461000

23077000

9850000

2547000

4432000

16753000

53466000

14995000

63847000

2978000

6111000

3757000

2786000

270000

2979000

1012000

25775000

1268000

6649000

879000

254000

461000

3858000

2979000

1089000

2000000

769000

115000

8624000

2033000

1852000

625000

500000

Claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006.

1000000

252000

75000

247000

8350000

-0.10

3545000

5712000

-0.05

9443000

-0.10

-0.05

9443000

160000

-1629000

409000

187000

-501000

506000

45909000

-525000

-45000

14000

-931000

-756000

50197000

768000

-931000

575000

-430000

31000

1537000

480000

21514000

95000

6234000

70000

2064000

2595000

-95000

-1011000

713000

-78000

10760000

-17000

63000

-470000

79000

3982000

4288000

30000

-255000

5973000

768000 7242000 67000 83000 61000 1215000

29554000

2116000

294000

769000

16168000

135000

283000

337000

187000

-2296000

191000

431000

4705000

98000

8572000

13623000

6844000

5617000

29554000

33842000

6143000

4288000

95000

16168000

91000

482000

513000

-79000

-12000

-4000

-1147000

6733000

319000

21000

<div> Note 11. – Commitments and Contingencies  Litigation—A settlement was reached on November 3, 2014 relating to litigation as a result of sellers failure to close on the sale of approximately 24.74 acres of real property located in Gilmer County, Georgia purchased by a subsidiary of the Company. In satisfaction of the Company’s claims against the sellers, a five year promissory note in the principal amount of $600 was issued to Castlemark Properties, LLC, (“Castlemark”) one of the Company’s subsidiaries. The note is secured by a mortgage on the real property. Castlemark will have a right to immediate payment of the note if the property is sold prior to maturity. If the owner does not sell the property prior to maturity and does not pay the note in full at maturity or deed the property to Castlemark, then Castlemark will have a right to foreclose the mortgage and take title to the property. The litigation was dismissed by joint stipulation on or about November 12, 2014. As a result of this settlement the Company recorded pre-tax income of $500, the estimated fair value of the real property, which is the most probable value of the judgment in the quarter ended December 31, 2014. The promissory note is included in long-term assets in the December 31, 2014 balance sheet. SunLink and its subsidiaries are a party to various medical malpractice and other claims and litigation incidental to its business, for which it is not currently possible to determine the ultimate liability, if any. Based on an evaluation of information currently available and consultation with legal counsel, management believes that resolution of such claims and litigation is not likely to but could have a material adverse effect on the financial position, cash flows, or results of operations of the Company. The Company expenses legal costs as they are incurred. Sale of Hospital Facilities—The Company has sold three hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and substantial liabilities. – See Note 3 Discontinued Operations. Office of Inspector General Investigation— In March 2013, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD is continuing to cooperate with the government with respect to an ongoing document production, as well as conducting a joint medical necessity review of a sampling of medical records. We cannot at this time estimate what, if any, impact these matters and any results from these matters could have on our business, financial position, operating results or cash flows. Contractual Obligations, Commitments and Contingencies Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2014 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr>  <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">866</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">712</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">333</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">708</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,951</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">601</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">508</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,682</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> At December 31, 2014, SunLink had a guarantee agreement with one physician. A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period (normally three years) or be liable to repay all or a portion of the guarantee received. The physician’s liability for any guarantee repayment due to non-compliance with the provisions of a guarantee agreement generally is collateralized by the physician’s patient accounts receivable and/or a promissory note from the physician. All potential payments payable under this one guarantee have been paid as of December 31, 2014. SunLink expensed $16 and $33 on physician guarantees and recruiting for the three months ended December 31, 2014 and 2013, respectively. SunLink expensed $31 and $67 on physician guarantees and recruiting for the six months ended December 31, 2014 and 2013, respectively.  </div>

0.06

<div> Revenues before provision for doubtful accounts by payor were as follows for the three and six months ended December 31, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,685</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,516</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,963</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,623</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,602</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,971</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,844</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,002</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,453</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,990</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,705</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,189</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,156</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,514</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,572</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,694</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,534</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,842</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,982</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,231</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,215</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,288</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,539</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,319</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,554</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Specialty Pharmacy Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,326</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,168</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">157</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Net Revenues </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,126</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,880</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,502</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,909</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

10-Q SUNLINK HEALTH SYSTEMS INC SSY

<div> Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2014 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="69%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap"> Payments due in: </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Long-Term Debt</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Operating Leases</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Interest on Outstanding Debt</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 1 year </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">866</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">712</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 2 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">775</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">333</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">708</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 3 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,951</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">200</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">650</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> 4 years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">601</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">74</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">508</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> 5+ years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,252</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,104</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">12,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,487</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,682</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 7. – Goodwill and Intangible Assets SunLink’s Specialty Pharmacy Segment has goodwill and intangible assets related to its Carmichael acquisition. Goodwill consists of the following:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Trade Name </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(950</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(879</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,908</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The trade name intangible asset under the Specialty Pharmacy Segment is a non-amortizing intangible asset. Amortization expense was $36 and $35 for both the three months ended December 31, 2014 and 2013, respectively, and $71 and $70 for the six months ended December 31, 2014 and 2013, respectively. </div>

<div> Goodwill consists of the following:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="9%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">461</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 13. – Financial Information by Segment Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Specialty Pharmacy.   We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of December 31, 2014 and 2013 and for the three and six months then ended is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,539</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">158</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,126</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,596</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,022</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">360</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">177</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">580</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,165</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,830</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59,838</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">271</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,319</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,502</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,374</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,266</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,327</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">720</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">345</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,215</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,165</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,830</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59,838</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">574</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">737</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,326</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,880</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,287</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,225</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">291</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">370</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">171</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">763</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,517</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,782</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,524</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">161</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">406</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,168</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,909</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,116</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">135</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,296</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">431</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,537</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,517</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,782</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,524</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">294</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">283</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">768</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   </div>

Smaller Reporting Company

<div> Note 2. – Business Operations Business Operations SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Healthcare Facilities Segment is composed of three operational areas:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Three community hospital subsidiaries in two states with a total of 183 licensed beds;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Two nursing homes with a total of 166 licensed beds, each of which is located adjacent to, or in close proximity with a corresponding SunLink community hospital; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">A healthcare facility which is currently vacant except for two medical offices which are rented.</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="5%"> </td> <td valign="top" width="2%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">The Specialty Pharmacy Segment is composed of four operational areas:</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Retail pharmacy products and services, all of which are conducted in rural markets;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Institutional pharmacy services;</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Specialty pharmacy services; and</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td width="9%"> </td> <td valign="top" width="3%" align="left">•</td> <td valign="top" width="1%"> </td> <td valign="top" align="left">Durable medical equipment.</td> </tr> </table> SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy business since April 2008. The Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of SunLink ScriptsRx, LLC. </div>

-52000

<div> Note 12. – Related Party Transactions A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $91 and $159 for legal services to these law firms in the three months ended December 31, 2014 and 2013, respectively. The Company has expensed an aggregate of $190 and $319 for legal services to these law firms in the six months ended December 31, 2014 and 2013, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2014 and June 30, 2014 is $113 and $115, respectively, of amounts payable to these law firms. </div>

6331000

0.09

<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Results for all of the businesses included in discontinued operations are presented in the following table: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Fulton Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,321</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,184</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,730</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,733</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Dexter Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">90</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">418</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">131</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">513</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Memorial of Adel </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,480</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,604</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,914</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,242</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (loss) before income taxes: </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(449</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(549</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(897</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,147</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dexter Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">532</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">410</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">570</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">482</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Memorial of Adel </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(40</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(64</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(79</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">109</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(359</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(756</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss on Sale </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss on Sale </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(236</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(255</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss from discontinued operations </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(123</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(314</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(501</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of December 31, 2014 and 2013 and for the three and six months then ended is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Corporate</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">and Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,539</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">158</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,126</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,596</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,022</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">360</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">177</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">580</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,615</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,830</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59,838</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">271</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">319</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,319</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,502</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,374</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">219</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,266</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,327</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">720</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">345</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">150</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,215</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,843</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,615</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13,830</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59,838</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">132</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">574</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">737</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,326</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,880</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,287</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">229</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,225</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">291</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">370</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">171</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">222</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">763</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,517</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,782</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,524</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">161</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">141</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">406</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2013 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net revenues from external customers </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,554</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,168</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,909</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating profit (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,116</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">135</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,296</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">337</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">431</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,537</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38,225</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,517</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18,782</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68,524</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expenditures for property, plant and equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">294</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">283</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">191</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">768</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   </div>

2014-12-31

<div> Note 3. – Discontinued Operations All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.   Results for all of the businesses included in discontinued operations are presented in the following table:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Net Revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Fulton Hospital </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,321</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,184</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,730</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,733</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Dexter Hospital </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">90</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">418</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">131</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">513</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Memorial of Adel </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,480</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,604</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,914</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,242</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Earnings (loss) before income taxes: </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(449</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(549</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(897</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1,147</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Dexter Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">532</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">410</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">570</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">482</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Memorial of Adel </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">56</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Life sciences and engineering </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(40</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(64</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(79</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Earnings (Loss) before income taxes </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">109</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(180</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(359</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(756</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss on Sale </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Fulton Hospital </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss on Sale </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(191</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Income tax expense (benefit) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(57</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(236</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(255</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Loss from discontinued operations </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(123</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(314</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">(501</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of December 31, 2014 and June 30, 2014 and for the three and six month periods ended December 31, 2014 and 2013. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. A loss of $191 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the RDA loan. Fulton RDA Loan—SunLink, Fulton and HealthMont LLC (“HLLC”), the direct parent of HOM closed on a $5,000 Loan Agreement dated as of March 16, 2012 (the “Fulton RDA Loan”) with a bank. The Fulton RDA Loan was repaid in full on December 31, 2014 concurrent with the sale of Fulton. Dexter Hospital—On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). The assets of Dexter consisted of a leased 50-bed acute care hospital and related clinics, equipment, and home health services in Dexter, Missouri. Subsequent to the sale, Dexter managed the hospital and related businesses for Southeast Health Center of Stoddard County, LLC through a transition period ended June 30, 2013. Dexter retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology and substantially all liabilities of the hospital as of December 31, 2012. Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013. Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013. Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and six months ended December 31, 2014 and 2013. The components of pension expense for the three and six months ended December 31, 2014 and 2013, respectively, were as follows: <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: bold italic 12pt 'Times New Roman'; MARGIN-TOP: 0pt; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">   <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center"> Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman'"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2">   </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">79</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: bold italic 10pt 'Times New Roman'; MARGIN-TOP: 12pt; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" align="center">SunLink contributed $56 to the plan in the three and six months ended December 31, 2014. </div>

-0.03

<div> Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,394</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,753</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,279</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,903</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable—net </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,115</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,850</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Note 4. – Shareholders’ Equity Stock-Based Compensation For the three months ended December 31, 2014 and 2013, the Company recognized $48 and $15, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2014 and 2013, the Company recognized $21 and $31, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 90,000 and 0 share options granted under the 2005 Equity Incentive Plan during the six months ended December 31, 2014 and 2013, respectively. There were 0 and 21,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2014 and 2013, respectively. </div>

false --06-30 2015

9478000

0.06

0.09

<div> Note 10. – Income Taxes Income tax expense of $799 ($643 federal tax expense and $156 state tax expense) and income tax benefit of $297 ($328 federal tax expense and $31 state tax expense) was recorded for the three months ended December 31, 2014 and 2013, respectively. Income tax expense of $985 ($863 federal tax expense and $122 state tax expense) and income tax benefit of $95 ($78 federal tax benefit and $17 state tax benefit) was recorded for the six months ended December 31, 2014 and 2013, respectively. At December 31, 2014, the Company had $5,190 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At December 31, 2014, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,755. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized. </div>

<div> Note 8. – Long-Term Debt Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,624</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,013</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">175</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less current maturities </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(866</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(561</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,579</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,948</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (formerly known as SunLink Healthcare, LLC) (“MedCare”), a wholly owned subsidiary of the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.   The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at December 31, 2014). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds were used to repay a portion of the Company’s senior debt under the Term Loan under the then outstanding Credit Facility. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs. The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ending December 31, 2014, $875; (b) for the quarter ended March 31, 2015, $750; (c) for the quarter ending June 30, 2015, $625; and (d) thereafter, $500. The Trace Working Capital Loan expires July 2, 2015. It is subject to annual renewal at the discretion of the lender. At December 31, 2014, there were no outstanding borrowings under the Trace Working Capital Loan. The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require our SHCH subsidiary to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge coverage, and funded debt to EBITDA, all as defined in the Trace RDA Loan. If SHCH is unable to remain in compliance with the financial covenants, SHCH would cease to have a right to draw on the revolving working capital loan (of which $0 was drawn at December 31, 2014 and June 30, 2014). SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia. The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at December 31, 2014). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and MedCare. Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Purchase Note”). On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue promissory notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note (the “PIK Notes”). The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note (the “Carmichael Note” dated April 22, 2014 for the remaining balance payable of $1,852. The Carmichael Note is payable in one interest only payment of $75 due on October 22, 2014 and five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company. </div>

<div> Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2014 and for the three and six month periods ended December 31, 2014 and 2013 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period. </div>

0000096793

-0.03

<div> Note 5. – Revenue Recognition and Accounts Receivables The Company’s subsidiaries recognize revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.   Revenues before provision for doubtful accounts by payor were as follows for the three and six months ended December 31, 2014 and 2013:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="68%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,685</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,516</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,963</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,623</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Medicaid </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,602</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,524</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,971</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,844</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Self-pay </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,002</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,453</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,990</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,705</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Managed Care & Other Insurance </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,189</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,156</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,514</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,572</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">43</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">96</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">98</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Revenues before provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,694</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,534</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,842</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Provision for doubtful accounts </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,982</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,231</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,215</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,288</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Healthcare Facilities Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,539</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,463</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,319</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">29,554</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Specialty Pharmacy Segment Net Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,430</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,326</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,884</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">16,168</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other Revenues </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">157</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">91</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">299</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">187</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total Net Revenues </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,126</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,880</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,502</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">45,909</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The net revenues of the Specialty Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Specialty Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss. Summary information for accounts receivable is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts receivable (net of contractual allowances) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,394</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,753</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less allowance for doubtful accounts </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,279</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,903</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Patient accounts receivable—net </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,115</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,850</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and six months ended December 31, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Three Months Ended December 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at October 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">213</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,330</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,016</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,096</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,078</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,147</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,055</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Six Months Ended December 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,649</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,903</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,251</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,331</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,845</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(110</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,955</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,055</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Three Months Ended December 31, 2013:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at October 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,317</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">482</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,799</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,899</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,941</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,456</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,501</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2013 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,760</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">479</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Six Months Ended December 31, 2013:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,286</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">475</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,712</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,143</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(91</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,234</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2013 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,760</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">479</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Net revenues included increase (decrease) of ($297) and $302 for the three months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($297) and $506 for the six months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. </div>

9443000

1000000

29000

-191000

239000

299000

-314000

-297000

45502000

1863000

56000

2327000

15000

564000

-359000

49717000

737000

564000

562000

878000

21000

1215000

464000

21406000

123000

5955000

71000

384000

2202000

985000

5342000

677000

6090000

863000

10072000

122000

48000

-4906000

66000

4140000

4215000

33000

-236000

4340000

175000

737000 6914000 <div> Long-term debt consisted of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trace RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,624</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> SHPP RDA Loan </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,013</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,033</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Carmichael Notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,852</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">175</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,445</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,509</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Less current maturities </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(866</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(561</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,579</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,948</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services. For the three and six months ended December 31, 2014, the Company reported no EHR incentive payments. For the three and six months ended December 31, 2013, the Company reported a net $1,215 gain for Medicare and Medicaid EHR incentive payments which were for successful Medicaid attestation by the three hospitals and also adjustments calculated at the time of filing Medicare cost reports for the preceding fiscal year. </div> 1 31000 11000 3 <div> The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and six months ended December 31, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Three Months Ended December 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at October 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,117</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">213</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,330</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,016</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,096</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,078</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(69</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,147</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,055</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Six Months Ended December 31, 2014:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,649</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,903</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,251</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">80</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,331</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,845</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(110</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(5,955</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2014 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,055</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">224</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,279</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Three Months Ended December 31, 2013:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at October 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,317</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">482</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,799</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,899</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">42</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,941</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,456</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(45</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,501</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2013 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,760</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">479</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Healthcare</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> Specialty</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">Six Months Ended December 31, 2013:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Facilities</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Pharmacy</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Balance at July 1, 2013 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,286</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">475</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,761</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Additions recognized as a reduction to revenues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,617</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">95</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,712</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Accounts written off, net of recoveries </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,143</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(91</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(6,234</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Balance at December 31, 2013 </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,760</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">479</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,239</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> Intangibles consist of the following, net of amortization:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center"> June 30,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Specialty Pharmacy Segment </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Trade Name </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,000</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer Relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,089</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Medicare License </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">769</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,858</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Accumulated Amortization </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(950</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom" align="right">(879</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,908</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"></td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,979</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The components of pension expense for the three and six months ended December 31, 2014 and 2013, respectively, were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center"> Three Months Ended</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="6" align="center"> Six Months Ended</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" colspan="2">   </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest Cost </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">15</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expected return on assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(14</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Amortization of prior service cost </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Net pension expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">66</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">79</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> P3Y <div> Note 9. – Insurance settlement In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the three and six months ended December 31, 2014 for this settlement. </div> 4842000 0

29319000

3374000

132000

720000

15884000

219000

574000

345000

299000

-1266000

31000

150000

3990000

96000

8514000

13963000

6971000

6251000

29319000

33534000

5845000

4215000

166 2 3 2 183 3

80000

15884000

110000

570000

131000

-64000

32000

53000

-191000

-897000

6090000

6730000

4745000

237000

2012-07-05

190000

2012-07-05

0.015

Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%

2015-07-02

0.060

P15Y

8500000

850000

0.020

The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%

0.05

P25Y

1800000

2012-10-31

2008-04-22

2017-10-22

185000

2012-03-16

90000

500000

P5Y 50

0.02

2941000

0.04

-0.01

9446000

0.02

0.04

-0.01

9443000

91000

-123000

302000

23880000

53000

291000

7000

227000

-180000

26111000

406000

227000

350000

15000

763000

238000

10722000

42000

3501000

35000

1350000

-297000

358000

328000

6485000

31000

32000

40000

2054000

2231000

15000

-57000

3030000

3604000 33000 1215000

14463000

1287000

161000

370000

9326000

229000

104000

171000

91000

-1225000

141000

222000

2453000

45000

4156000

6516000

3524000

2899000

14463000

16694000

3456000

2231000

42000

9326000

45000

410000

418000

-40000

-1000

2000

-549000

3184000

159000

0.10

3096000

0.10

0.00

9497000

0.10

0.00

9443000

1000000

-191000

157000

-12000

-297000

23126000

1788000

56000

2022000

7000

977000

109000

25108000

319000

977000

989000

48000

580000

234000

10589000

123000

3147000

36000

1025000

799000

329000

643000

5456000

156000

23000

32000

2034000

1982000

16000

-70000

1968000

3480000 16000 3 0

14539000

2596000

48000

360000

8430000

80000

271000

177000

158000

-654000

43000

2002000

43000

4189000

6685000

3602000

3016000

14539000

16521000

3078000

1982000

80000

8430000

69000

532000

90000

-30000

56000

69000

-191000

-449000

3321000

91000

0000096793 us-gaap:ManagementMember 2014-10-01 2014-12-31 0000096793 ssy:FultonHospitalMember 2014-10-01 2014-12-31 0000096793 ssy:MemorialHospitalOfAdelMember 2014-10-01 2014-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2014-10-01 2014-12-31 0000096793 ssy:DexterHospitalMember 2014-10-01 2014-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-10-01 2014-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2014-10-01 2014-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2014-10-01 2014-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2014-10-01 2014-12-31 0000096793 2014-10-01 2014-12-31 0000096793 us-gaap:ManagementMember 2013-10-01 2013-12-31 0000096793 ssy:FultonHospitalMember 2013-10-01 2013-12-31 0000096793 ssy:MemorialHospitalOfAdelMember 2013-10-01 2013-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2013-10-01 2013-12-31 0000096793 ssy:DexterHospitalMember 2013-10-01 2013-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-10-01 2013-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2013-10-01 2013-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2013-10-01 2013-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2013-10-01 2013-12-31 0000096793 2013-10-01 2013-12-31 0000096793 ssy:DexterHospitalMember 2012-12-07 2012-12-31 0000096793 ssy:CastlemarkPropertiesLlcMember 2014-07-01 2014-12-31 0000096793 ssy:TwoThousandFiveEquityIncentivePlanMember 2014-07-01 2014-12-31 0000096793 ssy:StockIncentivePlanTwoThousandElevenMember 2014-07-01 2014-12-31 0000096793 ssy:FultonRdaLoanMember 2014-07-01 2014-12-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2014-07-01 2014-12-31 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-07-01 2014-12-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-07-01 2014-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2014-07-01 2014-12-31 0000096793 us-gaap:ManagementMember 2014-07-01 2014-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2014-07-01 2014-12-31 0000096793 ssy:FultonRdaLoanMemberssy:FultonHospitalMember 2014-07-01 2014-12-31 0000096793 ssy:FultonHospitalMember 2014-07-01 2014-12-31 0000096793 ssy:MemorialHospitalOfAdelMember 2014-07-01 2014-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2014-07-01 2014-12-31 0000096793 ssy:DexterHospitalMember 2014-07-01 2014-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-07-01 2014-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2014-07-01 2014-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2014-07-01 2014-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2014-07-01 2014-12-31 0000096793 2014-07-01 2014-12-31 0000096793 ssy:TwoThousandFiveEquityIncentivePlanMember 2013-07-01 2013-12-31 0000096793 ssy:StockIncentivePlanTwoThousandElevenMember 2013-07-01 2013-12-31 0000096793 us-gaap:ManagementMember 2013-07-01 2013-12-31 0000096793 ssy:FultonHospitalMember 2013-07-01 2013-12-31 0000096793 ssy:MemorialHospitalOfAdelMember 2013-07-01 2013-12-31 0000096793 ssy:LifeSciencesAndEngineeringSegmentMember 2013-07-01 2013-12-31 0000096793 ssy:DexterHospitalMember 2013-07-01 2013-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-07-01 2013-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 ssy:MedicaidMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 ssy:MedicareMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 ssy:ManagedCareAndOtherInsurersMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 ssy:OtherHealthcareEntityMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 us-gaap:SelfPayMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2013-07-01 2013-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2013-07-01 2013-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2013-07-01 2013-12-31 0000096793 2013-07-01 2013-12-31 0000096793 ssy:MemorialHospitalOfAdelMember 2012-07-02 2012-07-02 0000096793 ssy:CarmichaelCashwayPharmacyNoteMemberus-gaap:PaymentInKindPIKNoteMember 2012-04-22 2012-04-22 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2014-10-22 2014-10-22 0000096793 ssy:CarmichaelCashwayPharmacyNoteMemberus-gaap:PaymentInKindPIKNoteMember 2012-10-22 2012-10-22 0000096793 us-gaap:SubsequentEventMember 2015-01-31 2015-01-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:ScenarioForecastMember 2015-07-02 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:ScenarioForecastMember 2015-06-30 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2014-06-30 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2014-06-30 0000096793 us-gaap:ManagementMember 2014-06-30 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-06-30 0000096793 2014-06-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-06-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-06-30 0000096793 2013-06-30 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2012-07-11 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:MortgagesMember 2012-07-11 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMemberus-gaap:ScenarioForecastMember 2015-03-31 0000096793 ssy:CastlemarkPropertiesLlcMember 2014-12-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2014-12-31 0000096793 ssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2014-12-31 0000096793 ssy:TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember 2014-12-31 0000096793 us-gaap:ManagementMember 2014-12-31 0000096793 ssy:MedicareLicenseMemberssy:SpecialtyPharmacySegmentMember 2014-12-31 0000096793 us-gaap:TradeNamesMemberssy:SpecialtyPharmacySegmentMember 2014-12-31 0000096793 us-gaap:CustomerRelationshipsMemberssy:SpecialtyPharmacySegmentMember 2014-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-12-31 0000096793 ssy:CarmichaelCashwayPharmacyNoteMemberus-gaap:ScenarioForecastMember 2014-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2014-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2014-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2014-12-31 0000096793 ssy:InterestOnOutstandingDebtMember 2014-12-31 0000096793 ssy:OperatingLeasesMember 2014-12-31 0000096793 us-gaap:LongTermDebtMember 2014-12-31 0000096793 2014-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2014-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2014-09-30 0000096793 2014-09-30 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-12-31 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-12-31 0000096793 us-gaap:CorporateNonSegmentMember 2013-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:SpecialtyPharmacySegmentMember 2013-12-31 0000096793 us-gaap:OperatingSegmentsMemberssy:HealthcareFacilitiesSegmentMember 2013-12-31 0000096793 2013-12-31 0000096793 ssy:SpecialtyPharmacySegmentMember 2013-09-30 0000096793 ssy:HealthcareFacilitiesSegmentMember 2013-09-30 0000096793 2013-09-30 0000096793 ssy:FultonRdaLoanMember 2012-03-16 0000096793 ssy:CarmichaelCashwayPharmacyNoteMember 2008-04-22 0000096793 2015-02-17 0000096793 us-gaap:SubsidiariesMemberssy:SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember 2012-10-31 iso4217:USD shares pure utr:acre iso4217:USD shares ssy:Segment ssy:Physician ssy:Hospital ssy:Beds ssy:State ssy:Areas ssy:Law_Firm ssy:Installment

EX-101.SCH 7 ssy-20141231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Business Operations link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Discontinued Operations link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Revenue Recognition and Accounts Receivables link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Goodwill and Intangible Assets link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Long-Term Debt link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Insurance settlement link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Financial Information by Segment link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Discontinued Operations (Tables) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Goodwill and Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Long-Term Debt (Tables) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Financial Information by Segment (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Business Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Discontinued Operations - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Revenue Recognition and Accounts Receivables - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Insurance settlement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Financial Information by Segment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Financial Information by Segment - Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) (Alternate 1) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 ssy-20141231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 ssy-20141231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 ssy-20141231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable, Current Accounts payable Accounts Payable, Related Parties Amount payable to law firms Accounts Receivable, Gross, Current Accounts receivable (net of contractual allowances) Accounts Receivable, Net, Current Due from third party payors Accrued Income Taxes, Current Income tax payable Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Allocated Share-based Compensation Expense Share-based compensation, amount recognized Allowance for Doubtful Accounts Receivable, Current Ending balance Beginning balance Less allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Additions recognized as a reduction to revenues Allowance for Doubtful Accounts Receivable, Write-offs Accounts written off, net of recoveries Allowance for doubtful accounts. Allowance For Doubtful Accounts Table [Text Block] Summary of Allowance for Doubtful Accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization expense Area of Real Estate Property Real property Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current Assets: Net Assets Assets Assets, Noncurrent [Abstract] Noncurrent Assets: Disposal Group, Including Discontinued Operation, Assets, Current Current assets held for sale Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Line Items] Business And Organization [Table] Business And Organization [Table] Business And Organization [Table] Carmichael. Carmichael's Cashway Pharmacy, Note [Member] Carmichael Notes [Member] Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents End of Period Cash and Cash Equivalents Beginning of Period Cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase in Cash and Cash Equivalents Castlemark Properties Llc [Member] Castlemark Properties Llc [Member] Castlemark Properties, LLC [Member] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitment And Contingencies [Table] Commitments and Contingencies Commitment and Contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, No Par Value Common shares, without par value Common Stock, Shares, Issued Common shares, issued Common Stock, Shares, Outstanding Common shares, outstanding Common Stock, Value, Issued Common Shares, without par value: Issued and outstanding, 9,444 shares at December 31, 2014 and at June 30, 2014 Compensation and Retirement Disclosure [Abstract] Compensation and Retirement Disclosure [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Earnings (Loss) Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Contractual Obligation Contractual obligations, commitments and contingencies Contractual Obligation, Due after Fifth Year Payments due in 5+ years Contractual Obligation, Due in Fourth Year Payments due in 4 years Contractual Obligation, Due in Second Year Payments due in 2 years Contractual Obligation, Due in Third Year Payments due in 3 years Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of Contractual Obligations, Commitments and Contingencies Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year Payments due in 1 year Corporate, Non-Segment [Member] Corporate, Non-Segment [Member] Cost of Goods Sold Cost of goods sold Cost of Services Purchased services Costs and Expenses [Abstract] Costs and Expenses Current Federal Tax Expense (Benefit) Federal tax expense (benefit) Current Fiscal Year End Date Current Fiscal Year End Date Current State and Local Tax Expense (Benefit) State tax expense (benefit) Customer Relationships [Member] Customer Relationships [Member] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Line Items] Debt Disclosure [Line Items] Debt Disclosure [Line Items] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Basis Spread on Variable Rate Floating rate of interest, spread Debt Instrument, Description of Variable Rate Basis Debt instrument description Debt Instrument, Face Amount Loan agreement amount Debt Instrument, Interest Rate, Effective Percentage Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated Debt Instrument, Interest Rate, Effective Percentage Rate Range, Minimum Floating rate of interest, lesser Debt Instrument, Interest Rate, Stated Percentage Interest rate percentage Debt Instrument, Issuance Date Date of loan agreement Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Maturity Date Note due date Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt instrument number of installment payment. Debt Instrument Number Of Installment Payment Number of semi-annual installment of interest payment Debt Instrument, Periodic Payment Principal and interest payment Debt Instrument, Periodic Payment, Interest Interest payment Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Term Debt instrument maturity period Deferred Tax Assets, Net of Valuation Allowance Net deferred tax asset Deferred Tax Assets, Net of Valuation Allowance, Current Deferred income tax asset Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred income tax asset Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Amortization of prior service cost Defined Benefit Plan, Expected Return on Plan Assets Expected return on assets Defined Benefit Plan, Interest Cost Interest Cost Depreciation, Depletion and Amortization Depreciation and amortization Dexter hospital. Dexter Hospital [Member] Dexter Hospital [Member] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Loss on Sale Loss on sale of assets Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax Earnings (loss) before income taxes Discontinued operation income loss from discontinued operation before income tax. Discontinued Operation Income Loss From Discontinued Operation Before Income Tax [Abstract] Earnings (loss) before income taxes: Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operation, Tax Effect of Discontinued Operation Income tax expense (benefit) Disposal Group, Including Discontinued Operation, Assets, Noncurrent Noncurrent assets held for sale Disposal group including discontinued operation revenue net of expenses. Disposal Group Including Discontinued Operation Revenue Net Of Expenses Net revenues Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Disposal Groups, Including Discontinued Operations, Name [Domain] Disposal Groups, Including Discontinued Operations, Name [Domain] Document and entity information Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Early repayment penalty on debt. Early Repayment Penalty On Debt Early repayment penalty Earnings (loss) per share continuing operations. Earnings Loss Per Share Continuing Operations [Abstract] Continuing Operations: Earnings (loss) per share discontinued operations. Earnings Loss Per Share Discontinued Operations [Abstract] Discontinued Operations: Earnings Per Share [Abstract] Net Earnings (Loss): Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Electronic health records incentive reimbursement receivable. Electronic Health Records Incentive Reimbursement Receivable [Text Block] Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives Employee-related Liabilities, Current Accrued payroll and related taxes Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Expenses on physician guarantees and recruitment. Expenses On Physician Guarantees And Recruitment Expenditure on physician guarantees and recruitment Extinguishment of Debt, Amount Loan proceeds applied as payment against the company's senior debt Extinguishment of Debt [Axis] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Extinguishment of Debt, Type [Domain] Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Fulton Hospital [Member] Fulton Hospital [Member] Fulton Hospital [Member] Fulton Rda Loan [Member] Fulton Rda Loan [Member] Fulton RDA Loan [Member] Gain (Loss) on Disposition of Oil and Gas and Timber Property [Abstract] Loss on Sale Gain (Loss) Related to Litigation Settlement Estimated fair value of the real property Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Goodwill [Line Items] Goodwill [Line Items] Healthcare facilities segment. Healthcare Facilities Segment [Member] Healthcare Facilities Segment [Member] Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. Health Care Organization, Medicare and Medicaid Electronic Health Records Incentives, Gain (Loss) Gain (loss) realized on incentive payments EHR incentive payments Health Care Organization, Patient Service Revenue Provision for Bad Debts Less provision for bad debts of Healthcare Facilities Segment Provision for doubtful accounts Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Receivable and Revenue Disclosures [Line Items] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Axis] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Revenue Sources [Domain] Health Care Organization, Significant Changes in Estimates Net revenues for settlements and filings of prior year Medicare and Medicaid cost reports Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings (Loss) from Continuing Operations before income taxes Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Earnings (Loss) from Continuing Operations Income (Loss) from Continuing Operations, Per Basic Share Basic Income (Loss) from Continuing Operations, Per Diluted Share Diluted Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Loss from Discontinued Operations, net of tax Loss from discontinued operations Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Basic Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Diluted Income Statement [Abstract] Income Statement [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid, Net Income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit) Increase (Decrease) in Restricted Cash Net change in cash in escrow Indefinite-Lived Intangible Assets (Excluding Goodwill) Indefinite-Lived Intangible Assets Insurance [Line Items] Insurance [Line Items] Insurance [Line Items] Insurance Receivable for Malpractice [Abstract] Insurance Receivable for Malpractice [Abstract] Insurance Recoveries Insurance settlement Insurance settlement Insurance settlements. Insurance Settlements [Text Block] Insurance settlement Insurance [Table] Insurance [Table] Insurance [Table] Intangible Assets, Gross (Excluding Goodwill) Finite and Indefinite-Lived Intangible Assets, Gross Intangible Assets, Net (Excluding Goodwill) Intangible assets-net Total Interest Expense Interest expense-net Interest on outstanding debt. Interest On Outstanding Debt [Member] Interest on Outstanding Debt [Member] Interest Paid Interest Inventory, Net Inventory Labor and Related Expense Salaries, wages and benefits Legal Entity [Axis] Legal Entity [Axis] Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities, Current Total current liabilities Liabilities, Current [Abstract] Current liabilities: Liabilities, Noncurrent Total long-term liabilities Liabilities, Noncurrent [Abstract] Long-Term Liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current Current liabilities held for sale Life sciences and engineering segment. Life Sciences And Engineering Segment [Member] Life Sciences and Engineering [Member] Long-term Line of Credit Line of credit, outstanding borrowings Line of credit facility borrowing base percentage of eligible billed accounts receivable. Line Of Credit Facility Borrowing Base Percentage Of Eligible Billed Accounts Receivable Line of credit, borrowing base Line of Credit Facility, Borrowing Capacity, Description Line of credit, loan description Line of Credit Facility, Expiration Date Working capital expiration date Line of Credit Facility, Initiation Date Date of loan agreement Line of Credit Facility, Maximum Borrowing Capacity Line of credit, ceiling amount Loan proceeds to be used to finance improvements. Loan Proceeds To Be Used To Finance Improvements Loan proceeds to be used to finance improvements Loan proceeds used for acquisition. Loan Proceeds Used For Acquisition Loan proceeds used for acquisition Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Revenue Recognition and Accounts Receivables Loans Payable RDA Loan Long-term Debt Total Total Long-term Debt, Current Maturities Current maturities of long-term debt Less current maturities Long-term Debt [Member] Long-Term Debt [Member] Long-term Debt, Excluding Current Maturities Long-term debt Total Long-term debt, excluding current maturities, total Long-term Debt [Text Block] Long-Term Debt Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Long term obligations. Long Term Obligations [Text Block] Summary of Long-Term Debt Malpractice Insurance, Description Insurance claim, malpractice description Managed care and other insurers. Managed Care And Other Insurers [Member] Managed Care & Other Insurance [Member] EX-101.PRE 11 ssy-20141231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R39.htm IDEA: XBRL DOCUMENT

Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) (Trace RDA Loan [Member], USD $)	6 Months Ended
	Dec. 31, 2014	Jun. 30, 2014	Jul. 11, 2012	Jul. 02, 2015	Jun. 30, 2015	Mar. 31, 2015
Debt Disclosure [Line Items]
Date of loan agreement	Jul. 05, 2012
Line of credit, ceiling amount	$ 875,000		$ 1,000,000
Debt instrument maturity period	15 years
Floating rate of interest, spread	1.50%
Floating rate of interest, lesser	6.00%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	600.00%
Loan proceeds applied as payment against the company's senior debt	8,500,000us-gaap_ExtinguishmentOfDebtAmount
Loan proceeds to be used to finance improvements	850,000
Debt instrument description	Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6%
Line of credit, borrowing base	80.00%
Line of credit, outstanding borrowings	0us-gaap_LineOfCredit	0us-gaap_LineOfCredit
Working capital expiration date	Jul. 02, 2015
Line of credit, loan description	The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ending December 31, 2014, $875; (b) for the quarter ended March 31, 2015, $750; (c) for the quarter ending June 30, 2015, $625; and (d) thereafter, $500.
Scenario, Forecast [Member]
Debt Disclosure [Line Items]
Line of credit, ceiling amount				500,000	625,000	750,000
Mortgages [Member]
Debt Disclosure [Line Items]
Date of loan agreement	Jul. 05, 2012
Loan agreement amount			$ 9,975,000

XML 13 R48.htm IDEA: XBRL DOCUMENT

Financial Information by Segment - Segment Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net revenues from external customers	$ 23,126us-gaap_SalesRevenueNet	$ 23,880us-gaap_SalesRevenueNet	$ 45,502us-gaap_SalesRevenueNet	$ 45,909us-gaap_SalesRevenueNet
Operating profit (loss)	2,022us-gaap_OperatingIncomeLoss	291us-gaap_OperatingIncomeLoss	2,327us-gaap_OperatingIncomeLoss	(45)us-gaap_OperatingIncomeLoss
Depreciation and amortization	580	763	1,215	1,537
Assets	59,838us-gaap_AssetsNet	68,524us-gaap_AssetsNet	59,838us-gaap_AssetsNet	68,524us-gaap_AssetsNet
Expenditures for property, plant and equipment	319	406	737	768
Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	14,539	14,463	29,319	29,554
Specialty Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	8,430	9,326	15,884	16,168
Operating Segments [Member] \| Healthcare Facilities Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	14,539	14,463	29,319	29,554
Operating profit (loss)	2,596	1,287	3,374	2,116
Depreciation and amortization	360	370	720	769
Assets	33,843	38,225	33,843	38,225
Expenditures for property, plant and equipment	48	161	132	294
Operating Segments [Member] \| Specialty Pharmacy Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	8,430	9,326	15,884	16,168
Operating profit (loss)	80	229	219	135
Depreciation and amortization	177	171	345	337
Assets	12,165	11,517	12,165	11,517
Expenditures for property, plant and equipment	271	104	574	283
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Net revenues from external customers	158	91	299	187
Operating profit (loss)	(654)	(1,225)	(1,266)	(2,296)
Depreciation and amortization	43	222	150	431
Assets	13,830	18,782	13,830	18,782
Expenditures for property, plant and equipment	$ 0	$ 141	$ 31	$ 191

EXCEL 14 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0#A_+]<%@(``"\>```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F4]OTS`8QN](?(?(5]2X M_L,8J.T.`XXPB?$!3/*VB9K8ENV-]MOCI%LU3:55126>2Z,F]OO\XL/OD&=V ML^F[XI%";)V=,U%.64&V/MF=K_U M%(N\V\8Y:U+RGSB/54.]B:7S9/.3I0N]2?EO6'%OJK59$9?3Z16OG$UDTR0- M,]AB]IF6YJ%+Q9=-OKTC"=1%5MSN%@Y9.: MV+0^OLL8C!],&)[\/>!IW_=\-*&MJ;@S(7TS?<;@FX[_=F']R[EU>7S(`4JW M7+85U:YZZ/,)E-$',G5LB%+?E>.U[$UKG[F/Y(^+(Q\OXL(@P_N-@\_DD"`< M"H1#@W"\!^&X`N'X`,)Q#<+Q$81#3%%`4(PJ4)0J4)PJ4*0J4*PJ4+0J4+PJ M4,0J4,PJ4P3')7I MJMLF-V@7/H3]W&/YN=:["\['7'`&.A_@N<$<=D]\'D0AM;3O,`]U@?O$7(Z> M'_BJC*2A?JVI/I#-Q[IW\0<``/__`P!02P,$%``&``@````A`+55,"/U```` M3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ? M>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSB MIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`S4_#WD4"``!T'0`` M&@`(`7AL+U]R96QS+W=O=^5WP/ M0]SV765D-C=%Z.J^V7:;RGQ]^71S9XJ8?-?X7=^%RAQ#-(^K]^\>/H>=3_E+ ML=T>8I%7Z6)EVI0.'\HRUFW8^SCK#Z'+3];]L/?#UJ]^$4N?S93E< MKF%6;]8LGIO*#,^-6%.\'`]YZ_\OWJ_7VSI\[.MO^]"EO^Q1_NB'U]B&D/*B M?MB$5)EQ*I:G)V)G6;,I_R$GGP=7SAV2HTNR'%TB.?:>+,?>(SDJ9#DJ2(YU M9#G6(3E.R7*<0CFW;#FW2,XBDW"Z0H_IN,OD'*'S>XSV9Y\&/`RV4Z!1A,T\ M@X5]M$(M(M.:I+FT;:!MA$U`@ M`85-0($$5#9R%"+'TJT#O6/916YAE3OV7`54P-; M#13#-L[HF_+-?Z6K7P```/__`P!02P,$%``&``@````A`&-BQNXZ!```"@\` M``\```!X;"]W;W)K8F]O:RYX;6R4EUMSVC@4Q]]W9K^#Q^\M^()),B$=3\/OR\X>K,#"6RH(*)=DDW#$3?KK[\X_;K=*_7I3Z%8"` M-).PM'9S,QB8O&05-1_5ADG862E=40M+O1Z8C6:T,"5CMA*#>#C,!A7E,MPK MW.BW:*C5BN?L4>5UQ:3=BV@FJ`7S3K"`-! MC7TJN&7%)!S!4FV9\T#7F_N:"]B]3H9).+CKG)SKH&`K6@N[!/<.ZA"O.(WC MK/EE$XH?G&W-\5"S#%Y_2?#=-[6/%9G)3QZ?6:_&=Q+GEFNUI(W5=82-LUS54/E=HD`YF MM(?W"PZ<"I9;K1P=G(3(`_0OI8HM%Z+5F4$6Y)J_"$:FQC!KL#T9ML/U:.$.8S]OATN#KC#Z8R]JCL337!><*8QAZF_7ERW,'$QAZQ M9]H6F18P0:$/4!BH7?EGF.'88_A2PA=YR8H:Z<`L/5;0?K#B-GI)9V\3TAGC M8H@]D"_I0`(V3CN*G?AX()]IK>?C$SOQ>2?(4$Q=H!/L&"Q.0.[OUU!-G=`8 MEWKB@=PO!-74"26XUF'Q+HN@FHY"N-@3#^K^$8*A'CL6>5#W%SL.]MBQR*.Z M7\@)-FX_B=>;^X6<8./"3SRNW?:SJ*N*ZEWSIZ7=0+$>XS:6>%R[.C`L8.(] M/TY!AL+\1SH)YAH6)\EW=19?YO.CS+1`.BG&&A:].@]45SPO*1/DF[+.P!CC M_I%Z5)^;W\>"Q?9@A%(/:CS)C^DSW"SE,XXZ6 M>DQ?_IO0^(D\&^/,IQ[2_2,(&W3EI-Y#NE\(%UGJ>-8R/6B;"[PJY53D\`[7 M?+0O0>DHVP_OP>$U]NX_````__\#`%!+`P04``8`"````"$`.J'I_9D'```( M(P``&````'AL+W=ONY/NI-/I?CS3A#1HDQ`!W>[^]V=EM_GZ?^9L8S M0\+CI^^'O?>M;-JJ/C[Y;![X7GEM_>O[YI\?WNOG:[LJR\Y2%8_OD[[KN]+!8M.M=>2C:>7TJCPK9ULVAZ-2O MS>NB/35EL>DW'?8+'@3+Q:&HCCY8>&BFV*BWVVI=BGK]=BB/'1AIRGW1J?.W MN^K4#M8.ZRGF#D7S]>TT6]>'DS+Q4NVK[D=OU/<.ZX??7H]U4[SLE>[O+"K6 M@^W^%\?\H5HW=5MON[DRMX"#NIK31;I0EIX?-Y52H-WN->7VR?_,'F28^HOG MQ]Y!_U;E>VO][+6[^OV7IMK\7AU+Y6T5)QV!E[K^JJF_;?22VKQP=G_I(_!G MXVW*;?&V[_ZJWW\MJ]==I\(=*T5:V,/FARC;M?*H,C/GL;:TKO?J`.I?[U#I MU%`>*;[W_[]7FV[WY(?+>9P$(5-T[Z5LNR^5-NE[Z[>VJP__`8D94V"$&R-J MAS'"^)RO8A8O;UM9P(EZ@:+HBN?'IG[W5-:HO]F>"IV#[$%9'I3!./BFW+IVE`RH"2^-U)B3,D'BG:@-BN&A7$/PUOD MP-#14XK.LI2SJ*Q0A?WC@`TJ]":B(L)_+W,I'#-REY$L,46X%&)$N@S+"!(: M8J'7!6JRRCT[!@D^6P:4J,\\'8.<+@BZ(*T%=+0('TVGUNT8Z$U/OM(_ILF* M'!$HJS[->,P"@N<(7S)&)0FC+A`VG@WDL79'4R&V8\Y"*L^&(,W+%)(97H^N0M"66=CVI-!E+6@5$$E!`DCHR)Q)QX)`,*>#R.8NIP&UY&*Y(EPH99$"3$NL1XLASCC42E]XC2 M9"**MA"@F)L1Q*LQS'V[R#&><')L8>.<10'QBL1XS,;BCV0QU4CL8$TK;/TN M(G#\`[V`S'`BN/N7XR8[K[3A4&O1L+&]F:2$#A&6+H<>X019N-A$#K";#P*W8C9 M>)Q:@R*.F&[#TX5!TT;"R,$S!ARX72&GU0/#,=DM$+Q,B-\L!N+TNUWNBAHUK:HE!PK M8\#Y\,RY`0?%SHPCKNV65W9C4;I33Q<%?1V)HM,"&WJ_?CR*Z8R3(SA9C@G4 MWSIA8',K'=$2XW$XYB>6I5OW=%G0Z)$LTG8R9@\#JHP1/#.Y>MT3;9]%89;$LW;JGRX)&K^K0^2$C)?[.&'"LX#T;SPHI:8R9X8!?9]QIK!2G]0SCT9+8EP2W\A4+(Q/#M&&(NY.#U>"@#QF. MR?C$>E:!/F1P<$!,XB?P[A6]3Q+MGL56^\;R5.Y/3RRNV21N=&XP'#AVDI)Z MGB-XQJV'3Z@#"$_IN"41/+-\BE7I%FQ=EXE!@\:-J@&YKAD'#JA+G0D=P>Y, MA.!50E)6(G@669,'5D+_Z MZ.$\ZV)]=PT1^K-!FI,DZ3+#,5&CLTV.8$Y+M$!P[!82.``8GZ76)Q98U5U3 M!'>G"#7[G/UE*LBU,<)8@&.1G>(:*"^`6,U=XP-WQP=F1=^H`1)\[I6Z0;+A M#X)DPQ\$R8:O!.FN\8'#:&#W64:?7!AQM&?G=I%^_H(T;-Q*V+T M:)DA75)&8+I=4)PJ0_@U962&N*$,9@><5://X+*$0+*RRED1SHJT5U!6A7>- M`3V;^IYFE2'!=2;U)S<@!$9[CB2=<`C$O'0(HX>P,MVPK5'@AN^AO>/[0A(^ M"X%T01F`5Y11@J.,$BXI(V/`#670FY7M\S,!HQ\09N'0P(=OJ')G13@KTE[! MOK^KD8=N(W=KE2%=O-%@8X!I,19D.W6`1+C*RS$ML;"[>GGX42]WD@I(P\G' M/PQ%V-@88%<8WNX*L_$KPG2;M&[+M-$RA.:*R-(H(GM_`Q0U<7L:QLKLZO'HM@(Z_'_1!(`W*Z$-7 M;HP,>$2>Z03!G0<7@EN>`V7PX@%\+W\HF]\?SN`K`OU(D2_OC@#ZCV$4_%:_E$TK]6Q]?;E5ID,YHFJ!`V\R0"_=/6I M_^[[I>[4&PC]CSOUQDFIO@,.YHJ\K>MN^$5_VWY^A^7Y?P```/__`P!02P,$ M%``&``@````A`%UGN%NG`@``K`8``!D```!X;"]W;W)K&ULG%7;CILP$'VOU'^P_+[<-=B22UD1#_*IBK>K8 M>/86.D[DX[&]R01O@>+`:J9?+"E&/(L?RD9(:5O_*!:;/.&2@P:4>2%@F^"^/]%/N;M6Z2O!D[LT6P20$.#I0I>^9 MH<0H.RHM^$\'"L]4CB0ZDX#'F22,O&@Y"V?S?[/X+B(K,"6:;-92G!`T#9RI M6F):,(R!N5/FXNBU_DDJ:#0D=X;%5YVDRGR[7_!#G-SIBMPRPPZC&+ MV1"RZR`F@X8W[0R_?<*AR[Y#F/*!I%X79&NL:P)U?[UBG0SC-)0119BW$R#S:`_ MTVEQT\%='DYE27>TKA7*Q-'<_`ABZ:UN*&W#&#H:&G-D3V%86;O?;\"P:$E) M/Q-9LD:AFA9`&7@+N)'2C1NWT**U_7D0&L:$_:S@KT#AK@0>@`LA=+U_]^_3P]SWQ.2-@6M>,/6_AL3_I?-[[^MSKQ[%D?&I`<, MC5C[1RG;91"(_,AJ*B:\90U8]KRKJ837[A"(MF.TT)OJ*HC",`UJ6C8^,BR[ M>SCX?E_F[)'GIYHU$DDZ5E$)^L6Q;,4[6YW?0U?3[OG4/N2\;H%B5U:E?-.D MOE?GRV^'AG=T5\&Y7TE,\W=N_7)%7Y=YQP7?RPG0!2CT^LR+8!$`TV95E'`" M%7:O8_NU_Y4L,S+S@\U*!^A'R<["^.Z)(S__T97%7V7#(-J0)Y6!'>?/"OJM M4$NP.;C:_:0S\'?G%6Q/3Y7\AY__9.7A*"'="9Q('6Q9O#TRD4-$@682)8HI MYQ4(@$^O+E5I0$3HJWZ>RT(>U_XTG22S<$H`[NV8D$^EHO2]_"0DKW\BB/14 M2!+U)/#L24@TB>8)2=(1+-.>!9X#RRT)`1Y'1^>12KI9=?SL0_S:Z;`KBZWRA!C7#-CP?),H.>9H?G MG2Y\PSLV3O.:QTGLU`M!$*9D'H?N_;+M:739;RM3'=$HF1O*L'_:RAS/6X(@ M,R[&BNU==<7[O6,/A<^A_5TW7F(T6JQ-<\7V/JKWDNOF^T%6$(19B4+BU&O6 MD[S;IQ>[K6Q4.U9CSM5-<1K(M@>96<%M>L7V/JKI$NR8-[*"(-.[L6)[']5: M8:1TSQXMKBH20?UOXMSM;FHN520?V%$9#ITX5M6L.[",597P\"0Z:QG,`3K]6`PP`S:T@/[3KM#V0BO8GN@#"&PO=V]R:W-H965T12(("`H^;B[)%VI=5J+\]I,!"5$)2DMV^_X]@) M]@R'YO2A+;_\/?COL3V.U]\^RI/UQNNFJ,X;VYNXML7/>;4KSH>-_<_?[&%A M6TV;G7?9J3KSC?W)&_O;]M=?UN]5_=(<.6\MB'!N-O:Q;2\KQVGR(R^S9E)= M^!F>[*NZS%KX6!^>ELW0@TG:]*\"!&':KYON-_>2M M4O_1=K;K;H#^+?A[H_UO-_%F<-H0YY$!IZKZD5(O^\$@L8.:M*P0(6TK?VW:JOQ/BCP52@9Y M5$'@KPKB0;R1C:>J,7Q=W]B;3/U9L/B9+LQ5%/C;1QG?A4`UAK]#X[&#X,@! M[?(39VVV7=?5NP63'H:LN61B"7DK""P2,P6/1)1-G8T!Z: M-S"]WK;36;!VWF!*Y$H32@W\'C2>J8AZA34E,)=/9PM0DMS1+4\-N:.:NJ4EO::[# M;8P,+(?Q(R/$L/BT@9C.KG&[K(52,QU&+\(@QB#!@&&0:L#H/:S+\;T7XFX3 M&=(X=>?FR(52,Y.3V'.7,_-Y))]?W<48)!@P#%(-&&9@X8TW(\3(S!S-RE!J M%IV913!S731/(BG0W.@M/-"3)@ENPC!(-6#8@UUOO#TAQO;0B@JE!D;SFL_Y M%.6KU_1K.<8@P8!AD&K`,`0;WGA#0HP-H[<"5YZD7RNF<$@P8!AD&K`,+,T MS8@Z-X=CS'U3HA$VA=!]/3_"TN.7EKI6 MV!.J0J$2S>6^(;8-LG$HB6:-D(001DBJ$].>J.3:]!MI3]9_*'_:EH`*:.A) MD6X/;1I*H;N3;:XD(1I&2*H3TYTHT,C=U_-1G%?QA`S0EAXJD;$K!JA&1X-H MV!8)20AAA*0Z,0V*@JT9O+_0/%G>C;0%:*\+E6C8/]"LC=3S:XIB0A)"&"&I M3DQ/HFZ/]R2KO.D)5S!/BJ;=2D.9C.X]C(>'?0830A@AJ4Y,;Z)HC_4+S@P6Q51RG?6Z"M,U("/6':T:$[3"9$PPA)=6*:$H5;,R7V$&_Q]1XI MZ[WI#I=JKS\4:#M-@/?_0=0G*28D(801DNK$="B*M^;PBV4F2[UI#&4E]+3S M0)>#B)"8D(001DBJ$].%J-KC7<@:#UO&=8\G+R&>=A!0+C")B28AA!&2ZL1T M(2KU>!>RKANY(.=W3RO^R@4F,=$DBLCZ=JMZ,T,Q]^F+06HHNC>'Z^YDN/;1 M,>3^#.S4Z/@1H(T\5*+KOA`1$A.2$,((275BND"GC2]D"9M/X&>@+-`D,-#A&PO=V]R:W-H965TOD("B9)4#5VW29LT3?MX=L`$JX"1[33M MO]^U31(P79KV@08X]_C<!- MP7B-)=SRG2=:3G"N@^K*"WU_YM68-L@P+/@U'*PH:$;N6;:O22,-"2<5EJ!? ME+051[8ZNX:NQOQQW]YDK&Z!8DLK*E\T*7+J;/%UUS".MQ7D_1Q$.#MRZYL1 M?4TSS@0KI`MTGA$ZSGGNS3U@6B]S"ADHVQU.BA6Z"Q9I,$'>>JD-^D/)0?1^ M.Z)DA\^L%"R!4"47_30@R43%W*DB'`EI`%9[643Q?>D_@7-9A-F-,,$2D M1X0R'-2<)$$RMJ0)5.IUCX^25-!04A@.U]N\`ADBTC$B2OP39B`2O.J+O"Q. M@:'4R#G[-;7EJ;@P&KF=,8JE+ MCQB[5M`JU]N@P+:8J27&8.)8=Y7O^E814_->VS1P9?8>(0IL"YE90@SF+,02 MFIKW8R'Q4(C:4+,WNU<%V8)B2Y#!=(*F;AC-^W_)IQO;*A,P5J@.H]Z6O]RZ M"FPI2ZR%-@8STR4+$O^\8W1_I>;U6,=\J..ZT:."+#VQM>#&8(8-;35]>L38 M#1U`K:YW1Z,M.4ED%:X#:0.,(_TG@RX.K'%\N38:_=9YX9O[9*-IH0CY3S6NB>)[I8PZ'7+T`DU_J[N4CCS1VWAVSNZ`TW- M@16$@=T3':!GC/D0,`=FBW?D.^8[V@BG(@4D[;LQC"-N/@/,C62M/H6V3,+Q MK7^6\+E&8*#[+H`+QN3Q1K7>Z0-P_0\``/__`P!02P,$%``&``@````A`$W6 M1J[,`P``A0T``!D```!X;"]W;W)K&ULE%==;^HX M$'U?:?]#E/>2#PP$!%0M57>OM%=:K>['LTD,6$WB*#:E_?<[]J2I;:#`2VG& MQ\?'Y8TP%P%#+1;A3JIE%D,Z>1+ZO6*V0I&4E5:!?[G@C/]BJ_!JZ MBK8O^^8N%U4#%&M>[\EA.8?W.;AB+[B>2NDV*@! MT$4H]/C.TV@:`=-R7G"X@4Y[T++-(GQ(9JLD"Z/EW"3H%V<':?T?R)TX_-7R MXA]>,\@V^*0=6`OQHJ'?"AV"S='1[F?CP+]M4+`-W9?J/W'XF_'M3H'=([B1 MOMBL>']B,H>,`LT@'6FF7)0@`/X&%=>E`1FA;^;SP`NU6X3#\6`TB8<)P(,U MD^J9:\HPR/=2B>HW@I*."DG2C@0^.Y(D':39*!F-;V`9=BSPV;-%G$T+Y$/O>=";S%9`2_#R=4E(/(]>(?]Y MAWE$S"0,>DSJ(E8G$,,>$H&^7B3DRQZ8NM MK(`C`#)C"_CZ8`V&\K!N3DC27\QD\!$QY/-D*^"<3&XY68,7(5SB,^?D,Z5X M,F(RXUHZC3-7V,I=GDS[94<55,CU^=!@5]4P&_6\J`HQ5CZL@'/R^):3-?B2 M$XBQ3K8"SLE0RO:=]9MRN0CU)O?NA/A5B)BQ<00RXSMR=ME1I[^GK/?XZPK5 M8%=5FA'/$<00H^IN.O)>[Y6SG)VKD^DMJC384W54O8C!7)VH7G?YG*H$>H>= MK.NL-+M1(7P>RRLF..(XE7NO]VC*#OE3+'<@^'9NLB;BGZU9W=<$DV!CM MSD*(7S$=J#,GCOV2.;_N*M.MT%)VI3O80%V%?I=)K"YK^L[*CK@J;FJ\";9- MH.\[[W'/[T"V.[CMA#LW-5@]QWAO#B%C[WWN0.A.$F>?G;W+!)*<6'?SXC7@ M*]W!INJZ,_$56IVWTV1%7!5>,[[P[F`+O>`.@FQWK(A[^DW-%J;:*]Q!$'XM M3\9'YIQ;1ETX]>)<5[%VRU:L+&60B[V>:%/HX7T4I^W'9`;##TRY7GP%4[B) M1_T"#,$-W;+OM-WR6@8EVP!E/)A`N;0X1N.#$HV9MM9"P?AK_MW!SQT&8U4\ M`/!&"/7QH`?U_@?4\G\```#__P,`4$L#!!0`!@`(````(0#_!G4!LP(``'(' M```9````>&PO=V]R:W-H965T%NE^/>O^ZLE1MK0MJ"-;%F*7YC&-^O/GU9[J1YU MS9A!P-#J%-?&=`DA.J^9H#J0'6OAI)1*4`-+51'=*48+=TDT))I,YD10WF+/ MD*AS.&19\IS=R7PG6&L\B6(--:!?U[S3KVPB/X=.4/6XZZYR*3J@V/*&FQ=' MBI'(DX>JE8IN&\C[.9S2_)7;+4[H!<^5U+(T`=`1+_0TYVMR38!IO2HX9&!M M1XJ5*;X-DVR!R7KE_/G#V5X/_B-=R_T7Q8MOO&5@-I3)%F`KY:.%/A1V"RZ3 MD]OWK@`_%"I827>-^2GW7QFO:@/5GD%"-J^D>+EC.@=#@2:(9I8IEPT(@%\D MN.T,,(0^N^>>%Z9.<3P/9HM)'`(<;9DV]]Q28I3OM)'BKP>%!RI/$AU(X'D@ M":,@6L["V?P"EOC``L^>Y2,)Q*?CW+FCAJY72NX1=!P(UAVU_1LF0&AMB<'< MMVT!/^R=6WO)706TAE(^K:?QP/_\@-EXS`*C'A.-$=D;B+B'$-#7BP2_ M+A=I+XU%1D<*-A[BNLXEE@TV1@+`F:&`_[MCP>#B(/-I?-TGY@)M/&;JNL-: MF@TV1I&GET2VX!1#$KWG)V7QD*4OVCP.QU)@GX_WPP+/I8T&T?=>,S` MC,'&*/+\DL@6_%$9/&80>;`QB@Q]?'[.%GR<\U'*'O)>&=X[]9+\C/-OL6"J M8AEK&HURN;/S*X+2]KM^M&["!%H=9MK1?@8CU^V3_@!&7D&ULE%7;;MLP#'T?L'\0]%Y?DS@UDA2-G6X#-F`8=GE6;#D6 M:EN&I#3MWX^R8B=RLK9[22SJ\)"'I.G%W7-=H2-W-KPAIL&&+Q'@Y>%"RC*<_V-6V4(1&T M(@KRER5K9<]69^^AJXEXW+XH*]9)KCDA7*`SC6)7FJ^=6]=8%HM<@8*=-F1H,42W_OQ9H;=U:*KSV]& M#_+L&8:J:,5Y``_**:ZQM%M=DU`E, MB2*KA>`'!$,#,65+]`CZ,3#WRDP>@]9_206-FN1>LW1YY6DW"Z<)^@ MIMD1LS:8"*,!$XT@20_1%=2\:6\X^?@VZZ9'Z/:!I$$75&NL*X2^7^]8+T,[ MV3*"P(ZWO@*Q$8E!6#IG-B2]A(S";"X1T8G$$AK:0E\7J,%:8%_@=6\X%3B\ MZ(K!1(-3.C9LS@Q6;A,[-SU<;S=!.P'N;$XFX4E[-Q=K@YD,*25C0SHV;,X, M5HXP]/\_*-IIB:%)PRQ/PLAN\MI@YMW;X-EWR?F='_BC]R`]OQZY;L[O+%=+ MU/)7RJ*2PPSP%P MP;GJ#SK`\/%?_04``/__`P!02P,$%``&``@````A`&;<-1:U`@``L@8``!D` M``!X;"]W;W)K&ULC%7;;J,P$'U?:?_!\GNYDZ0H MI&I"NENI*ZU6>WEVP(!5P,AVFO;O=XP##=#N]@7P^,SQG)GQL+YYKBOT1(5D MO(FQ:SD8T2;E&6N*&/_Z>7>UPD@JTF2DX@V-\0N5^&;S^=/ZQ,6C+"E5"!@: M&>-2J3:R;9F6M";2XBUM8"?GHB8*EJ*P92LHR3JGNK(]QUG8-6$--@R1^`@' MSW.6TH2GQYHVRI`(6A$%\*49U& M]T7#!3E4H/O9#4C:+&7W-4L$ESY4%=+8)=*[YVKZV@6FSSA@HT&E'@N8Q MOG6C?8#MS;K+SV]&3_+B&\F2G[X(ECVPAD*RH4RZ``?.'S7T/M,F<+9GWG== M`;X+E-&<'"OU@Y^^4E:4"JH=@B"M*\I>$BI32"C06%ZHF5)>00#P1#73G0$) M(<_=^\0R5<;87UCATO%=@*,#E>J.:4J,TJ-4O/YC0.Z9RI!X9Q+P.).XGN6M M0C=<_)_%-A%U`A.BR&8M^`E!T\"9LB6Z!=T(F'ME)HY!ZWM20:,FN=4L'1>H MD%">ITW@^VO["7*:GC%;@UEB-&"6X1BRZR$Z@YHWZ0VO/N[89=\C=/E`TJ`+ MLC75Y4/=WZY8+T,[C65XWOB\[1N0,6(W1RP78T@RATR.V<\1%R0CH?Y8Z+\% M:C`TWT4-/&6V[TQRFUSNSIUACNCS#7?HO);.*#,SPERAFHJ" M[FA5293RH[[_'D0T6,UHVKH1]#6TY\2>P,CJ[/:P`2.C)07]1D3!&HDJF@.E M8RTA9<(,';-0O.VZ],`5#(ONLX1_`X4;XU@`SCE7_4+?B^%OL_D+``#__P,` M4$L#!!0`!@`(````(0`),?=%\P0``*(2```9````>&PO=V]R:W-H965T-MLOK;7X4-5^9'[PUOZQ__FEY%LU+>^"\,\!#W:[,0]>=%I;5 M%@=>Y>U,G'@-FIUHJKR#QV9OM:>&Y]O>J#I:CFT'5I67M:D\+)I'?(C=KBQX M*HK7BM>=BR3='X/W.O+P8?/B4M%(&Q M-;%^[E?@C\;8\EW^>NS^%.=?>;D_=+#9>OEXTX&U`U\,[VE,L:9`OP/#!3<5RY M_A]5X"B=?)5>>E_`HH7U>5M[KKVTWB"GQ043*TQH&E=,Z&-(,D!D!J7?=!", M-@R;9`-"+A]0NO*";%%>+JS[[14;:$@C3,-Q\/OB&Q",2*:(,,"0=`HAK\FF M",T)(NK^"%%I!$6HK87'(AQDK#!>7X-R,1(J2*D@TP0H1@_'^/DB2/#*A`1< MZ\1SR:K'"C/O*RUT::DE2!U&A%FJJX/(=C'Q3%>'83"^&W&"S?+]!2:-,#?' M(YL@5IB@Y^;:$:F=1%<[D3=&IW:,K@YH"NI0'8[3J ML=ZE^A3I@\`C]9,A?>C,QUV'F,Y.C]G%F:C#KS-PYF00Q4R"M)4PDZ422Z1(Y5G M@[N]ZP+2(U5FHR2=8#)=@B.5,U"+],X>4!-3S^6-_J5`7O\IXK"Q/"\[0%=[ M=A3`K.00U%@]F'\U.G5V-WJ7`BEV0!["LBX2+":MJ,4JQDC&)7'?0=VQE6JKB)BMH!C+)Q&B3R55Q12;ET5<$-P MRO?\][S9EW5K'/D.7-JS$+I`H^X8U$,G3OVA=",ZN!OH?Q[@+HC#F`7@G M1#<\R!=<;Y?6_P$``/__`P!02P,$%``&``@````A``O@&HM@`P``*0H``!D` M``!X;"]W;W)K&ULE%;+CILP%-U7ZC\@]A,P$$A0 MDE$30EJIE:JJC[4#3F(-8&0[DYF_[[6=8<#TD=F$^-QS#_=EF\7]4UTYCX0+ MRIJEBR:^ZY"F8"5MCDOWQ_?\;N8Z0N*FQ!5KR-)])L*]7[U_M[@P_B!.A$@' M%!JQ=$]2MJGGB>)$:BPFK"4-6`Z,UUC"DA\]T7*"2^U45U[@^[%78]JX1B'E MMVBPPX$6)&/%N2:--"*<5%A"_.)$6_&B5A>WR-68/YS;NX+5+4CL:47ELQ9U MG;I(/QT;QO&^@KR?4(2+%VV]&,G7M.!,L(.<@)QG`AWG//?F'BBM%B6%#%39 M'4X.2_<#2G>QZZT6NCX_*;F(WG]'G-AEQVGYF38$B@UM4@W8,_:@J)]*!8&S M-_+.=0.^F&\62:^"$"NK,G0N942;I.<1:2U;\,"5VEC$AP%0DA M^JL]F`2S*9K&;U")KBKP[%1N#@&"U7G$/>>WAY!<5>!YJ:AN4(8E7BTX MNS@P]%`ST6*UA5`*@JHST5\[`RU1/A^4DW8%MH!I>EQ%P73A/<((%%?.VG!` MLN,$0\9FS(B">,C)QIP@'%*V8TIBJ>1C2A0D0YG=GSBSCN-!N;J:P239-0MA M3_QYFE]JIIR&-0NL@JP-)=%3J^J\L8',!K8VD-O`K@<,DH!MT$_BW\$K,FRZ M?C/]U^+HH5@;3O0:O0UD-K"U@=P&=CU@$#ULOW[T:FS_WP+EM'2A(*\C&=H] M,)R9'FHT"^=1-P(ZRXVQOV:9#1SB9&J/I^V0V\"N!PQRA&W8S_'?'5)D.S7A=%'M8E"JSWK@WGVG.$D'64;8R]U_.^PWPVM>JTM?FY#EA6]0"L?&&,]0"J?'&-^B M%`Z1,9ZC%,Z2,;Z#+P6->]V+X:9N\9%\P?Q(&^%4Y``A^Y,$VLG-76\6DK7Z M`-PS"7>T_GN"3S(")YT_`?*!,?FR@!=[W4?>ZC<```#__P,`4$L#!!0`!@`( M````(0`&]_$D"`4```(4```9````>&PO=V]R:W-H965T]A:N;;$ZYZ>BONSM?_ZF7[:V MU799?VZ6^0X;7YE5=8N^(W5 M<.7,FRKKX&MS<=I;P[)3/Z@J'=]UUTZ5%;4M(T3-G!C\?"YR1GC^5+&ZDT$: M5F8=Y-]>BUL[1JOR.>&JK'E\NGW)>76#$`]%670_^J"V5>71]TO-F^RA!-\O M7I#E8^S^BQ&^*O*&M_S<+2"<(Q,U/8=.Z$"DP^Y4@`,Q[5;#SGO[FQ>EWM9V M#KM^@OXMV+U5_K?:*[^G37'ZO:@9S#;4253@@?-'(?U^$@@&.\9HVE?@S\8Z ML7/V5'9_\?MOK+A<.RCW"AP)8]'I!V%M#C,*81;^2D3*>0D)P%^K*L32@!G) M7OK/>W'JKGM[N5ZL-N[2`[GUP-J.%B*D;>5/;<>K_Z3(&T+)(/X09`G9#]=7 MB\!?;;:?B1(,4>!SC`*!9Z8`R?8^X',:O/`"=_T)&^LA!GQ.,68GL!D&P^&8"CJQ)7V*2==EAU_"[!?L&9KV]96(7>A'$'6LK*S%5^[UB0Y5%D&\B2A\+ MZMC""GT^!-O5SGF&594/FMC4+,-`UQQ-C:9]7\\ZEA(UZV"[UC7'-\+H"O)6E*VN M2=[2A+J&FAI_J4M24Q*$[J31Y@QVI#IG'\^5$(NY&BL12["9P'%4O!8XV&ZF M._?U)'A0@@'%(%6`ECV MCJ+YV0OQWH;*3ELGPP(!@D&%(-4@FU_+BQ=]YUU!$?B?"]"C+R$ MN!)2HWB18+/I$W$7+MH[!`](,*`8I.^'U.H$.W^^-R%&WEQT6,12HWB38"7G M.%RM7R=9;AD$,&`8I`J0#,C?M/C#2_$R$R(3T>I4^)]FG54]!B'NJA[O[T2#$ M((E!J$%2E>@N1(^=[T)VY)^L+Z5M#^L+$^)ADAB$&B15B>Y"M-?Y+F0SUFN! M^F(,[S/P^L*$#!KYN]+'K371+P?H-*'&'<0[E.F>TI]$2*?ERO67-B1E65K MY?Q)O.X02WVB\E4,\2)X^H0S%?'8C^!)Q^3$C^!AQN2)'\$SC'W@'[U[Z M?Z_PKHW!<[.[`/&9\V[\(FXPO;T[_`\``/__`P!02P,$%``&``@````A`'U` M!\1)`P``,`H``!D```!X;"]W;W)K&ULE%9;;YLP M%'Z?M/^`>"^WA"2@)%438*NT2=.TR[,#)E@%C&RG:?_]CG&@8+HV?>'R^3N? MSXUCUK=/56D\8L8)K3>F:SFF@>N49J0^;LS?OY*;E6EP@>H,E;3&&_,9<_-V M^_G3^DS9`R\P%@8HU'QC%D(TH6WSM,`5XA9M<`TK.645$O#*CC9O&$99:U25 MMNHU']L:8,'4J(^\F=H[33;E\F\A5)&>4T%Q;(VKMO\_"'XS`?/!B_H^0LCV3=28T@VE$D6 MX$#I@Z3>9Q("8WMBG;0%^,&,#.?H5(J?]/P5DV,AH-H^!"3C"K/G"/,4$@HR MEN=+I926X`!I)2(=Q$!BXN(ZUG>RG?]Q0=4%A<5N'_8%5N%U68I0@)MUXR>#>@\<)PW M2/:Q&X)PEQX53)^P_^4+$B5%[J1*JP6IX%#CQ^T\6*[M1RA,>N'L%&=I&CUG MZ8\I^XXBRR!UHPYXL7'')G''Z$P2!<"UWV86S'LC&\+N8X>RZ+'/H,%>;XTN M5&DT#M7S>OG6Z]TKE#%C/V4L%V-*-*5HV\13ABZ23"GS8-5O-$K&;)R,MY,@ MR?`E#)(\#X)>5V5!<>;MAR"+N=>!2`=B'4@&P,C9^4>2-":GH.V*E^ZHH MJ[9S7<=QQJ'LA\O:6C1:Z MAD=N"%,?<+M?@`.[04?\';$CJ;E1XAPD'6L)/!&W:T7V@`H[J]K&` M/S,,T\FQ@)Q3*KH7N4'_K[?]!P``__\#`%!+`P04``8`"````"$`PQ,PDTP# M``"W"0``&0```'AL+W=O^QU@XP-#RA;L7HIMY'B_VN$%\3#O<@J6BK$$"EFSG\8YA5/9.3>V% MOI]X#2*MJQAF["T<"TG)<$%,BT.PQ7"_<^F&VFKK><]_GY3?"1:\\.W]/C)T;*KZ3%D&PHDRS` MEM)'"?U2RBUP]JZ\'_H"?&=.B2MTJ,4/>OR,R6XOH-HQ")*Z9N5+CGD!"06: M<1A+IH+6$`#\.@V1G0$)0<_]_Y&48K]PHV0B*1TG>+`!6W^ M*%!PHE(DX8D$/$XD03@.IW$0)_]G\51$O<`<";2<,WITH&G@G;Q#L@6#&3`/ MRE0<9ZW_D@H:)T^0T^*$62E,ZCIG3!J;D/4`D1F4 MO/FP MV"1XX8+P M5+=S+<&FGMB?F#&M%&;2"THFUHE9Z]8HG)J^N6Z=)I;O1K>.THNOH2=YCQX) MMO5<\M2?UY7"*#UP+YD1KW5K9!WD7#<&]K';Z-91<"FM(0?NEK>71X)M.5;` M*X5)U(469+ZE1YDO)R6_C=]H>"-N^96@W<&WVTJ"[;@O^5!E4!AU3I(TMJJT M5F8M[MMXF*SRE3U>Q:T&I9HC#68[O,9US9V"'N00#"%?YUTUGU?!#"YWN*.M M_1SF=K_OG0TP-SNTP]\0VY&6.S6N@-(?I]#03$U>M1"TZZ_J+14P,?O'/7P@ M8;BQ_#&`*TK%L)##X?S)M?P+``#__P,`4$L#!!0`!@`(````(0`7QNJI2@P` M``9T```-````>&POV_;R!'_OT"_`\&TQ1U01R_*DGR6 M#Y%LM@'2]'!QT0*]HJ`ERN:9#Y6B$OL._>Z=6;YFQ==26FK3&KU(E';F-\^= MG5U2U]^_>*[VV0YW3N#/]<';OJ[9_BI8._[C7/_;O7DQU;5=9/EKRPU\>ZZ_ MVCO]^YO?_N9Z%[VZ]JKW=ZLGVK-W;8&O[\,DF"#TK M@K?A8V^W#6UKO<-!GML;]ON7/<]R?#VF<.6M1(AX5OB\WUZL`F]K1`KE>L-DX*[N( M_/'-F_Z_O_WNGS_:ZW_]]$WQLY^^U7LI&T(3;%!/\VV_EBQ\'%/N)1+<7&\" M/Q=D-`,UH;:NGOW@BV_B9^`,(!Y^[>9Z]XOVV7+AR@#AK0(W"+4(K`SRL2N^ MY=GQ-Y:6ZSR$#GYM8WF.^QI?'N(%YAC)]SP'S(07>S&'\_)Y0#2I3%.$P
3V;.J4SZQ*NB0-GRL",.#D:M&!T*V)[XF)?^?PDS-/:-U8C%'EDCX+O3PW MWCN>O=,^VE^T'P//\E&Q=%)CW^;F9,[QY)/?4_/+)Y]Z%DMM=7J15+B@/L_` MAM53W?%!FU?%91=A4N!'Y,OF>=F))W6-8OUW$#*GN49!-N+DGEZPUD:AZ>7EG+N\8 M7X),%$4%4=-<3CH@>K>8+>4C71`HU]Q;%*$"BR*D&@R*H3R1EXHMRJ!($BJQ($BJS*UD,28Q4VS!3' M*D&@R*H$@2*K2BL^DPP,NY2*K4H0*+(J07!NJZ;+JN7=GG)6S\",ZYK&>&,677'(?-;`"M^8&/V),1Y> MQHLH2:P]>^WLO:)T&>]27P$UHFZ;!21>SD)-M6J,(SJL`S2`B) MX#F%OU'!'_0DK(]3^$,SJ-2(H!>E_,&YA/G+]`<\(YHX-9B`.G4='ID(8,F? M(@`CJ$"`9UH3'8![JD``2ZD4`3AHC@#@U'C%*7$P(-D,?"!G"?R[8@DY)I62 M8]FAE%7I%_C72&ERZ?JQG>U``XB655BE658HC9(=)R%<";&A68 M,.O*F?(&53E?F4)(T@4,N48@#=1I1)Y7DIP+/',`]1I92*Q#B%-@*E(-`>`H M@4`,`<>)U&-0-`-3;U`T!5,(W!Q\QIB@WL#-D(HP`!XE49'7"0-NQCBC&@@$ M51F2>,-058JD&%3ER-P40U4IDD!0E2&I)52E2(I!58XDIE"5(@D$T(B2#$DM MH2I%4@RJ?H&E:+SO]+*I[O4"DK2_<>B,/,)*3#E_:*[K6AOFTO5S`I;3%=$H M.5O4-S;F#SR#;VXW>D@C"&SNJ,:`NDXP2' MH+.CM0,.W.MVZ5RT2!//LRR7&GV7V*$2$.Z02O$*JJ2TYR$'(PV M41OUH"W+UC;%3-A)'%?Z3X/[5,X,;62OG`;.PAR+D#+-GX5YS8&;NIB0H_:: MPRW=,R>-9]!T3?'!S_R5DI^:GX:R%[UM(F"D<@%$FQ%-DSA741PQI3?V)C1\ M2$#(`%.A[)HE)C6D]+@X0E8TBK+9OI)YLS,JU&^+6L3"L1 M0MR65^HU*5EIK5D9+)622-R\5%KB#U5N+>$))ZE9X=C:N(O\?<*6!YU:I,^! M<7G2M(J1&]LJ^PDCTD_HPLYT)I)97U0F1"5EV4AE%W(DNRO3)D^,9!>DC!8"PCN9.?.P M`J4%[M:65F9'`V,]U_U84/>7I7;D?14G=A%%#X:N_"KZP%^!MM['8!K.P(%-R`%*+T9*^>M24\_24CQ,<# M3J,BA.Y>MJ[E6U$0OFIXBT!&CC?Z6)#T10#]&7[1#GXL3P.] MQ!KB?1BWA]N0R6*!5\]`T&(I&A@=H^']#U=M;=#`Z)@,GU2Q?A(A\][?[C,+ M\;D4IVX1$A\<_]E>\Y[#:W@(($4H?;3W46AE_L>'%#8XA(C@,X,R&GR*B']9 M('W`45)_?H1'!*5*Q-LG2.Q@#2W"\Z_[B*@11Q$B>`!4A,B]$\&CW=(@YD@@ M+"$2`=RVDY$XR"B"-/YNA3Y&"Q>Z!SY:(5%^$Q14_^N7_/E13.\1_N8C>[)4 MMAX`1:WMC;5WH_OLP[F>O_X+>V@B.%/RK1^.+V7AQ>S$VEHO;6W/6'_:7 M_P65X0]D7L$O+)[P`Y3LAS+A-JB!<;5SX6&POG!'B`'F56U#M_ZSJ?U[3]]N!UE[_)9,9R,?_=H:V/S49:/^Y/! M<'S]NT<_7+Q\>;3]YNO[O[CYY_6PR??SM_?C3I+V[S M\3QC'=GQ>#ZS[R7A^4_#J(!^D3X_R_D:V ML]7-MC>W=M.'+_/+C6SKB3W<2Q_&91PT+B/[\\%E,9_U^O-_:?WRXFZ:IP^W M-M?_D/YVP'8'MN67H]YU^C0NY#2?#2<"R2`[ZLUK(\?W7@Z+?F^4_2GOS;*7 M`+-H'=&_Z0=N?/$"8[O[N]G(S2I^?G?TI_\F=XEE\/!3%.]DWO MMK;\\Q_>O#YY\_OLU?'!ZXM7V?F?SB^.OS_/3MX+0!SZ_QY7"4S[)#H'L]F=4&/+_MC?3\+)].9G/!X'!R.^V- M:R_ZT7AZ.QEGY_-)_Z=N=G[3F^5%]G8Q-Q+C\]J")VQE7.0#QAT7D]%PP$(& MV8O>J#?NYPP`1159YX?SHVSM0?UZ,H9#-9@H)(#PH"J;^33KG8:^X,3+MZX_\7Q?#=[T1(*]A MW%G>SWEVR:+6Q_D\'>=D_(ZO&B!^E%_E'.(@&\*F;O-LWON0];26=(2C19Y= MS2:WV?QF.!MDT]X,KC'MW4UFM;6$/=DX17:3CP89W"4K6'HZ[.DLG_:&@RS_ M`)L#BF))!E.WBMK8%Y,Y&-GWB.=FJ(\)SV1YW6S*N3HV)]!-Q0&Z66\.GRQJ M&WRMX^SU88V+D6'%((?-]H>]>0-//)VMF*+I`-Y,QF'1+4=],D8N7`\Y0;_U MIF&^FTP&[X>C&E.H#/\0J+\5UF;CSW!TL.)[7$.NDQ/][EE'9RFK<=E`&I6PE'L-K$R]C=&7P M%`ROM>$+;?AU"9T-KD"_\%TJ*M\-!L6/]467$.>\#YG MFR[';:X\JA6OBI.GC^E4QOUO)J,!VM>OLV/H?5X3 M&W`;S^Z1X3F^BQB`[]W` MC8?ON3BY/C\^S@S5%V_NK@[/C5V]='QV?G MG-0??CBY^%.Z<([_(9+Z%(F/;IK/ARADC]LD]_DFD M,#"NT#1+A'&84$68=,GU=P,VI6]Z_`E#UO#GGO<=BM[S$@CYF5I0A!):S57V M%A%JH@^A"&&PY`I6''MLRCJOP0_!?=Q;@)/YH/4,EK6G_$,_G\XS]&*GM64H M8KW/4:IV'FR4[*2`\IP^;G?%\7L@H(?.VF014UI-*T"[OIN*.9JO/:R-S"196!^E?=&\YL^:)R][/6]A,S.\VNA:[KR M-TP=%I(^.T2E<4=U[%2I&MGJ#:W\&AVBR-!^!^D8Y^C!,]@M+*UWS5YU\)?Y M.+\:UA5.-*"V/9U+$V9;=]DI'/*VU[]KV]#Y8CH=-?#WT\6L?].3GE[DLW=# M`)LNU0DA*6$@*>?3)EW/`*/M8Y0S7G@M'>UD7"RPFS`!T'SG(^,5Z3O'K\ZD M)#.>^"(Z@DZHMJZCBM+H>/FM+)F_-&J1)7H!38#LR2F=V>W5'VO-1$!OS#%[ MYF%O36IC2J^FR#L)NQ#T*L1^F:.JYQ5SH`Y[3T`7F`I^45GGA4.3&OX_?.9T MU^(LSN(XPMPV;4`*7;G4;N9)$7TN_5B4DDR=ON*@NBSM.%^,H/3-E;RO_K+T ME@2JM4-[T2N&_?33H^%H`0NM_]RX_=J8#7NNO?/'?'A]PQSK!SBIH''Q=;.@ M:Z9S[=,6B1S9J+$SLU=?P@UE1=\K$^*W8DN53]L]/]JCO6CL9P`^7-XQDSC% M:;KYSELTSZ1(:LEOUR,YG5_ MF=8(]T)W94TH9ACN_']>]&>3]^EBC'X0G`LY+F0C3U<:EIX,1+*>]>'&^,HQ M!U7J:A_U'L@W03%=6`IYKXDMG58=\I[19DC/THZ0R;?>!(UTSM/VSQ^X\>6C M7UY".EL$DL?(H&PN;;'I(Q@/+ET$%)AB8#*=2Z@C0Z;%Y]/Z8O8"3^!8^KZP M%"4+KV8Z:_O'\N"M_NQ4'IN.C3:XN**Q$53I`NG: M*#2]MT";.\6#)_-PA0;W9C+/LZV-[.]__?<'C7YQ@_L%?X1Y'37'(G`QN0R; M3)+2GHCL#,W)MA&LNT\?E\P[T3DV"_^=Y<[C50P_9+#A^4V&0L-A%40-Q-Q: M!L#5OI/=]%!#+O-\#,_`A^9\>+;VV=7$=H=?_#<2[(!6T-O=_[^U_\X/S[\^U__\[&T&LP@-,A% M_Z:;#2;XD>;@;7^T&+`;?"W#,I:`N@K^:FWP:<%U858]2^:#X11O98:)CR@: MC>PY1H&Q!=3!%X\"*A\^3.?^9)/. MUN'%8$H6P<+DZ.>,QO]@T7`^"_Z8L/H41A[T55`)]L%%Q>M\5`6>]FL20K@Y MRAF[:7:#!FSD)^'OR:+6>7/(OR]T%^9 MIR(^`%&G!`GX\7%V,![+)',1!`F-EP3.1`&_-^AI)U\-9\^;N\[=_X&FS!["Z;3\0WQ&6SJ]YPQL<.-`&CI\$YXM"R0-4Q&BPUA`C/P+.&XP'4 M"V1])4W$CW;)GJR![R^BDJ$2+/) MXOH&IGM9#`=#;Z9/WH_A47XI,(P2>]`CWPWE"A50;DHG0["G`5O6)TB"=Q"$ MG?VDN!=_"@>6V.Y&H-Z___5OY509W%)\:"+%VT.=M3#=S7!J/[R?Q'5A4YLW MH^[X__M?_T\*M`L6L-(G4I]:0C1B):@/\?3J`MGV).?#;VO+Y>+P@_"_Y@2G9,,;^ M_O(877RSD#S#N],#M*.)D9%(MR>'`ROHBMWIS'#(XGV833X,\9;?A27V)P3Q MBBE24#,'5*KO]K>2WNFB#ZH(Y MR%X`NI*GIH*$\LW"#=+Y=,;M/J+T@*\0`@\X7_-TC[)I\#@!HL&B#U:+?P6L M1V]!/XF@%IN%A>H]#A3HSO`"C0(]U`X7+Q&Y$HO@>0\SA<%K[Y=[C*N*[S:= MPQ&S*_P7`!ICEC4(A@.N<@.G$);;$2E7"-^?J[3EP#`RT!27%_DC6P8E?6%1 M;//=Q34GKQ^@NXWTT5/'YLM=G@:(>/=E!7-`(T>BP#FPLD-\@PB[7CXRWB*# MY#W,.HQ2T0^J;_[G8PZQ)%J3>0$O#VM0:_$CI>C9\IJ! MB&
HZ[JW>@IBSS1T8"&%78X[L5?I9K M_&\N,JI9I"8!/GUTR4R?/F+FUGUMYQAB[H76;">O`6+1I>#O!;XZ^RF`SZNATQ+#ZG"?(]! M*HYEV?=;VT=G=_=9.G1GK^&WI\^>U-[;ZF[M-OQ:?Z^6$_5Z>`5SPMA7E,5( M,2=98IQCFM73?#H[F[4A=^L_[==@U'E2VUL)(Q?J:H!1;:ZMI_7)=O9J0W>> M[.VGWYK76[9&0ZY,9^O95OK^W__ZOYN"X9A6(9M'FJ\R:SH^DE-ST7>>U%>[ M5S^E[9W:8CO;>WOI@FP#9BFW$&_Z06=K>Z?VVTX]E["SMYGL?J9DQD:ZXHG^ M<\K_%']13)Y;L/3*"YA`Y*Q$G%@?WV3V\34P.5^%HU)/0/(QZ M;6`P9E@[X)A=7/4N]/%O#/NF\+LWNN7_M-ED= M+*Q2&F!OCEB;)<"MDD0H6=+G/D<0K?2E+5ONQABT`X$*/>/+W6MANX@VGT'A MO5?RRH14.YLN6%$N>\*=3S#931BQE)FB+A*4WYNN#(_5<;A_X$J5&L9!5\** M=GJ*.+Y8]>76O%J-L`4F#!;GD[FS"<7IE3\N;D*`WS_LW8[#] M&C0S%1BT6T:G2BZ.1A+(HE'D8*Z?4';0&Y`/VHM\6AO9`?$-]T/7(P636A:? M/J@D'D2'FT?7LZ.#[/6D9UZ2M=WND]T]!K,4$RU@#?;&0'(:(-2CL\T6X-?G MB3T`V9LHSO589&O;.T^4Z`+.:CT6H$5Q(:4)0\D-K$W$D:T% M[E%)@_9SASW`>+W:&8$@,%#:U#8$E<$>5/Q6.KW/:+CGSYN.1_4=M81V'&#U5:(.\R; ML)>]\4].74]>(M(OC+;3@S:O%M)!EQF9\W2)9+TE6#K&PMFX01-E#_"1:]ZD MQH@W_X+LF:-*>+-M:7N)-[,_YU>%=`+:`VMQZV6RT5//A77@^J?E%BCU#$I& M:5,PGD_%H*O,/@&%V2B&(.Z!1Y%)=@X%8;@QB$.F[%!F-#;PE1*=!X,>U'TH M1SJ4#6J)O)G7XU4YH;T?AXJR)&3=03'E=R$^`4/-M>]N#UJ&3D\ES>DL#"@I4L MD]S-60HH.:0N"SX6^&K<]\/`S83.$X=?B)01 MGT'FS*,F;S(FH`?;?WU)\L6"I!;'PBT:L!Z5J&*IEAK%/TR?^'GT`Z>R5D6$ M\;MHET4Z@T8.,-!@T/\>++!?F/_!_/YY,;HC:M'$]\3$Q*HJDHLE?Y=3:#0D M)0]+8J/"QKZ$33*U"4$ M/6(OO&U:DN<($?H'+K\7!8!57`ROYI%U^AT:[],#^URXT5O6?I]V=_;0?LM9 M_O]"6#.LSZN&]7%I6!/RJB0B_L)HZZRJX-LKN2?)DSBL$#7>H$6T*)1C:I(* M/KP#NC\AQ8FWZA+]K->$K5FX9P*^+['@O$XR29=856]Q?E$)(9 M2!1+#;(ZD#UH:MZ\;V`MEUBH0YFNOX`%+*H- M$I[4CK`=!2V"_P'X>CC*>:S@V`_(E'!:C-0[2BY) MV=1QRR52@5Z,"C;8C`^8H:N-*+YH/(D@+H@G(]AY)$,LJBHKYL_Q--[CBPP9 M-'"L>K72<8AG@OR+&185IH.5D-5<*75/SE;-:=.INUL.*GFK!C%S`WO-#"E0 M7Y+`"FM[^T&/,UKQJ/%9)Y%8'O/GQU;^<5]>T*YS MSY\K^=%7CN#>:*D=L2+#=9*(6+-$&1C4F)_T$IP7;KL-6%;/@U!(WW@1"3KU M)]=CJTI9VWUJ:M?:UEZ*9D"J4.4C9K86)0P/BS*$GDP5JL+-XXI18",ERQ/! M.I.!`C['`./T^#[\'F)>TE?M8-N%E]:4!+5,*/^X'5P`3>4UR&-'Y:)G^85. M&E;CX'*M4ED`)Q-8*:#4E_$O1=,)(?#]BU&O_]/Z>1_4D)"PKP@[P+)YX7:" M4F>LA1&-X)]MFN$NR/K"H=I,.',PY#0V\;,]CVA2L>!+ M_*NP75K9IF'0]E99TK1R95M;V9%Y*<`"PWJ2'"P7Z&=<7LH9?-PD.W.8;],) MDC[;K]"#4.!:_S8^NH_B<3C)5?LULPFS/)V:+S1:W`JM1L+E+U\PXOF9MQ#Y ME_-:11M7&,E#9!QQ7_QA+DENRT-[V%S[U;^0"(^8'>WJ5%8>ZZ ME(I0F&O'/H5+2>PY,=BVQUYRYK&W<`(6HU?*8)\(E%.Y(;5F M::Y3["N3]4IIX6S0KUM4T+8:P9&YV)@8$?DH?SF-K]=S2A"X8J@;,C!9'$YQYL8 MDCXEA9;6QQ+0SA>`5+OB@&9W6FYDUW8&592+:%:RZC$:!\@QXCRT)/O64=!, M>3"V4P:/I*A#;]HK_D\70O>;TCMFJVI%,0]/Q/?@Z+F.4,Q@)I7?4D()W+-< M1[5E.AJ[NK0WA>[U5!G/J)2("BDHZ%VMNJH#&6K`\0W1)"JH(R1@\5EJE>&H MDHUK4>`+BZVLBI0[=X(1WLM:85MMO$"D*6L/])K^?IZ/KJ#9N_3W[RWW$@4- M^'_Z^#]ZM]/?9J[0)Y9XI9_8X_3'SX1[^OGIZF-*7^]L=9\]K86\.]O=[9TD MY#E_WMGM;CA.+-,F'4B<)F&EJHQQ8I6S`4+*Z>22<]$ MWJK4K-Z$A6=XFS>F5!Y&SL%?.!)\WY'S.`9&-9AZVP M>LW*.5_\TB+7O\Q#!J>F9-ZLB7E,#>(QW2:3M/NMOU M7(S.?O?99BU9X-2I!$V[17 M=#K(]BK6D4I>HTDVU"-W=KJ;3VKLM;-?3^G9:J+!#N#W/WU6&*GL[;][,ECT]76=C:W(S-RJM[#'5!5]P$E,,$%%`OBG5AR MQ5'.B6HN02NC"?J;K2(H;4A'@MA.N<8$:=Z4)/8#-K:WN5\N*53+/<@K]0_> M5DJ^S9`X+M-T''/.SLPX*$KG3P&A>_/Q.PS.;+VT7!_R=;J."Q(O\&#)/;BB MG%HE*OO.)_*S+5P.ECC8ERR]_1O9V\>OSBQ4YQ-\P$HT0#`(-4H>@UD^O+VD M`L/K5H$$:R""-2].2?+R-$KB/BYC,)+OEK1,52#`Y/8 MD`-)1-H?*L-9/K02=0MP:7;>QGWXS+P/!V=G!YI[X]-'J37E@@02L0VIK-YF MQ%>4%\-KARSR8"M"C4O\4M027%'CX(A*0ZVBI!*43!365ZL]*)/ M'Z]RW)I`J%I8A]E(9E+3$Q2N4@S((+7"IDIQWWBI.*62YA78B2VN[GGP0!\&EJ$DJSN.`M8L]HUVISUS#Z.!9^:L@M=4J7. M9A[QE%/`E`!'"J+@BC2J+*CPR@+]^:/2E@#8Y93 MZN3N9-<#ZK[>*R6I4F=8N@0C#".U7L;2].&X]3SW:J:.D%L6D0KTY)Y9R&@2 MU+7DDOKC-)RA7JN60GO=3SX=#"]:L,X&9-#2FY6R)6<["24.SBU9+]LEGTF% MP_QD[!AHZZ!O3QM?<0'AL`MIFQ;C@;ZR:W%\;2<" M;`GI6C9I<>JE-#,.Q1R!=6*PQ)H2Y^`!]>-O0[8H>4F-H/[-G&W>GZUEQG!Y M1=YS)FS'VZ2DZ4M_T?[$;"S)L/JNJ1"PH,HK5%;3YK$WZH=Z=<\BER&Q3'(! M/V71O>L-1UJG,_G+?8<:W674YXM(I+?T`!6.8!2:+2!V.S$:0+PX7OC.RB_E MR^.]2'1=G'3S]RK(UR:;#[+D'H(;S'.)UY3LQ7GT<>MQQ2JVP MKC4V%GOII?3FG;SC20O3*..>#Y@E6L4[+=/TS!FUMB5WW1?3MXK!S94KVBD9 M>2F.>EBQP@[AM8>R6WQ$2Q.#O5$Q6>+0@;0X'.^=)OYI<5+?_2">3X50WN-48UW]-B')0GDQBC;"9'!%^S)' M1`-I"2YCM!U6Z)[*KC4+2Z".GJJ:]Z5]F>GF2MBK;MO&#SIG'#ZZ06!KL6-9 M;E/GC>VE#Q`$%T+-8\[H'?Z6E5S()V:"IT!35/QNL>-,+[=*3:@597'QS" MEFJPMK-OF+.VLV;I?KYC;VT\B.I8U#%55%FO' MX7[ZXV3VD[#MT+5WM>H9-T\E&5.)?C');U.%:01JG;QL*G.[@-$7>&/>9V<3 MDN7U_E6EW,VJXGQEFZXD^$TQ97&_>P3+1\MXES]ZCFOB;4@IWG*>1C*+8S4, M)*[PFTNL]U4.T@5S%>;\-,9>D#814L%*7[6]2O]0-&X_A'1JRAM0,$GY)8.7 M#A,NG],Z8%A*K^C&:]0JA*!;D)4\D!'GS?7#R0RY[P0D2/.*!N[T;*L4EY^_ M.C0C4)]#U0-7G^.F7+]W2DO5!!W94[;VK/OLR5[V/5SK6KWU5I3P..V-LE[S3A`]9%]D":_PJ ML>&L^_"KT$0C;,`&0N^,8%;=B?XSG0X].UE.@Q1_7MYZ)A%+<86(G@-#>9)Y MX!MI&',$%:*=QQND3ZB7%/:"``9?)OL2OR,6(GT*7&F3LP*2>2YMV)[R4D`/ MB$RI$IHR#D&5":,"?V$9I5@\MS*%'0DFSO5UW9SYVA!MO_5=;9W]C\E92QFN=ZUQ?B M).M'*BDA0XM2"H13L^T=4V*4&&$9%RQ.@(GU-@Y,K%;IQRR0!!H2EY4*QQ"E MF^R'C7,5:>@M\SP!&!!MB$&FC(\NG<7D\CDBS6DTF=H;+T)/'$UW0EL-S`?Z M.3B'"=;+%`N#MB4LF#G7GN+`WPQ\/-D:+[IVBZ;[FF7(*>@LL?XSZ?'>CM,A M>/*W31,&5K<"M0>L;.7"FJ:K\+#<'E]B'I5-DK-#`DBT8/4AK;OZ>O<^8[52 MU[&5\+QY/Z1'HJ"5NS-`R;NU["25\:MY"GT?AB-3JXT8M3L2V_$-#!SBZ0<5 M*()X'D#1:G[O)85O!&X3^"I-\\/7H\<7#.;@WL02+*C&L,2X2A_J4(WO>P%S6IJ`CPUG3C?E(NN<0?":0$4NSTF%3G M)V"S-'IK6)LP[;=.FET0^;ZFN;_X*Z/ER3=\"$)Z_]F1ODR_ZS5]HGAB. MEWS0%_O;S"&RZ@SXBI5!W5Z=?`3$6K%4!D0JY`FA%ZM1#!Z^ MGFN>1FEJ_IXS\9:A"OE58X&0XS`,!X47,TBDB5N9/8S\-]K%V*X2V64X^J)" MBNU(6--`2YP-FIUT0E5H%Z1_$8^"M0(6TO\$+!Z!EJR[J!9DE]U.)"?@:/:& M?3!24R5GO#AMH@=9FA>+R()&'.?7/.8?BA23$1C2*N,_$1ZN$6(Y2_D,CYOL M5Z\N>-R"%^)[XAQ<],#W_`-J,R,FK/[0+T#TA:MFRA=>5IM>8P2X="&*O>A_ MJ51YTZQ1?%%:G'B-!;O14]3N[@.+HA7/#*VE_%D;OA+'=/W*->KQBY.+HP-@ M(^M7\017B>/I;IF+@U]4K$J/8'-DT2E%CR$<0P-.;B\$&%A+9'<-8$.UU"#O M+1>Q#PAM&/-GPHM"9?U@YJ(L0L^20:5&)"7B\MMW=0I*+[)QP&B#A<2O)@_'IHP_U!*=< M6:V^!+$F!10++2B@GSY:B;7TPC:!.9]\^GB/[G],1NR//:(E)ZIIE)T!8B%< M[%>M@-KB\H/D4NG2FG;8A57 M-N^_X;.4JI0A!V8BK4>>YL)TF72\*./[OF5E@YAP,@21KD(\+=HD@83Y@P6D ML;86&=DH\=)U1AW3-W+USV^QA%P5`8J*36+Q6;'DJ!*`V5HPBI66:RTAJZYU MF9/I;.!FQ7*[O',VJ6?:-HWWHS0)K&8GUR\BLUJ\2O(&XE>R_H)4T5JQ^B:U MM,%3Y+O[9;Z]'Z2IFYK`\#6R\R`(*$3MJKGD3CUBO4Z!K13Y6;#OG_XJH(=S M2YECR57!5:`B>[Z2FU'QW6/GN^M)F%**5.B_4ODX7&""R)BKFS$LJMS:5JS# M9W5XI?W5E!YEVT9Q96I502S5#(JR/IT!2'*>"(]\M1IC&IA2X/"2(Y!5$`!7 M0T@5E'2>J+FZH^:WPW5O*CS`$:,");=4+:QU>P&*IR>_-ZA948VS;.)/1%CI MV=QRIF(E9G.PMF/,R_$DSL?O]XL0`AT^L2+1V\MCRB1"M;IJQ$Q*Q M33H8T&O/UI\NGFCG2?!YFK82P4%-E;DX*WL")*Q)DR@L9*?[/A^]R]?-LG4=.US3US8:!8GL,)M-W`=$+0 MH4=W=Q;GW"(&+)\4%!/]HJ^\'$A[IE9CU*.Y_VUO$-B1)33$FY^FNDQ"%98` M@$/!QK7T#E+A8+)*U+C&BQ`*J+4W>HE8J%ZQS"-AA'@0!4-8SJ25D M/Z@O-`U;/;L-PX!6S":&9KXO\W3+_Z5;B*N)4LKW(TT3NT6%>`X?)/*DJ,4\ M(IEG!O,'9"\$TZY\QSGS0Y(E93K.YX:8*.N5M/3.G/'X\ M7[VO=/*R#@LO!4$2U9:NJ>%QM0CCBB'RYL8]6NCM$@HWSE;4]YA-@:6A:^.5>,+$RRU!3,.9YX0T.` M*I_H1.GS^60/!4E.>04>89JNEYH$H-G,&J4H]$\W#BY_?6BI8J/A3PKK,/Y8 MRH![82E6(W;;L*@.#--7M^N-^@%R)A6(E]`&#\TEJ-G0]\0'8::ZNU7;#V80 MJ($BX6JB>XU`"V2;A)4JP#$-NX1%;!:AH"2.4+\`&L-;&*[&/EF*O]G6N:4/ MJZFDWR872ZQ\^7-8K+OT2'!XZ.3FR'R-PUP^[G"O6<4B_,?D&,B#>5"1/IZ[ M<"<"6`@.!M=FMN,;45:%KFZ4=JN5OU&A*;4/%1F2%\U-\I`[B:#XW"6AS6D9 M]1]_A]MRMZ_MW8TG:(.$.XQRT9^LHX`Y2BNNO.R[(6KA#.`NK`UCZ"46#$/S M>:BJ,+KN65$%*\7EZ:PZ'Q97U`E4`BL>:XW:3%]A4Q6:]IM"-\%G#UNPQ-G4 M[O5:0$5+M8X+IC;L>Z7!&3LX#":HU(5NO.0.$/F'M5.2B"T7PZ4XE\_-22L= M>WDS+O`:MLK'3CV$*DP_+W03#4>)%H0S*N1&>"UT"<`;U;489:5._B&:-9>? M,'!%L1=4&CFP@(3">:AH[@+Q.\#O7E5ZAU+8.6T1LYQV!BR:0C36;XN;NJEK;09@I:.39>2&T)- MNO4L(4>X&HE#=1!`S`'12[,28]<(/?IQ,;"F=4$=KL1PV70(X48-V`&)H9:< M1TS#R&JC10/6[AAK-'N"J\;T,B1>Y!*JJ)!/T,EX,&L2 M8YHAZL'53E/=.BRWD[YWUDG@%/Q0.6S63]#>FJ(PDF1KZ'SJJONBBR#MN318R?BFS<"K)UR< MZKFH]0UI`8C;9]!4=$,1NS8=PC,:Y:;8K0J]`:H$Q)9;?[\@,TJO,Q"RP#)7 M<,76-A:P<`+(A(=70]E7PC"]^>P-U]@K(.S7[G$V+(=C@@ZCD@7=C`6H3$A!<$7;C=F@9;H*^"JN&&^VU#9F@* M+.!N+SO+Z"D[,L>;1C M&I3I7_(=OT50&,:%[!C`%5M^&X#?NKP<>!8>"D468([?N1L+^<5NCOW%M24I M#Y94(C<(6E%@*!47R&!"&K7T=,`RG9"I$%I$)==[P0YE3]BK[-'G3`J>KQ8H MO`#.7;^=K8*#(I]O3[XS]:#A#!G&%3`&38V)(H>Q)"E.P7EGC!FBKBI^#,\B M?%%OW>2H)^[+B32V[K_QP#"E)&9S1A9+H&QU?NA1[P9>#^=9CA(?N6"N8YDA M*ET&A@]O9&:00(>)EZ9&`I'*H+&OKF"L7`\^9+/AO"P]'^RVNULCD*XHWT#K MFG&(W,*X&.E@/8LS=Y8L&+D?2>Q'*62#4Y!:+TV+N_X-^A)A"I0;?Y2(.F5S M.8V,5:A3%/_2(*1=WI1-Q%8/%&Q2TH!$__%`K-2D4$TGDJ52!.94"N*4P/)O MYE3JX+0=K<5JIT(B2E# M\JXA`(P#FA-9AR[^%=Z4#8N/8B/[(SYVG+%(93/7V8:5YP1MB:!/C]LEG>3E M_ZF+[,ODSD$39!A"#$V"HU6U9)!(X=J#RBL5V8?85L9114.(=YN6LLY+-+88 M!@5G2@'8J.T<`GYI+,KQ>XLA[K@E!L9G&*;SY]51)M51^HEYZT[;EVDZ)'.\ MI-3@%."EV(5R#D#IW([U6`E6MI"%&$(+97R[K;9DCFTZR909H^NNV2]A.?]YI_GFW^>>]_]G\ M^T$3:$L1*+<@U;3$""R?&>,Y7*!A+$;&:ZQK5Q`N_L.1/EG_MRW?0X+&:T$M MY5NC)=O8$*;L2K@O_\UT_1DDH8A!5-,U,8]ZL5"4UGXJ(9_B59)^AV@VSBOM M0J7(P?_?X9(AU'WSJ;$)!P[+4\79)?4[I-/)".4],]O2W.@2$D$Y<-PZ[MMX M<53FW5)@&M7O@JDMM&2S1CC*0DPR]TRLJ*FRJ;O-AU`"SQASFKPN"V-Y94&0 M$61S)=]N&[9YB/$;@UQJNP5.5X[%40.@*1H@L@!&Y+>D"+^+EH7XM,X/'"FW M7T9R[8H4R!=V72=NW4KA+CGVZKS"$/O&@]=V=F0_Q'V5@SL>S8YF"XP)N*H0 M03#XN@!"?27$+B0-UO:??.Y*?D:G_ID$/KSX%'WS3HGG]$\V,5IC1NUOWE?Y MN84G7?I^^P@I5SJ(79`3(\T@IL/PAHWS-9P,V6G.MS4N2K(# MW=I[9DCC3,?JH$X7B`M!GOP,F'51@L/LL?8%*BYC*]S9^LP5?@7&81>5'IOT MZ)#4.$/D]N(O#%3?@B_D&YB[IDUR:R?+.VMG;\,=1[TNBM'4<@GSO1#Y9J1&^, M[(*;SOL8TS0@V7Z*$Z^V!-P@0?<`S=W-ST8N(5D<'HK6-H7/^KP*T)L_\QG. M5I139RN*@(1B\FJHZ5`0>W,46RJMM M&@=(7+L&X!87*K44L-_PTSH_"9[7]#28RMRP)Z;]W1#'YRP1N9;:*UT8U9G& M+H8,$O46)M/7``*>CB'=)V?B+?IUVPJ6IG-62WF[=M6D=0/D'W"J6QV"JQM2 M"D%P!E:X4O5#7QE51K'<@L2X7(>N1`U>.KJR2#/41YFODCGK5=,UI,:6"6=2 M!8CXK4R.!FRA'H+C0VAB+^5CU`[;7<0JN.@5;LN.HKLDU@4,K&)&FYRVD>0U ML3^6Y:TFJ7`?$$9X*4-9>-:NMX<*TSR5+1K0.J*F#R[,-79/H7?ZT1L"MAX> MK`5W-6D1$(WBRMP/;*7W-4D:K0`9ZR7,TJ$[^WNU%G0'('&]1\.Q+A.EIH:( MC@`B-5?GIRJ"*;WK,5?9O MJ3X0C7F?U4J[U9^BP;&8=2Y$647MVE7N%:#_M4Q/%,KF;],=2#DHV>:I_#T0 MB9U)4<.^"S&\I0\XNE_\TI-25H7DAS/7]\A\O,*6AIH^&JNW`:WLT^K'*[(7 MKC7V:R==W9*D M==XP5S)YQRIA=K_3.!^HFSPUY.T<*1XSJA.WF:1W[0&*A MQ8)@!^: MKD/@$_2SB*#R0(FIUS?OKF*-]\9GK0M?OIBU];UP[UTYHCB1+C1L&WGUC7)M M7[4#,K1\1M%I(K\VV&W1B&,\ORFR8^EPZ5%OKGR*@V]DI^!O<":P;(\V@*[B-LA0UW?!]$L%7M/EOE9&)4J'GHDKN0AL M^I9Q>MWO)?T$6REH'M(1TW=+C@$C(%W+PL1W%D-.7_6X'4N_VW#)&J^4KE]G MB*>#'7EGBI4$QY?3M]JFS/XM7'T=0^]MJ\$X]W=1`R\"7#&,H)G3^:!X[%7K M=&%!62"GZZO3U]H.=]W<5:TZXKT,IWH5VJ_#_53W2L`V$CP9$QJD)!\MY3L;].:$6!=C-8=P62SO9?Q[)WB=7NVK=6<8HHD(H5RJR$$9]).9 M7WWOU(/]P/J3KL+[ZE>08QS=B@`6F#4X:?V%;.E)K+C(JPTAVF=+;B:KS[7Z M:JZV"3]+]49R?;&2?2]^A:9,0H&J#D0[F:AN&\L+2Q:B(_O,WEQU@@]3;*#: MF%/0!JS/'(F>G5\]TKENLP%;OWZD[ROWWV2-U]]\_1SFTF@=)AS<`\P\*4D> MU:J"O<4*NQ>WZ""-T,8EB7^GYLZH/MQ)Z0K?;ORR]O#4YU(TA*#6259/Q_JR M_4NG6FU*WKO]%[&QLO=IIRM##Y)>T/+T,];]`)NH32(L.[$PM\O<4><^_=+K M!=+-1C*7_N3^`:6V=Y9';T+Y(GWF*]OPWV\NMH%F2:IIU6?Y/%QK7'+!%0[^ M[WKXGKVAH-19:PF&_C4,6XMASQ18][@EUK/XPGT&2WQQ%:^.+VF7-3\&$'R0 MO^->@C"W!UE[\YE+A5NU))P*0\(,;D$6J."?ZZ_!AX85=J5M%S4;@)#FP+5& MC?,%-B6MT]179\4*T@-L[KWZE@(HUYA,*E=/U@X]8D?<:2^&%]//E%C1M.DY2ZEW$\TZ'2R&6K$Z4YWYJ M:F#V^"%L-1DQK+B;-?M6S&0/[4O3U5;M^5K(H*HNU!Z:L1]ZO:7#VK&#/JY? M'LGC.3G1G&F+A2J_K>KY/`.+525$7*@03@A_0;(2>0H% MKH9BBJ"H#;3B`]?+[\$SE+W]%'Y=[J!I$5E"OE_80%/=WES(TC7N<$FKY97R?0C9?+7RL^(?233S2Z/B'/CTJY/L81EN+:Y M;JJM']/OC1=43I6^BEQ28AS8 MZ$_-[>I>)#F\*W10]8K$+VL"-G"&T.(2OCUTZ?O67N*^)%>E!V9Z_.Z]K(L??N-*IZ4M8NSM394Z7:OM( M'=>C?J]]JE6FH;!8=3IX@8_)1FKG(J"-7[G5YJABL2S67"%W#D?_Q?O2U.&* M(H4L57CRRX_NI;]43I7#WD*CRS+9]^0QU0*E%CZKMGMI?]6<"S&73''5Y0XA MZ6[T?KUM1?K6_^7L6FX0AF'H*@P`8@,D#G#B@%@`L0!"*HCU>8GC.'VJG=!K MZWSKQJ[]GHOH38".6)U!294(>*BK_IB/;V@FBJ_;W#9'O(0I.0?S*G\R"\$' MM[;\`?=J!XBB#31YAT]27[CBX+4"M&'M:Q(N:"X56$J19"&M*?LBN0SCK`N> M8491";(MY3?K-!VX_I)QL$H)7$FAVB,>%0G7&>V\.>`S>K@GGR($+%/*P_+E MTZ0UVYHZB,AVKG^S($._T%\5`=[X1/R$3S34:P-2AS`YL'D+-.36,JA M*[&80U]B,8?.Q&(>O:G=OW&>&S\Q@WT*V\M5OVJ_H?$-STL08]XV^^2*D<-> M,E39*]`!/"?M\OC>SZ!1\/(6NF"1%GPC^:I@UI'UO^0B!`&S@D=&9/$#)^%5 MB$6(#U02!HO:"5I%D&@6E@S:P=?(X3UNAK@L_*-$8VJS9D82Z#^%%3TJ1*P= MLO?::AMC)[2MHUTW!2Y]V)<90NIC&5I>9-SGBC!]Q7UOX=$^=[I:U6H;?S]- M[\,/``#__P,`4$L#!!0`!@`(````(0"OP3O[E@(``),'```8````>&PO=V]R M:W-H965T&ULE)5;;YLP&(;O)^T_6+XO#CF0@T*J)E&V2ILT M33M<.\8$JQ@CVSGTW^^SG::%5*S)!6#R^/7[O1^8^?U)ENC`M1&J2G$<]3#B M%5.9J'8I_OUKD:( M8067U$2JYA7\DRLMJ86AWA%3:TXS/TF6I-_K)4124>&@,-,?T5!Y+AA?*[:7 MO+)!1/.26O!O"E&;%S7)/B(GJ7[:UW=,R1HDMJ(4]MF+8B39['%7*4VW)=1] MBH>4O6C[P96\%$PKHW(;@1P)1J]KGI(I`:7%/!-0@8L=:9ZG^"&>K<:8+.8^ MGS^"'\V;:V0*=?RB1?9-5!S"AC:Y!FR5>G+H8^9NP61R-7OC&_!#HXSG=%_: MG^KXE8M=8:';(RC(U37+GM?<,`@49*+^R"DQ58(!."(IW),!@="3/Q]%9HL4 M#Y)H-.X-8L#1EAN[$4X2([8W5LF_`8K/4D&D?Q:!\UDD[D?]R2@>)3>H#,XJ M<+ZH_,\"">7X=-;4TL5>@:"+90#AOA\+Y.'F/+A)?BK0 M!EIY6"3)G!P@?G9&EM=(OTFLWB$&%X2`O8M'B.MVCVX2U(+1J\?Q1=Z7L0S( MT+?(U;5Z&N@.Q\$I!JG7A2>MA0.2^.1@&W"_)K'J(AK6AK=8"\^GIJ#F];&K4R6`8'E+\&.6AU==2(-<\DMYAS<,A>W M<@M(R&TZ'`ZO6]I%-*R-;['FX):UUHNV#$B7M2XB6`O[:M@Y:KKCWZG>B:XZ&AV>&1[3X^.'[Z>A]J]JN;LYK7RP" MWZO.FV9;G_=K_^^_/C^DOM?UY7E;'IMSM?9_5)W_X>GGGQY?F_9K=ZBJWM,9 MSMW:/_3]9;5<=IM#=2J[17.ISCJR:]I3V>NO[7[97=JJW`XWG8[+,`CBY:FL MSSYD6+7WY&AVNWI3?6HV+Z?JW$.2MCJ6O>;?'>I+]Y;MM+DGW:ELO[Y<'C;- MZ:)3/-?'NO\Q)/6]TV;U97]NVO+YJ.?]7:AR\Y9[^#))?ZHW;=,UNWZATRV! MZ'3.V3);ZDQ/C]M:S\#([K75;NU_%*M"*7_Y]#@(]$]=O7;.WUYW:%Y_:>OM M;_6YTFKK.ID*/#?-5P/]LC67],W+R=V?APK\T7K;:E>^'/L_F]=?JWI_Z'6Y M(STC,['5]L>GJMMH176:11B93)OFJ`GH_[U3;5I#*U)^'SY?ZVU_6/LR7D1) M((6&>\]5UW^N34K?V[QT?7/Z%T`"4T&2$)/H3TPBPD681B**9V21F$5_CEG^ MC$2IC.H\ZGLRZ?'MGGU=,MIPMVE-`TL5CJAD45J<:_+HO4P]WPT-PVW:G2G M:_GM*12/RV]:_@U".WK.5C)(S8P M0-*A9#)+6-$*$H[29+R;D-+]?K\:!LQ(Q6-:*`-`XH&4T/\8Z<*-9VD4C+<3 M5O$<5@;,6-G)`BN``"L5*!8NW+!,(ALFI'3_WR^5`3-2Z3A7(`40(!5*D=%P M0<)98N\FI,PCS5GR[W>S`3-2;-0<($@J3M@J*T@X26WU":EL#BD#IJ2D[0I0 M"B!J:"H6*]Q8F-@H(22T"]XOTX!FE-CJRA$#0LE(6B4&R@6)AY'3`@9&E4"D#%!00R-0N'$IMELN+ MJ(<9Y][A4Z M^"Q+%U-/EW96J(OKVF$66(/$9J+QY%;!9MFZF/JZ9`/GB`&[4C%SCN)FF.HU MR]C%%6>?T'*]6RE>S`)S0!OIN#462FR6N8LK[FX+@85T+7SB5A`$5K'>4(Q/ M2<(JG&7P`YH:O&(#YXB!@47D[%2@O6@\$#?D"F<9_(!FQ.R,02[$`+%,1LPO M"A(7*LLL@$IFS/9N$PW!FET357;*R`PPP"S*4KXR"DR"Q93IK:=B.,O?!S1U M*L4\,D>,XU3N%:K++`&SA'#.@E)#.R@H036V4JURQC#Z?&KKBQ(^;Z]AB#J%7JK%G*:I:K MAU-75TR,'#$P,XU+N%3KX+/>64_>.N'LC!G41D;-A`CM@@,QI1$J- MN?=]KZ$D[,#=!TQDEQ`8`V*@T[/8M@P2A!1C9>U"H?QF&;R<&GS$!LX1`[S< M7\7("U)`.'7ZC=*:9>]R:N]$Y`C!O60,F1KM*``%3@_+2BU618OIQ8?V26$ ME02,%F;\=>&\=D'9WL50@K.L7L(F7G>+'=SV"A($C+L4G2MT<.;H=_;[U-DC M5I]<`N:ZL]\(4FK,U@TUI3OG_=<,!4.VG*QRD-SY,&N%_H`;KB^'`/Z_.M2[JO?RW9?GSOO6.UT MRF"1:#=HX00-OO3-93AI>6YZ??(U_'G0)YV5/E()%AJ\:YK^[8LYHQO/3I_^ M`P``__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE M+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F6 M6%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6 MU8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/, M>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7 M$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29- MG!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6: M]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W! M&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&+ M+Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<% M#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y* M#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8 M**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS M=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*& M'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D2 M7UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/ MEN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC M`S5GY*8TO;>$#6C M\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@ MSK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z M&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5'; M:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@ M58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`- M005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)") MJ(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK M<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M- M^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@ M^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^ M/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\ M-I@Q)4TPP:&PO=V]R:W-H965TGQ_Y3M/F MQTV^KX[%@_NC:-P/C[_^5O-YL]X5A[R95:?B MJ#W;JC[DK?Y8/\^;4UWDFV[083^7BT4P/^3ET84(JWI*C&J[+==%6JU?#L6Q MA2!UL<];G7^S*T_-.=IA/27<(:^_OISNUM7AI$,\E?NR_=$%=9W#>O7Y^5C5 M^=->\_XNO'Q]CMU]L,(?RG5=-=6VG>EPOVM+C=?RF.A9UNODUF!IZKZ:J"?-\:D M!\^MT9^Z%?BS=C;%-G_9MW]5K[\7Y?.NUT0<1I=Q"8XH?XH6M#Q*?9[OK]@W#/J7RZ6PWC"2V\8 M7&37>1DPYQ4-<;MZCP$3`*\%+[X$W!ZXEVPKI&2PDFS.,CSXSANW'F$4O(>1 M`5-&/*<8()"QSYG$@(&L_&6DV!(FV!]$OO08*^R_,#[#?CJ>\#)'"]:W;_"*_ES_`R@QBOD&4>`P:U,VY(N2%# M!I*CT$+R_LGO1MUJNCT(I6E94LN280O-U,@C*I/K'4J`F%YOO3VHWY:>K]A$ M)PS@6?N:`.32*K*,`7Q_W$.4G5')Z>Q`4PF[B#656``(SS^WI!8FPQ::H5%$ ME*$Y7MW>I@)T5/\=)-"6YQZ$,T7RV^VXU,)DV$(S-9*',KU1*2"09"XMD18` M@DJ)/,4Z:4+\2\5%/"5^X4?16`;04"@@$&_U%'-4Q]S,*GC:=H,C"";FZ'M, MH^(NM(XVGI(L2VI9,FRAJV!$#:W"Q'H!*;Q1+P#"F7)+*K@EPQ::J=$IE.F- MN015PW-I'^H$ECYQJ;-0P(7.@@$7.PL%O-U9C%9-9P?*1MF-^M85:RP`!+M! M^DNFG0GQ"QF-YYE^+^/Q2H769L!^*<08GZZ;$;7IS$`",3/KB"?.,FFN?2JP M=CEQA\R=DM&A9.Z,NH-1:P@IR03Y>C%V:'9 M*3E=6[@>)Y(SH^@2^M[X#;#C)(!0Q[,LJ67)L(5F:N05[9R)F8(H7^_-$D`X M4VY)+4R&+333=VFYG*+E/>A-+2?^"UI._)>TG`+>UG+S4Q=>A1M;W=9PQ"MDS=_+Z4$;=08X^@"V9T%Y76#5*@TE>;LCPKN>$D M0B8F"7-;.QN/5NBW@HYS1D9K*1HZ(R5EM'8Z*5!F3,J^>TLLW_HG@6"^?_V[4K3MX M#T*96I;4LF380C-E\GU]`3N(F04 MH'OY"*#DC/A.)P=2K;,;;NM\SF-UEG/3CJVC)/%*_JMO2MR"GU0SXO;4V"XH MIW>="=2%,P'_XK@'P7P+%5D7?`J(PH@=$5,*L"-D%$`B4';L5#"M&^LG0ZLL MK2-R#X*W!G8]28A3\">OE+C1RO3E"%\/D06J&:`&KY'P6'K3RF"%5]!8K)+NR9#94_TZVMGG@T,_3I[RY^*/O'XNCXVS+[8ZY&(6 MZHQJ>-Z$#VUUZM[#GJI6/TMV_]WI9^A"/PUH"``"*!0``&0```'AL+W=OD+;AU#LY%$JGAS.[L+I=W>]63+1@K]5#1+$DI@4'H6@YM M17_]?+JZH<0Z/M2\UP-4]!4LO5M]_+#<:?-B.P!'D&&P%>V<&Q>,6=&!XC;1 M(PSXI]%&<8=+TS([&N!U.*1Z-DO3:Z:X'&AD6)A+.'332`&/6FP4#"Z2&.BY MP_AM)T=[9%/B$CK%S-N)@::B]]GBH:!LM0S^_):PLR?? MQ'9Z]]G(^JL<`,W&,OD"K+5^\=#GVF_A879V^BD4X+LA-31\T[L?>O<%9-LY MK':!"?F\%O7K(UB!AB)-,@MA"-UC`/@D2OK.0$/X/KQWLG9=1?/KI"C3/$,X M68-U3])34B(VUFGU)X(R']1$,CN0X/M`DA7)?%:4-Q>PL!A12/"1.[Y:&KTC MV#2H:4?N6S!;(//;&6$4'GOOP14M*<%@+59ANRKFZ9)MT3IQP#Q$##XG3#8A M&(I.RJAVN;('>V5OB`_E(6ZELG?(^/!_\C$C5.9O"S>%IJ_1\B#L0M. M7,K/G(R8>>C,4^.P92XWSH,KBFY-YADQ\U#0_UV,,Q%;1H%IX1/T MO25";WR_9WAFVIU&\3X/,4\_0T.N MM<,A")\=WGF`]4X3!#=:N^/"C^MTBZ[^`@``__\#`%!+`P04``8`"````"$` MPBU\9VT#``"("@``&0```'AL+W=O[QH%@ITO;EQ". MSSW<>ZZ_5G?/=64]8<8);=:V.YG:%FXRFI-FO[9__TIO%K;%!6IR5-$&K^T7 MS.V[S>=/JR-EC[S$6%B@T/"U70K1AH[#LQ+7B$]HBQL8*2BKD8!7MG=XRS#* MNZ"ZS1H49`,QS0[U+@12H3A"@G(GY>DY;U:G;U'KD;L M\=#>9+1N06)'*B)>.E';JK/P8=]0AG85U/WLWJ*LU^Y>+N1KDC'*:2$F(.>H M1"]K7CI+!Y0VJYQ`!=)VB^%B;=^[8;JPG1W).4$O%.(A!Q$G&]B;<(W&#V`979206>@\I;*3BJG,Z=&`FT63%Z MM&#&0<*\17+^NB$(]K:H(@:C_N<3&"1%[J5*IP46<.CMTR;P_97S!`W)3IQ( M<>:V-7#F@4[9]A1IO]2->^`^[L5U#R19>M`[ M'"E@/@!;$XC[D'/;`O_6*,@,2D>`ENSM1Y*5Y+4-3@R3+/"-618ISNTY?Q.( M32`Q@70$:,G"RO[X+)-!L)]H21LS)%*<4=(F$)M`8@+I"-"2AG4_3OKZ=)!D MT^&YWMM(<1;=1K`T5NQV/.@&2STTUD:74WTT&8_ZKA&;JM'.(ZT^6)SOKT^2 MS?H6>AJ1XJCZ7/>\R+I-:ZM&SZV*K](3DY[J]//LU6J2UY+1OGV]9Y)LUF28 M%RG..>NM"<0](+=W8X]+^K%^DX"C7'YRU`MU,JNSI\9LC[>XJKB5T8,\=6
"#O4)9YX8?(:GGHA[$7`=X8/ MPT6@17O\';$]:;A5X0)2GD[FL*"8NDJH%T';[K3840%7@.YO"3<^#$?9=`+D M@E+1O\@/#'?(S3\```#__P,`4$L#!!0`!@`(````(0#R_U<$#`0``(@/```9 M````>&PO=V]R:W-H965T997NY7[X]^7+['K")E465+PBJW<#R; M>/TJ]HQ)!R)48N7NI3PL/$^D>U8F8L(/K()?MKPN$PF/]^S-.:"[Z5$PCG8:)] MS7-O[D&D]3++08$JNU.S[GW.L_^S"L& MU88^J0YL.']5T.^9^@H6>[W5+[H#?]=.QK;)L9#_\-,?+-_M);0[!$5*V"+[ M>&8BA8I"F`D-5:24%Y``_'7*7&T-J$CRKC]/>2;W*S>()N',#PC`G0T3\B57 M(5TG/0K)R_\01$PH#$)-$/@T00B=T#@D870_BH<9:8'/B4S6RYJ?'-@UP"D. MB=J#9`&1E;((ZC.L#"2I-=_4(KT4T`+:\;8.:;#TWJ"$J<$\(6;F.@V&-@@/ MR)L,@-7.(+B;@5K4S8"VX7623PB9Z<9>\@5=OMM*%7CE0JA&14BGC0XD0LRT M1S3M$JG2WA>F%@'NDI#8RA#3)X2]=%G)V\H4V%866LH0$^L.QU'4_-KI7S2& M58%MUC8NUA,Q4\TZF[4Y=5AA8SVN58%MUEFC!ED1$VE6,@])\W.'5CGZQ;C< M+K$"V[1Q$Q=I$8-B(_\*ZWP,JP+;K'.+%3$H-J9AN\$Z8@F,X:7:QW:P7F4E M$/A6`@9DRDVGTRMM)I8_W2ZX1MO4;4VQX@;4'Q_R*2?2J^Y-K`$-<(YR(S)D M1VWEC+ZS'RE?CL-VPW5[:[G3G<*BY71]T)Y;; M[=$U(!PB.!HU>ZU+/,JHR)!3M;4TI>Y85?M>Z/*.LBHRY%7V^!J0$7QM>BVO M>G!Z!TRK/[T(,M,[C=N&=)5;OO5@!@,&%K0:3>41U!\H^BG/TJON#;$!#7". M,BF*)Z/N+-E#;$#F)7AQ`N@4F%J.=7N(-=IR1VH/L0$98K_=\5WB4;9%AVRK MW3/840-"XBB\,L1TE&UIM*VXE62(+VTKO*IXE&VI`WG/MNPI-B"`OK59;TWAP;$![PPBANIPR[C1&ULE%?;CJ,X M$'U?:?\!\3Z`24BZ49+1<.F9D6:DT6HOSP2)XMD6;G!5ELU_;?_WY\NG)MGB?-456L8:N M[0_*[<^;WW];G5CWR@^4]A8P-'QM'_J^#5V7YP=:9]QA+6U@9<>Z.NOAL=N[ MO.UH5@Q.=>7ZGK=PZZQL;,$0=H]PL-VNS&G"\F--FUZ0=+3*>M#/#V7+)5N= M/T)79]WKL?V4L[H%BFU9E?W'0&I;=1Y^WS>LR[85Q/U.YEDNN8>'"7U=YAWC M;-<[0.<*H=.8G]UG%Y@VJZ*$"##M5D=W:_L+"5.RL-W-:DC0WR4]<>6WQ0_L M]+4KBQ]E0R';4">LP):Q5X1^+]`$SN[$^V6HP*_.*N@N.U;]'^STC9;[0P_E M#B`B#"PL/A+*<\@HT#A^@$PYJT``_+7J$EL#,I*]#_]/9=$?UO9LX01+;T8` M;FTI[U]*I+2M_,A[5O\C0.1,)4C\,PEXG$F([_A/`0D6]UE5^P8YS<^8 M2&"6MC5BEH$.B24$,XB\B31)-$"G>F!W@X0P1B@3'`D#9<$!]ZSKC86F.7H ME%QQ(I[NE"I.FMSY_Y&+8$VN:8B%0=$F$4I`Q.P9Q4G3!OVO]LSM5")8TV8: M8F%0M$F$HLU,=JHX:=H6NC;\3N_W,SH!3OGD`F(VM,#,Q^K&IB$Q#:EBT#1" MSS^>/P2O;>CS<3L(R$QOHDA@YL.&XL^=Y5Q?C^6Z;.=$&G`'NN*0RG5SM\!! MK>R"MRN/8%.YH2P2&"6KIB&1!I1JQ)W*-5/FLR[SL29`)U.NL?%&`J/(-0V) M-*!<\WN2:Z9<`ANNFE;4.X<&OYW>P:_VF1(< M+DID=\HA1I$>T62V"Y!:#M.2#*^%!AAWFE2UZ`IQ>B@*'\R]F#FWMSLB0!<5 M\<223"RI:M&5XBQ1E-[)I9@\>BZ-<1L1`1*[WL(S!FL\+D/#G@])-QU2U4'7 MCK/F<>UB,FG:?4-(#"\SBX"5DI!"RQ9U"'+EKVNUI3*N*6SD[XGT!BSQ:Q5TF M(B&<@Z&XACW!.\X5>^R'<-*8XE,_A,,$[FHC$5Q)VFQ/?V;=OFRX5=$=2/"< M)>2Z$Y<:\="S=C@%;UD/EY'AYP$NGQ1.Y)X#X!UCO7S`%XS7VP(1<%5(U5-TF;=*TZ[,#)E@%S&RG M:?_]CC%0<*J*OG`QG[_S^=PXNYNGLG`>J9",5Q'"KH\<6B4\9=4I0K]_W<_6 MR)&*5"DI>$4C]$PENME__+"[):QA-[QY%S22AD200NB0+_, M62T[MC*90E<2\7"N9PDO:Z`XLH*IYX84.66R_7*JN"#'`L[]A$.2=-S-RQ5] MR1+!)<^4"W2>$7I]YHVW\8!IOTL9G$"[W1$TB]`MWL8X1-Y^USCH#Z,7.7AV M9,XOGP1+O[**@K;7O0+NT-A;#8[0"N(6(0FA>=S[.^\1G)^TB(-!P+5'X#$B[A`Z M?J"A%P*NF2Y$@[40'2ZM[&`6AG8#R^XU8MXC1D+`"T,A.E_FD*IO>T9O`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`9ZVZVFV"SM3V*A/-=V M'A_Z#?JW+%Y:XV^KW=4OOS7E^FMY*&"WH4ZZ`D]U_4U#OZRU"18[D]6?^PK\ MV5CK8I,][[N_ZI??BW*[ZZ#<`3#2Q!;KGVG1YK"C$&8F`QTIK_>0`/QK5:5N M#=B1[$?__TNY[G9+VPMGP=SU!,"MIZ+M/I#.,:09>H M$T*7#RB=><%N<5[0(:]4[$1#+Z(TI*3?M[H`H8ADBIB'%)).(>QKU!1A!"%$ MO7N(ZD70A$8M?!'3)%>(\?L>U,5(N"'E!F482([^/3GJ14L;-N+<+W*2(V*B MON-D(%S6"S0W%_-'8!H07S)[WETF#*:^(TT((TH*D)3OF"?5'?'UJ M^OT@<-FV*.J/W;&8A)9^RF`C_/JHTXLH/6\^QL4&91A(C@+TX?:-[%?1G9S.J0&$K2+"0+(.3Q@@C'UZA%(" M\+S`8P#%`)$_=A-EJ173:)>WAY5`?2536/)S,(!>/]\4<.&`4\"%$\X!KQUQ MH87S_>Q09DUV_)"N^HA+>RB='WCLE"0,X(<>+QU^RS`G8H^KF"(19!P$8VUI MZ;2^&N3TP]KUDRY0E4V2_K2$AG3WAS\9EHTG*YU8E&FAF6KAO#U3E%M(Y2SY MT\<2@:`QKV1B22<695IHIEH1;\\4==3D$HTP+S51+WNV9 MHE!>Z1L$F9ER2RJX19D6FJE6NMLS17TT]_1"WR`(^\(+^6-!(H@_D..T&%Z: M3'\(3[6T9HJL#R-_7$\9:IV\G2&JJ\G0G[Q$"4."AVG#+>D$HTP+R53>)=S] MJFN/%P/(Z)J))9U8E&FAF3+Q?=\$EQ=$F(O(:@`-*N-.NH;Z0<=H5Z3$[\4Q M$WE%_/[<':<990B5YUWCPZ![^S%#ZE7T(2O4%UAVU0`$U&?I\&J[ZT$O;K`4N&RWI!*-,"ZW% M75HJ412O=`U7SF189F;*,WRB!YIY>Z)J33O8W?6R2)))XQSF! MZD2\,>LG1;VOO,=++7`&LRNS!>709.3Q9[%5'Y)V"2XS]YY;E+F*[OU=VBE1 M!*]T"5?*9%AF9LHQRL203/7[P_OWLD?3.3UY81HP>"D7^1X3DH3X8X_?FJ3$ M+X(HXC.%`D(1\C;!>WR\YJZ*9ELDQ7[?6GG]K._H)5Q#G:WX^\%*+.#N&:Z0 MF3V%WQ5ZNW-VP+7^,=L6?V3-MCRTUK[80$AW-H>9TN`/`_BAJX_]3?)3W<&% M?O_G#G[`*>`BU9T!>%/7W>F#OKL^_R3T^#\```#__P,`4$L#!!0`!@`(```` M(0"`<%<4(`,``!()```9````>&PO=V]R:W-H965T"'-)D+*?-88-^?+^]6B!'2-SDN&(- MV:!G(M#U]N.']8GQ!U$2(AU@:,0&E5*V*\\364EJ+%S6D@8L!>,UEK#D!T^T MG."\%^![B<_Q%G/W2TNZ&N:<298(5V@ M\W2@EYJ7WM(#INTZIZ!`I=WAI-B@&W^UBY"W77?Y^4G)28R>'5&RTR=.\WO: M$$@VE$D58,_8@X+>Y6H+G+T+[]NN`%^YDY,"'ROYC9T^$WHH)51[!H*4KE7^ MG!*104*!Q@UFBBEC%00`OTY-56=`0O!3]W^BN2PW:#IW9]%DZ@/MZ$_67N/D-/LC(DU)D+.@(EF M)B3I(2J#BC?M-UY\?--EUR-4^4#2H`NR9>N:0MU?KU@O0SF9,H+`/"]^!6(B MDDM$-##JAB)O9':&[O1 MAA%C:,;X=A$4>(,@`4.?^$NK46*-672=YEO930RCY9F.C=.I*7EG&%_ZU]`" M+\FXL=[6HL"V%BO<6&/"3LN5583D+6-J&'U+Z^OC`+;6JR[)=88W65V MN,G8&%I92,?&N55P&%3J:$T;+0>A6HN>0?J*K@D_D(14E7`R=E3S)8`N&7;U MZ(O]%=R;&PO=V]R:W-H965T?C2R^RE:`V3`F M',!&ZWM,O2LP!,7A2?5M/X#OAA2B9-O&_="[+T)6M8-I3Z$A["LKGFZ$Y6`H MP`3)%)&X;D``/(F2N#/`$/:8TP2(9>'JG$YFP70>36)()QMAW:U$2$KXUCJM M_OBDN!?EL7II-\RQU=+H'8%Q0[;M&&Z>.`-@U)0"FD<85)X3">H09(TH.9U3 M`N46C'U8);/+9?@`;O!]SK7/@>>0$P\9(:@9)(&,L:27[3DP8S(RHUTHY=H' MQC3)RS23_Z'!9/![)#Z9+091^``C&C/#'/V`FV\"-YD MQ;ICUGWDF/7,;&$G/F\V3F%/O.XY5AUS[B/'G)-G!OL#[T^5$J82GT336,+U M%@]S`L=AB`[WS#K!;?(\GF;K?B>'PP]@!,1H=FEUNZP`.)P^.M8_04``/__`P!02P,$%``& M``@````A`$D\%3+Q"```HB@``!D```!X;"]W;W)K&ULK)I;;^.V$H#?"_0_&'YO;,F6;TA2K*T[6N#@H.UY5FPE$=:V#$G9[/[[ M#B_#VUA*O#@OZ\VGX0QG-"2'%.]__WXZCKZ535O5YX>Q=S<=C\KSOCY4YY>' M\=]_Q;^MQJ.V*\Z'XEB?RX?QC[(=__[XZR_W[W7SM7TMRVX$&L[MP_BUZRZ; MR:3=OY:GHKVK+^49GCS7S:GHX,_F9=)>FK(X\$:GX\2?3A>34U&=QT+#IOF, MCOKYN=J78;U_.Y7G3BAIRF/10?_;U^K2HK;3_C/J3D7S]>WRV[X^74#%4W6L MNA]7SP_B+M\G]]7CR>,\#]$]5OK?&_T?M:_V>--7AC^I<0K3A M/;$W\%377YEH=F`(&D](ZYB_@?\THT/Y7+P=N__6[VE9O;QV\+H#$@YMCG\ M",MV#Q$%-7=^P#3MZR-T`/X=G2J6&A"1XCO_?:\.W>O#>+:X"Y;3F0?BHZ>R M[>**J1R/]F]M5Y_^)X0\J4HH\:42^+VB9*#A3#:R(?S>UD,/-]4[^/8+C!RVHO!1N\WH9IPYP0;JHLZ4L2R`ZFY0M3\S"& M`,#[;R&SOSWZR_G]Y!MDXU[*;*F,9TOL4(*E'E,;NB!R0>R"Q`6I"S(7Y`:8 M0%A4;"!%_Q^Q86I8;-"K+0(C6$X@4`*;A"Z(7!"[('%!ZH+,!;D!K$#`T".! MF$&R7)\X,"=8*Y@BK)P(;$>W0L9;J.#L"`D)B0B)"4D(20G)",E-8H4`9ATK M!,.N,VD841#/@?$@A!8P+1E""SM`.R6D4H&0B)"8D(20E)",D-PD5CB@TS>$ M@TGS<*`36TGL"6/I^*Z$L%E(2$1(3$A"2$I(1DAN$LMW6`YN$U)V[Y+8ON^ M$8`V/"-;0#H,@"STO[@@) M"8D(B0E)"$D)R0C)36+YS,I?9M.VH(*:CBN@I+G!&>2AD`OA1TZ`7S.SA$"DA'`ZQ4HTD M440KXI"6E5&48Z(:[?CQ2I*,UY7)@(S+K(`-=-7(IB#5&+ZJZF;ODH*\S[T M"(HHBBE**$HIRBC*+62'@5629AB,P?U!1$0-"A%&Q[:>0'-^VL%GT!U%(441 M13%%"44I11E%N85L]UDQ:;K_@<^R]C1]ED@,6!N*"Q$46L-'H$,'W>>0KK[-*A" M:*"P4`+H7JP5(THTZK>52J%>6YD60,6Y5DQ"R0I>,Y0?##Y1'ULQDR4SY)6> M@FD%(:4@#DJ*AE$)8<\CCZ"8HD2C?NVI%D+M&46YA>RL8X7N#:$2=;$5*H'F MX),*@K]R*J"=)QM".:6D:*B4$#H3R7;SM:QNI\XR&*-B6/IZ%2HYM>JQ;H?;=G<-P5G)QNV"2*`!%RE=_Y3N%@92:#V:E%D)G(]3N\5![ MTY53,,3 M72(GV9V]ZPX;#J5;J(4P!I%$`=LG?GM<+L@+D!WJR39>&"5:[]`+D)IT)9%] M8#Q'O3W&[?BS"MV,_P>I+@IZ*]`"F7L#7Z%^QT(4TFG>RX4C@XT.=J(4611($87[-5X)P_QB@` M41X8W<*\82NEMC)4U66W8N#6PD/E\7^713(9$SEIW3DQTVU",EI"B2 M"$:N#IZ_N>;=\SE&@Q[R=FVRO,?0./G<*Y8LMB_42!+)R5B$=7IJS4DC/Q)'4'F@4 M(S)S]A/:4VRG5644Y8BNY"S;8ICQ^F`%%CL2*RX204VNU@-_Y9SE[WPEA=D1 M4A11%%.44)12E%&46\A.&[:C,,/`AJX?W,&T<>-]![BF0V8[B>P(.8-LAPWY M-1\^I$**(HIBBA**4HHRBM@E(]Y[W@D1(7%I2%P-.97-2[DKC\=VM*_?V(4@ MJ/8>[Q46MY6VRPU\,X/W[')OMF$G@=>>S.$)STZWC;^"JT\\N\F3-5Z* M55<1>'[5\6`#'YII1[>+#7R$I3Q<;^!;&.7I>@.?K2B'[T$0)'Y0ZO0(OMY` MD*X]@?,S:'/-.AQT01O^9*+4P0VQ2_%2_EDT+]6Y'1W+9TB8*?\DW(@[9N*/ M3GX8>*H[N!L&=2Q<-H*[@"5\$)VR$?A`@``%PF```9````>&PO=V]R:W-H965T547Y7D[MB:S\2@_[\M# M<7[>CO_^&GY9C4=UDYT/V;$\Y]OQC[P>_W;_ZR]W[V7U6K_D>3,"#^=Z.WYI MFLMF.JWW+_DIJR?E)3_#DZ>R.F4-_%D]3^M+E6>'MM'I.+5GL\7TE!7G,?>P MJ3[BHWQZ*O:Y7^[?3OFYX4ZJ_)@U,/[ZI;C4Z.VT_XB[4U:]OEV^[,O3!5P\ M%L>B^=$Z'8].^TWR?"ZK[/$(<7^WG&R/OML_B/M3L:_*NGQJ)N!NR@=*8UY/ MUU/P=']W*"`")ONHRI^VXP=KD]K+\?3^KA7HGR)_KSO_']4OY7M4%8??BW,. M:L,\L1EX+,M79IH<&(+&4](Z;&?@SVITR)^RMV/S5_D>Y\7S2P/3[4)$++#- MX8>?UWM0%-Q,;)=YVI='&`#\.SH5+#5`D>Q[^_E>')J7[=AV)H[M+E<6V(\> M\[H)"^9S/-J_U4UY^I=;6<(7]V(++_`IO,P7$W[%BWA\[;!6I`0 M?'Y89@CIAX<[Y3/<)HR?-=G]756^CV`5PA36EXRM:6O#_&*J$AE\ES+'4@: MYN6!N=F.00O(BAH2_MN]O5K?3;]!DNZ%S8[:6+J%AQ8L(YE;WP2!"4(31":( M39"8(.V`*<@BM8'$_3^T86Z8-AC5#D%'+$,(M,`FO@D"$X0FB$P0FR`Q0=H! MFA"P(#4A^O<1S`5FO1W#ORH7UC,]P!VWL192%(\0GY"`D)"0B)"8D(20M$NT MT&$/NB%T9@TK"714L9-UP(T6L*THH[6Y%*213`%"`D)"0B)"8D(20M(NT>2` M0=\@![-NY<`@=H)H&\7:UI/#DT;8S"X)'B$](0$A(2$1(3$A"2-HE6LPP45K,PX$R:SU007AA MP+9TCQ"?D("0D)"(D)B0A)"T2[1`6>G;/0>'`V76>J"<.+R::@.51"US=ZEG MNL]M7*@`Y%9@N7/=*)!&N!Q"Z1I))(ER9'862S_*QIX;^TXBC=!U*ET#T22# M46N2==9#\U+L7W.'`G.A*X2"XA.5:LUUJ01R M8/G*_+'71OYX:`6Y+ZV(?GU&4/P:*@HKUVIE7CDS5S<(T:![`II]17U]F49Q MGQ$94(+]B0$M;&/>4S2X,B`MH2U6"'Y\$VC-C0GAI:2K3X@Q)@\;@O'`A'!7 M8(N9%(AVSAJ3W)CI$!U#-7/5<81&0[W'R@A[3\S>YT;O*;:YTKLN-2LU;Y": MF1M2M>E9K5M5^I/[=.6J)!MF8X[@?1DMU;ZCN!APZ%T\Y41:A"@ M=W94?+NWEL;,AMCD2K:UITN$1D.=QV@TEZ$E`BU@[Y:S:RV-"VVJ&BJKSCZF MSP(KJ;NS$/-GE?@,,\HR,[BR'4D\A3J'8"X0XMVJC0)L)U"(2+E/5+HNO<8 MC92KA*(44>M=UX65VS?H(JKSKBX6)M".=Q;2SQ.S,G9$$&^Y,%Y+5\%TA/[?,^4U`RSN.]&6^-BH# M#Z[R[0ZMCBN?HD`@M[MH[;51%8?8L&ME+8RO$"*T4CW&%"7]/1J;5(H-K_6H M*\TN$5VE?[*4Q9VCF[(<:4M9(I7%G;U$+&5AI!9;8!$4(NHNY0]XC[&=\IY0 ME"+J65B2/*OY07*IMX[6/=JP>\H MFN8<:2DJD1*8IJ@P4G,56`2%B+HI^@'O,;93WA.*4D0T16WSRL52=`X]W_AU M=^M'KT<%,K[6,W9T3UEAWO@4!12%%$44Q10E%*4:TO+)AE31\FEX:VO-#1F8 MA^UXT?EF5UAUD$]10%%(44113%%"4:HA/698:%K,+"=@?[@Y)Y@?0PR!8/>5 MI8K]LOAS1(Q5X9$`ND2 M&=]*>;:T4A(1%%"KD**(HIBBA*)40[I$9G'?;BN?DX@6_K9`ND3&A=135DHB MV1!10*U"BB**8HH2BE(-Z1*Q4M8\J>S%I[*(5\7=TXKE(MMUX*.ST,P[@+)" M/7R*`HI"BB**8HH2BE(-Z1+U5?"+>?L#PZWG$RWC;8'T+#*_FE)62B+9$%%` MK4**(HIBBA**4@WI$L'H21:MX5"_51_FQ]B(.#)2R+C^>?#6AD@T%,.G**`H MI"BB**8HH8B].J(&P?7AKX+P7_9/>?6<>_GQ6(_VY1M[S0,._/L[B?D[*#O; M@9=0VA*)/''A27L+($\6\*0]VLF3);[28CX!9[V^P%6_IQEX:M]O,3W9[+69 M]KI'GMCPI+U@D2=S>-)^LV,\\5<;^&4%9M'@\6H#/X)0[J\WP;J'Q^L-?.E/ M[>$=GX?>$4$0_3'`0'O\[""`OO$_.."_O?X8`>Q@7GGE*Q_`NSV7[#G_(ZN> MBW,].N9/D!2S=F.I^-M!_(]&W!8>RP9>ZH'U`>^#P%M<.?QN-YO`WOI4E@W^ M`1%/Y7MA]_\!``#__P,`4$L#!!0`!@`(````(0`@ES^M;`(``+8%```9```` M>&PO=V]R:W-H965T=/RX,VC[8%<`09>EO2 MUKFA8,R*%A2WB1Z@QR^U-HH[W)J&V<$`K\(EU;$\3>=,<=G3R%"8]W#HNI8" M[K78*>A=)#'0<8?QVU8.]IE-B??0*6X>=\.5T&I`BJWLI'L*I)0H43PTO39\ MVV'>QVS*Q3-WV%S0*RF,MKIV"=*Q&.AESC?LAB'3:EE)S,#;3@S4)5UGQ=V, MLM4R^/-7PL&>O1/;ZL-7(ZOOL@U-*,!/0RJH M^:YSO_3A&\BF=5CM&2;D\RJJIWNP`@U%FB0/80C=80#X)$KZSD!#^#&L!UFY MMJ1YFF33=(YHL@7K-M(S4B)VUFGU+V(R']/(D9\X<#UQ3.;);)%.LK=)6(PG MI'?/'5\MC3X0;!F4M`/W#9@52/QZ/AB$QZX]N*0+2C!6BS78KZYOEFR/OHD3 MY"Y"\#E"LA'!4',41K'W"WNP%_9V^$CNXL&Y3/ZZS.0C,AY<4GR.P>?SEPE& MS#1TRWD^TX\(>3`ZCEF,2A=.1LP4EQ$S2>>O9XE-=&YFZ,[\VK?B&Q7U%T,@ MH[.G$YR0,]G%"]DX)[&1%)@&OD#762+TSL]`CJTQGH[CND@QHITV2!@9DX>''C]!#:=ZL=3DQX;?'_"-@>:8+@6FOW MO$%A-OYQ5_\!``#__P,`4$L#!!0`!@`(````(0!-,23??AL``,.7```9```` M>&PO=V]R:W-H965TEW?[JX"0*6P')(OW^ MGW\]?#O[X_#T?/_X_O_GX]-OSU\/AY+BX?;^^[EU6#V] MQN/Q\^?[NT/\>/?[P^'[BS5Y.GR[?:'Z/W^]__',;@]WK[%[N'WZ[??[M_^?MH>G[V<+T=>Q__`O8/]W=/C\^/ MGU_>D=V%K2C>\_7%]04Y?7S_Z9[NP#3[V=/A\X?S7R:K_?+Z_.+C^V,#_>_] MX<_GWO^?/7]]_#-[NO]4WW\_4&M3/YD>^/7Q\3/WZ@"]-^S MAWLS-*A%;O_Z_'IY?TGMC>7YV]_OSR^/# M_UG1Q%E9DZDSF74FD^C=9':Y,!XCY>CJ,3C].1!\I.#"%:0_7<$)U6&DP-(5 MH&'/!5Y5PVM7COY\6PTGU)/'>S/_PR''ZSCAOIA(9[RN'E+/V7KVNG"PGA=VA!\G3'S[T"E'S/O^X-6O:9#4A%YXJ=MATDRKH]HY/\G^LC8F#[BUKUAT.LTU2&LX"*Q!HD&J0:9!KD&A0:E M!I4&M0:-!JT&&PVV&NPTV/>`UR$TQ;P.&7ZN\-PP:GJ">'/CRF_H&ZNAM8-; M>@TD!I(`28%D0'(@!9`22`6D!M(`:8%L@&R![(#L^\3K"EJ@W]`51DTK'?7K MR#IE10M:T'NB:[_#UIV(.RP&D@!)@61`:D2O>\SC97IE=EUN8_+J)XQQ.G8=-_B-(]Y#9W*I^JD3<;$82`(D!9(! MR8$40$H@%9`:2`.D!;(!L@6R`[+O$Z^?:-/B]=/XBF;4?E]8LNBM7T!B(`F0 M%$@&)`=2`"F!5$!J(`V0%L@&R!;(#LB^3[R&I]'[AH8W:K_A'?$G@=Y7=:)N M$@!)@*1`,B`YD`)(":0"4@-I@+1`-D"V0'9`]GWB]05M?[V^L'OA=TN:->/S MP13TN\62A6RVUD!B(`F0%$@&)`=2`"F!5$!J(`V0%L@&R!;(#LB^3[P^H#.E MUP?C#6_4?L,[8H_BY@RQ!A(#28"D0#(@.9`"2`FD`E(#:8"T0#9`MD!V0/9] MXC6\.9*_H>6/O]W6\WC]3F)!J89U,ZQ[O3O3V9TKZ9JW]C\C(T]7KMM18D3:';*W:B M!8VVKK,G\ZGN;.M.*@Z82D%&&:(<48&H=*A7^4J0U$M7OA8K$4'E&U%Q35M$ M&T1;1#M$>X>&.MN<5__]SK:G7J^S+>JUU]JS M=2$!-U4JQHPR0>%8.<128ZH0`1N78LRH$A2.58N5S73I^VI$P,:M&#/:"`K' MVHJ5BZ7N:R<"-MZ+,2%_/3`'Z?X0&9CW=#CK)KX[=_2#E&*:),4-@]%Q%;%8A*1)6@L'LM(G9O$+6(-H+" M[EL1L?L.T=Y#?C>;`_D;NMF>WVG8<+B;B44SVJAU'1CI<;YV*K,D=2KL9N?> M%TWF"[T4N(#7Q[5BL;B:^X*48]&@"<;*6-2/I2N4#XF@0H53S5R%YA-5XY)M MQBI4L6BL0O60""K4^!6:3*\7:M:U[#-6HPV+QFJT'1)!C7:Z1HM(U6C//H$: M^8/69"?>,&A=,J,_:"V:]S<7T40-I+7Y)/#TVM2)>$HDKMSN-'GUY?JW1NRV7&HF]8-!9]*R*.OO.CSY:7:N78@:/EI(%8]$K,0Y'KT7$T1LVM]&OYGI?T[)@+/I&C,/1MR+B MZ#LVY^A+-<'W+`A$]X>9R:3UAUDO:?F&`[[-QWF+G$5JD5.?6Z[-*P.G%[E. MQ&V0N')SDV/XX^-,;1M2M@U,-#?V.MMP^^?L)"?,0L56D[SD$F.Q*Q:-+3&U MB/B^&S_VM7IFM%QB+/:&16.QMR+BV#L56W7EGDL$8ONCSJ01^Z/NQ#'291W[ MBYM%\UEWY%A/.A3NSYA%DF1,$*6,Q#T3%';/623N!:*2D;A7@L+N-8O$O4'4 M,A+WC:"P^Y9%XKY#M&=T=/?Z--()8+.21/-WM%\=[]UC03\5[)!*$J@GS)I5 M\BE)C"AQR#VH)HMYI/:>*2L"ZZ5=+=`Y1U2PE5V;)XO%M=IJEJP8"U:A"T>,JT5=-%BIBAO8YHF(XHFKHD@N. M1JQ8)?=8(VJ&(ZKG:W:.G*J_D,$4.)4_!"A M8ZUZ&*6LH%'3+3QZN&08+$=4L)5[B,QF.E%7LF(L6(7.-:*&K6RPZ'HZ47?6 MLF(LV`:=MXAV;,7!YG.8][;MYX%@_K0W*=_7[R(CET?N[2(=4D\+M:M>1JK*)9<9BU6Q2(QK M1(T?:S*_NE)]UG*AL6`;%DFP+:*="K:8+/0Q@PL%@OD#Q.1*^P/DYW89-N/: M/]R:]P]IM5%+BTZML*J_M+B"@A*GFB^/1]F)7C-2OAZ8$6YW"KXY1B_8RH:Z M5CN9DB^/1:K0MD;4L)6-%%W#FF+K&YKFQYO:H.\6T, M28WV!\R)C83+I/97%(N\C42'PO,^CIQ('I<)HI21/(PS06'WG$7B7B`J&8E[ M)2CL7K-(W!M$+2-QWP@*NV]9).X[1'M&`QL)DV+L]^G/+0(V4>DM`BYW26FD M;CV/(K5>K2-74-:]6)`4A`QFXE2:"7[C,6O6"3W7PL:B=_X\6?SN?X@HV6?L?@;%DG\K:"1^#L=__I2 M+6)[]@G$]U<6DVP<&X7_>OQ!V]>3N1*7L^RO.!9Y*TZ'Y`;U1`FB%%&&*$=4("H158AJ1`VB M%M$&T1;1#M'>0W[WF'Q:8*4\T5,N$]=;'*<6S>1%T#6B&%&"*$64(#T%%"-*$*6(,D0Y MH@)1Z2'_GNG)_I9[-G)USQ;UWWR==DC6=G@X.Y'W3CN\*9R(BE>85-P998+" M`7.Q$E$T52?$0E3L7HH[(;_U='KFIS;>4\S:..0UJE41DNICHUH1O14^_-IM MXHS[KXUCK$Q0.%8N5L.Q"A%(4W8W`4UICLMZ37S-9VM3>\[N'UL<\G,74_49 MPYI5='KH=B#8H-;=>TL7#A*)L^+7<9>U-7#G_TRW]"6+*[K1H=>[XZ1:KQNJ0BXA'?#%PJ'^@FG9(6@';V(DD49%P.4$I(SF49(+"[CF+Q*I`5#+" M0\G4'/?Z[?)SJ[$]-'JCU"*UGJADPF^GW< ME!6!N6K3(!*,X^>"1N(7[&[7BNNKN"TJ'ATQH@11BBA#E",J$)6(*D0UH@91BVB#:(MHAVCO(6\XS\SI M*K"FG.@I>R[KKR-',UHA>D^P]J)%M,NZ]P@:L6*W/V^,6>D?M_H)^BKOI`\ MLR3B=I6I"SHCRD=*QN*I47YD`@J5'`\ M]ZF[_E9MR=?'ZE,-A=+UJ8=$4)^&X]F]\W*J4^0M"P(5\@>(.<+JF?^:'(@Y MF>CGFT7^>S\S=>Y<<\&Q4VTL(A[DB4/ND]OII?[F9\IEZ)$0'(,9B\:BYR+B MZ(5#[JL1\*$MEQB+7;%H+'8M(H[=.-3=.7Q!@A[$(N(V2!RB]WGZ[K`TV#IX+\!@7D7LQ4O7(1<1 MUZ$8KH/:1Y2LZL\^J$,E]N$ZU"+B.C3L[K>#^@RS956H#OZ(T#F,$\\(3%:8 MKR/1:.@?DP6%[R]FD61?$D0IH]XQ65#8/6>1N!>(2D;B7@D*N]2/9GK6>*/Y1/L9N6H_BVCWRD^[M7F0D\IL:+L] M!8Y:*SIQO'=6I&+W5-P998+"`7.Q$A$>[T7%[J6X,ZH$B9>^P]J)^L=[1*U8 MD;O?-[0<>7WS4\=[\YF6[C*+_./]7)W)UZ[@B5YT5K0H=EV-QWMGU?\L6=RY M43-!XJ4;-1'Q7E3L7HH[HTJ0>.F`M5B)"(_WHF+W5MP)^1VK\S8G)ATF M:,SG&&:&^;L%_;DUJ_J[3GU_\9`(]P].10N)>80N%C/U"$U90+.Z&P@Z5C84 M2XOR(1%4J.!X[GBOOSM3\O6Q^E1#H71]ZB$1U*?A>*Z!KB_51],M"P(5\@>( MSO^8F?^:X_T<,T$.G3C><\&Q0VXL(A[DB4-N:T7_'(=:15(N0^O$R+APU1Z+ MGK.3;/\*AVBFF5$)QWLN,1:[8M%8[%I$?.>-0WSG4_U^4,ME`M']#CMMT=0ATJL1<5K@>N2>5K2\UP'=01JV55J`[^B*#[\4;$ MB6>$D:N-F46T[G!;K4U'DR4H[%ZS2-P;1"VCH[O?ZCJI\G-;+LRUS%VNA<9.U_(1'.^=BG[FBKLL%B0% MX>F3.!6?[UDDX7-!(^$+IW+K,![OV64L>L4BB5X+&HG>.!7? M/![OV280WA\!)A4PMA*_\GCO,@J]5ZG,2<=./N[JVF M:W5$,:($48HH0Y0C*A"5B"I$-:(&48MH@VB+:(=H[R%O9M`/"[^I+XQ<]85# M,L/71U-2"8H1)8A21!FB'%&!J$14(:H1-8A:#_GM1\_]MXQE(U?M9U$_U6+. M\*0:/Z0[D9EF\O"!-RE$Q3,E%7=&F2#QTDM6+E8BPE2+J-B]%'=&E2#QT@%K M)^JG6A"U8D7N?M_0H\'KFY]Z[E-XZ#*+3&1I>OU[O6M7\$0O.JOQ5(NSHFG, M+9B*.Z-,D%1+-VHN5B+"5(NHV+T4=T:5(/'2`6NQ$A&F6D3%[JVX$_([]FVI M%DKY0@\.IEK41YAK5W#\!#4DPKV<4[E4RW(*;U*PH#^F=%MF0[&T*!\2084* MCF=3+;,KE68J^?I8?:JA4+H^]9`(ZM-P//I.""8PF'6$0\R!.'W#8WNM*WG7(96B>Z\+J),Q:-1<]%Q-$+ MA]P67[]/57*)L=@5B\9BUR+BV(U#?.?7^O6QELL$HOL=;H[O8QO\5[TT1_\Z M%_2^12=2+:[@B87"64F*(7'ES-&UZ]QHKMYB2%G5'_F0YLA>4X=<1-P/!;O[ M=5"9X))5HW6HQ%[N1P_66D1)>("H9B7LE*.Q>LTC<&T0M MHX&CW7\DU;+`5(M#_BJ\4'GI-1?L'SR<5W]Y@J=/X@JZQ6BQU&,O9>?`8F13 M+2R2\+D@:74(7S@5K\/Z58:27<:B5RR2Z+6@D>B-4W6I%OUV=,LV@?#^O#.) MC?Z\TYONUZ5:%C8_TG^9QB%O/KHLRFCJD\M)NB)!E#*2&9,)DM;3JUG.(G$O M$)6,Q+T2%':O623N#:*6$<['Y=M2+4>YOPHZU&]UAVA#Q@MXC"A!E"+*$.6( M"D0EH@I1C:A!U'K(&\U+6C:\T3S^%#G*5?L9A^-9GAMK[53C!T,G.G&\%Q6[ MI^+.*!,4'FJY6(D(C_>B8O=2W!E5@L1+SYS:B>B8Q^4:1*U8D'VC M5YI7[?F6QD5UF47^\7ZA#DAK5_!$+SJK\>.]L^H?[\6=&R<3%&[47*Q$A,=[ M4;%[*>Z,*D'BA;TX>(?J<_(&`[;B#AU+SQFO8T],.B-7/6B1OVO7OS&Z7CH5 M;>JZW;>^OWA(!`_PQ*GX>!]=J7>M4Q90:P5C94.Q=(7R(1%4J.!X[GB_5!]; MEGQ]K#[54"A=GWI(!/5I.!X?[_76K65!H$+^S-?Y'S/S7_,FQ1(S00[Y&TLX MWG/!_BY2MT0L(IY"B4-N:S5?0-J'R]!0'!D7KMICT7-VDNU?X9#;5E[#&'"V M8[$KL0U7L!81WWGC$-_Y4O]SI2V7"43W.WPHG_/F+TJ8?Z98+Q06^0L%O$GA M"HX?[T7$;9`XY!_O%^K'95-6]4<^'N_%/MP/N8BX#@6[]Q>Y:`%#P26Y1NM0 MB7VX#K6(N`[-1O;#H7O+^9RZ+9?-HO3/=DN+ M_%58/R/63M7_7%&0W#8\?1*G"A_OV2:P&-GC/8MDA7L>@5 MBR1Z+6@D>N-4X>,]VP3"^_/N5(+G=OA\-+ M?/MR^_']P^'IRV%]^/;M^>SN\??OU,ITIN_ALZ?#YP_G-XO+E7E-@]JW*^"N M+*]7)L;`E045&>)+*C#$KU;[XTC3$2**0+\F.A!A2K6B'[(U2+G% MRVB5T.$.R]#A=%4,7JGIBCDC8IE?)JM?AO@-A1^*?A/1K0SXW$RIN@/\E]GJ ME^'&G:WVQPFG;N]FOMH?'Y^*KY>7*Y/@PEN@'-?*I*OP"F6L5B;YA%?BY80: M<>@&*4]#C3ATA1(JU(A#5^(%=0FE,S`.O=2Q*@:OT-L7JV;P2KR8DMM08]++ M!>0V=(7>`B"WH2OQG.I&;_`.U(VN%(-7Z$LXJV;P2CRGNM%S=LB-ZC9XA;X, M0FY#9>BW/%;FQSO0+9[-5N;W+?`*_53%ROP0!5ZAWY0@MZ$KZ_ED9;YFAF7H MFV8K\Z4QO$+?&UN9KX#AE7A*;4`_6HE7Z#B24 M6,>[DK>Z@X(^@Z5WB\^?YGMMGFP#X`@R=+:@C7-]SI@5#2AN$]U#AW\J;11W MN#0UL[T!7@Z'5,NR-)TQQ65'`T-N+N'0524%K+38*NA<(#'0^`D((N0\0_$;(*"(8:D9A%+M(R=))C.95,K&(+D^F!P_B,9MAYXW4]'VIV6LIWPG9["9!BO_7CC_W6O6X M@\UX8G#V1C6T9"A9!::&+]"VE@B]]>V681'&W?@2+#-_.V_W)_ER>"%8_($= MVO,:'KFI96=)"Q52ILDU>C&AQ\/"Z1XCQS[5#GMSF#;X%`,68NJ-5UJ[EP4* ML_BX+_X!``#__P,`4$L#!!0`!@`(````(0`SD2R8+!8``#F!```8````>&PO M=V]R:W-H965T&ULK)W;Z)= M/)_)F-V]5LME6]&6RB&IVS-OOXDBD@GD3U(JS]RTW!\3?X)(($DD*?']W__Y M\/WDK]W3\_W^\KTY/GE]O'S[??]X^[ M#Z?_VCV?_OWC?__7^Y_[IS^>O^UV+R>D\/C\X?3;R\N/F[.SY[MONX?;YW?[ M'[M'.O)E__1P^T+_^_3U[/G'T^[V\Z'1P_>SB_/SS=G#[?WC::]P\_06C?V7 M+_=WNV!_]^?#[O&E%WG:?;]]H?X_?[O_\O)P=Y-^?=P_W?[^G<[[GXO5[1UK'_X'Y!_N[Y[VS_LO+^]( M[JSO*)[S]=GU&2E]?/_YGL[`#/O)T^[+A]/?%C?=9G5Z]O']88#^]W[W\]GY M]\GSM_W/^.G^DGMYP_*5J+AS[23VXP[^':-J"?QYW4@N97'VXST6PH MWWA:BV&JT#^X[?R)+7ABF']PD_E36_"4,/\X\N1X>G+4JWY@Z!_< M]I63XQFR<*;(*R?'4V,A<\-=;C.3:L&3Q/R#.SA__9!%II((90^C\IN1^7!*9T+YX9DRWU\?%ZO- M^[._*%O=69M/(S:^Q98M3&HRLH$&H0:1!K$&B0:I!ID&N0:%!J4&E0:U!HT& MK0:=`\XH/$.,:,'\)V)D9$R,>'0_,9"@7:B`L`4W"30(-8@TB#5(-$@UR#3( M-2@T*#6H-*@U:#1H->@P-.-BC?POWCA-S)^1"RA'\[JN%:K8S#B0`9`0B`1D!A(`B0% MD@')@11`2B`5D!I(`Z0%TKG$"Q+=4'E!FE\=QMJ/A27.Z@`2``F!1$!B(`F0 M%$@&)`=2`"F!5$!J(`V0%DCG$F_@*;P-,V]HB!-];^P%OBS'@@`9`02`0D!I(` M28%D0'(@!9`22`6D!M(`:8%T+O$&WI0#O)'_Q0O"0<>/"2-*2L&40!HA!1A"A&E"!*$66(\F-A-HQN+/HU].Z2 M[L)>"4N_U:2-!T_^3V830I%:'6J^AW+(%E&`*$04(8H1)8A21!FB'%&!J$14 M(:H1-8A:1)V'_+"87:,;EE=B83>9;BQZ=*C=VU!H$I@BI8G7$,$02`0D!I(` M28%D0'(@!9`22`6D!M(`:8%T+O&'WFS\W*'_U:M*OX&D&,OZZ)&,]];4>@\1 MD,O,6A58`FNSI&`YUZ*%?RT*Q8K=18AB1`FB%%%FD70]'XCT2G>]$"$Q6JQ5 MR:X4*^YZA:A&U"!J$746';KN1]KL-#'2A]SW\NW^[H]/>QIPNOJ,++XE58QM M'=GN5]TX]T@&:VOJ.J_&N;=9TI1PXKS4<1ZL>+`B*TX-&<6($D0IHLPBDS6?WWXVRWO&Z<>R2#M34/4UZ- M.ER<+U8ZQ(,!QS,:=)G$`Y$1UV%)K(UX4A%)Q8!ULT&723Z0:4^% M")D'*7A.I1BP;C7H,JD',NVI$2'K29U3*P:LVPVZ1/P,8';3[LP86>GTN'18 MZG;S[4Z!'EUXY=>UBNC6/#"C:7'AIG`=K4",N.,AH@A1+&AZW!(Q8O44488H M%S2M7H@1JY>(*D2UH&GU1HQ8O474><@/L]F['Q'F?JOO7;E[Y$=Y[:_;K7D8 M^>KB1QMZ).\+A5;H8G7($,OEA;K81\9@N$;HB12_H1_)B`WT(U7]6%RI>9W- M]B,?\:'[6HS80#]*OQ^;RZ7:B%>S_:A'?.A^-",VT(\6^J%R3S?5#W\VFH+& M$;/1UC_-V8:WFD\Y@Q$LKY';]]>E:C77$A^DB-3,%!]EIHX25 MEL-]2\JH][U:J$=4&1^?;L%@P^=MU-.7R!R>GFZ#W+1-,MBPR]1WJ78EV:S'?%";]E@,-NRQ]#WJ&^1J MUF4]R$V[;`8;=MF*2VFV6*OA[3S/BXVL>7]>'5>XN\#"G47T@SNX%20=Q/G2 M2UU<#>U";B(JH8B7HM:%J]82-1 M;Q%UC`[J?DQ-SD2+KPA M6UWW-T2K*YF@ATUXQ`83V?%@%+.1N$\$R1"#^Y2MK/O-N;X/8H,Y]SD;B?M" MT(S[DJUZ]YMKO6&LV&#.?_>7%2F7*C@TFW/O3C0(].]W^ ML?\Q57-Q=F)F)Z7G6X]HIO/DVEHK,_DGKQV!-:*7H;A=B"@2*;:*!4VK)RB5 M(LI$BM5S0=/J!4J5B"J18O5:T+1Z@U(MHDZD2-V/M2ENNJEE?G=-VQV(:8^\ M^XV-NBW;VG92A0F`A$`B(#&0!$@*)`.2`RF`E$`J(#60!D@+I'.)'PU3HSLB M&GU)S\OH/3++?5A.B[7>!=,J-6&D:<&S+1#D-M2[7K:B]B*_4J8*6C,U4U%C_P9J#>^%[V1FQ`T":W- M1;_=6"]AFE&+81;JV]$8/"1`4M_#:J%N63)S?-)##GH%D-+W0+_UXI>1JED/ M->@U0%K?P^I*C5(WY<&/^G%%5@H)1'VTR`K[SJ'(*HD'4&CE:=Z:^K%>>A$? MG@M.S$:RIA)$*2-_`:FLE[&5ZQ#R6O0/3=_FIC*J'M]^K6-2%]?]2Y;/?)RQ@8F3V_DY@Q-0MI] M'JYL-*F&A;O`2@59.8?5HHRMB#A*@*2CCO3RSHS5M*,<9`L@Y;@C=8-5S3NJ M0;8!THX[@G0R=4;^1#&5,'>BO');V1?.O!EA:VGN5F%`,J9Z;007UDCVVB&B MB)&HQX*FU1,V$O444<9(U'-!T^H%&XEZB:AB).JUH&GUAHU$O474,3JH>S$U MOXKBQ?27%O]!Q;]AL,B_9[U4]W-;MI*D%R`*&=GZ\+DJHD5\W$UW>@[%;"2N M$D0I(R^_7JH[P(RM7(=N?CW<"^=L)1X+1"4CWZ.ZW:O8:M9CS5;BL4'4,O(] MJNMCQU93'OUI=%R!L)&HEX@J1J)>"YI6;]A(U%M$':.1U$`7;B\US*?[I3%7.:!'W@W` MI;I7V=IVF= M*?,NFPZ2+=]Y48+B@FWH%A<0A8S\S*)N^2*VFLHL?26!K227)8SD[>/4(C.+ MY9;L4ET@,FDH5OH"D;.1."P0E8QF3[%BJ]E3K-E*/#:,Y!1;B^9/L9.&HZ?H MSZ7CZH/FQ3@]:6Q]4'+2UEK-UWS92')2B"AB).JQH-'3.TR9A(U$/464,1+U M7-"T>L%&HEXBJAB)>BUH6KUA(U%O$76,#NI^3&E">MGZUV[DC(I*XCWRT@,F M\=[(3>*:A/0VG-$V>U-GJ4)R("LY[#P0M5E!RZ96UB1.:8<9P)7%I:]5"ZLJ M)U2^J?N5L9)NZ.[7(-M:,M_]SI-UNN]/`^3=A`U(SLOI MP"$JP=(:R>0-$46,9&G$@J;5$S82]111QDC4D5$K.5>$P0I8Q\CZJLD;'5K,>AAB0Q!4SA#62=1":/XI@K@>" M(D:RRF)!T^H)&XE4BBAC).JYH&GU@HU$O414,1+U6M"T>L-&HMXBZAB-9`A3 M&W-C^FL9HJ^P>1G"%MW=_UX(E]-P.9 M\=V.^U;W7]VD;R^1T&\:SD^ZM[U-BUH6KU!J191)U*D[L?ZN-K>"FM[ MC&13NT44(`H118AB1`FB%%&&*$=4("H158AJ1`VB%E'G(3\6M,N!9+^B.X1C M_W:1T5$+KT?&M^3<*U5)V:X&*YZ$`:(0480H1I0@2A%EB')$!:(2486H1M0@ M:A%U'O+CIJMW\S=>*RS3,7+7D+42%*!5B"A"%"-*$*6(,D0YH@)1B:A"5"-J M$+6(.@_YL=#5K_Z&Z?@UA&6QE47>S;C^18ZM6,D:&AHR"M$J0A0C2A"EB#)$ M.:("48FH0E0C:A"UB#H/^7&C-.?EOE?6D#%7*[%PJPA8W[L=F4-8=UH M99$LF"VB`%&(*$(4(TH0I8@R1#FB`E&)J$)4(VH0M8@Z#_FQ,/4/O7$W3]V/ M74-]'<7=NJ]ZI-:0*H]MQ4K6T-"048A6$:(848(H190ARA$5B$I$%:(:48.H M1=1YR(^;*3NX<7ME#?55"B\\%KEK"%"P`A0BBA#%B!)$*:(,48ZH0%0BJA#5 MB!I$+:+.0UXLUF-UB%]80P<=_SIDD5I#JN"[%2M>,`&B$%&$*$:4($H198AR M1`6B$E&%J$;4(&H1=1[RXW9<36&--05&SAI"%"`*$46(8D0)HA11ABA'5"`J M$56(:D0-HA91YR$_%F,UA<7Z#7^);(U5!(MH)\SK88LH0!0BBA#%B!)$*:(, M48ZH0%0BJA#5B!I$+:+.0WY8CBL9K+%D8)'4YK=``B`AD`A(#"0!D@+)@.1` M"B`ED`I(#:0!T@+I7.(/_7^H0K#&"H%%;DQZ(_KO4':#XK9M9=[Q&8P6:[4G M"L6*UUZ$*$:4($H1919)UW,@A31S.GJMGEF68L4=K1#5B!I$+:+.HD-'_;B: MS;Y[Y_9+C\K6MF0@*>Z313(TVX'(.&!4>R'S3H\3576'$5HELN+!BA#%B!)$ M*:+,(E'/@132;*:CI5AQ1RM$-:(&48NHLV@DJF.U"'O]>OLOTJ^Q$F&1#,UV M(#(.&-5>B-[8&?^+7*$5(0,>IVC091(#2:39^-_?2L6`53)0R8$4W$P^]E$B MJJ!=#:3A9L.9JZG=+LG,;^W7 M6'FQB&Z,AQ@OKM5,V%HC-^_KB1`,-KQ40I:FN>AHJW<'(F,EA_4+B#'()D#2 M-SG*YAWE(%L`*<<=J3<2JGE'-<@V0-IQ1^K99C?IR)\CIBSS[]]$V.*.>Q/1 M(R]?T5<1_=\MWJZME9N*\Y2SD7@J$)6,>D\KF#CVE.<\U:PAGAI$+:/>TT:-7L>')SQY\V>C M2U;S.>9@[E>F+')?D1$DBQ]F!1O)FV8AHHB1O,<6(TH8B5:**&,D6CFB@I%H ME8@J1J)5(VH8B5:+J&.$;]-M=&'JE[8(!Q45M+Z$Y5X8Z*^UJL5MVYG7@8<< MCF'LE=RK!]P.A%:)7K`S=XOZ-](C(O3TG>Z4=?::M9IC4Z;MSAM?:?ZMPVZ*:=^(IBINQWV+6][AVZ#13B+O`31 M6Q&:CGM@V[GOT"&*4#U&E&##%%&-$!38L$578L$;48,,64>" MTM$QL3#F*A8],B\+#>GPXES=LFSI0\RF(5EQ/@P0A8@B1#&B!%&**$.4(RH0 ME8@J1#6B!E&+R'RE6@:G#T__U>G^V[$/NZ>ON^WN^_?GD[O]G^:+TO2&S\?W M`^X_=_UI=7UC'O/1^.HCZ_,;\R!I[`A](YL>:XP=N:`CAUMKK;99TG>U#W&$ M(RO^XK8^LJ(V?>SA"+6ATQGIP6I-1PX5'FBSH2.'M0]'+NG(H0P#1Z[HR.&6 M1A^A81L=M06->(:*1G"QHU^BS-V!$:M?XQM?:RHC;T('2DS8K:]`][5!OZ M@/EOHQ$P[L>42&C4G@9_+%Z_K6Y^HZDWUB7JT1BGB(P&A.(Q&@Z*QF@P*!9C MH0C6JQM3-L<>457\QM2I\4BP7E.;L5Y1S97:C!T)UIL;4T-$-2H1DMK8$2KR MW9BJ'K:AHAWY&3M"GS^Y,1\DP3;T=9$;\[T//!(LZ'SH"18 MT/GT[]^I*42?42"UL;[19P]NS)<-4(T^4T!^#D?.!CGZ'!YQ/]U_-'7[_/R_V3V#^OG^A3];3E8*^<;V[_;RCSTN?OZ-B M_9?]_H7_AUR?_=P__7'X3/;'_Q<```#__P,`4$L#!!0`!@`(````(0"ZBF'J M?P4``(T6```8````>&PO=V]R:W-H965T&ULK%A;CZLV$'ZO MU/^`>#\A$')5DJ--8-LCM5)5]?+,$B=!&W`$[&;WWW?&%S+&)&&EOBR;SS/C M;SZ//>#E]X_\Y+RSLLIXL7+]P=!U6)'R758<5N[??SU_F[E.52?%+CGQ@JW< M3U:YW]<__[2\\/*U.C)6.Q"AJ%;NL:[/"\^KTB/+DVK`SZR`D3TO\Z2&G^7! MJ\XE2W;"*3]YP7`X\?(D*UP985'VB<'W^RQE$4_?W\[>4YV<(\9*=LOI3!'6=/%W\.!2\3%Y.D/>''R:ICBU^6.'S M+"UYQ??U`,)YDJB=\]R;>Q!IO=QED`'*[I1LOW*?_$4JYOF_TLI'5DV40$6!IXKB3P;CZ7#DPZ3W'$?* M$9YZ^L'4'\Y'./F="4/E!\^O30AA1;[P5(XCPO1^NI[43BQ%E-3)>EGRBP/U M#>)4YP1WB[^`P'H-)/]F56XM"NB(09XPRLJ=N@[(74$EO:_]4;#TWF'U4V6S MZ;`Q+;;:`I<'PT9M(":`!PDT6<#B_0]98!3,0L^_T<`UK5926VVA7:(V$!/` MH`QE0REW%[W6%XU7+OR]ZAO,3?4VTL:?-/2W%A)92$P1@Q^49W]^:`P5!+E> M"5H%H(S,*AF966P;HT91"XDI8G"&`N[/&8T%9SW31B'07VYGL6V,M%MD(3%% M#((3DR#NMM$,3S=U8/3>%JZ_NFAL$I1( M('J"V-Y;"XDL)*:(P0;?`EH'5S`>@)+W=Q*ZF;P4(KL"'CM;A4"9D3H8FU)& MRDCT1Y%.W.DV:=P,]K!,E/U]SFALT)-=`PY4O5$W>+AB%5!A%63JTRY4[4B%[72^!44V%!N0*2RD3#F1@_0!/71LK;N"J+`*@L>=$\!75E383L=K MIS:3P#;17UBT;C&7D"&L!47X2@V.Q"HV(),3GOZ$4^^30'4-NNP*HKHJZ(&N MRHKJVN48#F\4+/8,DL.#BI`=QMAJM.G(5N5;4&1#L0&9NF)S()QZZZJ:"M55 M0537SM9C'03*BNK:Y1CZ-W3%_D%R>*"K[#:&KK0!*5TM*/(M*#8@0U>HZB]P M$M;F'M(045-#]ZM46Q$U-60XAM=/!I/YE_I5()L355-!,*GN$5L;BFPH-B"3 M$_:%WBLU(U>QR#*_?"R;S+S6IP&Y2"C+4M)N4;14; MD,D)FT%_-=&Z59L*HFHJ"!YW.E.@K*B:78[A]?O`9(XM@S#'TVH,%?C%6P'\ MKFFGI"#8XU?^8:L:MMIQWI1V9$-X-R7""RO)7]XUR0N.G)4'MF6G4^6D_`WO MD?P97$TTL+SDV@0CN.4:X436R%C??[5'?+@9DR]BU@A$@]>6CF@^1(.^VS4R MA1%QZV!%F\.(2*\]$N#=G*B+U@AI!WI_UD`9^:'?:@1J<8H(5U(>LJ)R3FP/BSP4 MK]>EO$Z4/VI^AL6'&T%>PRV@^/<(U[X,OO6&^,6XY[S6/X"0UUPDK_\#``#_ M_P,`4$L#!!0`!@`(````(0";ZNW*&PO=V]R:W-H965T M&ULE%3;3MPP$'VOU'^P_$Z<9._19M%21(M4I*KJY=GK3!*+ M.(YL+PM_W[&]A"T@`2].[!R?,W-F)NOS>]61.S!6ZKZD69)2`KW0E>R;DO[^ M=76VI,0ZWE>\TSV4]`$L/=]\_K0^:'-K6P!'D*&W)6V=&PK&K&A!<9OH`7K\ M4FNCN,.M:9@=#/`J7%(=R]-TSA27/8T,A7D/AZYK*>!2B[V"WD42`QUW&+]M MY6`?V91X#YWBYG8_G`FM!J38R4ZZAT!*B1+%==-KPW<=YGV?3;EXY`Z;%_1* M"J.MKEV"="P&^C+G%5LQ9-JL*XD9>-N)@;JDVZRXF%&V60=__D@XV)-W8EM] M^&ID]5WV@&9CF7P!=EK?>NAUY8_P,GMQ^RH4X(DY*Q-XZK?Y&5.:C&EGR(PL^CRR3>3);I),,1=\@83&BD.`E=WRS-OI` ML&E0T@[K^S!7MG[X4.YB`>G,OGK,I./R'AP27%]"CY?C;Q1.6*FH6%.\YE^ M1,B#T7+,XD3IN95'$+;K$VB2CN'\YR9VP*F;OD.GZ2J9OU52?R\$,CI[/#FU M-IMDSU3CJ,1.4F`:^`)=9XG0>S\&.?;&>#I.Z#;WGCT_GQ;;,#)L_("3,_`& M;KAI9&])!S52IHF?%!-G+VZ<'D+_[K3#D0FO+?XB`=LC31!<:^T>-RC,QI_N MYA\```#__P,`4$L#!!0`!@`(````(0!ZP(7!900``*8/```8````>&PO=V]R M:W-H965T&ULG%?;CN(X$'T?:?\ARCLD=BYF^^^G['(N-DP#\])-4L?E4\?E$WOQ^:TLG%=6BYQ72Y>, M?==A5<:W>;5?NO_^\SR:NHYHTFJ;%KQB2_>="??SZH]/BS.O7\2!L<:!#)58 MNH>F.N4V?S;ON)UNBF@[C<2IEF;6SU\8J`VK)-<@0WG+Q+Z M;2M?P6#O8O2S6H&_:F?+=NFI:/[FYZ\LWQ\:6.X(*I*%S;?O3TQDH"BD&=-( M9LIX`03@KU/FLC5`D?1-_3_GV^:P=(-X'$W\@`#MD)]'P\G\$ MJ8JZ)%0G"8"]CM,QG48DBF]G\9"1*O`I;=+5HN9G![H&YA3'5/8@F4/FMC+D MT=7ZJU*A1IGDB\RB(2=Q!#(Z@W9#CQ]PD&'I@*(4_Z_(J M2=>("54W28V3P0MCYM"<6:[@;77DH*4+Y?6+07R+`6*F:CE'D25>,HP&41AU M@PURT-[WRR+!EBR$='E1%L0,9!F\,&:.'YE9@FTYK(+7B(F5'+$_L]1*,*R( M&3R@X>]70()M'H&E`&(&"K0OY+8;D;@G9O"0WR)KH]]N$SG(YA-:?!`38IM, M@HD93LQPW+N"P6[V.^SD()M=WX?8+XC1[.QN2HSHM%?:X$;`:QZ73HVRV?7F M@>PT")LJ"D*KYQ(C/B+^H`"3HF7C']L/0:,U_(=8Z[;6H$&?#=^8LTN;?+BW M")JKZ4%]>VB!$*37CP:62R8ZB8Z'`Q&9C*T;/S&"E[Q;]IO?*T=@G!B,K%V1D+:L/VYE2>;H5@WJ*`!&R+1 MODA-!4&M2#/?V@B)FG/IMNLXZ6LQ5;)<_;Z/';EB[Q>'`0U"!L'41K_<"M;'X$;_H8?#)NN/,M3J]35IC5Z>S=5I:OC&T(=: M;O_Q[`IMN3RUFGNM0=A:<%JWOI!F>+!/35X/63Q%BS=W9=\1N%X:A"<\:AF; MO%#)SZL^_Y%X`$!B>%W"VT3)ZCU+6%$()^,G>14B<"#HWN(U;0W7-'6G\;H` MW)*.Z9[]2.M]7@FG8#L8ZH\GX!%'=9C?\`;N1^KG`>[##`[&_AC` M.\Z;]D'Z67?#7OT$``#__P,`4$L#!!0`!@`(````(0"+`-&PO=V]R:W-H965TD(G5&2E[3M?]"I7^[^?AA=>+B41:4 M*@\4:KGV"Z6:91#(M*`5D0/>T!I6*UHK+2)H213XEP5K9*=6I>^1JXAX/#8W*:\:D-BSDJF7 M5M3WJG3Y<*BY(/L2\GX.QR3MM-N+GGS%4L$ES]4`Y`)MM)_S(E@$H+1990PR MP+)[@N9K_RY<)N'0#S:KMD"_&#U)X[\G"W[Z)%CVA=44J@U]P@[L.7]$ZD.& M$`0'O>C[M@/?A)?1G!Q+]9V?/E-V*!2T>P(986++["6F,H6*@LP@FJ!2RDLP M`-]>Q7`TH"+DN?T]L4P5:W\T'4QFPU$(=&]/I;IG*.E[Z5$J7OW6I/`LI46B MLPA$G$7":!#-)^%D>ETET([:!&.BR&8E^,F#J8%[RH;@#(9+4.XRTSXNN;Z5 M*N2((G>HTFI!%A+Z\[09A^$J>(*:IF?.5G-FOG?AS"8V9==1L(*H&W?`:XRC MFG0,;!^D=,D+JN7F-8*^_[UC71H8Y*81V1ZW?8[#V/49LZDM$OSRQ2#8`J-9HS#D6URJSGC=@BQ&SL7B%T@,0#+X[CO\7HW,&CM M0R$N`S,.QXY'S9GKD9O;BSMS,71F+387(W>JS,71ZZ*5$]38G+!_3Q:2W5P< M1UO-,>KM`K$+)`9@>9O:WO"IOCX3&'1M)C3'\.@"L0LD!F!YA#>!63_T>'TF M,,BMH_-P;37'\.@"L0:F[=0LAO"Q!R?I`O!%]KIFN<>MW7EO7G>/0:[[F7WO MK>88[ET@=H'$`"R/B[['ZU.`0=>F0',,CRX0NT!B`)9'V+;_HY!ME%M)=P[. M),-F#XDOB-WJ=O?!(P760L])%)ISHG/0!P:]GU94'.B.EJ7T4G[$PT`$\W5! M]4%E&RYADX.]RL%C/,`@'EP6X/S0D`/]2L2!U=(K:0Z2P\$,'GFA3R#Z0O&F MW;+V7,')H?U;P$F1P@M[.`!RSKGJ+O`&E[/GY@\```#__P,`4$L#!!0`!@`( M````(0`39DD!A`(``#`&```9````>&PO=V]R:W-H965TZ MA9P^@:4WRX\?%GMMMK8&<`096IO3VKDN8\R*&A2WD>Z@Q3^E-HH[7)J*V":A&PP`GT1)WQEH"'_LWWM9N#JGHS@:IY/9/$$\V8!U=])S4B)VUFGU M)Z"2`U=@20\L^#ZR3*/)+!Y=0,)"1'V"M]SQY<+H/<&F04G;<=^"28;$KV>$ MJ7CLRH-S.J,$8[58A8?E*)XOV`-:)PZ8=<#@<\`D`X*AZ*",:I[!7]M[Z M4-9AXU0F?5UF]!X9#\;BG`0_BJ\'WJ`<,..^84[S&;]'R(/1[-+CS7U!_M(!FL/.S@E)[)O%'%Z+ILFL^B_ MJO[<<]7#SG/5ES4-$QH:6(&IX!,TC25"[_STI=B2P^YP,:Q27ZJ7^^-LU5\8 M;/B!`]OQ"KYQ4\G6D@9*I(Q[!TT8^;!PNL/(<6JUPTGM/VN\F0&[,O:)EUJ[ MXP*%V7#7+_\"``#__P,`4$L#!!0`!@`(````(0"SS?NF<@(``+H%```9```` M>&PO=V]R:W-H965TVT"B>4:UR7>),7M M#)/UROOS2_"CF;PCTZKC9RVJKZ+G8#:4R15@I]2C@]Y7[@@ND[/;6U^`;QI5 MO*;[SGY7QR]<-*V%:L\@(9=743W?<L,,(0^^?4H M*MN6.,NC=#E+9G/`HQTW=BL<)T9L;ZR2OP,J<5&-+.D+"ZPGEGDT6\19\G\2 M$B+R"=Y12]>(248$`=%1&=0N5W9@I^S\<*'&0>&XDR"S[+Y MR!N4`R;W#3/-)W^/D`.#Y9#%:-.YE0&4PS(!+<9P_G(3VFCJINO0-,ZCQ3^[ M]%13=]%',EK[<@)3,I%=OI(-LQ):27+=\$^\ZPQB:N_F((7F&$_'$=VDSK37 MYWFQ\3-#Q@\P.@-M^`/5C>@-ZG@-E+'/18?A"QNK!M_`.V5A9OQK"_](#OT1 M1Y!%K90];4"8C'_=]1\```#__P,`4$L#!!0`!@`(````(0#)%;J(?0D``'0L M```9````>&PO=V]R:W-H965T3J.?N27\E"<'\;6S70\RL_[XOEP?GT8_^LO[X_;\:BL=N?GW;$X MYP_C7WDY_O/Q[W^[_RPNW\NW/*]&X.%Q^F?Q&>2'U[<*TFW#'8D;3'S"P]\IFS6TLTV*#%F(4"[=;"EP*/`I\"@(*0@HB"F(*$@I2"K(6F("T MC;XP*/X?^@HW0E]49HU`"SXC8J(%=ME2X%+@4>!3$%`04A!1$%.04)!2D+6` M(2;,$R;F'.9?]UJ(8U/T@E7/&)L+4ZRUM+&6C<`;1K:,N(QXC/B,!(R$C$2, MQ(PDC*2,9&UB2`E3W9!R6$)A#2L$Y&5@?BLC673_ZAX>H)<\.L+M"1=8*+>K20'T4VG"TY1SY'`4L(4=0N0=`D?C95-=DQ;962; M"P6I#;C:"N>`I[TC\C7J#QAH5]IH/B/GD%!;H?=(>T<4:Z1]T3M,M"MM-)\1 M'5)MA=XS[1V0F4%QP+@B@^H\TLZ@1)!!#+<1Y1V9+D1;A4ARR.'8U5;8T>.^ M?(X"W;&M##FRA-H*W4?<5\Q1HCNVW9/M9JJMT'UF^#*%%R>/MO"R'E:OXM7; M8?]]7ML.3 MIC>4WQ6*7D_09<2N)\1XZGIL,O(C;!^ZGK@K%+V>I,N(74^*\>3UK"SRO,BP MO>=ZS.$ASE=7#`]Y'#-FG$2V,3SF=*-OJ8[MXP"]_:TVPH'M*F2+2?_C<;4B MSQ:",,'IK!YW/R-(VPRU#P&(V&@B?:"(.G9O#5E(RZ#+OT M!#>S+$YY5V19'@J-+$MD+@)S=@Y15I#LWIFYM1HCO%=7(=NJLVS=V<2QAP8] M0[I^'/C:<7_T0!MA]!"=R_D$O[N:A]0(VX>"Q]IO?_!$&V'P%)W+X$N;!,^P MO2>XF69Q$+TBS?+<:J19(C*9R0*S@7.F6.O%R6(@S8T1WJNK^JG)O)RR+*LN M/4-:9;GQVQ\\T%>(P4,S^(H\5"/L,10[1J.A&T^T$<9.S=@VG\O#-VXD>49K M"K^U=:J]0`I;SWF%R!0G:]X&K0:GN#9""5R%U!2_G=ED4'EHT#/09?*UXX'D M:R.,'J)S-<5)[`B;AV+'VFU_[$0;8>P4G\A1Q$B[3W6 MJ-][@D;:>\I1AJCV;JH.J3%4_[TY)[R09"BD+VPS4ZA50-%(WR/;%KK*:G$G M'Z*SQ8)NEM#/T!KGHY&.'V@T$#\D\1>WY&@>H9NA\#$:Z?")1@/A4S.\O;PE MDSQ#-SWAS82#T6#"_RK>(9.=Y]/6:6HFW)",2V1,OP;I^V-[8^7*OFU.L2Y' M'B(]07R-^KT':*2]AQQ%B+3W6*-^[PD::>\I1QFBCNDG*BKM?8V8?O-;\2+6 MM;]'PBMD+",*P3.XVK!=YA_%9ON(BOM1"Q(_IZ!A)V M<0C0=;7?%N"_ZV+7D(LN#I5>1]2T^(U#>=<1Q=NNE@6T='F#4ABT='F#FJ\C M2F#<&Y1^'5$)XRUK:!'E/-ZR@99-9PM4P1U1X^9]H`0++5U7#<5`:.F*`Z5Q M1Q0!P=NDR1B\\_F^>\W3W>7U<"Y'Q_P%IL:T+EQ>Y%NC\DNE'A!/105O>];/ MBC=XNS>'?=-4O$?Q4A05?A$!FO>%'_\+``#__P,`4$L#!!0`!@`(````(0"2 M_X>\EP,``&(,```9````>&PO=V]R:W-H965T,U=:R#PB=#`D'L]CF8A\%Y$_OQ]O9L33AN4)2V7.(_+* M-;E;?OZT.$KUI/><&P\\Y#HB>V.*N>_K>,\SI@>RX#F\V4J5,0./:N?K0G&6 ME(NRU!\-AU,_8R(GUL-<]?$AMUL1\P<9'S*>&^M$\909X*_WHM"UMRSNXRYC MZNE0W,0R*\#%1J3"O)9.B9?%\V^[7"JV26'?+W3,XMIW^7#F/A.QDEINS0#< M^9;H^9YO_5L?/"T7B8`=8-H]Q;<1N:?S-0V)OUR4"?HK^%$[OSV]E\$?DO0!(O]L]6/905^*B_A6W9(S2]Y_,K%;F^@W!/8$6YL MGKP^IG`UH",L)?R^R@2LX](,!U,PF%``>YMN#:/ M`ET2+SYH([-_%D0K5];)J'(2`/OJ_60P'DW"60\OOF54;O"!&;9<*'GTH&L@ MIBX8]B"=@^>W=P1;0>P]@B,2$@_(:BC#\S((QPO_&5(75YB5QH#FYGPAEP,X&"$("L7#X^ MN*A+YK8=<&4Q3D8<0XL!WBV]#RZ"/^H"BW$B.X96Y-MK(B.XL^?9L+-GBW$B MUX9281IPBP2%;/???XGNT`B[?5"!'!Z-Y1(15+/>A:!6^UJG8G92/RM<%<@E M8I?9'GWG7%!4,X=(OYXL5W4R,SM%J`A9H70)U1;,#)T%[Q0)5]2D5+]$?Z48'PXPR'`!X*Z6I M'S!`\^]@^1\``/__`P!02P,$%``&``@````A`$%04+/M!0``3QD``!D```!X M;"]W;W)K&ULE%G;CN,V#'TOT'\P_)XX\B4W)%EL M+$V[0`L412_/'D=)C(GCP/9<]N]+6;Z(5&;KO.Q.#H\8DJ)X-)K-EX_\XKS) MLLJ*Z]9ETYGKR&M:'++K:>O^_=?39.DZ59U<#\FEN,JM^UU6[I?=SS]MWHOR MI3I+63O@X5IMW7-=W]:>5Z5GF2?5M+C)*UB.19DG-7PL3UYU*V5R:!;E%\^? MS>9>GF175WM8EV-\%,=CEDI>I*^YO-;:22DO20WQ5^?L5G7>\G2,NSPI7UYO MD[3(;^#B.;MD]??&J>ODZ?K;Z5J4R?,%\OY@89)VOIL/EOL\2\NB*H[U%-QY M.E`[YY6W\L#3;G/((`-5=J>4QZW[E:U%,'.]W:8IT#^9?*^,GYWJ7+S_4F:' MW[*KA&K#/JD=>"Z*%T7]=E`0+/:LU4_-#OQ1.@=Y3%XO]9_%^Z\R.YUKV.X( M,E*)K0_?N:Q2J"BXF?J1\I06%P@`_G7R3+4&5"3Y:/Y_SP[U>>L&\VFTF`4, MZ,ZSK.JG3+ETG?2UJHO\7TUBK2OMQ&^=P(K6"?.G_C)BT?S_O7@ZHB9!GM3) M;E,6[PYT#7QG=4M4#[(U>.XRTW'TN7Z6*N2HG'Q57AI?D$4%^_.V"Y;SC?<& M-4U;SEYS%J[34=,*QA>(GH&&K[(*4^+Z@6S0LZY),=Z])0 MBW`:OH^_;W^'@AFQS5B04G";0KY&V`S#"4HTP(G>;\DN046&YC/V@$4ACG^O M.6'3>VH38@IP"@@#0+&%C\2FR%L7$N_[8SDCH6G*4C=82,TQ,L]G)#%NFNT)0TQR@W M!3@%A`&@V)2Z&Z/SQZV@R+C MB5N12=QTI_>:T\:]((@_)(L-&\NB-?E:CCY]*S*W M8F0-&5$>CLPL(%-3('/$/AEZ_D.*V+#)E=`:>BW)Z`L+X18B3`17';IP?%_X MBHVK;@^]EJ3+'@7T,H+,(2/;PI$97AWPA4`@<[@DWJ@F]VL?8'))9S+%Y/IP[?2JQ>3&<=YV5?K_6S[NY+$\R MEI=+Y:3%JWJ;]N'7E1[5[^9[MH8W5[AL$)S#>WJ#>[T!GK-OR4G^GI2G[%HY M%WD$E[/I`@90J1_$]8>ZN#4OJ,]%#0_9S8]G^,.%A(?$V13(QZ*HNP_JSM?_ M*63W'P```/__`P!02P,$%``&``@````A`'ISPWYG!0``ZQ8``!D```!X;"]W M;W)K&ULE%C;CN(X$'U?:?\ARON0*Y>@AM$$V[LC MS4JKU5Z>T\%`U(2@)-WT_/V6XQ#*Y1:D7YKFY%1QJESQ2?ST];T\.F^R;HKJ MM'*#B>\Z\I17V^*T7[G__"V^+%RG:;/3-CM6)[ER?\K&_;K^]9>G2U6_-`VC;\]+SFOP@RZR95&=Y@BN[JBZS%K[6>Z\YUS+;=D'ET0M]?^:5 M67%R=89E/29'M=L5N615_EK*4ZN3U/*8M:"_.13GYIJMS,>D*[/ZY?7\):_* M,Z1X+HY%^[-+ZCIEOOR^/U5U]GR$NM^#.,NON;LO5OJRR.NJJ7;M!-)Y6JA= M<^(E'F1:/VT+J$"UW:GE;N5^"Y8BG+K>^JEKT+^%O#3H?ZPH5J<*6 MVY],-CET%-),M(R\.H(`^.N4A1H-Z$CVWGU>BFU[6+G1;#*=^U$`=.=9-JTH M5$K7R5^;MBK_TZ1`B1J2A'T2B.B3!--)'$[GB\]DF?59X/.:)1PKQ=-E=5UB M69NMG^KJXL#H@?#FG*E!#I:06+4G@B9_W!XH2<5\4T%=*+`;6-.W=92$3]X; MK$/>9=>KU^'C%!`(,,J`FW)\&8I,RR!W M;-O8OL>G$H@@("`481ZND$[=KWQTB1S2*B!9UYS4%C1`%&`4X! M@0!#;&**'7>CJJ!'-ZKF(-$48!3@%!`(,$0'L)6,;W''-GL<^\2HTIZ$]%H( M&Q!EJE-R\_+AZG5B!$9,_=RD!-K@[N_I/>FF=&,AS$*XA0B,F-J532'M]V_)0)L:[K>]M?=;X"K3#X0JBQ>VQ0C\1!,@&.V1C(#(LSB<`L1&#$U*_M"FD?.OS:] M!_./G+'73A$64(1;B,"(H3W\E,-V;.JPY'4H[4FW^W%C(O_^' M*HHN!GGO3'L2+D6'W1!F<;B%"(R8VI4;?GKX0^VA]X>_)]V4;BR$60BW$($1 M4_NGS#:TS3;VJ=GV)*Q9A^DQCN@SPKU*5@IZ[WY M`=5GE&FX3"-U'$#P3;B$,PX;Y^$2CC%L7(1+.,T`W!L2P5'C.=O+/[)Z7YP: MYRAW(,&?S$%TK0\K]9>V.G='3L]5"X>,W;\'.%26<.[B3X"\JZKV^D7]P'!, MO?X?``#__P,`4$L#!!0`!@`(````(0`&PO=V]R M:W-H965T7\616>S,,#]5ON:NJV_V1A]^_GT^#;]FM MS(O+X]`838:#[+(O#OGE[7'XQQ?OM\5P4%:[RV%W*B[9X_!'5@Y_?_KO?QX^ MBMO7\IAEU0`4+N7C\%A55V<\+O?'[+PK1\4UN\`OK\7MO*O@Z^UM7%YOV>Y0 M-SJ?QM/)9#X^[_++D"LXM\]H%*^O^3YSB_W[.;M47.26G785/']YS*\EJIWW MGY$[[VY?WZ^_[8OS%21>\E->_:A%AX/SW@G?+L5M]W*"?G\W9KL]:M=?B/PY MW]^*LGBM1B`WY@]*^[P<+\>@]/1PR*$'+.R#6_;Z.'PVG*UA#\=/#W6`_LRS MC[+U_T%Y+#[\6WY(\DL&T88\L0R\%,579AH>&(+&8]+:JS/PO]O@D+WNWD_5 M_XN/(,O?CA6DVX(>L8XYAQ]N5NXAHB`SFEI,:5^I#K8M,(;0BOA"%?P;\64R M++X8F14"&?"I%DRTP":N#C8Z\'3@ZR#00:B#2`>Q#A(=I#K8MH`23!@@))@F M#+CNV0YKD[6">:U=F\9,#=:*VQAS$>`U(2XA&T(\0GQ"`D)"0B)"8D(20E)" MMFVBA!*&.@GE5$Q4GQ[W3`:F#DA8:^!KPWK%C>8P14NCJ6:T%D:B7@G9$.(1 MXA,2$!(2$A$2$Y(0DA*R;1,EWM!Y$F_#&K'W5G_ULH9UA#$N*T[L5JT2XA*R M(<0CQ"_$#!FK0:,$QMFUM:`U=\OW&@.,XPP MLFQU6G6YC07+*&%C3DW5:".,L,(](8W$%T0*Z0'R0N M)UHVM#?A1AAA,X$^80$HE4['',M]L((I2,B%!.2B%9MZ84JG0HCE-ZVA91( M0S$JD>8KWGHFKH[Y_NNJ@%J%Y5Q'!DQ8V?+U+A-1$\!).P& M:>43$I!6(2$1:143DHA6[=!J!9$*(Q':MI`26K;Y46+;$4/85V(0:W,UB@V: MP=36FC&6:K;7:`6C25CI(]3M,C(LK28WC95EUYN6Q5S[WN,N5_CQ)EQ%YGA3]\>>Q#>TML,7?[SR/6AYL MD_3Y2<[@>RI87&+EK1ID*>5A:AO--3:$]CWET:C+5<$&U=DP__9DV]J[PT/= MOE>>CT9]S@-IA%T+5>>FJ;TE(VS2YSQ&HS[GB31"YZGJW)YH5;?%)G>^!-$+O(8KS\02GI>K4%N'O?3XA66YTX:,GRY]P'E#G MH>K>XZT M(:[->>NFX4^&>",E#\=_QGL@C3`!(8HW0USS M'>'/?;YC*7N_.A-IA+Y3%.>3FVE,M-+;HL$=[VKVV8Z\G?V?+.?X!AXF$7R< M%;N*@,Q;,X'6$MWOF8M&_,J";=DW%'F(I+HOT7WU`(VD>DA1A$BJQQ+=5T_0 M2*JG%&T1U>IJU-FVOAWU?S;FFL.!=C(:)!]L#0>>S>2**7,EDGTDR$-8S5; M\I?H=#8CBZ5&NF^.\Z4S]!](U.,_U/S/%MK6.T*9/O`%V[DC;NRE^MJ`,/XZ4X2>0[)^^-7#AQK(> MM@LQ;#<4>8CD`/$ENJ\>H)%4#RF*$$GU6*+[Z@D:2?64(G8G*R'2^7G>EQK?E?LLKE#9S5UX$J%ZJ],!RX(*'^>.<\0(/K#:N;` M"3?EONW`*07E@>W`@5L'7SAA5R""I0,G&=0^LATXSZ`\MATXU:!\93NK+KZV MG747=VT'3B&ICKMPX#RL@R\=.+FAW+,=.+\!/A:9@WM_Q2#D[9 M*Q33I#YMNO'K>OZE:L;X2U'!-7L]W(_P9Q49O/HF(WB+OA9%A5^8`_&'&D]_ M`P``__\#`%!+`P04``8`"````"$`SY3*W3H/``"^3@``&0```'AL+W=O7Y>/ZXFF\>?;ZOWO139 MKEZ7>Y'_[F7]L8/:V^,IMZ__=!]/+B[7&4?G_? M;)??7D6[__)ZRT=H'WYA\F_KQ^UFMWG>7PFY:YDH;_/M]>VU4+K_\K06+6BZ M_6*[>KZ[_.J-ZB"XO+[_=GR]V+YO?T^WZ*5^_KT1OBW%J1N#; M9O.CH:9/#22"KUET?!B!_GS=UYO?R6K]_64OACL4+6H:-GKZ>[+: M/8H>%3)7?M@H/6Y>10+BWXNW=5,:HD>6?]U=^L)X_;1_N;L,^E?AX";P!/WB MVVJWC]>-Y.7%X\_=?O/V7TGRE)04"91(3XM<#<.PUQ\.A(@C4/SUX"[^5^Z> M2,01T%&XI!;D]%Y7A[ZH_GA1#?1==)-]V'ORNO= M])MA<'1(,]8R4'3-F6D.$"I^.#%-T>_230^`*\UK66V'XITL]\O[+]O-[PNQ M(HAZVGTLF_7%&WE""V4K6]H6LJV.10$W*E\;F;M+D;XHT9V8?+_N@X'_Y?J7 MF#"/BO/`.9[)&(/1S(Y&=D*!B`(Q!:842"B04F!&@8P".04*"LPIL*!`28&* M`G4'N!;#TXZ1J/O_QQ@U,LT8H7N7XV,6`+%@'<6L(`,DB3UQ4*O23U"&K>D=LXP)&)(S)`I0Q*&I`R9 M,21C2,Z0@B%SABP84C*D8DC=18QQ$YW(QLT+KYIMBGLV-8&'D4+_/DADT)D[ M#)DP)&)(S)`I0Q*&I`R9,21C2,Z0@B%SABP84C*D8DC=18PQ$!L58PS<'=^P MS8Y7B-R"-L_K,4,F#(D8$C-DRI"$(2E#9@S)&)(SI&#(G"$+AI0,J1A2=Q&C MX\7Z=$;'-VRSXR72D\>(0\>WB%Z:PH&Y?$TD)Q0;[W;Y\H.A28I:$J97W$H# MF;:(%J)F2:NC.7YP:YJE+0G2LU8:2-8B6HB:Y:V.Y@2]GFE6M"1(SUMI((L6 MT4+4K)2<_N$H>=BE5@RI6QVA;(R\V&$;(R^WVX=E;_^R?OSQL!%C(_:!1Z9B M(+;5F+\Y4NB![9DT2L-9-$B6HB:E:V.YOAT M6U"U)$C7K;1`C!H1$]2HD2.U(,ZB*(:&;1:#1`;&7J;7-QL_EJ2>*-1V[&G# M)BT'.4<,B1DR;1&[] M7DB7[Q@Z8G-N-9N"Y,HH.49B&:5F1L->0$Y1,\BX$LI`]%Y*'Z1PJKGP6(+GR*8^16#Z58JDA\\75(1G4&CJ6C,R:%1F=4[,-G=2L MA'IFS9)>&GN*Y5R+-`G3+U)0Z!UZWP]O26-C$+HK(9T,4RUL+^)$D^">0GQP MF9:U>^>:!.]">^NXH$=V5W.PNBEX?9+H0LMK+=I)I28AAPKJ MJO=O?/(LKT'HVG>$S5(3I'-*K:&34I.0L3S>DKW,N#G?-W%B;*P+UD23T-9( M06J>![0/8X189M5AUS8%R66>:!+,4]/<&Y`E?X80EWD&DLL\UR28%Z8YW=7, M$>'R7H#D\BXU"=Z5Z1W2*58CQ&)N%I@@G5-@#9T4F(3,M2PDLVGWVN2;!OH"XL@^&],D^!\-EO]#*=OM2DV!?05S:A[=#>BJNP;#8FZ76W'G1 MEU3\\$I%&2L:D'(EC45Z)I@$ZCKVYH(ZG+[TB//Y1@1 MHJ0=%7>"=P(E[9V:WOZ`M&F&$)=Y!I*KX;DFH5L+TYS,X3D"7-8+D%S6I2;! MNC*M`X\\M&N$6,S-2FMN]KJ5]DE]R8M`H[[4W6"WKH.0/,G'S4N;GR]J+0EM MC7012+%P$+EE=1Y#QU+G:LMT MQ*RSA3R0$BAUTV89I69&XJ@V)/>#,^BX,LI`ZIK1C/)C))91H5AJ4^G?DI5@ M#A57/@N07/F4QT@LGTJQU)CUPO"&K`,U="P9F47;7(&>4;3RQM18FR1D;KCH M0VKL*9;XS_J0FF@29F"DH';#-2#E$(/071KI2$^UL-T]T22XIQ"7AT>?/@5F M^+O+/-.Z=O-0+S;94%(]IMSL+HI'#D]GM#])<^A@KHZ/08^.=74('3M M.]UOUEISE7I&K0:2J^6Y)J'EA8+:^S'2\CE"7.8+ MD%SFI2;!O%(0[B]]>J2I$6-Q-TNLN=D]H\3D1;!18NIN6#S2VH4JX.?']@99 MLSIE?ZB%B=>2T-A(0>UR=N3\*(.<%U)3K6RW3S0)]JEI?_3\>()]II7M]KDF MP;X@]L?.CR?8+[2RW;[4)-A7IOW1\Z/;WB@UG[Y4<'A+RPGGQT.@>6FA(&-= MX^='!+IFV$23T.X(ZNKZ.R#[A1@AE@DF%S:07.:))L$\-(<1EGH'D M,L\U">:%:1Z0P^L<$2[O!4@N[U*3X%V9WH.`/CD18C$W:TV8G[&L^0V=5)B$ MS%<;0[*9&JM`][68)J&M$8=B#DTU9)^WB29!/>70C$.9ANSJN29!O>#0G$,+ M#=G52TV">L6AVH#,81:[J'.&N:&389:0N9"P$Z2O`ETE/3E&8J>12+'P].[U M^F2#&D/'4N=J=3DAHP1*W;191JF9T6U`7UN;0<:54`92UXL^X/-C))90H5AJ M=T6WJW.(N-)9@.1*ISQ&8NE4BH4S?S!D%_;0L61DEJP@G5.R#9V4K(0^.3_Z MBM4]#-'QF&@2YE^D(+7A\OPA689C$$0!MOL]*CS5PG92HDEP3R&NSH\^N3N8 MX>\N\TSKVLUS38)Y`?%NEP4A><%@#E8W!7Y^U/+V'$I-0@X5U%4'T.*O\?>N M>Z?WS5*C%_;N:U2?7],KR%@=:4ICQ+FFVD23T-0(XNH$-R"'J!@AHI`=A7;* M-3V4.L='T]QCU_0(<9EG(+E:GFL26EZ8YCY]A7F.$)?Y`B27>:E),*],\P%] M_-0(L9B;%=;FP^:407,W6[[CX]JL!/MEG\HE[%X?0X]'TRFV,P+/-) M/6Q;97LE)CI'='4*&RS[2RW3[7)-@7$%?VP\&0'&3F8+CL M%UK9;E]J$NPKB$O[_C#TR>ZY!L-B;Y9:+;633X_JKKWSLH$O(6-9.W)Z M5(&N"3914N*=%VAW!'5U>NR30U2,$,L$4R5W@GD")6V>$O,;TN4SA+C,,Y!< M+<\U"2TOB#E]R^T<(2[S!4@N\U*38%Z9YN)SC>;[#&J$6,S-8FMN?[O%]LF3 M4UX6=V_%FH_JB*6.'!])3F/%^F1=DU*"A+9&.@Y0S*&IANP3-]$D2*4JE)4*\X5!N0.**Y\%2*Y\RF,DED^E6&K, M>N'M#3G6U-"Q9&06;7/E>D;1RAM:8VV2T&<'2,42JT];VG1`)GY+P@R,%*3V M7+[GD44O!L'RU%<%V@K;W1/NGD)JF<.0`>4('E#R'"NK=',1;B,U%H@;+EH-1<0&]N'<_#0]T\\I"0<:& MBYTC$>>:<1--0J]'$)?[K4&?M#5&B&5RR7H#R66>:!+,4],\H)?6,X2XS#.0 M7.:Y)L&\,,U[[+H>(2[S!4@N\U*38%XI"!>9(6UZC1B+NUEBPOV,12UHZ*3$ M)&0N:NQE2!7HWG!I$AH;*>:A)87IKE''Q5SA+C,%R"YS$M-@GEEF@_H=K9&B,7<+#9!,HKMDT=G M0R/FY_-UU:)-__=?VGA]CNUOAY. M>01_$-^U=9@C%/=']5%^(+Z;JQDXPO_:&WT5B?(_//1&=>\8'H[JPZ?BB=!# MT#@<4YH,1N(S[]PA&8S$Q],YG@]&XI/D'"\'H^H8/AF.Q$>H.3\9CL2GG3F> M#T?%,;P_&]88-YL]OA%)'3=?O/<_?\```#__P,` M4$L#!!0`!@`(````(0#=>\1Z-`@``-(D```9````>&PO=V]R:W-H965T)\?\G#X,?Z;E\.OZUU_NW_/BM7Q)TVH`'L[E MP_"EJBZK\;C7(DWV=:/3<6Q/)O/Q*COM;G%W2HK7M\N777ZZ M@(NG[)A5/VNGP\%IMXJ>SWF1/!TA[A_6+-FA[_H/XOZ4[8J\S`_5"-R-^4!I MS'?CNS%X6M_O,XB`R3XHTL/#\-%:Q;8S'*_O:X'^SM+WLO'_0?F2OP=%MO\M M.Z>@-MPG=@>>\OR5F49[AJ#QF+3VZSOP1S'8IX?D[5C]F;^':?;\4L'M=B`B M%MAJ_]--RQTH"FY&?!B[_`@#@'\'IXRE!BB2_*A_W[-]]?(PG,Y'SF(RM+$^ M[F0FG,`OQM,[=!A>'3_\"OO%:&%-[J9LX#TAST4[^,60;Y9K(=K"[^<#A0E< M#QQ^6YSTC/Q.-(1?T=`96;/)G-WOGF86I";/%):C/`O@?O=GR)AG6YV\;E(E MZ_LB?Q_`B@#Y5%X2MKY8*^89TY8/0"9R5QY#[C$OC\S-PQ!TA!0M8?)]7T_G M\_OQ=Y@P.V&SH3:6;K%%"Y;2S*UK`L\$O@D"$X0FB$P0-\`89)':@*K_AS;, M#=,&H]H@4&+9AA!H@4U<$W@F\$T0F"`T062"N`$T(6`A($),(5G:US;,"=8* M5K%&3M@+1P]TPVVLN11G2XA+B$>(3TA`2$A(1$C<))H$L(QI$O2'SJQA1H&> M:CXLC="YS1PFN[2Q%X;15AK)3"#$(\0G)"`D)"0B)&X230T8M*8&7S5&;*GN M%X8UK(7!>#:<+!H90(A+B$>(3TA`2$A(1$C<)%K,L,%H,?<'RJSU0#F9U25( MO;IM"7$)\0CQ"0D("0F)"(F;1`L45O$/!,JL]4`Y:08JB4IU9Z%/!Y?;.+`9 MRNE@.5/=R)-&F#Z^=(TDD$0Y,CL+I1]E8T^-W2B21N@ZEJZ!:)*Q(I[NHO5\ MJ%ZRW>LFAZ!@FVG)F2GLEGP/94YT)3EI*BF)&K@9G,MMYI-Z&[8GULP045[' MN'SI%4D@27<_H?3#MGO:3R2OH]=8>C7U@[O^W_5C3G3].)E!ILNH;SQNY"QJW6=S(YU\<;FY)YC]!"W]F#9ABPT92]0_EKA_ M+%IJLZ*P]]Y\RR]=N0V5+"9W[4:_.P(Y,[7Y*]1S,]!H*=MY%/F(E/=`H6[O M(1HI[Q%%,:+:NZX7JR:;:T'+G&_JPHM/O528&XOCQN)6>K&PG!B9K*QPQKD4 M>13Y%`44A11%%,4:TI5AY653F9NK!J:.,;4%:M8-%+D4>13Y%`44A11%%,4: MTL-GM64S_"N)(4I16V;YQA*(G_G9`6E+D4N11Y%/44!12%%$4:PA/69607X@ M9EYP@H:8P!N+H^8>J%#W-':%T95Z0EEAA[[RCBA0J+O#4+E21K2F4%;H/5;> M`>GJL5JTJ5YCPMQ>5K"'4.;DX4@352(U?'/K<86K[M)"&6!XOD"-O@*%NOL* ME:N.\D(98%^Q]9;32@C'+E'D4]1 MH%"?<'((Z#U2[1#%&M*SCE6Y'Y"*%\6:5!S-H-R3)96]-.JAK24:PM8FK6C& M22,Y$?3LQMD$?'<-JV>DX0*.^WD-EA+U'UWJ/L4U'[[K4K"#^@-2\ M?M:DYLB!(DW&:B_-QTD6M[J2E=((@_5$.\>JI;8F2Z-V]M&@MZB]I?=0&6'O M$3KOZCU&@X[>=:E9R=N4^G-K*2^GF*B/4P!/(8:?$ M[^O%G-P`X;#%H\A'U#@N*-3M/40CY3VB*$9$CPLVJ^R;>7E%%V9NZ,+1 M7!U8MK73>A?">^E2Y`DD9O=TZ1@/'WTTZ)A?/+FHXY"B"%WQN4S[BM&@HR\] ME\!(T^Q3<]EF7@PI.3+FLO'\9(L-51GN4N0)!#-798^]-)Y_^]BP:67-C1TM M0"O58TA1U-ZC\90BQH9=/>I*@Y6F])7L9.:&I!QILU8BI8RY'+FV,%+SRJ/( M1]29S&4B/.[8X[FA5YLS<3=!*O5-R%5*BDL=" MGK`24]Z^FY`IS_MW.J:AF/)BD*K[\*;N([-[\UENY>>UT=-N#*?:V MU'85\1,V/G>O%/UG@ M;WU/:?&<;M/CL1SL\C?V.0(44>M[B?FW$G#06WEPF(+=P[@"Q[)5U'H%OJ]X MK,_M1HL-?'=1KULFM^%[C)8>-M,5O(6C/3_.5H_PU(U>V,Q6\**JA3LK>)E# M^:/%1MIVQ5VLX`T#;1$N5O`R@')WN?+JNV&$%BY7\/"[Q=Z:@:QM8PWA2M1Z M!1[]@7ZM`EJ@(*]$QW(`\$7))7E.?T^*Y^Q<#H[I`6[QI'X14?!O4O@?E7AH M^Y17\"T)9`&\^8=OAU)XIC0900H=\KS"/R"0L?P::?TO````__\#`%!+`P04 M``8`"````"$`>)34)O@/```X5```&0```'AL+W=O%<,,<[_5N3P3&\=4;.,"DNS] M]T="ZNE1-U),U7F)X\726KJT>M3"\.G/OUY?+GZN=_O-]NWSI7=UOGV^_/>_XC^FEQ?[P^KMKP\7 M0N%M__GR^7!XGUU?[Q^>UZ^K_=7V??TF7GG:[EY7!_'K[MOU_GVW7CT>&[V^ M7/LW-^/KU]7F[5(IS'8?T=@^/6T>UHOMPX_7]=M!B>S6+ZN#Z/_^>?.^![77 MAX_(O:YVWW^\__&P?7T7$E\W+YO#WT?1RXO7AUGZ[6V[6WU]$>/^RQNM'D#[ M^`N3?]T\[+;[[=/A2LA=JX[R,=]>WUX+I;M/CQLQ`CGM%[OUT^?++]ZL"\:7 MUW>?CA/TG\WZUW[P_XO]\_;7UT^K'R^';OLK66^^/1_$_%^O]@YA1(7/EAU+I8?LB M.B#^O7C=R-`0,[+ZZ_CSU^;Q\/SY,O"N1GXXF7J"?_%UO3_$&ZEY>?'P8W_8 MOOY7L3RMI51\K2)^@LKX*IS(!%IDU(MX-U?>Z&8L.^(P%Z\>AR!^@KF' MYHZ&8]U0[`7=\&.&M[J=^'F>H2>65\TV3M3'+#V8'/F?,TW%?"K3P<2ZEU,& MD&HBINBLJ?$FT%+\Y\Q^BF50IH/U.-G/:Q7#QRVQ6!U6=Y]VVU\7(L\(]OY] M);.6-_.$"FP&%0/]]K#M#K$MI,H7*?/Y4@Q`Q/U>;.F?=T%P^^GZI]B&#YIS MSSF>R9@#0^XY*;N@0$2!F`)+"B042"F042"G0$&!D@(5!6H*-!1H*=`-@&NQ M//T:B&-V8$WVO.-[QJ7<,_3E# M%@R)&!(S9,F0A"$I0S*&Y`PI&%(RI&)(S9"&(2U#NB%B+(5(T&1.\9$R_9YL1KQ-P$ M@?EPF?>D?A,P)&)(S)`E0Q*&I`S)&)(SI&!(R9"*(35#&H:T#.F&B+$6XO1K MK(4Z"E]-Q*YQ[P?9T%P6A8SQK#5GR((A$4-BABP9DC`D94C&D)PA!4-*AE0, MJ1G2,*1E2#=$C#40]:&Q!NZ)EVQSXC6B2FU90LP9LF!(Q)"8(4N&)`Q)&9(Q M)&=(P9"2(15#:H8T#&D9T@T18^)EG7W&S!_IYM1K:*2N3(YSCQ`>I<*)F9T6 MFA2*KO7G+3^8FJP(69#$8E0':(D0:E'#!*60Y--J-446J&>H#E".$&I1PP*E MD!2,1N8(2V2!>H7J`-4(H18U;#1I'/2U7LNA#J6$NAD,LA+EMP+'5'AXWCQ\ MO]^*I1*D$]LS$-6_OA-0]:PX;4/O[ST%&3'20_8!+72[L0A2C!%Z)H^0!88Q M-UPBA%IT!A.40I)/3Y8!U"M4!ZA& M"+6H87/*T!^1HT.++%#O4%U`9MC(>GD8-B?"0UQ,]O&ARFLC/G3%;11HH[$Y M"W-9OXF\/Q)/\CX:Z/@62(*>1QR*.;1$R*Z>(`G44PYE',H1LJL72`+UDD,5 MAVJ$[.H-DD"]Y5!G0.8RRV+\C&76M?LP#2@H%,?B?@&#$7DPS.6]K7R\BYCO M67R93Y"\D$1,I*5&M\>K26\4TG0?@YF0LYHM@>3J47**Q'J4FCV:C@)R(Y2! MC*M#.9!<'2I.D5B'2LT*9?[^>>>%Y`%<@8JK/S607/UI3I%8?UK-TDOFB[=% MR*)VH&/ID1FS\H;BC)A5%QIB#\`6N?<4-#)CELS2'%CNU*2EL#R(=+O0.\Z^ M']Z2P<9`&&9&NAF6'W%/D`1C2T%\0,HWG'Z?'7L2C#72[?0^#^@8$D,"]-P3T%<;6;/]\;D%)T!PV6?H[+=OD`2V)<@KNV#*7VR5\!PV=>H M;+=OD`3V+8@K^_!V2BOI#A@6>S/4Y&79,-3P_OXW9WM]RS;,:@HRLEH0LK2F M&[HVV$*^9:YR'XP[TI!.:R/R7(ZAA65_Z8CK9>USGH`27C&EIK<_(6/*H(G+ M/`>2:^`%DF#@I6E.]G`%#5S6-9!<2A' MR*Y>(`FD2@Y5'*H1LJLW2`+UED.=`9G++"\@SUAF?5\Y3",*,M,(KQUU0U=( M+[P3)%:(1)H%A<@MB_,8="QQKI/+";/!$?)(2D!IV&W6H]3LD2C5IN0N,0,= M5X]R(`W-:(^*4R36HU*S=/;U;TDFJ$#%U9\:2*[^-*=(K#^M9NDU&X7A#A8>F0$K7_>W?B1;MZ-:\@\<-&'U!Q8XC%DO8-8(`EV8*2A_L`U(>$0`V&8 M&NE*+U'8[IX@"=Q3$%?%HT^?`AF\[C+/4==N7B`)S$L0'TY9$)+S9@6L81=X M]8CR]CXT2((^M*"NJ\?`)U5-!X2A_6#ZS5@3T7]&@O0EG<2:@HP$R:I':.?: M:PLDP5@C#>F-/O')>2.&)I9MI5(AD%SF"9+`/#7-V>UX!DU^1DJ:#-A9W,\1$')X38I).0DQ!9CJC M,S+W-6NX-P=A?XR%!9)@L)&&^G3&ZT=@"`-KHERBLIV4(`GL4Q"WUX_`<-GG MJ&RW+Y`$]B6(V^M'8+CL:U2VVS=(`OL6Q.WU(S`L]F:HB7@T0NVC]:,O&Y*@ M4Y"1UWC]"`U=.VR!)!AWI"&=V+R`G!=B:&+98#JQZ5Z[S!-0&A20IGE(G]\9 M-'&9YT!RF1=(@I&7IGE`BM<*6KB\:R"YO!LD@7=K>D\"]N34$VHQ-V--WE)_ MO+3PU:7VL(+4$*D@R6%JKEGN=Q^1!&.-.!1S:(F0?=\F2`+UE$,9AW*$[.H% MDD"]Y%#%H1HANWJ#)%!O.=09D+G,\DK[C&76-^"#"E)^-D;D%C.1L`I2L]SO M/IXBL6HDTBQX>H]&8W)`C4''$N1F?1=N/C1'W@"7C]JEOO`U9-@_T6^@O2!R_.G)`W'0+`\ M\G5X]L+81QH-B582R1/<4Q#7]:-/[@XR>-UEGJ.NW;Q`$IB7(#Z]#"^IZ`FCP=_#ZT'TPL6:HB8&<$VJ23HY9"C*R(^W2W-?M M7%MM@228[DA#>IL'$U8^:EW+KM*!]@'SA)NGIKG'KNFAB[3=Y@K:.(RKX'D,F^0!.:M:3ZACY\.FEC,S0B3M]=G)#-UV6TD,WW_+;8+ M)C->/?:WY,@:1/TQ%!9^3X*Q1AJ"ZG'J^V0WQ\"P["<=9+VRW3[A]BF(Z_+- M"SV23#-@N.QS5+;;%TB"T9<@KNVGDRDI9"I@N.QK5+;;-T@"^Q;$E?UX&OKD M]-P!PV)OAIJ\,A^&VH>K1WW7/CST*JQP].8%%$Q M-+%L,!URO:Y]TA-0&E:/>FCZ+[=NR)1GT,1EG@/)E5H*),'(2PW!R.G?Y%;0 MQ&5>`\EEWB`)S%O37'SLW?P[@PZ:6,R-8`O.N^0_TLTGIX9(^4CZ--[WF0-))\NL(#.3L/(1&KI">G&*Q(J12+.@&+D-0[+#8]"QQ+E*+T!R M]2@Y16(]2LT>>6-O3/[>(@,=5X]R(+EZ5)PBL1Z5F@5IB%8P%:BX^E,#R=6? MYA2)]:?5++UFH_#VAI0U'>A8>F0&K7A:GA.TDDZ"5D'FC3TK(`/-$@?L_F3& MSEQ(@AT8:4B?N7S/(TDO!H+0MPHO4=A.2I`$[BF(J_K)"\AY+X/77>8YZMK- M"R2!>0GBPRD+Z)Q5P!IV@1>0*&_O0X,DZ$,+ZL,^B#\A)@]#8-GZ8$:<",MS M(D[22<0IR$B3K(X,=#O7CEL@"48<:4AO]\F8C#6&)D+>$6\?,$]`:7#>,LT# M>FF=01.7>0XDU\@+),'(2]-\Q*[KH8G+O`:2R[Q!$IBW&H*+S)`.O8,V%GP4<+ MR8"_>Z`A(Z_Q0A(:NG;8`DDP[@C452WGW[*3GNZ098/ID]Y'WBC@YBDQGY)W M*3)HXC+/@>0:>8$D&'EIFGOT45%!$Y=Y#227>8,D,&]-\PD]SG;0Q&)N!IN\ M!A[>6ORFPE"WQL,+,O'E=_)I&MSVE^1S#BTX%'$HYM"20PF'4@YE',HY5'"H MY%#%H9I##8=:#LDO"\3Y4FNAOOQ/?=/9ZWKW;3U?O[SL+QZV/^07^XD__KO[ MU,/J6P?O@S%\[2!Y17P?X9?C31+![\7W%!Z/!13W9]U)?B`,Y)(2_I?1[(L8 M`G_A?C3K1J?P<-8=/V5/A.[%"$[J3&;=\0T7RI_.NND)??&1_)G\P#WOD?CL M_$Q^,IZ_(C[D/I,?8>>OB$^CS^3'S_DKXF/=PN?4%(K/7PN?4Z^(#TH+GU.O MB$\T"Y_C*]?]0,7W-KZOOJW+U>[;YFU_\;)^$LM_<_P@^TY]\Z/ZY;!]%V$A MOKQQ>Q!?V'C\[[/XALZU^`:)&_EM14_;[0%^$0.Y[K_S\^Y_````__\#`%!+ M`P04``8`"````"$`R'F6CGT2```18P``&0```'AL+W=OYS8]I?)?X$D$!BX>*W__[S\>'LC]WSX7[_].Y\]N;R M_&SW=+?_?/_T]=WY__PG^M?U^=GAY?;I\^W#_FGW[OROW>'\W^__^8^W/_;/ MOQV^[78O9TKAZ?#N_-O+R_?-Q<7A[MON\?;P9O]]]Z2>?-D_/]Z^J'\^?[TX M?'_>W7X^%GI\N)A?7JXO'F_OG\Z-PN;Y%(W]ER_W=[M@?_?[X^[IQ8@\[QYN M7U3]#]_NOQ]([?'N%+G'V^???O_^K[O]XWG^X?[EKZ/H^=GCW2;]^K1_ MOOWTH-K]YVQY>T?:QW^`_./]W?/^L/_R\D;)79B*8IMO+FXNE-+[MY_O50MT MMY\][[Z\._\PVW3+]?G%^[?'#OK?^]V/@_/WL\.W_8_X^?YS7;O\CV=U__?:BPKU2+=(-VWS^ M*]@=[E2/*IDW\Y56NML_J`JH/\\>[_704#UR^^?Q]KJ\O% M3)F??=H=7J)[+7E^=O?[X67_^'_&:&:EC,CU$8U18]55:]]P9/:>&,+JM>?:^-,#3\S&O0X-)&>OSFIE;-^ M(*F_]$5/:N>,AH_^2U_TI);.:`#IO_QD6VD(S=PQ=%I;:1#IB=97^+2VTC": MN>/HM+;20)KQ2+I^_SA3J5Q%]_#] M5B\,LXU6HWQCIER?@<82D,H\6N6#EGEWKAJB>`"Q6> M/D9J&OU_Q$C+Z!A1[WXDP$&;BX"0!14))`@EB"2()4@D2"7(),@E*"0H):@D MJ"5H)&@EZ!S@!40E)PC(0J78X46:YH@NI99C9X[,EE=^AW\T-BJ94(]O@01` M0B`1D!A(`B0%D@')@11`2B`5D!I(`Z0%TKG$"XE*^EY(ID.AK57&4_%U\M6- MB(4QNE(OO=%L=>D;;7LC"E@`)`02`8F!)$!2(!F0'$@!I`12`:F!-$!:()U+ MO/"HA?4GPJ.MC^&A3OUHB3,O@`1`0B`1D!A(`B0%D@')@11`2B`5D!I(`Z0% MTKG$ZWBU+?$ZWJSO;_0>=WJ*Z()^#`Q1)2DJ6R`!D!!(!"0&D@!)@61`#*8[7EO['6_(DOM=@D""4()(@EB"1()4@DR" M7()"@E*"2H):@D:"5H+.`5X_J^VKU\^_N)?5,GX`#'$"0(!7AI58R0-CLE`+ MEK-ZB`UOV!O1E(J`Q$`2("F0S!"N]ZF&U=QZ85@MU%#$'%"WB!]40[J$M M`6Z][*'`F"S4,N<$=>%O"<+>B'HH`A(#28"D0#)#N,HY`:Z.K'+1J[#-;"6J M7/9&5.4*2`VD`=("Z0S!H.JKB;\?U:.*'U:+N).V/>$>D+T46)O%ZGAVG5_. MEB*H;$!=%/6Z1.*>C'M*6$B?DI4G$8N4#4@WZW6)Y#T9]U2PD/4DVE2R`>E6 MO2Z1NB?CGAH6&FY3RP:DV_6ZBGC37=\\>2-C8%ZKVT2:V$=S,03,07KN;N]G M*]'ZK2TX=S,TC@LKM>@7WY#+45LB1#&C\7Y+V(BD4D09HIS1N'K!1J1>(JH0 MU8S&U1LV(O464>/+T29G,65TCO/+G[=8:N1D; M@VR$7!MU8^T+A>1M:6ZW%G.QED?:H%\5I(_XA'HD`S90CU348W8MQG4V68]\ MP(>L:S%@`_4H_7JLKQ;B9%Q-UJ,>\"'KT0S80#U:J(?(I]U8/?S1J"\6?F(T MVGL(=S0:))*.V!5N];VV'K/J972L!&Q$8STD9-:G&]'7$3U61Y!1V9B,IGPG M;$2^4T+&]W(F[G4S>C[E/">C*><%&Y'SDI!Q/EN(65?1\RGG-1E-.6_8B)RW MA(SSE5RJ.WH^XMP?8?INQ!UASDG\]&VL?G-#[&,MY1; MXVK29=W+C;ML>AMRV;)++C9;B>[M/,^S-<]Y?USIJQ]W7+VRCMJ;(C=S&30W M[P'K]UVV^HTPG:;4[F(JH(L7K-:%R](2-6;Q%UA([J?DQ50O%B^FNY0JN(G;%!:I&BL;C5;UR: M%8E0P(C;"`MO2%8W9D.TO.8!>CQR1V2@'(P.HIB,>(.=,.)RX#XE*^M^?0G[ M(-NP*?%R.'VG_UW-8X&;UCH-2+:*. MI92Z'VM]R^;&^I7EPES*>3$UR-MOK,6V;*L_2J`"S['KU3LO(K(_*CK>\W3$X\^"(BMI$4B M\8B[@2U9\4@/$(6$[#E;7+U%]-@=SQA^4T5ULT(+:D+E&*6$_`DD'&9DY3J$ M?):3%]!B1H\<@+V>L8?`8(S=G2!):[;G:,/:I808W%?XH=8[29F6R(NPH M`9(..I+3.YMVE(-L`:0<=B0V6-6THQID&R#ML"-()WZ,.)_Y`T5=K7D#Y955 M1)N+5<0@-3QI_F[U+:FRTB.VCZV<&P$9\5D[1!018O68T;AZ0D:LGB+*"+%Z MSFA,DY,5>RP0E81\CV*[5Y'5I,>:K-AC@Z@EY'L4ZV-'5F,>_6&DM+QA]$IJ MT.8B-1CDI88>C4^`0-U-'/,'3X`0442(IU?,:%P](2-63Q%EA%@]9S2N7I`1 MJY>(*D*L7C,:5V_(B-5;1!VA@=2@(O\S,=7F(J8&>8O+E=BK;.?&B-?E`$@( M)`(2`TF`I$`R(#F0`D@)I`)2`VF`M$`ZE_@S3-^6_?U$;>[2R_3G%D"1"$A-2?[Q7QV);9\$5FIP+,5[M?`8\(%:?N06K1PMP^S*[%` M9%R0/VP(\8>@6XNFF]AQP<$F^F/IY^X' MYW@_:)&7K>V5H1L)V<.<%"**"''&BQD--N^XX"9DQ.HIHHP0J^>,QM4+ M,F+U$E%%B-5K1N/J#1FQ>HNH(S20K?55W]_/#^;"T,L/]@[1G:R8Q(V1F\0E M">=62,UKGO:8')05/\:L(&53*[OP5QG(`*ZL'):YU>#J%T#*DZI?::OQZM<@ MVUHR7?W.DW6J[TUK_>TD;PA,;\*.YOZ";9$[K1EQNYP*'"=>0$8\>$-$$2&> M&C&CVH+OL(PH)>6OBM;C-B,AJ1[%$?1CJS&//H90D7; M&TVO9`AM+H:-05Z&Z-'X/`AT?M/#C>=!B"@BQ+,L9C2NGI`1JZ>(,D*LGC,: M5R_(B-5+1!4A5J\9C:LW9,3J+:*.T$"&D+=ROY8A\+).?ZU%A\Q=T*[EN<`: M\!I"=.,7BG<=#WM;C^R*9]Y[TG M\EWT9,)W.>Q;M+N:]EWWGLAWTY,)W^VP;W$XZT9]^XGDM6O#TSY-HK]D(Q., MO3?D:;2U5BKGB6TY1P4L119Q8S&U1.42A%E+$7J.:-Q]0*E M2D052Y%ZS6AHT$HI*\I\$:(8 M48(H1919Y%0^1U1P06[/[$8<34JVHJI6B&I$#:(646>1J:H?0WU)Y,ZG7]L2 M:Q4QS0QR>F>[Z!%W!8;6&*W=SS;!%W1#*Z6LJ+\B1#&B!%&**+/(J7R.J."" MW!ZH:LE65-4*48VH0=0BZBP:".U2WG']4FB/*GYH+7)Z9\N(NP)":XW6L^,G MY`>^5,P&U%41"Q.*$25<6VW!I5H0^P,FAM9*N49X ME+52*_.!QIDX1T;TV#U&2T\Q5X?Z*&'$-03G*:E;YZ*9&3V>,)IP M7I*Z<;X0@:_H\93SFCV1\X;1A/.6U*US_LC2\4:ZH\*50:?- MQ:`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`)J@5##0@6UQM] M784>U%W41M\.X9-@<:/*'._)1//4)8_=;8)U:]OH6?UVV0; M_?-C^$3]EMA&_UP8/E&__;71/^^EGEST7:G^0X+OMU]WY>WSU_NGP]G#[HL: MRI?'MQ*>S7]I8/[Q8K]7_FG_HOXK`K6O5;\_KO[KB9WZ"8K+-VHQ^[+?O]`_ MM(/^/[-X_U\!````__\#`%!+`P04``8`"````"$`ZCD'&LX&``#T&P``&0`` M`'AL+W=OSN,XVHI$4,T-TS_WYO45]4E3HZV9>F/9PZEWOKU!RPO+5.K\D?DJJQY M>[]\R>OJ`A*OY:GLOO>BQJC*O>1PKIOL]01Y?T-VEC/M_H5,]Y82Y,4%HO=R5D@,L^:HK]RGA!7HKFAKE>]@7ZIRP^V\'_H_98?T9- MN?N]/!=0;>@GW`.O=?V&J`/Z.JA);`RJ2?>NOG^6N.ZX,RQW/T&0Q MG8'*:]%V88DEC5'^WG9U]2\A(2I%1"PJ`E/8[OP)E2E5@2M3>5[$ MIB)P9?F,G=EDBB#[>RG`W;X.<*7MYF-D3]P?-'-I,[BR<`]7;4;;PE#\^7P7 M5`2N5,1YNOL0N(Z8`-N/NN!':9C$2+TO_:S+ULNF_AS!8`>KM)<,3QW(P\K, MD<0_W*.W+`K>Q"HO6&9E0(W`?2V,JX_UU)TOS0\8"SGE;'0.DAE;QL#&Q[*^ M"@0J$*I`I`*Q"B0JD`X`$\K":P,#Y/^H#9;!M6%9;1@@BF4IA6`,UL17@4`% M0A6(5"!6@40%T@$@%0+&N%2(Z],5\P)FKPSXR[U@+29R@AO"02XORE9#?`T) M-"34D$A#8@U)-"0=(E+J,#,]D3IFPTB".O+-^Z;`#?O*L'PV!)D-+*`AOH8$ M&A)J2*0AL88D&I(.$2EG6"VDG.\GBMERHA0ABS">UK8:XFM(H"&AAD0:$FM( MHB'I$)$2A>G[B40Q6TZ4(#;9N/2)61#X$D!HLYCJ"8TV592CA)":=:(%LI(K_/\@JY*D,BCMR.$W,= MO,[K<1)^GZFF7%6M'_2Z5+\K=8(]'2L49LN%(H@-EN;FL1:*>;:4!)W(25KM MKG"0XRH%)"0']06>VQ-'OA_2^\/I7PT470FD&NR87P[?Z(!8E%3Y@X&6%Z])01;D272PTDJ=2#S MS*D]0"#9[$@Y[FQ9PWMV\P6)U2"@D(/7AX\UFBD]&[(F-]S6+RD1(]T+'C/2 ME._"$PJY,'GP@81FR@XV%0T%:S")R;V`M]9/&![3%<,3R+'Y8VX1AZX^`#T\ M4I+8CP2LG8!"!@GU2$"WU6-&$E*)#J4,ZM7ENN`]]A-U(5MRJ#PSR@81R(') MF_>592N3TY:R8")@#7T="I@6'7B6;6NVH]%NC#QJ.T(:!(OU8(D:S)EH!KL? M3"XDWK@/"_ESPYQL_Z7Z$D@>Y@ME3[#%K^^P8<7VWM>A@$(PJ`=]M5"VPB%K M.&0A5SD[1XPE(L8ZE%R/J$Q2*6MX*Z)<:7QR&%;Z!VL7/6@,+4L@:2AS2%1F M,)?0H4Q)8K`%\.X`U]T14,B@X5!^0#UF[814HD,I@ZX,97P\&-;EYQQ(#AF2 M`PGD]F^D^TIL$8$&(\P7D*B@MET,*(LM[,A19_60,>Z/<"U^_%#\A*G3&08M M;,V+1-JY$5^V(CY1W"OYU_H"@_+JP6MPH(!W_=IJ0R#)HAP2!=8M2DFBKP*J M[@@H9-#0H@^HQZR=D$IT"'^ZZ,?$P*+D4P1YY5L5S:'8%J=3.\KK=_R9`6:M M]9+#Y!O(QO'@70@L%@KNSSPXANMX///@Q*SC_MP+^L=5=.*Y!R=$G0_?7E[Z MJ4+A;_`WF2O\C>7!"TM=9S/UX'6>CK_8W@L42+^QL3UXX06XR2/#-Y=+=BC^ MR)I#>6Y'IV(/Q9KTQ_J&?+4A/SKJLM>Z@Z\MO>&.\'6M@)<\DS$L#/NZ[M@/ M'(!_KUO_!P``__\#`%!+`P04``8`"````"$`BFGI[OCX\?+D?OKB\O#H]WQR_WC]\^7/[W/Y/_NKF\>'ZY??QR^^/X M>/AP^>_#\^4_/O[G?[S_Z_CT^_/WP^'E@AP>GS]*0K7X]/#[#C]N7ZC^S]_O?S[#[>'N'+N'VZ??__CY7W?'AY]D M\=O]C_N7?Y],+R\>[E;YM\?CT^UO/^B^_S6:WM[!^_0/9?]P?_=T?#Y^?7E' M=E>VHOJ>EU?+*W+Z^/[+/=V!:?:+I\/7#Y>?1JO]8GIY]?']J8'^Y_[PUW/G M[Q?/WX]_I4_W7ZK[QP.U-O63Z8'?CL??C33_8A`5OE*EDU,/;)\NOAR^WO[Q MXV5__"L[W'_[_D+=/:,[,C>V^O+OZ/!\1RU*-N_&,^-T=_Q!%:#_7CS'XY/ORO%8V< ME369.)-I:S)]-QW/%C3=XO1]7*R(#10<.X*TI^NX/2L M<@M7CH9_6^ZLFBY=0?KS;34=49>>[M'\I8UYSCV.T#6-] MJ1-M?;N]>59]T9NC;J^W+[_+BA+47,__[PU.6^T&I$9II(=ANWD"LTMFE3&Y9.Q^7!)]T'3YID2PI\? M)_/Q^ZL_:1+?.!U".47KT/ZGSN8&T9-3YC.W!A?W_@C_[/5 M4`Y!2Z\5B12)%4D4217)%,D5*10I%:D4J15I%-DHLE5DI\B^2[RNH'S]AJXP M:LITU*^=/#41?6%%+UP7##&[7?$[8U:]Y+*\5 MB12)%4D4217)%,D5*10I%:D4J15I%-DHLE5DI\B^2[R&I^70&QK>J/V&MV1J M=S"GAF$IZ;9PD]?D=7,:,W>25_BP1ZW(DRO1)%4D4R17)'"DDZERY9PA62E MJ]:'-:.9J'3=BE#I1I&-(EM%=HKL+;&5]KJ05L1>%W;RU\OW^[O?/Q^ID6G= MUC.G)K0,MHMC8^+WK"6=1EJWA!M`-E)D-7/:4K4].YJ)IU?*;!39*K)39&])3\_2_/C_]ZPQ\7O6 MDDXCK5O"#2`;*;*:^>BT0LB7A.%7KX^*(^ZG;ZW!M6E>034O"<;:M3__][-KK<-VWKD2\F6Y. M*KP!T3.EZ70(<_HD][O>H2D]#]KY.99-O(:*4DZK4N.!1:AXK%&B4\4BN-<:-1IM&(7=MRR"^TZCO8?\;C:;[.Z!QRO=;/?DM&-` MN,_FA(HF_90R2]N!8SECUTYE_FA5NIN=>USSZ_)_%JLW!((J.C`"&V-PZ*,JXCH.U.9\W!8?F6<0BW&SLT-0F0OK,30TS9TQ_#`RS M,Z)G.GHNHD_ERKM`F:'H)41#]UZQ"/=>^]$GR^6U_Q!H4&8H^@:BH>A;%B'Z MSH\^75R+S+%'F4!T?YB9TZ(W9#-[N$0#&=7Y/+)(9#.Q$5X[U2O9S%J1".XQ MW.V>$SUC$:+G,$=TN1PH(!B*7K)Q>"94+$+T&N8V M^LU,KFL:"(:B;]@X''W+(D3?P1S1%V*"[R$(1/>'F3D0ZPZS7]J[FX^599*S M2"0Y<:*_1L&AJ1:Q"&T0.S0SQP=_?IR*94."$H&)YL:>J_10[`Q.?*Z7B]AB MDA/:. M9MDKO6O/%;U'ET7BD$`\8=;FC0#J\,Y3*=(H=L@MNT?SV5BL/1,H`OG290L5 M+-/!)V/!;+P#4*)KFHT%Q%3;9]IE/='%`U=H.!@Q!(JOL=*H[H_HGB>-B@X M&'$#%4?<:K3KCRA&[AX%0Q']T63.*[NCZ96$8X\WO81CD?ZY1`<3N):.P>P41N]<:-4#LOF$4=M]"Q.X[C?9` M^G$R?MM)\TGN;[,=\A\B8[%<6T/%6YM(H]@A/$1H6RL>1@D4@>QG'R+:.=,H MAY5[B$RG\J"N@&(H6*F=*XUJ6-E@X^5D).ZL@6(HV$8[;S7:P0K!9C,Y[Z$( M!/.F_9A6L&^8]B>Y&"+&@9:,_M-"K*K7*,AY+=(H=LB=N]Q,)^(1D*!,-Z7) MA))"Q+$RC7(_UG(R%E4N4&8H5@D1QZHTJOU8H]G-C>BS!H6&@FT@XF!;C78B MV'PTE]L,%`H$\P<(C2)O@/S2YG9L7,2XL4BD%GFTX@IVUZ<:Q0[-%J>M[$B. MB`37`S/")197(B%/:X'[LH?,#2JO`$SO)`8&[D8&19U%Q).-;POA8@?E[%& M"1`_C%-&X8=Q!A&[YQH50.Q>,@J[5Q"Q>ZU1`\3N&T9A]RU$[+[3:`_4LY`P M9Y?=Q>&O)0%[`MI=,X[=H2BM_SM;#9&OUDY%Q_@X2(D8<4'UX5@,>W>.3]^Z M$$D^@4\@%;K,X"K.\3.4ZQX`J?BYC']S(QYH!7R&XI<0$3B.]G%G/8.#0*_WG\29GDM;,2\\T; MF7$L\C).B_@&Y7,E,PNY;B-A]I]$>J"?CF(/(;E^_\A2QYY:46KA.D[E89'T>6Y7_PK5< M8ZY9Q=FF+0@4:U6B4:I1IE&N4:%1J5&E4:U1H]%&HZU&.XWV'O)GISFZZO98 MYQGQ2N?90R_ON6!1]QWLL4*11K%&B4:I1IE&N4:%1J5&E4:U1HU&&XVV&NTT MVGO([Q9SM-;MEE?ZPIW$=3XF&#O$V7^M4:11K%&B4:I1IE&N4>$A_Y[-B=(; M[MD>0'GCSZ+NVY7C%G&*T0\$*_+>B58OH<;.BE1()PF[`Z6,P@$SMF+1>")V M)3FKX%ZP.R&O]2;RU*@SD<\_5SZY^.MZA[J-RHBKKQK5B>AUY/Z7/&,6X/82 M-@9*&85C96S5'RMG`8P+-E9-*4]73%.>\WG.Q!ZJ=(>D0_Y^>2+.M==04;)L M%]2Z0:V[][Z"6KS&S@KG=3<3^3E,`D7WJ2N#I>?4*.L3J1KEB.<.]>8+]68, M%($:^>.<1%Z6^+5Q;ES$.+?(/Q&;B,\#UA-7D/IBH*=:$49;[,KYGZC(3ZT2 MN'?7U?H3%:B&ZI"Q"'7(^^L@CH4+%`S5P>\-4GF],?RQ1@D0+X131N$>S"!B]URC`D@OA"=_R];[Y"*:RVV]:6G;CK_Q1.R/ MUZY@]_R-$1=4Y8GDSDSMO M"`+A_<'Y]^P\)WKGZ9`W:,_9>:(<[Z]BC1*@[J`]PSU#.7;/-2J`>@:MV2]U M%V"GYQX]D][X9?^)W7>);9W(,Y^=2FSKQ!GFFE5(8Y%&L4:)1JE&F4:Y1H5& MI4:51K5&C48;C;8:[33:>\@?^F;;);O2O67P2HJV&S9O#6-1=ULW42C2*-8H MT2C5*-,HUZC0J-2HTJC6J-%HH]%6HYU&>P_YW?*V;=U$;^N`.MLZC2*-8HT2 MC5*-,HURC0J-2HTJC6J-&@_Y[6$G6N1$ MWA9Q/!%'WC&KX)ZP.U#**!PP8RL6C>5G[SFKX%ZP.U#)B+WD,[MRHOFDW=[6 M&C5L1>Y>WTS_E@WHR<5?\C@T[S[RQU.Q,%@[%6U3P_<8PK0$5Y91GT@O8YW*+6,7HY%85B00=,>4;,NT M+Y8497TB5:$<\=RGPO);GP6N#]6G[`LEZU/UB51]:L2SZ^S%1!ZG-Q`$*N0/ M$!)Y`^3<\Y*I*2@FNT7^+GPJUHYK%!S:`4T%#G\&P M/7O).F0L0AWR_CJ(=40!57?VJ3J4;!^N0\4BU*&&N]\.XC/>!JI0'?P1(<\[ MAA=F4WL^X#TC+.INJ9UJ^!P((CZIB35*@#I;:D;AULL@8O=\'N0"4C]I+SLG*B[O9> MHX:MR-WO&WGT\FMK/GTB0XGP-)B[ZXSQ3.S)UT[U2B\ZJU>V]ZT*+9BP.U#* M*-RH&>KN!Q2?[N:L@GO![D`EHW#`BJU8U+.]5W?8L#L%]#K6?$O^#4GK)/>3 MED,F+[8S;"Q_G6T-%>6N5B5':=0G4@_PV*G<]GX^GXI':`)!=TS)6&E?+"G* M^D2J0CGBN>V]_&Y'@>M#]2G[0LGZ5'TB59\:\>SV?KZ\%A]C-Q`$*N0/$'.@ MTWVJG;N]I_Z1^=FA5[;W*#BTR8U8A"D4.T1CW;P&,E=9)$&9P-+*OC<,T5#T MC$6(GCL4VMZCQ%#L$J*AV!6+$+MV"'<^D>\2-2@3B.YW.(T*U>'=1>59OVIH M-M#BZ>R0GRBF2[5FE\X%JA[J_#F*+U4`5JH,_(FC8>"-B>&%KWG*1 M76]1=V'K5,/;>XAX01=KE`#Q&CEE%&Z]#")VSS4J@-B]9!1VKR!B]UJC!DAO M)TS+>*W^2TNNDXMX8+NS%O^!+3]104'>X4:,^+;5TR=V*I>,>K;WL`DD(Y>& MW1D1A\]0KIL=5?C,@J[5Q"Q>ZU1`]0S'\WY1[ZYFUCV4&.E#5&YUA2*M MBC5*-$HURC3*-2HT*C6J-*HU:C3::+35:*?1WD/^S#!'(&_H"R,72=`AGN%K MLW0P*D:11K%&B4:I1IE&N4:%1J5&E4:U1HV'_/9[VU$+'>>I]M-'+4XUO$EW MHE>.6EB%F9*P.U#**#SM,[9BD3YJ817<"W8'*AFQE\R1E1-UCUHT:MB*W/V^ M,=OW[MC^M>>^/03PTH\[%^BN^<;R!^36IF=H%KS2B\[*/_D0IS:QLZ+O`*`% M$W8'2AF%&S5C*Q;I-RE8!?>"W8%*1NRE>['W#L5&NM8!&W:G@%['FI]F]SIV M^`%RDOM)RR%_!R6KOH:*TEF[OY"BJ$^D%E.Q4]'VT2RF%A/U)@4$W3$E8Z5] ML:0HZQ.I"N6(9X]:IC?BL*W`]:'ZE'VA9'VJ/I&J3XUXKH$6Z@O_$`0JY`\0 M6MEZ`^3.^26^/)]J@(EAF*7$`W%KEB$V+5#N/.E?'VL09E`=+_# M:52H#N\N\,\Z:C&OQHG5C4-^HE!'+5`-)PKKWCUJ<>7,\H+'UDR\Q9!`U1WY MZI@C/:<.&8O0#SG<_3J(D^`"JL$ZE&S/]R-G0<4BU*&&NU<'^0MH#52A.O@C M@H:--R)>>488N7A&6-3=VM%2Q*C,UK/M+WE_$41\7!%KE`#QYBME%';/(&+W M7*,"B-U+1F'W"B)VKS5J@/36CCY*]5O]EY9<)Q?1&7U'+7.Q3EJC8&?CP8AO M6SU]8J=RR6B^D&,O@0T-@&#/IQ!Q^(P1EU/A0L31*T8# MT6NG:H]:Y-O1#6P"X?UYYQVU4*_)$7#>48OY.HNTA2G>O,[?(:W6+:%2@]2*GZJ!8HT2C5*-,HURC0J-2HTJC6J/&0_YHIB?2 M6]K/R$7BLHAV@6BL];Q%X9Z/G,AL@MJ$H[\HP2JX)^P.E#)B+SE-,K9BD=[> MLPKN!;L#E8S82P:LG(@>)BA7:]2P%:G\OO&.7GHRS7EK/GTB,[?(+#>XZ>7_ M9G?M5,/;>U@-;^]9A99(V!TH9<35DHV:L16+]/:>57`OV!VH9,1>,F#%5BS2 M;U*P"NX-NQ/R.]:<&+PA:=D#!B]I6>2OVN5O8*[G3D73L>UG>7]1GT@]P&.G MPO9^?",^C$T@Z(XI&2OMBR5%69](52A'/+>]7XB/+0M<'ZI/V1=*UJ?J$ZGZ MU(B'[;UV=ZCX-`F-V(1!GGLD%M: MS>;JV`=E`DLKN[V':"AZQB)$SQURR\JE'`,H,12[A&@H=L4BQ*X=PITO1N*` MJ4&90'2_PRFZEQ'DHO*L5+\P+J+W+?(3A=K>NX+FAR]_E M2J#JCGR]O6?[ZO@TB1#52A M=O!'!*F\$3&\L%T8N>AZB[H+6Z<:WMY#Q`NZ6*,$B-?(*:-PZV40L7NN40'$ M[B6CL'L%$;O7&C5`>CNQH,GJM?JOS4/C(CK#(C\+RV?$^A2>"O(.-V+$MZV> M/K%3A;?WL`DD(Y>&7;TY?(9R-'W:S*#"YTX5W-[#92AZ"1%'KQ@-1*^=*KR] MATT@O#_OZ&D[.`+.V]XOC(T8`A9Y\[%%?']R_1$YJ\Y>/M8H`>(9DS(*NV<0 M\08\UZ@`8O>24=B]@HC=:XT:H,Y\O'K^?CB\1+OAW6AQ\_GB_N MCG\\TCBD:=3!%T^'KQ\N/XWGJT_TFR64E-L"]@K],.3*_+)AWY4%73F]&BC* M?)J0&]6KIPQ=,3^HT7>%W.@W'7JNS*@,55I?B>8WJYAV"OH*[716>>\5VI*L MZMXKGT:K3Z=W=\3=?!ZM]J=I)?F8;K\G]N<)W4@/_S0E_]XFGJ[VO8TUH_ON M,5K/YRMS6J)OFPY,5N;L0U^AXX^5.%=N?4B'U7 MHAEUB9UMHKGH#8%5WGN%/LI?U;U7HMF2W$[O\2BW);GU7:FHC/G`N.=.IU0W M^NZ%OD)?%%GEO5?H&QVKNO=*-*6Z4=KLA^Z&OCI7B]6NCTC"O7QBCJXCV^7J]V) M7[7=^_SQ_<_;;X?Z]NG;_>/SQ8_#5TK;UZ?_>='3_3>SJK+_>'&_Z?S;\>7E M^$`/3#I//]Q^.3P9`9UK?ST>7_`/:M2KOXY/OY\>#1__3P````#__P,`4$L# M!!0`!@`(````(0!!Z:B=70,``"0,```0``@!9&]C4')O<',O87!P+GAM;""B M!`$HH``!```````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````````````````````````)Q676_:,!1] MG[3_@/+>AK9LFJJ0BD*[(K4K`MH]6L:Y@%7'SFR'P7[];I)!2&?E@G.J,57Q@^< M:674W+9NU@Q$%.X?1LAN`BS7W&[B=A3N;Z,)HP+ZZ#B>4V$@"NL/T1W00K01 MY=K$TKH!9I5N&_T'9SH/6C!HHZ'2#%=6<2HNT"K-J4ZY%9JR.?RK]8I8` MUD0A&E0?R^6^[?Z:=^+.M]("5TW+PD/%!`^:'*?<"C"/\Q'5UD&Y@Y&O.98&N9$6]2)#646;JWWFNS?T%09:&D@(KHP2/*$6-]=44,E0S9UA MH4MUBQ]R=@QF8O&V]*AK_D',:_2>/?8 M>R474]`I&<#,.GD,IY=3==\XI.X$ M?TY)?A2DNNDH".J2':@41]V^]19_V,^=S/R8BP]@.A_`?'%B_/W%G0+^-'9K MX,>X-?!CW!HTRV62IRG5F^+'4!XX)6A"L+U@DQL/>HB@V)[?`9G\ M`]*G.N5L24&0'\H>:#&NGEOGI_.6(8Z+V^Y;FVX[H1/B[QON#/!CW!EPN(L7 M1)W4_/W)?8T?TTBTQCCV:@"[Y_+%/&53-:1R/,G4!&.5$U7"99A"AGP`1 M?RF-DO\5\P4``/__`P!02P,$%``&``@````A`"/(&=8R`0``0`(``!$`"`%D M;V-0$+YUQ$() MH-W^O:SKZHR>/)+WY>'Y/LK%7C?))SBO6E.A/",H`2-:J4Q=H>?U,IVAQ`=N M)&]:`Q4Z@$<+=GU5"DM%Z^#1M19<4."32#*>"ENA70B68NS%#C3W66R8&&Y; MIWF(1U=CR\4[KP$7A-Q@#8%+'C@^`E,[$M&`E&)$V@_7]``I,#2@P02/\RS' MW]T`3OL_+_3)15.K<+!QID'WDBW%*1S;>Z_&8M=U63?I-:)_CC>KAZ=^U%29 MXZX$(';<3\-]6,55;A7(VP/;O[DF\7Y7XM]9*45O1X4#'D`F\3UZLCLG+Y.[ M^_42L8+DTY04:3Y;%X22.9W.7TM\;@WWV0C4@\"_B6<`Z[U__CG[`@``__\# M`%!+`0(M`!0`!@`(````(0#A_+]<%@(``"\>```3```````````````````` M``!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@````A`+55,"/U```` M3`(```L`````````````````3P0``%]R96QS+RYR96QS4$L!`BT`%``&``@` M```A`,U/P]Y%`@``=!T``!H`````````````````=0<``'AL+U]R96QS+W=O MG]F0<```@C```8`````````````````&$/``!X;"]W;W)KX6Z<"``"L!@``&0`````` M```````````P%P``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-&1>XZ&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`/\&=0&S`@``<@<``!D````````````` M````4RL``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A``DQ]T7S!```HA(``!D`````````````````8C0``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`'U` M!\1)`P``,`H``!D`````````````````8D(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*_!._N6 M`@``DP<``!@`````````````````E9$``'AL+W=O&PO=&AE;64O=&AE;64Q M+GAM;%!+`0(M`!0`!@`(````(0!++([J$0<``!T?```9```````````````` M``.B``!X;"]W;W)K&UL4$L!`BT`%``&``@````A M`!F+=WM:`@``B@4``!D`````````````````2ZD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$V!&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+6`MKLB M!@``5QH``!D`````````````````!;P``'AL+W=OP@``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`$D\%3+Q"```HB@``!D````` M````````````BL@``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`$TQ)-]^&P``PY<``!D`````````````````!-T` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#.1+)@L%@``.8$``!@````````````` M````:OL``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`'K`A<%E!```I@\``!@`````````````````*AH!`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`)+_A[R7`P``8@P``!D`````````````````&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!S9FRK=!P``[2$` M`!D``````````````````T$!`'AL+W=O&PO=V]R:W-H965T\1Z M-`@``-(D```9`````````````````(A8`0!X;"]W;W)K&UL4$L!`BT`%``&``@````A`'B4U";X#P``.%0``!D````````````` M````\V`!`'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT` M%``&``@````A`(IG)&%Q&@``IH\``!D`````````````````VXH!`'AL+W=O MFHG5T#```D M#```$`````````````````"#I0$`9&]C4')O<',O87!P+GAM;%!+`0(M`!0` M!@`(````(0!D4<_'E@```*H````0`````````````````!:J`0!X;"]C86QC M0VAA:6XN>&UL4$L!`BT`%``&``@````A`"/(&=8R`0``0`(``!$````````` M````````VJH!`&1O8U!R;W!S+V-O&UL4$L%!@`````Z`#H`OP\``$.M $`0`````` ` end XML 15 R46.htm IDEA: XBRL DOCUMENT v2.4.1.9

Related Party Transactions - Additional Information (Detail) (Management [Member], USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Law_Firm

Dec. 31, 2013

Jun. 30, 2014

Management [Member]

Schedule of Other Related Party Transactions [Line Items]

Legal services to these law firms $ 91 $ 159 $ 190 $ 319

Amount payable to law firms $ 113 $ 113 $ 115

Number of law firms related to entities 2

X

- Definition

Number of law firms related to entities.

+ References

No definition available.

+ Details

Name: ssy_NumberOfLawFirmsRelatedToEntities

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ssy_ScheduleOfOtherRelatedPartyTransactionsLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount for accounts payable to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of transactions with related party during the financial reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 16 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Receivables [Abstract]

Net revenues for settlements and filings of prior year Medicare and Medicaid cost reports $ (297) $ 302 $ (297) $ 506

X

- Definition

Amount of increase (decrease) in estimates of the allowance for doubtful accounts of health care organizations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 310

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35755819&loc=SL9156395-115594

+ Details

Name: us-gaap_HealthCareOrganizationSignificantChangesInEstimates

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 18 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9

Business Operations - Additional Information (Detail)
3 Months Ended 6 Months Ended

Dec. 31, 2014

Segment

Dec. 31, 2014

Segment

Business And Organization [Line Items]

Number of segments 2us-gaap_NumberOfReportableSegments

Number of community hospitals 3ssy_NumberOfCommunityHospitals

Healthcare Facilities Segment [Member]

Business And Organization [Line Items]

Number of operational areas 3

Number of community hospitals 3

Number of states 2

Number of licensed beds at community hospital 183

Number of nursing homes 2

Number of licensed beds at nursing center 166

Specialty Pharmacy Segment [Member]

Business And Organization [Line Items]

Number of operational areas 4

X

- Details

Name: ssy_BusinessAndOrganizationLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of community hospitals.

+ References

No definition available.

+ Details

Name: ssy_NumberOfCommunityHospitals

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of licensed beds at community hospital.

+ References

No definition available.

+ Details

Name: ssy_NumberOfLicensedBedsAtCommunityHospital

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of licensed nursing center beds.

+ References

No definition available.

+ Details

Name: ssy_NumberOfLicensedNursingCenterBeds

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of nursing home.

+ References

No definition available.

+ Details

Name: ssy_NumberOfNursingHomes

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of operational areas.

+ References

No definition available.

+ Details

Name: ssy_NumberOfOperationalAreas

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of states.

+ References

No definition available.

+ Details

Name: ssy_NumberOfStates

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_HealthcareFacilitiesSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 19 R42.htm IDEA: XBRL DOCUMENT v2.4.1.9

Insurance settlement - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 0 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Jan. 31, 2015

Insurance [Line Items]

Insurance settlement $ 1,000us-gaap_InsuranceRecoveries $ 0us-gaap_InsuranceRecoveries $ 1,000us-gaap_InsuranceRecoveries $ 0us-gaap_InsuranceRecoveries

Subsequent Event [Member]

Insurance [Line Items]

Insurance settlement $ 1,000

Insurance claim, malpractice description Claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006.

X

- Details

Name: ssy_InsuranceLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InsuranceRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Description of insurance coverage used by the entity to manage the financial risk of malpractice claims (including general and professional liability). Disclosure may include a discussion of the entity's risk management policies, a description of the insurance arrangements (including type, coverage, coverage limits, deductible), description of the insurer, and whether the entity is self insured or retains significant self-insurance risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 450

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

+ Details

Name: us-gaap_MalpracticeInsuranceDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R37.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Goodwill and Intangible Assets Disclosure [Abstract]

Amortization expense $ 36us-gaap_AmortizationOfIntangibleAssets $ 35us-gaap_AmortizationOfIntangibleAssets $ 71us-gaap_AmortizationOfIntangibleAssets $ 70us-gaap_AmortizationOfIntangibleAssets

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9

Financial Information by Segment - Additional Information (Detail)
6 Months Ended

Dec. 31, 2014

Segment

Segment Reporting [Abstract]

Number of segments 2us-gaap_NumberOfReportableSegments

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9

Shareholders' Equity
6 Months Ended

Dec. 31, 2014

Equity [Abstract]

Shareholders' Equity

Note 4. – Shareholders’ Equity

Stock-Based Compensation

For the three months ended December 31, 2014 and 2013, the Company recognized $48 and $15, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2014 and 2013, the Company recognized $21 and $31, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 90,000 and 0 share options granted under the 2005 Equity Incentive Plan during the six months ended December 31, 2014 and 2013, respectively. There were 0 and 21,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2014 and 2013, respectively.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 23 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E M.#=B9#'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M#I%>&-E;%=O&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R M:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9I;F%N8VEA;%]);F9O5]396=M M93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E=F5N=65?4F5C;V=N:71I;VY?86YD7T%C M8V]U;C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E M;%=O5]!9&1I=&EO;F%L/"]X.DYA;64^#0H@ M("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E=F5N=65?4F5C;V=N:71I;VY?86YD7T%C8V]U;C,\+W@Z3F%M M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D=O;V1W:6QL7V%N9%]);G1A;F=I8FQE M7T%S#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS7T%D M9#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O M#I! M8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E M;%=O7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^9F%L'0^1&5C(#,Q+`T*"0DR,#$T/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q-3QS<&%N/CPO'0^43(\2!2 M96=I'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE M3QS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M"!A2P@ M<&QA;G0@86YD(&5Q=6EP;65N="UN970\+W1D/@T*("`@("`@("`\=&0@8VQA M"!P87EA8FQE/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XQ,SD\3PO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F5D(&%N9"!U;FES'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)FYB M'0^)FYB7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$#PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`H57-E9"!I;BD@3W!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;F1I='5R97,@ M9F]R('!R;W!E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&]N(&QO M;F&5S/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/&1I=CX-"B`\<"!S='EL93TS M1"=M87)G:6XM=&]P.C$X<'0[(&UAF4Z,3!P=#L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B`\8CY. M;W1E(#$N("8C>#(P,3,[0F%S:7,@;V8@4')E'0M:6YD96YT.C0E.R!F;VYT+7-I>F4Z,3!P=#L@9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N)SX-"B!4:&4@86-C;VUP86YY:6YG('5N875D M:71E9"!#;VYD96YS960@0V]N$$P.S,Q+"`R,#$T(&%N9"`R,#$S(&AA=F4@8F5E;@T*('!R97!A#(P,4,[4T5#)B-X,C`Q1#LI(&%N9"P@87,-"B!S=6-H+"!D;R!N M;W0@:6YC;'5D92!A;&P@:6YF;W)M871I;VX@2!'04%0(&9O<@T*(&-O;7!L971E(&9I;F%N M8VEA;"!S=&%T96UE;G1S+B!4:&5S92!#;VYD96YS960@0V]N7-T96US+"!);F,N("@F(W@R,#%#.U-U;DQI;FLF(W@R,#%$.RP@ M)B-X,C`Q0SMW928C>#(P,40[+`T*("8C>#(P,4,[;W5R)B-X,C`Q1#LL("8C M>#(P,4,[;W5R#(P,40[+"`F(W@R,#%#.W5S)B-X,C`Q1#L@;W(@=&AE M#0H@)B-X,C`Q0SM#;VUP86YY)B-X,C`Q1#LI($%N;G5A;"!297!O65A$$P.S(V+"`R,#$T+B!);B!T:&4@;W!I;FEO;B!O9B!M86YA9V5M96YT M+"!T:&4-"B!#;VYD96YS960@0V]N"!M;VYT:"!P M97)I;V1S(&5N9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!A2!B92!E>'!E8W1E9"!F;W(@=&AE(&5N=&ER92!F:7-C86P@>65A3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B M9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA'0^/&1I=CX-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP M="<^#0H@/&(^3F]T92`R+B`F(W@R,#$S.R!"=7-I;F5S6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@ M8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T M/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#Y4 M:&4@2&5A;'1H8V%R92!&86-I;&ET:65S(%-E9VUE;G0@:7,-"B!C;VUP;W-E M9"!O9B!T:')E92!O<&5R871I;VYA;"!A$$P.SPO<#X- M"B`\=&%B;&4@2!H;W-P:71A;"!S=6)S:61I87)I97,-"B!I;B!T M=V\@$$P.SPO<#X-"B`\=&%B;&4@&EM:71Y('=I M=&@@82!C;W)R97-P;VYD:6YG(%-U;DQI;FL@8V]M;75N:71Y(&AO$$P.SPO<#X-"B`\=&%B;&4@2!W M:&EC:"!I2!V86-A;G0@97AC97!T(&9O$$P.SPO M<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P M,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H/3-$.24^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,R4@86QI9VX],T1L M969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F M=#Y2971A:6P@<&AA6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q! M4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$ M,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('=I9'1H M/3-$.24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M,R4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P M(&%L:6=N/3-$;&5F=#Y);G-T:71U=&EO;F%L('!H87)M86-Y('-E6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0[($U!4D=)3BU43U`Z(#!P M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T M:#TS1#,E(&%L:6=N/3-$;&5F=#XF(W@R,#(R.SPO=&0^#0H@/'1D('9A;&EG M;CTS1'1O<"!W:61T:#TS1#$E/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1'1O<"!A;&EG;CTS1&QE9G0^4W!E8VEA;'1Y('!H87)M86-Y('-E$$P.SPO<#X-"B`\=&%B;&4@'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C M>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C M;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P.TUO M;G1H$$P.T5N9&5D/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L M:6=N/3-$8V5N=&5R/CQB/E-I>"!-;VYT:',-"B!%;F1E9#PO8CX\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N M=&5R/CQB/D1E8V5M8F5R)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.S,Q+#PO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R9V(H,"PP M+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ("=4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L M-S,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$S,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,3,\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-C`T/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XV+#DQ-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@&5S.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X.3<\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0Q,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-S`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4V/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XH,3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T,#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@Q.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@Q.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B@R-34\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP M+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@Q,C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R M9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>#(P,3,[($]N($1E8V5M8F5R)B-X03`[,S$N#0H@,C`Q M-"P@=&AE($-O;7!A;GDF(W@R,#$Y.W,@2P@2&5A;'1H36]N M="!O9B!-:7-S;W5R:2!S;VQD#0H@2!A;&P@=&AE(&%S M#(P,4,[1G5L=&]N)B-X,C`Q1#LI(&%N9"!R96QA=&5D(&-L:6YI8W,@:6X@ M1G5L=&]N+"!-:7-S;W5R:2!F;W(-"B!A<'!R;WAI;6%T96QY("0V+#`Y,"X@ M1G5L=&]N)B-X,C`Q.3MS(')E$$P.S,P+"`R,#$T M(&%N9`T*(&9O"!M;VYT:"!P97)I;V1S(&5N M9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30-"B!A;F0@,C`Q,RX@1G5L=&]N M(')E=&%I;F5D(&%C8V]U;G1S(')E8V5I=F%B;&4@86YD(&-E6UE;G1S("@F(W@R,#%#.T5( M4B!&=6YD#(P,40[*2!F;W(@;65A;FEN9V9U;"!U2P@86YD('-U8G-T86YT M:6%L;'D@86QL(&QI86)I;&ET:65S(&]F('1H90T*(&AO6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z(#$R M<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@1G5L=&]N(%)$02!,;V%N)B-X,C`Q M-#M3=6Y,:6YK+"!&=6QT;VX@86YD($AE86QT:$UO;G0@3$Q##0H@*"8C>#(P M,4,[2$Q,0R8C>#(P,40[*2P@=&AE(&1I'1E M$$P.S,Q M+"`R,#$R+"!T:&4-"B!#;VUP86YY(&-O;7!L971E9"!T:&4@'1E#(P,4,[1&5X=&5R)B-X,C`Q1#LI+"!T;R!3;W5T:&5A M2P@3$Q#+"!A M;B!I;F1I#(P,40[*2X@5&AE(&%S'1E2P@3$Q##0H@=&AR;W5G:"!A('1R86YS:71I M;VX@<&5R:6]D(&5N9&5D($IU;F4F(WA!,#LS,"P@,C`Q,RX@1&5X=&5R#0H@ M6UE;G1S("@F(W@R,#%#.T5(4@T* M($9U;F1S)B-X,C`Q1#LI(&9O$$P.S,Q+"`R,#$R+B!$97AT97(F(W@R,#$Y.W,@;W!E$$P.S,Q+"`R,#$T(&%N9"`R M,#$S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE2!A;&P@=&AE(&%S M#(P,4,[365M;W)I86PF(W@R,#%$.RD@=&\@ M=&AE($AO2`D."PS-3`N($UE;6]R:6%L)B-X,C`Q.3MS(&]P97)A=&EO;G,@:&%V92!B M965N#0H@8VQA"!M;VYT:"!P97)I;V1S(&5N M9&5D#0H@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!A;F0@,C`Q,RX\+W`^#0H@ M/'`@"!M;VYT M:',@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-`T*(&%N9"`R,#$S+B!4 M:&4@8V]M<&]N96YT2P@=V5R92!A"<^#0H@/&(^/&D^)B-X03`[/"]I M/CPO8CX\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ("=4:6UE"<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/"]T'!E M8W1E9"!R971U$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,34\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T'!E;G-E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@'0M7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA3QB2!;06)S=')A8W1= M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3X\8CY.;W1E(#0N("8C>#(P M,3,[(%-H87)E:&]L9&5R#(P,3D[($5Q=6ET>3PO8CX\+VD^/"]B/CPO M<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+51/4#H@-G!T)SX-"B`\8CX\:3Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\ M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[ M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#QB/D9O M2X@1F]R('1H92!S:7@@;6]N=&AS(&5N M9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,30@86YD(#(P,3,L#0H@=&AE($-O M;7!A;GD@2X@5&AE(&9A:7(@=F%L=64@;V8@=&AE('-H87)E(&]P=&EO;G,@9W)A;G1E M9"!W87,@97-T:6UA=&5D#0H@=7-I;F<@=&AE($)L86-K+5-C:&]L97,@;W!T M:6]N('!R:6-I;F<@;6]D96PN(%1H97)E('=E2!) M;F-E;G1I=F4@4&QA;B!D=7)I;F<-"B!T:&4@$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN M#0H@5&AE'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3X\8CY. M;W1E(#4N("8C>#(P,3,[(%)E=F5N=64@4F5C;V=N:71I;VX@86YD($%C8V]U M;G1S#0H@4F5C96EV86)L97,\+V(^/"]I/CPO8CX\+W`^#0H@/'`@28C>#(P,3D[2!P87EO#(P,3D[(&%B:6QI='D@=&\- M"B!C;VQL96-T(&]U='-T86YD:6YG(')E8V5I=F%B;&5S(&ES(&-R:71I8V%L M('1O('1H96ER(')E2!P87EO#(P,4,[4%!/#(P,40[*2!A;F0@;W1H97(@<')I M=F%T90T*(&EN'!E8W1E9"!T;R!B92!R M96-E:79E9"X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*(#QB M/B8C>$$P.SPO8CX\+W`^#0H@/'`@2!P87EO6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T* M(#QB/B8C>$$P.SPO8CX\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E"!-;VYT:',-"B!%;F1E9#PO8CX\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#DV,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-C`R/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,L-3(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8L.3$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C8L.#0T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L M,#`R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L-#4S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.3DP/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L-S`U/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#$X.3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XT+#$U-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XX+#4Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XX+#4W,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY.#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S+#4S-#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XS,RPX-#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(%!R;W9I$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y M+#,Q.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.2PU-30\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%-P96-I86QT>2!0:&%R;6%C>2!396=M96YT M($YE="!2979E;G5E$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L-#,P/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CDL,S(V/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$U+#@X-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-BPQ-C@\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]T M:&5R(%)E=F5N=65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CDQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y M.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L($YE="!2979E;G5E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(S+#@X,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M2!0:&%R;6%C>2!396=M96YT(&ES('!R97-E;G1E9"!A'!E;G-E6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($QE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@W+#(W.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!A=&EE M;G0@86-C;W5N=',@#(P,30[;F5T/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$Q+#$Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\ M=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E!H87)M86-Y/"]B/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS+#`Q-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#`Y-CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@S+#$T-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E"!-;VYT:',@16YD960-"B!$96-E;6)E M$$P.S,Q+"`R,#$T.CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@870@2G5L M>28C>$$P.S$L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($%D9&ET:6]NF5D(&%S(&$@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M($%C8V]U;G1S('=R:71T96X@;V9F+"!N970@;V8@$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#@T-3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QT M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,B!A;&EG;CTS1&-E;G1E3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`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`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(L.#DY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0R M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.30Q/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPT-38\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B@T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0W.3PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E!H87)M86-Y/"]B M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XU+#8Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@V+#(S-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($YE="!R979E;G5E65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\8CX\:3X\8CY. M;W1E(#8N("8C>#(P,3,[($UE9&EC87)E(&%N9"!-961I8V%I9"!%;&5C=')O M;FEC($AE86QT:`T*(%)E8V]R9',@26YC96YT:79E#(P,3,[($UE9&EC87)E($5L96-T6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$ M14Y4.B`T)2<^#0H@/&(^16QE8W1R;VYI8R!(96%L=&@@4F5C;W)D#(P,4,[2$E414-(#0H@06-T)B-X,C`Q1#LI M('=H:6-H('=A2!A M;F0@4F5I;G9E#(P,4,[05)2028C M>#(P,40[*2XF(WA!,#M4:&4@2$E414-(($%C="!I;F-L=61E$$P.V9E9&5R86P@9FES8V%L('EE87(@,C`Q,@T*("AF961E M65A2XF(WA!,#M#;VYV97)S96QY+`T*('1H;W-E(&AO2!A6UE;G1S(&)E9VEN;FEN9R!I;B8C>$$P M.V9E9&5R86P-"B!F:7-C86P@>65A#(P,40[*2`T-3`M,S`L#0H@)B-X,C`Q0SM'86EN($-O;G1I;F=E M;F-I97,F(W@R,#%$.RP@*"8C>#(P,4,[05-#(#0U,"TS,"8C>#(P,40[*2X@ M26X-"B!A8V-O6UE M;G0@:7,@879A:6QA8FQE+B!4:&4@9&5M;VYS=')A=&EO;B!O9B!M96%N:6YG M9G5L('5S92!I2P@;65E=&EN9R!T:&4@2!M;W)E('-T2!R97!O6UE;G1S+B!&;W(@=&AE('1H65A M6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@ M1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*(#PO<#X-"B`- M"B`-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E$$P.S,Q+#PO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*(%-P96-I86QT>2!0:&%R;6%C>2!396=M96YT/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($EN=&%N9VEB;&5S(&-O;G-I$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS M1&-E;G1E6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\ M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P M,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%-P96-I86QT>2!0:&%R M;6%C>2!396=M96YT/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(L,#`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($UE9&EC87)E($QI8V5N$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XW-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QTF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*($%M;W)T:7IA=&EO;B!E M>'!E;G-E('=A"!M M;VYT:',@96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`Q-"!A;F0@,C`Q,RP- M"B!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\+W`^#0H@/"]D:78^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A M8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/B8C>$$P.SPO8CX\+W`^#0H@ M/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@ M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L-C(T/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($-A$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@U,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@U,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ-S4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C$R+#4P.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M.R!415A4+4E.1$5.5#H@-"4G/@T*(#QS=')O;F<^/&D^5')A8V4@4D1!($QO M86X@86YD(%1R86-E(%=O28C>$$P.S$Q+"`R,#$R+"!3=6Y,:6YK+"!-961#87)E(%-O=71H+"!, M3$,@*&9O2!O9B!T:&4@0V]M<&%N>2P@86YD(%-O=71H97)N($AE M86QT:"!#;W)P;W)A=&EO;B!O9@T*($AO=7-T;VXL($EN8RX@*"8C>#(P,4,[ M4TA#2"8C>#(P,40[*2P@86X@:6YD:7)E8W0@=VAO;&QY+6]W;F5D#0H@2!O9B!T:&4@0V]M<&%N>2P@8VQO28C>$$P M.S4L(#(P,3(@*"8C>#(P,4,[5')A8V4@4D1!#0H@3&]A;B8C>#(P,40[*2!A M;F0@=7`@=&\@82`D,2PP,#`@5V]R:VEN9R!#87!I=&%L($QO86X@06=R965M M96YT#0H@9&%T960@87,@;V8@2G5L>28C>$$P.S4L(#(P,3(@*"8C>#(P,4,[ M5')A8V4@5V]R:VEN9R!#87!I=&%L#0H@3&]A;B8C>#(P,40[*2!W:71H(&$@ M8F%N:RX@4TA#2"!O=VYS(&%N9"!O<&5R871E#(P,4,[5')A8V4F(W@R,#%$.RD@:6X@2&]U6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R M<'@G/@T*(#QS=')O;F<^)B-X03`[/"]S=')O;F<^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@/'-T2!0 M&EM871E;'D@)#@L-3`P(&]F('1H92!42!A('!O6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G M/@T*(#QS=')O;F<^5&AE(%1R86-E(%=O$$P.V5Q=6%L('1O('1H92!L97-S97(@;V8-"B`H M:2DF(WA!,#MA($)O2!P97)C M96YT("@X,"4I)B-X03`[;V8-"B!%;&EG:6)L92!!8V-O=6YT$$P.RAA*28C>$$P.V9O<@T*('1H92!Q=6%R=&5R(&5N9&EN9R!$96-E;6)E M$$P.S,Q+"`R,#$T+"`D.#$$P.S,Q+"`R,#$U+"`D-S4P.R`H8RDF(WA! M,#MF;W(@=&AE('%U87)T97(-"B!E;F1I;F<@2G5N928C>$$P.S,P+"`R,#$U M+"`D-C(U.R!A;F0@*&0I)B-X03`[=&AE2!B87-I6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G M/@T*(#QS=')O;F<^/&D^4TA04"!21$$@3&]A;CPO:3XF(W@R,#$T.T]N($YO M=F5M8F5R)B-X03`[-BP@,C`Q,BP-"B!3=6Y,:6YK($AE86QT:&-A2!O9B!T:&4- M"B!#;VUP86YY+"!E;G1E$$P.T]C=&]B97(@,S$L(#(P M,3(@*'1H92`F(W@R,#%#.U-(4%`@4D1!($QO86XF(W@R,#%$.RD@=VET:"!A M#0H@8F%N:RX@4TA04"!O=VYS(&%N9"8C>$$P.VQE87-E2P@26YC+B`H)B-X,C`Q0SM32$,-"B!%;&QI M:F%Y)B-X,C`Q1#LI+B!32$,@16QL:6IA>2!O=VYS(&%N9"!O<&5R871E#(P,4,[3F]R=&@@ M1V5O#(P,40[*2P@;&]C871E9`T*(&EN)B-X03`[16QL:6IA>2P@ M1V5O65A$$P.U-( M4%`@4D1!#0H@3&]A;B!B96%R$$P.S4E M("@U+C(U)2!A="!$96-E;6)E$$P.S,Q+`T*(#(P,30I+B!4:&4F(WA! M,#M32%!0(%)$02!,;V%N(&ES(&-O;&QA=&5R86QI>F5D#0H@8GDF(WA!,#M3 M2%!0)B-X,C`Q.3MS(')E86P@97-T871E+"!E<75I<&UE;G0F(WA!,#MA;F0@ M;&5A2!G=6%R86YT965D('5N9&5R('1H M92!5+E,N($1E<&%R=&UE;G0@;V8@06=R:6-U;'1U$$P.U-(4%`-"B!21$$@3&]A;B!P$$P.W5S960F(WA!,#MB>2!32$,@16QL:6IA>0T*('1O)B-X03`[86-Q=6ER M92!A(&UE9&EC86P@;V9F:6-E(&)U:6QD:6YG(&EN)B-X03`[16QL:6IA>2P@ M1V5O28C M>$$P.W1H92!#;VUP86YY(&%N9"!-961#87)E+CPO#(P,3,[($]N($%P$$P.S$R+"`R,#$R+"!A;B!A;65N9&UE;G0@=&\@=&AE#0H@0V%R;6EC M:&%E;"!0=7)C:&%S92!.;W1E('=A6UE;G0@;V8@=7`@=&\@='=O('-E;6DM86YN=6%L('!A>6UE;G1S M(&]F#0H@<')I;F-I<&%L(&%N9"!I;G1E$$P.S(R+"`R,#$R(&9O6UE;G0@=&AA="!W;W5L9"!H879E M(&)E96X@9'5E(&]N($]C=&]B97(F(WA!,#LR,BP@,C`Q,BX-"B!4:&4@0V%R M;6EC:&%E;"!0=7)C:&%S92!.;W1E(&%N9"!T:&4@4$E+($YO=&5S('=E$$P.S(R+`T*(#(P,30@ M9F]R('1H92!R96UA:6YI;F<@8F%L86YC92!P87EA8FQE(&]F("0Q+#@U,BX@ M5&AE($-A6%B;&4@:6X@;VYE(&EN=&5R M97-T(&]N;'D@<&%Y;65N="!O9B`D-S4@9'5E(&]N#0H@3V-T;V)E$$P M.S(R+"`R,#$T(&%N9"!F:79E('-E;6DM86YN=6%L(&EN6%B;&4@:6X@87)R96%R"!A;F0@='=E;'9E+6UO;G1H(&%N;FEV97)S87)Y(&]F('1H92!I2X\+W-T#L@34%2 M1TE.+51/4#H@,3AP>"<^#0H@/"]P/@T*(#PO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0@0FQO8VL@ M6T%B'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B`\8CX\:3X\8CY.;W1E M(#DN("8C>#(P,3,[($EN6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&(^26X@2F%N=6%R M>2`R,#$U+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A("0Q+#`P,"!S971T;&5M M96YT(&]N(&$-"B!C;&%I;2!M861E('5N9&5R(&ET2!T=V\@;F]W#0H@9F]R;65R(&5M<&QO>65E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q.'!T)SX-"B`\+W`^#0H@#0H@#0H@/"]D:78^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B M9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)' M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^/&D^ M/&(^3F]T92`Q,"X@)B-X,C`Q,SL@26YC;VUE(%1A>&5S/"]B/CPO:3X\+V(^ M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&(^26YC;VUE('1A M>"!E>'!E;G-E(&]F("0W.3D@*"0V-#,@9F5D97)A;"!T87@@97AP96YS92!A M;F0@)#$U-@T*('-T871E('1A>"!E>'!E;G-E*2!A;F0@:6YC;VUE('1A>"!B M96YE9FET(&]F("0R.3<@*"0S,C@@9F5D97)A;"!T87@-"B!E>'!E;G-E(&%N M9"`D,S$@2X@26YC;VUE#0H@=&%X(&5X<&5N"!E>'!E;G-E(&%N9"`D,3(R('-T M871E('1A>`T*(&5X<&5N"!M;VYT:',@ M96YD960-"B!$96-E;6)E$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P M96-T:79E;'DN/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E)SX- M"B`\8CY!="!$96-E;6)E$$P.S,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H M860@)#4L,3DP(&]F(&5S=&EM871E9`T*(&YE="!O<&5R871I;F<@;&]S2UF;W)W87)D"!A2!T:&%N(&YO="!T:&%T(&$@ M<&]R=&EO;B!O9B!I=',@9&5F97)R960@=&%X(&%S2!I=',@;F5T(&]P97)A=&EN9R!L;W-S97,@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+51/4#H@,3AP="<^#0H@/&(^3F]T92`Q,2X@)B-X,C`Q M,SL@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+V(^/"]P/@T*(#PA M+2T@>&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@ M/&(^/&D^3&ET:6=A=&EO;CPO:3X\+V(^)B-X,C`Q-#M!('-E='1L96UE;G0@ M=V%S(')E86-H960@;VX@3F]V96UB97(-"B`S+"`R,#$T(')E;&%T:6YG('1O M(&QI=&EG871I;VX@87,@82!R97-U;'0@;V8@2`R-"XW-"!A M8W)E2!A('-U8G-I9&EA2X@26X@$$P.W1O($-A2!T;R!#87-T;&5M87)K+"!T:&5N($-A2X@5&AE#0H@ M;&ET:6=A=&EO;B!W87,@9&ES;6ES2!R96-O6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!4 M15A4+4E.1$5.5#H@-"4G/@T*(%-U;DQI;FL@86YD(&ET2!P;W-S:6)L92!T;R!D971E2!T;R!B=70@8V]U;&0@:&%V92!A(&UA=&5R:6%L M(&%D=F5R#(P,30[5&AE($-O;7!A;GD@:&%S#0H@#(P M,30[($EN#0H@36%R8V@@,C`Q,RP@4W5N3&EN:R!R96-E:79E9"!A(&1O8W5M M96YT('-U8G!O96YA(&9R;VT@=&AE(%5N:71E9`T*(%-T871E#(P,4,[3TE')B-X,C`Q1#LI(&EN(&-O M;FYE8W1I;VX@=VET:"!A;B!I;G9E#(P,4,[ M4TA#1"8C>#(P,40[*2P@=VAI8V@@;W=N2!A;F0@8FEL;&5D(&9O2!R979I97<@;V8@82!S86UP M;&EN9R!O9B!M961I8V%L(')E8V]R9',N(%=E#0H@8V%N;F]T(&%T('1H:7,@ M=&EM92!E2!R97-U;'1S(&9R;VT@=&AE6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T M)SX-"B`\:3X\=3Y#;VYT6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@0V]N=')A8W1U86P@;V)L:6=A=&EO;G,L(&-O M;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S(')E;&%T960@=&\-"B!L;VYG M+71E6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!R M9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/D]P97)A=&EN9SQB$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^ M#0H@/"]T2`M+3X-"B`\='(@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#$@>65A$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C@U.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`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`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XR,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4P.#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT65A$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#(U,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#$P-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPT-#4\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$L-#@W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#8X,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E. M1$5.5#H@-"4G/@T*($%T($1E8V5M8F5R)B-X03`[,S$L(#(P,30L(%-U;DQI M;FL@:&%D(&$@9W5A7-I M8VEA;BX@02!P:'ES:6-I86X@=VET:"!W:&]M(&$@9W5A65A2!F;W(@86YY(&=U87)A;G1E92!R97!A M>6UE;G0@9'5E('1O#0H@;F]N+6-O;7!L:6%N8V4@=VET:"!T:&4@<')O=FES M:6]N7-I8VEA;B8C>#(P,3D[$$P.S,Q+"`R,#$T+B!3=6Y, M:6YK(&5X<&5N$$P.S,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T M:79E;'DN(%-U;DQI;FL@97AP96YS960@)#,Q#0H@86YD("0V-R!O;B!P:'ES M:6-I86X@9W5A"!M M;VYT:',-"B!E;F1E9"!$96-E;6)E$$P.S,Q+"`R,#$T(&%N9"`R,#$S M+"!R97-P96-T:79E;'DN/"]P/@T*(#PA+2T@>&)R;"QN("TM/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T M)SX-"B`\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B M9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX-"B`\<"!S='EL M93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3AP="<^ M#0H@/&(^/&D^/&(^3F]T92`Q,BX@)B-X,C`Q,SL@4F5L871E9"!087)T>0T* M(%1R86YS86-T:6]N2!A$$P.S,Q+"`R,#$T(&%N9"`R M,#$S+"!R97-P96-T:79E;'DN(%1H92!#;VUP86YY(&AA$$P.S,Q+"`R,#$T(&%N9"`R,#$S+`T*(')E2X@26YC;'5D960@:6X@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]N M9&5N$$P.S,P+"`R,#$T(&ES M("0Q,3,@86YD("0Q,34L(')E2P@;V8@86UO=6YT6%B;&4@=&\@=&AE'1087)T7S$X8V%B8F)D7SAA,3%?-#-B9E\Y,C=F7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!396=M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q.'!T)SX- M"B`\8CX\:3X\8CY.;W1E(#$S+B`F(W@R,#$S.R!&:6YA;F-I86P@26YF;W)M M871I;VX@8GD-"B!396=M96YT/"]B/CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1% M6%0M24Y$14Y4.B`T)2<^#0H@/&(^56YD97(@05-#(%1O<&EC($YO+B8C>$$P M.S(X,"P@4V5G;65N="!297!O#L@34%21TE.+51/ M4#H@,3)P>"<^#0H@/&(^)B-X03`[/"]B/CPO<#X-"B`\<"!S='EL93TS1"=- M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E. M1$5.5#H@-"4G/@T*(#QB/E=E(&5V86QU871E('!E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG M;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/F%N9"!/ M=&AE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#QB/CQU/E1H M$$P.S,Q+"`R,#$T/"]U/CPO M8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!R979E;G5E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@L-#,P M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3@\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(S+#$R-CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#4Y M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-C4T/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`R,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-C`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C0S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C4X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$R+#$V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ,RPX,S`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'!E M;F1I='5R97,@9F]R('!R;W!E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R M/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C0U+#4P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XS+#,W-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XR,3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XR+#,R-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XW,C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(Q M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+#$V M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPX,S`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE'!E;F1I='5R97,@9F]R('!R M;W!E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C4W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW M,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(#QB/CQU/E1H$$P.S,Q M+"`R,#$S/"]U/CPO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!R M979E;G5E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CDL,S(V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$L,C@W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(R.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,2PR,C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y,3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-S`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(R,CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-C,\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,X+#(R-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PU,3<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8X+#4R-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT2P@<&QA;G0@86YD M(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V M,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,#0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P-CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.S,Q+"`R,#$S/"]U/CPO8CX\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!R979E;G5E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$V+#$V.#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P97)A=&EN9R!P$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#(Y-CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XW-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0S,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ+#4S-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$Q+#4Q-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ."PW.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'!E;F1I='5R M97,@9F]R('!R;W!E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(X,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XQ.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[(%=(251%+5-004-%.B!N;W)M86P[(%1%6%0M5%)!3E-& M3U)-.B!N;VYE.R!73U)$+5-004-)3D#L@0T],3U(Z(')G8B@P+#`L M,"D[($9/3E0Z(#$P<'0@)U1I;65S($YE=R!2;VUA;B<[($U!4D=)3BU43U`Z M(#!P=#L@3$545$52+5-004-)3D'0M"<^#0H@)B-X03`[/"]P/@T*(#QT M86)L92!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B`G M5&EM97,@3F5W(%)O;6%N)SL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@ M5$585"U44D%.4T9/4DTZ(&YO;F4[(%=/4D0M4U!!0TE.1SH@,'!X.R!,1514 M15(M4U!!0TE.1SH@;F]R;6%L.R!415A4+4E.1$5.5#H@,'!X.R`M=V5B:VET M+71E>'0M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P M+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!R9V(H,"PP+#`I(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R M)B-X03`[,S$L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@)U1I;65S($YE=R!2;VUA;B$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(')G8B@P+#`L,"D@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,3@T/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XV+#$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT,3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C4Q,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XV.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4S/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8L.3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#(T M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ("=4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ("=4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@Q+#$T-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C4W,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT.#(\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,R/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@S,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P.3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,3@P/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,S4Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-S4V/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q M.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@Q.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G M8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U-SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(')G8B@P+#`L,"D@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#%P>"!S;VQI9"<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(')G8B@P M+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B!R9V(H M,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(')G8B@P+#`L,"D@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B!R9V(H,"PP+#`I(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X- M"B`\+V1I=CX\'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4 M+4E.1$5.5#H@-"4G/@T*(#QB/CQI/E1H92!C;VUP;VYE;G1S(&]F('!E;G-I M;VX@97AP96YS92!F;W(@=&AE('1H6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@ M8V]L$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,CX-"B`\<"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,P/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE'!E8W1E9"!R971U$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/B@W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH,34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%M;W)T:7IA=&EO;B!O M9B!P$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XR,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT.#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XV,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,R/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8V/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!2979E;G5E'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4G/@T* M(#QB/CQI/E)E=F5N=65S(&)E9F]R92!P6]R('=E"!M;VYT:',@96YD960@1&5C96UB97(F(WA!,#LS,2P- M"B`R,#$T(&%N9"`R,#$S.CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU! M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0 M.B`P<'0G/@T*(#QB/CQI/B8C>$$P.SPO:3X\+V(^/"]P/@T*(#QT86)L92!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$-B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@ M/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/CQB/D1E8V5M8F5R)B-X03`[,S$L M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N M/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,30\+V(^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X] M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*($AE86QT:&-A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C8L-3$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,RPY M-C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#8R,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#8P,CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#4R-#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#DW,3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#@T-#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR+#`P,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR+#0U,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XS+#DY,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT+#$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(%)E=F5N=65S(&)E9F]R92!P$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$V+#8Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS M,RPU,S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M M1D%-24Q9.B!4:6UE6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$T+#0V,SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR.2PS,3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$U-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0U+#4P,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L M:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#PO<#X-"B`\+V1I=CX\2!I;F9O6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-RPR-SD\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V+#DP,SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/CDL.#4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0 M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#PO<#X-"B`\+V1I=CX\'0^/&1I=CX-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$58 M5"U)3D1%3E0Z(#0E)SX-"B`\8CX\:3Y4:&4@9F]L;&]W:6YG(&ES(&$@2!O9B!T:&4@86-T:79I='D@:6X@=&AE(&%L;&]W86YC90T*(&9O6QE/3-$)T9/3E0M4TE:13H@.'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E!H87)M86-Y/"]B/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#`Q M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#`Y-CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XH-CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@S+#$T-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E"!-;VYT:',@16YD960-"B!$96-E;6)E$$P M.S,Q+"`R,#$T.CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($)A;&%N8V4@870@2G5L>28C>$$P M.S$L(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(U-#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($%D9&ET:6]NF5D(&%S(&$@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C8V]U M;G1S('=R:71T96X@;V9F+"!N970@;V8@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U+#@T-3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(R-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@#L@34%21TE.+51/4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$ M,B!A;&EG;CTS1&-E;G1E3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`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`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#DY M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0R/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.30Q/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XH,RPT-38\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@T-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C0W.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,B!A;&EG;CTS1&-E;G1E3PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E!H87)M86-Y/"]B/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#8Q M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY-3PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XH.3$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@V+#(S-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q M,G!T.R!415A4+4E.1$5.5#H@-"4G/@T*(#PO<#X-"B`\+V1I=CX\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]4 M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E M)SX-"B`\8CX\:3Y';V]D=VEL;"!C;VYS:7-T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*(#QB/CQI M/B8C>$$P.SPO:3X\+V(^/"]P/@T*(#QT86)L92!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@'0^/&1I=CX-"B`\<"!S M='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P M=#L@5$585"U)3D1%3E0Z(#0E)SX-"B`\8CX\:3Y);G1A;F=I8FQE6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1R M861E($YA;64\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`P M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`P,#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$L,#@Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$L,#@Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*($%C8W5M=6QA=&5D($%M;W)T:7IA=&EO;CPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/B@Y-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@X-SD\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.36QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#PO<#X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T M)2<^#0H@/&(^/&D^3&]N9RUT97)M(&1E8G0@8V]N6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/ M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T M;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B M;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C@L-C(T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($-A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ+#@U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XQ+#@U,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-S4\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`@86QI9VX],T1R:6=H=#X-"B`F(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$R+#4P.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,7!X M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@ M-"4G/@T*(#PO<#X-"B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&(^ M/&D^0V]N=')A8W1U86P@;V)L:6=A=&EO;G,L(&-O;6UI=&UE;G1S(&%N9"!C M;VYT:6YG96YC:65S#0H@6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D]P97)A M=&EN9SQB$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(#$@>65A$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@U.#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW,#@\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(#,@>65A$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#DU,3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,#`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X- M"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4 M:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4P.#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT65A$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX+#(U M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#$P-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ,BPT-#4\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L M-#@W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#8X,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z M(#0E)SX-"B`\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E M.#=B9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R2!396=M96YT("A486)L97,I/&)R M/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0[ M(%1%6%0M24Y$14Y4.B`T)2<^#0H@/&(^/&D^5V4@979A;'5A=&4@<&5R9F]R M;6%N8V4@;V8@;W5R(&]P97)A=&EN9R!S96=M96YT6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N M/3-$,B!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@8V]L$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@ M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB M/D9A8VEL:71I97,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$ M8V5N=&5R/CQB/E!H87)M86-Y/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'1E$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($]P97)A=&EN9R!P$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO M;B!A;F0@86UOF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$W-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU.#`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S+#@T,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,BPV,34\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Y+#@S.#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT2P@ M<&QA;G0@86YD(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C0X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,Q.3PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.S,Q+"`R,#$T/"]U/CPO M8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YE="!R979E;G5E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+#@X M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P97)A=&EN9R!P$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q+#(V-CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,T-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-3`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C,S+#@T,SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ,BPV,34\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C4Y+#@S.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT2P@<&QA;G0@86YD(&5Q=6EP M;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S,CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-S0\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE'1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C(S+#@X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#(X-SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,CD\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`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`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C$W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XR,C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`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`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$T,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XT,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z M("TQ96TG/@T*(#QB/CQU/E-I>"!M;VYT:',@96YD960@1&5C96UB97(F(WA! M,#LS,2P@,C`Q,SPO=3X\+V(^/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE'1E$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C M;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(L,3$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$S-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH,BPR.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@T M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M*28C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@86UO MF%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S-SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,S$\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%S$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,X+#(R-3PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2PU,3<\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8X+#4R-#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT2P@<&QA;G0@ M86YD(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR.#,\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C#L@34%21TE.+51/4#H@,3AP M>"<^#0H@)B-X03`[/"]P/@T*(#PO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAAF%T:6]N(%M,:6YE($ET96US M73PO'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!H M;W-P:71A;',\+W1D/@T*("`@("`@("`\=&0@8VQA2!H;W-P M:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S"!E M>'!E;G-E("AB96YE9FET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$&5S.CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M&5S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XU,S(\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X M83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$2!$:7-P;W-A;"!'2!$:7-P M;W-A;"!''0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9? M.3(W9E\W.&)E.#=B9#'0O:'1M;#L@ M8VAA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!);F-E;G1I=F4@4&QA;B!;365M8F5R73PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R92UB87-E9"!087EM96YT M($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3:&%R M92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA2!O9B!2979E;G5EF%T:6]N+"!296-E:79A8FQE(&%N M9"!2979E;G5E($1I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N+"!296-E:79A8FQE(&%N9"!2979E;G5E($1I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F%T:6]N+"!296-E:79A M8FQE(&%N9"!2979E;G5E($1I'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S M8F9?.3(W9E\W.&)E.#=B9#'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X M83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAAF%T:6]N+"!296-E:79A8FQE(&%N M9"!2979E;G5E($1I'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$2!0:&%R;6%C>2!396=M96YT(%M-96UB97)= M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\F%T:6]N+"!296-E:79A8FQE(&%N9"!2979E;G5E M($1I'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R65A3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S M8F9?.3(W9E\W.&)E.#=B9#'0O:'1M M;#L@8VAAF5D M(&]N(&EN8V5N=&EV92!P87EM96YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q M.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!0:&%R;6%C>2!396=M M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M/B@Y-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$2!0:&%R;6%C>2!396=M M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W M.&)E.#=B9#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!O9B!,;VYG M+51E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&-L=61I;F<@8W5R'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0@86=A:6YS="!T:&4@8V]M<&%N>2=S('-E;FEO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2`@<&5R8V5N="`H.#`E*2!O9B!%;&EG:6)L92!! M8V-O=6YT'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A M8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3V-T(#,Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9? M.3(W9E\W.&)E.#=B9#'0O:'1M;#L@ M8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^07!R(#(R+`T*"0DR,#`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^3V-T(#(R+`T*"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@:6X@2VEN9"`H4$E+*2!.;W1E(%M-96UB97)=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6UE M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$65E('1H969T(')E;&%T:6YG('1O("!M:7-A<'!R;W!R:6%T M:6]N(&]F(&9U;F1S(&)Y('1W;R!N;W<@9F]R;65R(&5M<&QO>65E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!E>'!E;G-E("AB96YE9FET*3PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S2UF;W)W87)D/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XU+#$Y,#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7-I8VEA;G,@=6YD97(@9W5A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;F1I='5R92!O;B!P:'ES M:6-I86X@9W5A2!N;W1E(%!R:6YC:7!A;"!A M;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA2!N;W1E('1E65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$65A65A65A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G1S(&1U92!I;B`R('EE87)S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XS,S,\6UE;G1S(&1U92!I;B`S('EE87)S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`\6UE;G1S(&1U M92!I;B`T('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW M-#QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UE;G1S(&1U92!I;B`R('EE87)S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,#@\6UE;G1S(&1U M92!I;B`S('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV M-3`\6UE;G1S(&1U92!I;B`T('EE87)S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XU,#@\6UE;G1S(&1U92!I;B`U*R!Y96%R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q.&-A8F)B9%\X83$Q7S0S8F9? M.3(W9E\W.&)E.#=B9#'0O:'1M;#L@ M8VAA2!396=M96YT("T@ M061D:71I;VYA;"!);F9O'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'1E'!E;F1I='5R97,@9F]R('!R;W!E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1EF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XS-C`\'!E;F1I M='5R97,@9F]R('!R;W!EF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ-S<\'!E;F1I='5R M97,@9F]R('!R;W!EF%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XT,SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\Q M.&-A8F)B9%\X83$Q7S0S8F9?.3(W9E\W.&)E.#=B9#&UL#0I#;VYT96YT M+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT M+51Y<&4Z('1E>'0O:'1M;#L@8VAA&UL;G,Z;STS1")U'1087)T7S$X F8V%B8F)D7SAA,3%?-#-B9E\Y,C=F7S XML 24 R43.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Income Tax Disclosure [Abstract]

Income Tax Expense (Benefit) $ 799us-gaap_IncomeTaxExpenseBenefit $ (297)us-gaap_IncomeTaxExpenseBenefit $ 985us-gaap_IncomeTaxExpenseBenefit $ (95)us-gaap_IncomeTaxExpenseBenefit

Federal tax expense (benefit) 643us-gaap_CurrentFederalTaxExpenseBenefit 328us-gaap_CurrentFederalTaxExpenseBenefit 863us-gaap_CurrentFederalTaxExpenseBenefit (78)us-gaap_CurrentFederalTaxExpenseBenefit

State tax expense (benefit) 156 31 122 (17)

Net operating loss carry-forward 5,190us-gaap_OperatingLossCarryforwards 5,190us-gaap_OperatingLossCarryforwards

Net deferred tax asset $ 6,755us-gaap_DeferredTaxAssetsNet $ 6,755us-gaap_DeferredTaxAssetsNet

X

- Definition

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Paragraph Question 1-7

+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 25 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9

Shareholders' Equity - Additional Information (Detail) (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation, amount recognized $ 48 $ 15 $ 21 $ 31

2005 Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation, options granted 90,000 0

2011 Director Stock Option Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based compensation, options granted 0 21,000

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PlanNameAxis=ssy_StockIncentivePlanTwoThousandElevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=ssy_TwoThousandFiveEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations - Components of Pension Expense (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Discontinued Operations and Disposal Groups [Abstract]

Interest Cost $ 16us-gaap_DefinedBenefitPlanInterestCost $ 15us-gaap_DefinedBenefitPlanInterestCost $ 33us-gaap_DefinedBenefitPlanInterestCost $ 30us-gaap_DefinedBenefitPlanInterestCost

Expected return on assets (7) (7) (15) (14)

Amortization of prior service cost 23 32 48 63

Net pension expense $ 32 $ 40 $ 66 $ 79

X

- Definition

The amount of the prior service cost or credit recognized in net periodic benefit cost relating to benefit changes attributable to plan participants' prior service pursuant to a plan amendment or a plan initiation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

An amount calculated as a basis for determining the extent of delayed recognition of the effects of changes in the fair value of assets. The expected return on plan assets is determined based on the expected long-term rate of return on plan assets and the market-related value of plan assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 30

-Glossary Expected Return on Plan Assets

-URI http://asc.fasb.org/extlink&oid=6512136

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 60

-Glossary Expected Return on Plan Assets

-URI http://asc.fasb.org/extlink&oid=6512171

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (h)(3)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (h)(2)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=35743120&loc=d3e1928-114920

+ Details

Name: us-gaap_DefinedBenefitPlanInterestCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of pension and other (such as medical, dental and life insurance) postretirement benefit costs recognized during the period for (1) defined benefit plans (periodic benefit costs include the following components: service cost, interest cost, expected return on plan assets, gain (loss) on assets, prior service cost or credit, transition asset or obligation, and gain (loss) due to settlements or curtailments) and for (2) defined contribution plans (to the extent that a plan's defined contributions to an individual's account are to be made for periods in which that individual renders services, the net cost for a period is the contribution called for in that period; if a plan calls for contributions for periods after an individual retires or terminates, the estimated cost is accrued during the employee's service period).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 715

-SubTopic 70

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6414718&loc=d3e28014-114942

+ Details

Name: us-gaap_PensionAndOtherPostretirementBenefitExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 27 R44.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

acre

Dec. 31, 2013

Dec. 31, 2014

Physician

Hospital

acre

Dec. 31, 2013

Commitment And Contingencies [Line Items]

Real property 24.74us-gaap_AreaOfRealEstateProperty 24.74us-gaap_AreaOfRealEstateProperty

Number of hospital facilities 3ssy_NumberOfHospitalFacilities

Number of physicians under guarantee agreements 1

Number of years required for maintaining practice within a hospital geographic area 3 years

Expenditure on physician guarantees and recruitment $ 16 $ 33 $ 31 $ 67

Castlemark Properties, LLC [Member]

Commitment And Contingencies [Line Items]

Promissory note Principal amount 600 600

Promissory note term 5 years

Estimated fair value of the real property $ 500

X

- Details

Name: ssy_CommitmentAndContingenciesLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expenses on physician guarantees and recruitment.

+ References

No definition available.

+ Details

Name: ssy_ExpensesOnPhysicianGuaranteesAndRecruitment

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of hospital facilities.

+ References

No definition available.

+ Details

Name: ssy_NumberOfHospitalFacilities

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of physicians under guarantee agreements.

+ References

No definition available.

+ Details

Name: ssy_NumberOfPhysiciansUnderGuaranteeAgreements

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period or be liable to repay all or a portion of the guarantee received.

+ References

No definition available.

+ Details

Name: ssy_PeriodOfPhysicianGuaranteeAgreement

Namespace Prefix: ssy_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Promissory note term.

+ References

No definition available.

+ Details

Name: ssy_PromissoryNoteTerm

Namespace Prefix: ssy_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Area of a real estate property.

+ References

No definition available.

+ Details

Name: us-gaap_AreaOfRealEstateProperty

Namespace Prefix: us-gaap_

Data Type: num:areaItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_GainLossRelatedToLitigationSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Carrying amounts due as of the balance sheet date of the sum of amounts receivable other than from customers.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_NontradeReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: dei_LegalEntityAxis=ssy_CastlemarkPropertiesLlcMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts $ 25,108us-gaap_Revenues $ 26,111us-gaap_Revenues $ 49,717us-gaap_Revenues $ 50,197us-gaap_Revenues

Other Revenues 157us-gaap_OtherSalesRevenueNet 91us-gaap_OtherSalesRevenueNet 299us-gaap_OtherSalesRevenueNet 187us-gaap_OtherSalesRevenueNet

Provision for doubtful accounts (1,982) (2,231) (4,215) (4,288)

Net revenues 23,126us-gaap_SalesRevenueNet 23,880us-gaap_SalesRevenueNet 45,502us-gaap_SalesRevenueNet 45,909us-gaap_SalesRevenueNet

Healthcare Facilities Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts 16,521 16,694 33,534 33,842

Provision for doubtful accounts (1,982) (2,231) (4,215) (4,288)

Net revenues 14,539 14,463 29,319 29,554

Healthcare Facilities Segment [Member] | Medicare [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts 6,685 6,516 13,963 13,623

Healthcare Facilities Segment [Member] | Medicaid [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts 3,602 3,524 6,971 6,844

Healthcare Facilities Segment [Member] | Self-Pay [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts 2,002 2,453 3,990 4,705

Healthcare Facilities Segment [Member] | Managed Care & Other Insurance [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts 4,189 4,156 8,514 8,572

Healthcare Facilities Segment [Member] | Other [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Revenues before provision for doubtful accounts 43 45 96 98

Specialty Pharmacy Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Net revenues $ 8,430 $ 9,326 $ 15,884 $ 16,168

X

- Definition

Amount of the provision for bad debts related to patient service revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35755891&loc=SL9156442-115640

+ Details

Name: us-gaap_HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a),(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_OtherSalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_HealthcareFacilitiesSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Receivables [Abstract]

Accounts receivable (net of contractual allowances) $ 18,394us-gaap_AccountsReceivableGrossCurrent $ 16,753us-gaap_AccountsReceivableGrossCurrent

Less allowance for doubtful accounts (7,279) (7,330) (6,903) (7,239) (7,799) (7,761)

Patient accounts receivable-net $ 11,115us-gaap_ReceivablesNetCurrent $ 9,850us-gaap_ReceivablesNetCurrent

X

- Definition

Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Subparagraph a, b

-Article 5

+ Details

Name: us-gaap_AccountsReceivableGrossCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations
6 Months Ended

Dec. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

Note 3. – Discontinued Operations

All of the businesses discussed in the note below are reported as discontinued operations and the condensed consolidated financial statements for all prior periods have been adjusted to reflect this presentation.

Results for all of the businesses included in discontinued operations are presented in the following table:

 Three Months Ended Six Months Ended

 December 31, December 31,

 2014 2013 2014 2013

Net Revenues:


Fulton Hospital
 $ 3,321 $ 3,184 $ 6,730 $ 6,733

Dexter Hospital
 90 418 131 513

Memorial of Adel
 69 2 53 (4 )









$ 3,480 $ 3,604 $ 6,914 $ 7,242









Earnings (loss) before income taxes:

Fulton Hospital
$ (449 ) $ (549 ) $ (897 ) $ (1,147 )

Dexter Hospital
532 410 570 482

Memorial of Adel
56 (1 ) 32 (12 )

Life sciences and engineering
(30 ) (40 ) (64 ) (79 )









Earnings (Loss) before income taxes
109 (180 ) (359 ) (756 )









Loss on Sale

Fulton Hospital
(191 ) — (191 ) —









Loss on Sale
(191 ) — (191 ) —









Income tax expense (benefit)
(70 ) (57 ) (236 ) (255 )









Loss from discontinued operations
$ (12 ) $ (123 ) $ (314 ) $ (501 )









Fulton Hospital – On December 31. 2014, the Company’s subsidiary, HealthMont of Missouri sold substantially all the assets of its Callaway Community Hospital (“Fulton”) and related clinics in Fulton, Missouri for approximately $6,090. Fulton’s results have been reclassified as discontinued operations in our condensed consolidated financial statements as of December 31, 2014 and June 30, 2014 and for the three and six month periods ended December 31, 2014 and 2013. Fulton retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology, and substantially all liabilities of the hospital as of the sale closing date. At closing, Fulton repaid the outstanding balance of its RDA Loan of $4,745. A loss of $191 resulted from the sale of the Fulton assets, which includes $237 early repayment penalty resulting from the repayment of the RDA loan.

Fulton RDA Loan—SunLink, Fulton and HealthMont LLC (“HLLC”), the direct parent of HOM closed on a $5,000 Loan Agreement dated as of March 16, 2012 (the “Fulton RDA Loan”) with a bank. The Fulton RDA Loan was repaid in full on December 31, 2014 concurrent with the sale of Fulton.

Dexter Hospital—On December 31, 2012, the Company completed the sale of substantially all the assets and the leasehold interest of its subsidiary, Dexter Hospital, LLC (“Dexter”), to Southeast Health Center of Stoddard County, LLC, an indirect subsidiary of Southeast Missouri Hospital Association (“SoutheastHEALTH”). The assets of Dexter consisted of a leased 50-bed acute care hospital and related clinics, equipment, and home health services in Dexter, Missouri. Subsequent to the sale, Dexter managed the hospital and related businesses for Southeast Health Center of Stoddard County, LLC through a transition period ended June 30, 2013. Dexter retained accounts receivable and certain other assets, including the right to Medicare and Medicaid incentive payments (“EHR Funds”) for meaningful use of electronic health record technology and substantially all liabilities of the hospital as of December 31, 2012. Dexter’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013.

Memorial Hospital of Adel – On July 2, 2012, the Company and its HealthMont of Georgia, Inc. subsidiary completed the sale of substantially all the assets of the Company’s Memorial Hospital of Adel and Memorial Convalescent Center (collectively “Memorial”) to the Hospital Authority of Tift County, Georgia (“Tift”) for approximately $8,350. Memorial’s operations have been classified as discontinued operations in our condensed consolidated financial statements for the three and six month periods ended December 31, 2014 and 2013.

Life Sciences and Engineering Segment – SunLink retained a defined benefit retirement plan which covered substantially all of the employees of this segment when the segment was sold in fiscal 1998. Effective February 28, 1997, the plan was amended to freeze participant benefits and close the plan to new participants. Pension expense and related tax benefit or expense is reflected in the results of operations for this segment for the three and six months ended December 31, 2014 and 2013. The components of pension expense for the three and six months ended December 31, 2014 and 2013, respectively, were as follows:

 Three Months Ended Six Months Ended

 December 31, December 31,

 2014 2013

2013

Interest Cost
 $ 16 $ 15 $ 33 $ 30

Expected return on assets
 (7 ) (7 ) (15 ) (14 )

Amortization of prior service cost
 23 32 48 63



Net pension expense
 $ 32 $ 40 $ 66 $ 79



SunLink contributed $56 to the plan in the three and six months ended December 31, 2014.

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2941-110230

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Beginning balance $ 7,330 $ 7,799 $ 6,903 $ 7,761

Additions recognized as a reduction to revenues 3,096 2,941 6,331 5,712

Accounts written off, net of recoveries (3,147) (3,501) (5,955) (6,234)

Ending balance 7,279 7,239 7,279 7,239

Healthcare Facilities Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Beginning balance 7,117 7,317 6,649 7,286

Additions recognized as a reduction to revenues 3,016 2,899 6,251 5,617

Accounts written off, net of recoveries (3,078) (3,456) (5,845) (6,143)

Ending balance 7,055 6,760 7,055 6,760

Specialty Pharmacy Segment [Member]

Health Care Organization, Receivable and Revenue Disclosures [Line Items]

Beginning balance 213 482 254 475

Additions recognized as a reduction to revenues 80 42 80 95

Accounts written off, net of recoveries (69) (45) (110) (91)

Ending balance $ 224 $ 479 $ 224 $ 479

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of increase (decrease) in the allowance for doubtful accounts.

+ References

No definition available.

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of direct write-downs of accounts receivable charged against the allowance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 310

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35755819&loc=SL9156395-115594

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_HealthCareOrganizationReceivableAndRevenueDisclosuresLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_HealthcareFacilitiesSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R40.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) (SHPP RDA Loan [Member], USD $)
In Thousands, unless otherwise specified
6 Months Ended

Dec. 31, 2014

Oct. 31, 2012

Debt Disclosure [Line Items]

Debt instrument maturity period 25 years

Floating rate of interest, spread 2.00%

Floating rate of interest, lesser 5.00%

Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated 5.25%

Loan proceeds used for acquisition 1,800ssy_LoanProceedsUsedForAcquisition

Debt instrument description The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%

Subsidiaries [Member]

Debt Disclosure [Line Items]

Loan agreement amount $ 2,100

Date of loan agreement Oct. 31, 2012

X

- Details

Name: ssy_DebtDisclosureLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Loan proceeds used for acquisition.

+ References

No definition available.

+ Details

Name: ssy_LoanProceedsUsedForAcquisition

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage points added to the reference rate to compute the variable rate on the debt instrument.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentDescriptionOfVariableRateBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

When presenting a range of interest rates, the lowest effective rate for funds borrowed under the debt agreement as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentageRateRangeMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_DebtInstrumentTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 33 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2014

Jun. 30, 2014

Current Assets:

Cash and cash equivalents $ 3,971 $ 3,587

Receivables-net 11,115us-gaap_ReceivablesNetCurrent 9,850us-gaap_ReceivablesNetCurrent

Inventory 4,047us-gaap_InventoryNet 3,757us-gaap_InventoryNet

Deferred income tax asset 2,319us-gaap_DeferredTaxAssetsNetCurrent 2,978us-gaap_DeferredTaxAssetsNetCurrent

Due from third party payors 2,672us-gaap_AccountsReceivableNetCurrent 2,786us-gaap_AccountsReceivableNetCurrent

Current assets held for sale 0 270

Prepaid expense and other assets 3,536 2,547

Total current assets 27,660us-gaap_AssetsCurrent 25,775us-gaap_AssetsCurrent

Property, plant and equipment, at cost 54,307us-gaap_PropertyPlantAndEquipmentGross 53,466us-gaap_PropertyPlantAndEquipmentGross

Less accumulated depreciation 31,484 30,389

Property, plant and equipment-net 22,823us-gaap_PropertyPlantAndEquipmentNet 23,077us-gaap_PropertyPlantAndEquipmentNet

Noncurrent Assets:

Intangible assets-net 2,908 2,979

Goodwill 461us-gaap_Goodwill 461us-gaap_Goodwill

Deferred income tax asset 4,436us-gaap_DeferredTaxAssetsNetNoncurrent 4,432us-gaap_DeferredTaxAssetsNetNoncurrent

Noncurrent assets held for sale 0 6,111

Other noncurrent assets 1,550us-gaap_OtherAssetsNoncurrent 1,012us-gaap_OtherAssetsNoncurrent

Total noncurrent assets 9,355 14,995

TOTAL ASSETS 59,838us-gaap_Assets 63,847us-gaap_Assets

Current liabilities:

Accounts payable 5,433us-gaap_AccountsPayableCurrent 4,530us-gaap_AccountsPayableCurrent

Current maturities of long-term debt 866us-gaap_LongTermDebtCurrent 561us-gaap_LongTermDebtCurrent

Accrued payroll and related taxes 4,097 4,186

Income tax payable 139us-gaap_AccruedIncomeTaxesCurrent 73us-gaap_AccruedIncomeTaxesCurrent

Current liabilities held for sale 0 4,842

Other accrued expenses 2,072us-gaap_OtherLiabilitiesCurrent 2,314us-gaap_OtherLiabilitiesCurrent

Total current liabilities 12,607us-gaap_LiabilitiesCurrent 16,506us-gaap_LiabilitiesCurrent

Long-Term Liabilities

Long-term debt 11,579us-gaap_LongTermDebtNoncurrent 11,948us-gaap_LongTermDebtNoncurrent

Noncurrent liability for professional liability risks 964 1,268

Other noncurrent liabilities 786us-gaap_OtherLiabilitiesNoncurrent 807us-gaap_OtherLiabilitiesNoncurrent

Total long-term liabilities 13,329us-gaap_LiabilitiesNoncurrent 14,023us-gaap_LiabilitiesNoncurrent

Commitment and Contingencies

Shareholders' Equity

Preferred Shares, authorized and unissued, 2,000 shares 0us-gaap_PreferredStockValue 0us-gaap_PreferredStockValue

Common Shares, without par value: Issued and outstanding, 9,444 shares at December 31, 2014 and at June 30, 2014 4,722us-gaap_CommonStockValue 4,722us-gaap_CommonStockValue

Additional paid-in capital 13,464 13,444

Retained earnings 16,050 15,486

Accumulated other comprehensive loss (334) (334)

Total Shareholders' Equity 33,902 33,318

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 59,838 $ 63,847

X

- Definition

Professional liability risks, noncurrent.

+ References

No definition available.

+ Details

Name: ssy_ProfessionalLiabilityRisksNonCurrent

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph b(1)

-Article 7

+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

+ Details

Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1436-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2510-110228

+ Details

Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1107-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name: us-gaap_OtherAssetsMiscellaneousNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_ReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568447-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4568740-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4I

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4590271-111686

+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 R45.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2014

Long-Term Debt [Member]

Commitment And Contingencies [Line Items]

Payments due in 1 year $ 866

Payments due in 2 years 775

Payments due in 3 years 1,951

Payments due in 4 years 601

Payments due in 5+ years 8,252

Contractual obligations, commitments and contingencies 12,445

Operating Leases [Member]

Commitment And Contingencies [Line Items]

Payments due in 1 year 858

Payments due in 2 years 333

Payments due in 3 years 200

Payments due in 4 years 74

Payments due in 5+ years 22

Contractual obligations, commitments and contingencies 1,487

Interest on Outstanding Debt [Member]

Commitment And Contingencies [Line Items]

Payments due in 1 year 712

Payments due in 2 years 708

Payments due in 3 years 650

Payments due in 4 years 508

Payments due in 5+ years 3,104

Contractual obligations, commitments and contingencies $ 5,682

X

- Details

Name: ssy_CommitmentAndContingenciesLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing after the fifth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueAfterFifthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the fourth fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInFourthYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the second fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInSecondYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the third fiscal year following the latest fiscal year.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationDueInThirdYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.

+ References

No definition available.

+ Details

Name: us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=ssy_InterestOnOutstandingDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=ssy_OperatingLeasesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ExtinguishmentOfDebtAxis=us-gaap_LongTermDebtMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9

Basis of Presentation
6 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

Note 1. –Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2014 and for the three and six month periods ended December 31, 2014 and 2013 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets - Goodwill (Detail) (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2014

Jun. 30, 2014

Goodwill [Line Items]

Goodwill $ 461us-gaap_Goodwill $ 461us-gaap_Goodwill

Specialty Pharmacy Segment [Member]

Goodwill [Line Items]

Goodwill $ 461 $ 461

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_GoodwillLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt (Tables)
6 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Summary of Long-Term Debt

Long-term debt consisted of the following:

 December 31, June 30,

 2014 2014

Trace RDA Loan
 $ 8,405 $ 8,624

SHPP RDA Loan
 2,013 2,033

Carmichael Notes
 1,852 1,852

Other
 175 —





Total
12,445 12,509

Less current maturities
(866 ) (561 )





$ 11,579 $ 11,948





X

- Definition

Long term obligations.

+ References

No definition available.

+ Details

Name: ssy_LongTermObligationsTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R36.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2014

Jun. 30, 2014

Debt Instrument [Line Items]

Total $ 2,908 $ 2,979

Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Finite and Indefinite-Lived Intangible Assets, Gross 3,858 3,858

Accumulated Amortization (950) (879)

Total 2,908 2,979

Trade Name [Member] | Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Indefinite-Lived Intangible Assets 2,000 2,000

Customer Relationships [Member] | Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Finite-Lived Intangible Assets, Gross 1,089 1,089

Medicare License [Member] | Specialty Pharmacy Segment [Member]

Debt Instrument [Line Items]

Finite-Lived Intangible Assets, Gross $ 769 $ 769

X

- Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before accumulated amortization of intangible assets, excluding goodwill.

+ References

No definition available.

+ Details

Name: us-gaap_IntangibleAssetsGrossExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ssy_MedicareLicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=ssy_SpecialtyPharmacySegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9

Financial Information by Segment (Tables)
6 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Segment Information

We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of December 31, 2014 and 2013 and for the three and six months then ended is as follows:

 Healthcare Specialty Corporate

 Facilities Pharmacy and Other Total

Three months ended December 31, 2014


Net revenues from external customers
 $ 14,539 $ 8,430 $ 158 $ 23,126

Operating profit (loss)
 2,596 80 (654 ) 2,022

Depreciation and amortization
 360 177 43 580

Assets
 33,843 12,615 13,830 59,838

Expenditures for property, plant and equipment
 48 271 0 319

Six months ended December 31, 2014


Net revenues from external customers
 $ 29,319 $ 15,884 $ 299 $ 45,502

Operating profit (loss)
 3,374 219 (1,266 ) 2,327

Depreciation and amortization
 720 345 150 1,215

Assets
 33,843 12,615 13,830 59,838

Expenditures for property, plant and equipment
 132 574 31 737

Three months ended December 31, 2013


Net revenues from external customers
 $ 14,463 $ 9,326 $ 91 $ 23,880

Operating profit (loss)
 1,287 229 (1,225 ) 291

Depreciation and amortization
 370 171 222 763

Assets
 38,225 11,517 18,782 68,524

Expenditures for property, plant and equipment
 161 104 141 406

Six months ended December 31, 2013


Net revenues from external customers
 $ 29,554 $ 16,168 $ 187 $ 45,909

Operating profit (loss)
 2,116 135 (2,296 ) (45 )

Depreciation and amortization
 769 337 431 1,537

Assets
 38,225 11,517 18,782 68,524

Expenditures for property, plant and equipment
 294 283 191 768

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 41 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9

Business Operations
6 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Business Operations

Note 2. – Business Operations

Business Operations

SunLink Health Systems, Inc., through subsidiaries, owns businesses which are providers of healthcare services in certain markets in the United States. SunLink’s business is composed of the ownership of two business segments:

• The Healthcare Facilities Segment is composed of three operational areas:

• Three community hospital subsidiaries in two states with a total of 183 licensed beds;

• Two nursing homes with a total of 166 licensed beds, each of which is located adjacent to, or in close proximity with a corresponding SunLink community hospital; and

• A healthcare facility which is currently vacant except for two medical offices which are rented.

• The Specialty Pharmacy Segment is composed of four operational areas:

• Retail pharmacy products and services, all of which are conducted in rural markets;

• Institutional pharmacy services;

• Specialty pharmacy services; and

• Durable medical equipment.

SunLink subsidiaries have conducted the healthcare facilities business since 2001 and the specialty pharmacy business since April 2008. The Specialty Pharmacy Segment currently is operated through Carmichael’s Cashway Pharmacy, Inc. (“Carmichael”), a subsidiary of SunLink ScriptsRx, LLC.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)

Dec. 31, 2014

Jun. 30, 2014

Statement of Financial Position [Abstract]

Preferred shares, authorized 2,000,000us-gaap_PreferredStockSharesAuthorized 2,000,000us-gaap_PreferredStockSharesAuthorized

Preferred shares, unissued 2,000,000 2,000,000

Common shares, without par value

Common shares, issued 9,444,000us-gaap_CommonStockSharesIssued 9,444,000us-gaap_CommonStockSharesIssued

Common shares, outstanding 9,444,000us-gaap_CommonStockSharesOutstanding 9,444,000us-gaap_CommonStockSharesOutstanding

X

- Definition

Face amount per share of no-par value common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of nonredeemable preferred stock (shares) (or preferred stock redeemable solely at the option of the issuer) allocated to investors to buy shares of a new issue of preferred stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockShareSubscriptions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9

Related Party Transactions
6 Months Ended

Dec. 31, 2014

Related Party Transactions [Abstract]

Related Party Transactions

Note 12. – Related Party Transactions

A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $91 and $159 for legal services to these law firms in the three months ended December 31, 2014 and 2013, respectively. The Company has expensed an aggregate of $190 and $319 for legal services to these law firms in the six months ended December 31, 2014 and 2013, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2014 and June 30, 2014 is $113 and $115, respectively, of amounts payable to these law firms.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9

Document and Entity Information
6 Months Ended

Dec. 31, 2014

Feb. 17, 2015

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Dec. 31, 2014

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Trading Symbol SSY

Entity Registrant Name SUNLINK HEALTH SYSTEMS INC

Entity Central Index Key 0000096793

Current Fiscal Year End Date --06-30

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 9,443,408dei_EntityCommonStockSharesOutstanding

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ssy_DocumentAndEntityInformationAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9

Financial Information by Segment
6 Months Ended

Dec. 31, 2014

Segment Reporting [Abstract]

Financial Information by Segment

Note 13. – Financial Information by Segment

Under ASC Topic No. 280, Segment Reporting, operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Our chief operating decision-making group is composed of SunLink’s chief executive officer and other members of SunLink’s senior management. Our two reportable operating segments are Healthcare Facilities and Specialty Pharmacy.

We evaluate performance of our operating segments based on revenue and operating profit (loss). Segment information as of December 31, 2014 and 2013 and for the three and six months then ended is as follows:

 Healthcare Specialty Corporate

 Facilities Pharmacy and Other Total

Three months ended December 31, 2014


Net revenues from external customers
 $ 14,539 $ 8,430 $ 158 $ 23,126

Operating profit (loss)
 2,596 80 (654 ) 2,022

Depreciation and amortization
 360 177 43 580

Assets
 33,843 12,165 13,830 59,838

Expenditures for property, plant and equipment
 48 271 0 319

Six months ended December 31, 2014


Net revenues from external customers
 $ 29,319 $ 15,884 $ 299 $ 45,502

Operating profit (loss)
 3,374 219 (1,266 ) 2,327

Depreciation and amortization
 720 345 150 1,215

Assets
 33,843 12,165 13,830 59,838

Expenditures for property, plant and equipment
 132 574 31 737

Three months ended December 31, 2013


Net revenues from external customers
 $ 14,463 $ 9,326 $ 91 $ 23,880

Operating profit (loss)
 1,287 229 (1,225 ) 291

Depreciation and amortization
 370 171 222 763

Assets
 38,225 11,517 18,782 68,524

Expenditures for property, plant and equipment
 161 104 141 406

Six months ended December 31, 2013


Net revenues from external customers
 $ 29,554 $ 16,168 $ 187 $ 45,909

Operating profit (loss)
 2,116 135 (2,296 ) (45 )

Depreciation and amortization
 769 337 431 1,537

Assets
 38,225 11,517 18,782 68,524

Expenditures for property, plant and equipment
 294 283 191 768

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Income Statement [Abstract]

Operating revenues (net of contractual allowances) $ 25,108us-gaap_Revenues $ 26,111us-gaap_Revenues $ 49,717us-gaap_Revenues $ 50,197us-gaap_Revenues

Less provision for bad debts of Healthcare Facilities Segment 1,982 2,231 4,215 4,288

Net revenues 23,126us-gaap_SalesRevenueNet 23,880us-gaap_SalesRevenueNet 45,502us-gaap_SalesRevenueNet 45,909us-gaap_SalesRevenueNet

Costs and Expenses

Cost of goods sold 5,456us-gaap_CostOfGoodsSold 6,485us-gaap_CostOfGoodsSold 10,072us-gaap_CostOfGoodsSold 10,760us-gaap_CostOfGoodsSold

Salaries, wages and benefits 10,589us-gaap_LaborAndRelatedExpense 10,722us-gaap_LaborAndRelatedExpense 21,406us-gaap_LaborAndRelatedExpense 21,514us-gaap_LaborAndRelatedExpense

Provision for bad debts of Specialty Pharmacy Segment 123us-gaap_ProvisionForDoubtfulAccounts 42us-gaap_ProvisionForDoubtfulAccounts 123us-gaap_ProvisionForDoubtfulAccounts 95us-gaap_ProvisionForDoubtfulAccounts

Supplies 2,034us-gaap_SuppliesExpense 2,054us-gaap_SuppliesExpense 4,140us-gaap_SuppliesExpense 3,982us-gaap_SuppliesExpense

Purchased services 1,025us-gaap_CostOfServices 1,350us-gaap_CostOfServices 2,202us-gaap_CostOfServices 2,595us-gaap_CostOfServices

Other operating expenses 1,968us-gaap_OtherCostAndExpenseOperating 3,030us-gaap_OtherCostAndExpenseOperating 4,340us-gaap_OtherCostAndExpenseOperating 5,973us-gaap_OtherCostAndExpenseOperating

Rent and lease expense 329us-gaap_OperatingLeasesRentExpenseNet 358us-gaap_OperatingLeasesRentExpenseNet 677us-gaap_OperatingLeasesRentExpenseNet 713us-gaap_OperatingLeasesRentExpenseNet

Insurance settlement (1,000)us-gaap_InsuranceRecoveries 0us-gaap_InsuranceRecoveries (1,000)us-gaap_InsuranceRecoveries 0us-gaap_InsuranceRecoveries

EHR incentive payments 0 (1,215) 0 (1,215)

Depreciation and amortization 580 763 1,215 1,537

Operating Profit (Loss) 2,022us-gaap_OperatingIncomeLoss 291us-gaap_OperatingIncomeLoss 2,327us-gaap_OperatingIncomeLoss (45)us-gaap_OperatingIncomeLoss

Other Expense:

Interest expense-net (234)us-gaap_InterestExpense (238)us-gaap_InterestExpense (464)us-gaap_InterestExpense (480)us-gaap_InterestExpense

Earnings (Loss) from Continuing Operations before income taxes 1,788 53 1,863 (525)

Income Tax Expense (Benefit) 799us-gaap_IncomeTaxExpenseBenefit (297)us-gaap_IncomeTaxExpenseBenefit 985us-gaap_IncomeTaxExpenseBenefit (95)us-gaap_IncomeTaxExpenseBenefit

Earnings (Loss) from Continuing Operations 989 350 878 (430)

Loss from Discontinued Operations, net of tax (12) (123) (314) (501)

Net Earnings (Loss) 977us-gaap_NetIncomeLoss 227us-gaap_NetIncomeLoss 564us-gaap_NetIncomeLoss (931)us-gaap_NetIncomeLoss

Other comprehensive income 0 0 0 0

Comprehensive Earnings (Loss) $ 977us-gaap_ComprehensiveIncomeNetOfTax $ 227us-gaap_ComprehensiveIncomeNetOfTax $ 564us-gaap_ComprehensiveIncomeNetOfTax $ (931)us-gaap_ComprehensiveIncomeNetOfTax

Continuing Operations:

Basic $ 0.10 $ 0.04 $ 0.09 $ (0.05)

Diluted $ 0.10 $ 0.04 $ 0.09 $ (0.05)

Discontinued Operations:

Basic $ 0.00 $ (0.01) $ (0.03) $ (0.05)

Diluted $ 0.00 $ (0.01) $ (0.03) $ (0.05)

Net Earnings (Loss):

Basic $ 0.10us-gaap_EarningsPerShareBasic $ 0.02us-gaap_EarningsPerShareBasic $ 0.06us-gaap_EarningsPerShareBasic $ (0.10)us-gaap_EarningsPerShareBasic

Diluted $ 0.10us-gaap_EarningsPerShareDiluted $ 0.02us-gaap_EarningsPerShareDiluted $ 0.06us-gaap_EarningsPerShareDiluted $ (0.10)us-gaap_EarningsPerShareDiluted

Weighted-Average Common Shares Outstanding:

Basic 9,443 9,443 9,443 9,443

Diluted 9,497 9,446 9,478 9,443

X

- Details

Name: ssy_EarningsLossPerShareContinuingOperationsAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: ssy_EarningsLossPerShareDiscontinuedOperationsAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

+ References

No definition available.

+ Details

Name: ssy_HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=35737396

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the provision for bad debts related to patient service revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35755891&loc=SL9156442-115640

+ Details

Name: us-gaap_HealthCareOrganizationPatientServiceRevenueProvisionforBadDebts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section E

-Paragraph Question 3

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InsuranceRecoveries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LaborAndRelatedExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6453985&loc=d3e41499-112717

+ Details

Name: us-gaap_OperatingLeasesRentExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount after tax of other comprehensive income (loss) attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 3

-Article 5

+ Details

Name: us-gaap_OtherCostAndExpenseOperating

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of expense associated with supplies that were used during the current accounting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.14)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_SuppliesExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets
6 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Note 7. – Goodwill and Intangible Assets

SunLink’s Specialty Pharmacy Segment has goodwill and intangible assets related to its Carmichael acquisition.

Goodwill consists of the following:

 December 31, June 30,

 2014 2014

Specialty Pharmacy Segment
 $ 461 $ 461





Intangibles consist of the following, net of amortization:

 December 31, June 30,

 2014 2014

Specialty Pharmacy Segment


Trade Name
 2,000 2,000

Customer Relationships
 1,089 1,089

Medicare License
 769 769





3,858 3,858

Accumulated Amortization
(950 ) (879 )





Total
$ 2,908 $ 2,979





The trade name intangible asset under the Specialty Pharmacy Segment is a non-amortizing intangible asset.

Amortization expense was $36 and $35 for both the three months ended December 31, 2014 and 2013, respectively, and $71 and $70 for the six months ended December 31, 2014 and 2013, respectively.

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives
6 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives

Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives

Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services.

For the three and six months ended December 31, 2014, the Company reported no EHR incentive payments. For the three and six months ended December 31, 2013, the Company reported a net $1,215 gain for Medicare and Medicaid EHR incentive payments which were for successful Medicaid attestation by the three hospitals and also adjustments calculated at the time of filing Medicare cost reports for the preceding fiscal year.

X

- Definition

Electronic health records incentive reimbursement receivable.

+ References

No definition available.

+ Details

Name: ssy_ElectronicHealthRecordsIncentiveReimbursementReceivableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies (Tables)
6 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2014 were as follows:

Payments due in:
 Long-Term
Debt Operating
Leases Interest on
Outstanding
Debt

1 year
 $ 866 $ 858 $ 712

2 years
 775 333 708

3 years
 1,951 200 650

4 years
 601 74 508

5+ years
 8,252 22 3,104







$ 12,445 $ 1,487 $ 5,682







X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-K (SK)

-Number 229

-Section 303

-Paragraph a

-Subparagraph 5

+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations (Tables)
6 Months Ended

Dec. 31, 2014

Discontinued Operations and Disposal Groups [Abstract]

Schedule of Discontinued Operations

Results for all of the businesses included in discontinued operations are presented in the following table:

 Three Months Ended Six Months Ended

 December 31, December 31,

 2014 2013 2014 2013

Net Revenues:


Fulton Hospital
 $ 3,321 $ 3,184 $ 6,730 $ 6,733

Dexter Hospital
 90 418 131 513

Memorial of Adel
 69 2 53 (4 )









$ 3,480 $ 3,604 $ 6,914 $ 7,242









Earnings (loss) before income taxes:

Fulton Hospital
$ (449 ) $ (549 ) $ (897 ) $ (1,147 )

Dexter Hospital
532 410 570 482

Memorial of Adel
56 (1 ) 32 (12 )

Life sciences and engineering
(30 ) (40 ) (64 ) (79 )









Earnings (Loss) before income taxes
109 (180 ) (359 ) (756 )









Loss on Sale

Fulton Hospital
(191 ) — (191 ) —









Loss on Sale
(191 ) — (191 ) —









Income tax expense (benefit)
(70 ) (57 ) (236 ) (255 )









Loss from discontinued operations
$ (12 ) $ (123 ) $ (314 ) $ (501 )









Components of Pension Expense

The components of pension expense for the three and six months ended December 31, 2014 and 2013, respectively, were as follows:

 Three Months Ended Six Months Ended

 December 31, December 31,

 2014 2013

2013

Interest Cost
 $ 16 $ 15 $ 33 $ 30

Expected return on assets
 (7 ) (7 ) (15 ) (14 )

Amortization of prior service cost
 23 32 48 63



Net pension expense
 $ 32 $ 40 $ 66 $ 79



X

- Definition

Pension expense.

+ References

No definition available.

+ Details

Name: ssy_PensionExpenseTableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of disposal groups, which may include the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the classification and carrying value of the assets and liabilities comprising the disposal group, and the segment in which the disposal group was reported. Also may include the amount of adjustments to amounts previously reported in discontinued operations such as resolution of contingencies arising from the disposal transaction or the operations of the component prior to disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1474-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=8077374&loc=d3e2443-110228

+ Details

Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9

Income Taxes
6 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

Note 10. – Income Taxes

Income tax expense of $799 ($643 federal tax expense and $156 state tax expense) and income tax benefit of $297 ($328 federal tax expense and $31 state tax expense) was recorded for the three months ended December 31, 2014 and 2013, respectively. Income tax expense of $985 ($863 federal tax expense and $122 state tax expense) and income tax benefit of $95 ($78 federal tax benefit and $17 state tax benefit) was recorded for the six months ended December 31, 2014 and 2013, respectively.

At December 31, 2014, the Company had $5,190 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At December 31, 2014, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,755. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt
6 Months Ended

Dec. 31, 2014

Debt Disclosure [Abstract]

Long-Term Debt

Note 8. – Long-Term Debt

Long-term debt consisted of the following:

 December 31, June 30,

 2014 2014

Trace RDA Loan
 $ 8,405 $ 8,624

SHPP RDA Loan
 2,013 2,033

Carmichael Notes
 1,852 1,852

Other
 175 —





Total
12,445 12,509

Less current maturities
(866 ) (561 )





$ 11,579 $ 11,948





Trace RDA Loan and Trace Working Capital Loan - On July 11, 2012, SunLink, MedCare South, LLC (formerly known as SunLink Healthcare, LLC) (“MedCare”), a wholly owned subsidiary of the Company, and Southern Health Corporation of Houston, Inc. (“SHCH”), an indirect wholly-owned subsidiary of the Company, closed on a $9,975 Mortgage Loan Agreement dated as of July 5, 2012 (“Trace RDA Loan”) and up to a $1,000 Working Capital Loan Agreement dated as of July 5, 2012 (“Trace Working Capital Loan”) with a bank. SHCH owns and operates Trace Regional Hospital “Trace”) in Houston, Mississippi.

The Trace RDA Loan has a term of 15 years with monthly payments of principal and interest until repaid. The Trace RDA Loan bears a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 1.5%, or (ii) 6% (6.0% at December 31, 2014). The Trace RDA Loan is collateralized by Trace’s real estate and equipment and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Approximately $8,500 of the Trace RDA Loan proceeds were used to repay a portion of the Company’s senior debt under the Term Loan under the then outstanding Credit Facility. Approximately $850 of the Trace RDA Loan proceeds were used for improvements to the hospital and its medical office building with the remainder of the loan proceeds used for working capital and closing costs.

The Trace Working Capital Loan as amended provides for a revolving line of credit to SHCH equal to the lesser of (i) a Borrowing Base equal to eighty percent (80%) of Eligible Accounts Receivable (as defined in the Working Capital Loan Agreement dated July 5, 2012) or (ii) (a) for the quarter ending December 31, 2014, $875; (b) for the quarter ended March 31, 2015, $750; (c) for the quarter ending June 30, 2015, $625; and (d) thereafter, $500. The Trace Working Capital Loan expires July 2, 2015. It is subject to annual renewal at the discretion of the lender. At December 31, 2014, there were no outstanding borrowings under the Trace Working Capital Loan.

The Trace RDA Loan contains various terms and conditions, including financial restrictions and limitations, and affirmative and negative covenants. The covenants include financial covenants measured on a quarterly basis which require our SHCH subsidiary to comply with a ratio of current assets to current liabilities, debt service coverage, fixed charge coverage, and funded debt to EBITDA, all as defined in the Trace RDA Loan. If SHCH is unable to remain in compliance with the financial covenants, SHCH would cease to have a right to draw on the revolving working capital loan (of which $0 was drawn at December 31, 2014 and June 30, 2014).

SHPP RDA Loan—On November 6, 2012, SunLink Healthcare Professional Property, LLC, a subsidiary of the Company, entered into and closed on a $2,100 term loan dated as of October 31, 2012 (the “SHPP RDA Loan”) with a bank. SHPP owns and leases a medical office building to Southern Health Corporation of Ellijay, Inc. (“SHC Ellijay”). SHC Ellijay owns and operates North Georgia Medical Center (“North Georgia”), located in Ellijay, Georgia.

The SHPP RDA Loan has a term of 25 years with monthly payments of principal and interest until repaid. The SHPP RDA Loan bears interest at a floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5% (5.25% at December 31, 2014). The SHPP RDA Loan is collateralized by SHPP’s real estate, equipment and leases and is partially guaranteed under the U.S. Department of Agriculture, Rural Development Business and Industry Program. Of the SHPP RDA Loan proceeds, $1,800 was used by SHC Ellijay to acquire a medical office building in Ellijay, Georgia which was then sold to SHPP, with the remainder of the SHPP RDA Loan proceeds used by SHPP for working capital and closing costs. The SHPP RDA Loan contains certain financial covenants with respect to the ratio of current assets to current liabilities and debt service coverage, all as defined in the SHPP RDA Loan Agreement, which SHPP must maintain and that are measured at the end of each fiscal year. The SHPP RDA Loan is guaranteed by the Company and MedCare.

Carmichael Notes – On April 22, 2008, SunLink Scripts Rx, LLC issued a $3,000 promissory note with an interest rate of 8% to the former owners of Carmichael as part of the acquisition purchase price (the “Carmichael Purchase Note”). On April 12, 2012, an amendment to the Carmichael Purchase Note was entered into under which SunLink has the option to issue promissory notes to the former owners of Carmichael in payment of up to two semi-annual payments of principal and interest due under the Carmichael Purchase Note (the “PIK Notes”). The PIK Notes bear an interest rate of 8% and were to be due on April 22, 2015. A PIK Note for $247 was issued on April 22, 2012 for the principal and interest payment that would have been due on April 22, 2012. A PIK Note for $252 was issued on October 22, 2012 for the principal and interest payment that would have been due on October 22, 2012. The Carmichael Purchase Note and the PIK Notes were combined into one note (the “Carmichael Note” dated April 22, 2014 for the remaining balance payable of $1,852. The Carmichael Note is payable in one interest only payment of $75 due on October 22, 2014 and five semi-annual installments of $185 of principal and accrued interest commencing on April 22, 2015, with the remaining balance of the Carmichael Note of $1,255 due October 22, 2017. Interest is payable in arrears semi-annually on the six and twelve-month anniversary of the issuance of the note. The Carmichael Note is guaranteed by the Company.

X

- Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9

Insurance settlement
6 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Insurance settlement

Note 9. – Insurance settlement

In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the three and six months ended December 31, 2014 for this settlement.

X

- Definition

Insurance settlements.

+ References

No definition available.

+ Details

Name: ssy_InsuranceSettlementsTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_TextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 54 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9

Commitments and Contingencies
6 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 11. – Commitments and Contingencies

Litigation—A settlement was reached on November 3, 2014 relating to litigation as a result of sellers failure to close on the sale of approximately 24.74 acres of real property located in Gilmer County, Georgia purchased by a subsidiary of the Company. In satisfaction of the Company’s claims against the sellers, a five year promissory note in the principal amount of $600 was issued to Castlemark Properties, LLC, (“Castlemark”) one of the Company’s subsidiaries. The note is secured by a mortgage on the real property. Castlemark will have a right to immediate payment of the note if the property is sold prior to maturity. If the owner does not sell the property prior to maturity and does not pay the note in full at maturity or deed the property to Castlemark, then Castlemark will have a right to foreclose the mortgage and take title to the property. The litigation was dismissed by joint stipulation on or about November 12, 2014. As a result of this settlement the Company recorded pre-tax income of $500, the estimated fair value of the real property, which is the most probable value of the judgment in the quarter ended December 31, 2014. The promissory note is included in long-term assets in the December 31, 2014 balance sheet.

SunLink and its subsidiaries are a party to various medical malpractice and other claims and litigation incidental to its business, for which it is not currently possible to determine the ultimate liability, if any. Based on an evaluation of information currently available and consultation with legal counsel, management believes that resolution of such claims and litigation is not likely to but could have a material adverse effect on the financial position, cash flows, or results of operations of the Company. The Company expenses legal costs as they are incurred.

Sale of Hospital Facilities—The Company has sold three hospital facilities since June 30, 2012 and in connection with the sales has retained certain assets and substantial liabilities. – See Note 3 Discontinued Operations.

Office of Inspector General Investigation— In March 2013, SunLink received a document subpoena from the United States Department of Health and Human Services Office of Inspector General (“OIG”) in connection with an investigation of possible improper claims submitted to Medicare and Medicaid. The subpoena was directed to SunLink’s indirect subsidiary Southern Health Corporation of Dahlonega, Inc. (“SHCD”), which owns and operates Chestatee Regional Hospital in Dahlonega, Georgia, and requested documents concerning possible false or fraudulent claims made for intensive outpatient psychiatric services provided by and billed for a third-party outpatient psychiatric service provider. The subpoena also sought information about SHCD’s relationship with the outpatient psychiatric service provider, including financial arrangements. SHCD is continuing to cooperate with the government with respect to an ongoing document production, as well as conducting a joint medical necessity review of a sampling of medical records. We cannot at this time estimate what, if any, impact these matters and any results from these matters could have on our business, financial position, operating results or cash flows.

Contractual Obligations, Commitments and Contingencies

Contractual obligations, commitments and contingencies related to long-term debt, non-cancelable operating leases and interest on outstanding debt from continuing operations at December 31, 2014 were as follows:

Payments due in:
 Long-Term
Debt Operating
Leases Interest on
Outstanding
Debt

1 year
 $ 866 $ 858 $ 712

2 years
 775 333 708

3 years
 1,951 200 650

4 years
 601 74 508

5+ years
 8,252 22 3,104







$ 12,445 $ 1,487 $ 5,682







At December 31, 2014, SunLink had a guarantee agreement with one physician. A physician with whom a guarantee agreement is made generally agrees to maintain his or her practice within a hospital geographic area for a specific period (normally three years) or be liable to repay all or a portion of the guarantee received. The physician’s liability for any guarantee repayment due to non-compliance with the provisions of a guarantee agreement generally is collateralized by the physician’s patient accounts receivable and/or a promissory note from the physician. All potential payments payable under this one guarantee have been paid as of December 31, 2014. SunLink expensed $16 and $33 on physician guarantees and recruiting for the three months ended December 31, 2014 and 2013, respectively. SunLink expensed $31 and $67 on physician guarantees and recruiting for the six months ended December 31, 2014 and 2013, respectively.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Segment

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Compensation and Retirement Disclosure [Abstract]

Gain (loss) realized on incentive payments $ 0 $ 1,215 $ 0 $ 1,215

Number of community hospitals 3ssy_NumberOfCommunityHospitals

X

- Definition

Amount of increase (decrease) in Electronic Health Records of health care organizations. Electronic Health Records ("EHR") payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the "HITECH Act") which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 ("ARRA"). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals ("CAH") participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015.

+ References

No definition available.

+ Details

Name: ssy_HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of community hospitals.

+ References

No definition available.

+ Details

Name: ssy_NumberOfCommunityHospitals

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_CompensationAndRetirementDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9

Goodwill and Intangible Assets (Tables)
6 Months Ended

Dec. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

Goodwill consists of the following:

 December 31, June 30,

 2014 2014

Specialty Pharmacy Segment
 $ 461 $ 461





Net of Amortization Intangible Assets

Intangibles consist of the following, net of amortization:

 December 31, June 30,

 2014 2014

Specialty Pharmacy Segment


Trade Name
 2,000 2,000

Customer Relationships
 1,089 1,089

Medicare License
 769 769





3,858 3,858

Accumulated Amortization
(950 ) (879 )





Total
$ 2,908 $ 2,979





X

- Definition

Schedule of intangible assets excluding goodwill.

+ References

No definition available.

+ Details

Name: ssy_ScheduleOfIntangibleAssetsExcludingGoodwillTableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 57 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations - Schedule of Discontinued Operations (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Net Revenues:

Net revenues $ 3,480 $ 3,604 $ 6,914 $ 7,242

Earnings (loss) before income taxes:

Earnings (loss) before income taxes 109 (180) (359) (756)

Loss on Sale

Loss on Sale (191) (191)

Income tax expense (benefit) (70) (57) (236) (255)

Loss from discontinued operations (12) (123) (314) (501)

Fulton Hospital [Member]

Net Revenues:

Net revenues 3,321 3,184 6,730 6,733

Earnings (loss) before income taxes:

Earnings (loss) before income taxes (449) (549) (897) (1,147)

Loss on Sale

Loss on Sale (191) (191)

Dexter Hospital [Member]

Net Revenues:

Net revenues 90 418 131 513

Earnings (loss) before income taxes:

Earnings (loss) before income taxes 532 410 570 482

Memorial Hospital of Adel [Member]

Net Revenues:

Net revenues 69 2 53 (4)

Earnings (loss) before income taxes:

Earnings (loss) before income taxes 56 (1) 32 (12)

Life Sciences and Engineering [Member]

Earnings (loss) before income taxes:

Earnings (loss) before income taxes $ (30) $ (40) $ (64) $ (79)

X

- Details

Name: ssy_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTaxAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disposal group including discontinued operation revenue net of expenses.

+ References

No definition available.

+ Details

Name: ssy_DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: ssy_NetRevenueAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss), before tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Overall income (loss) from a disposal group that is classified as a component of the entity, before income tax, reported as a separate component of income before extraordinary items. Includes the following (before income tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.12)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 05

-Paragraph 15

-Article 3

+ Details

Name: us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Tax effect allocated to a disposal group that is classified as a component of the entity reported as a separate component of income before extraordinary items. Includes the tax effects of the following: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b),(c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=18498875&loc=d3e38679-109324

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

+ Details

Name: us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_GainLossOnSaleOfPropertyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of income (loss) from a disposal group, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount allocable to noncontrolling interests. Includes, net of tax, income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

+ Details

Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_DexterHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_FultonHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_LifeSciencesAndEngineeringSegmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_MemorialHospitalOfAdelMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 58 0001193125-15-052611-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-15-052611-xbrl.zip M4$L#!!0````(``9Y4D8QX,8C\:T``%E?"0`0`!P``L``00E#@``!#D!``#<75MSVTAV?D]5_@.BAU12 M-9#ZBHMJ["U<)ZKR6(KLW4SRHH+(IH0:$N`"H"WMK\]ID)3()DB")`!"ZQ?; M!$#V=_K\U/DT2,Q^)5^V,@QB*+"J'=)/*) M@8"+@]E$),4OVF.4BZ&6)MH?[OT7C5QB37LNBNGUU=7/GS\OLVRX_)K+03JY MTG1]^1-_FX_N6M.,2T(NV*GYT+[C\%_PLV(Z_`$U>XO[R]7@/V[]BU-/+CRS1[NH*?H%?Q0CH7 M\SNOY=7QCOO'6N\?7<> M5WTSW(JO_OC]R[?!LYA$NHH`-.4IBJ9O3XZB_+%\;G$!GL=,1UBG>/G(4+S_ M4#FB7`PNG](?5W"AXO8\?UT;5SY+),YG$8V+YU)EY#.8O#\!/UV\3D5>.:CR M2L7/R)$,B_6!+?#SJ_G%M5OCREN-^:WQV^"+:58-5EZ1P\#KPQB`8A?9:_4S MBXOR,:H\-LLR,-]MSRVN5L`6+X/GZH?DE8H'DB@>Y-5/E)+V]Z>FDVJGQ@6V974E"NX0V3Q MX.T!\`S[GTD377EN5F0[A@97+\"':%KI1<;7>6EK]V*DE29]+;_UTT4>3Z9C M:7CE9U$VD(CJ.8_RB>=,C.!;\E=]:3"7+_GP"-=2WVM=S5$M?,&U+QX+&2"R M,C*$T4`X$ZG2VB!-"O%2W,L!BG3\H>_OK-O]"&8A!/HC$H ML4XOM!AT)AX^<&R:V+(>;,]WK<`+]2"@ILY"8NF6@VV=V\1%.$2FAYT'##[Q M`5U\AH'(/[]>[0,X%P/XM^L@*>+B%>+))$V^%>G@SV_/42;RVUE11EJ(O@<* M@R,);!5L7G[C*LZ;K^$&4(1"SGT(>X[#N,ZH8^B.[U/=L"T/=-(*`YL_D`=^ M\=EFC#)D_7I5;_R[IOP&D,'=Q3T8X;="6N*=R`9P(7H2A^%&%F*$K"D!@5&; M*W*8SC*Q3PHX\!W3#)D..F/HS`L-W2+,U4UN&M3!F-NA/9]N?/$974HI'(ZL M#2.H@;^^TM>7`B@]10GLL1C-QLZ@#.3YO1B(^$?T.!9> M&:`/E05%-D4/Q_DYSV4>]7D`WLVC.K/<0'IQM2V7S`U.$6X50'A4D`4FQ]30*;)+=*J@(@4$+/(AY"/ MS(K:M"@N+0H3T!A"FS.I/!=%_E5TB=9R"/*I3W33]0CD28:E`T17QY:!;.83 MVZ26])V0E;&+SX;%"5N'NQSS.A0ORI^=9"C_"OX^`\QC0)L[A1=EV2LD%W^+ MQK,#,X738+H6\6W'U[%A!3H+3*1#:A3J)#2"P,:!:5AE.DA*F(P;>`UE+3B- M3J8T;<2H(9-@C`AKQ!?6G6Q<2H%:A/`ZD]T>U..]6EVH\PF'U$AU_*U#)<@X M+LNK"XW.H4'^0VI!:]\?=Q?0>:G$X)\-2`$_4,3J+J+S4O=!0LS\$#DA:SM) MEAZ?RN6A2>F'4!G6=98L)50NH$W\,=+D30FU;%120D1*B&#:E(`V]FAN\GPF MAH>*8B-YVMQ>JD!-7(B.WT%K&2*M`W'K_ME=)D8"9G?X?O.WV6,^R.*I?-F5]PHKA94>4?=) M]B%0S#H3T>WH7D3C()?;:'=9.A59\7HRSFBP?S?0M;%G<&,3OV(^0JX`6`=;WO*< MCH*(!X/99#:6;S)\,19%#-+V9!J".\N9]FXPV\H;(,SV.H?*[:H5NSA=N3'^33-H_%O63J; MOKD+^%3"C!-(W&ZGLC0(9-9?TU\7P(GXM@JKO_@A;\/$0.N+LWUN#RP&,HLA MR"2=B._12Y\!&@!0W7#?-ORM\R?#75\14KEE1RFQMTWA^^"W)J4]=4\,RJ6E/HED`')H%E\C23;E&TGV2C0JX[0L0,S$LTCR M^(>8J^R7-)>;L;3AI8G$[IUAA;!]6&2,IMC[OH]82=G0Y\#>1:G%&J M(J\8_#K`>U%$<2*&090EH*[Y6D8RB@=Q#\$R#F['0'Q]A;4?B>)C5[+0_LXK M>%C+,-;]Z^;`%:4=#F.9&D3CNRB&6.-%T[B(QBO>JW]`61E*F*'8[EXDN]=] MO0Z>8+*F9>Q<^6V+GZLJT&N,N'Q=J;RTJ1[]U@P(@NGF'D'_L#)8RG/;HM:V M9*@2QSKJ8#(=IZ]"W(O2;WV(-!Z<,4/V>A:_%\=V=>[?-H;T3(0QOE6'.WQ' M=`):G_F.:]FACCWNR'I+0&N@4"<8T`>4^QXQ'^9OS$B#;UF/K$$X!6FMF@,F MRX18E?*:V>7*%T&]I.OP9C\?]`XBE`U)*H):C5??%MFR?=:N> M=7'!S!%BD?6R%6!Y7Z;YP67]1GRUQ_ MM78"MG4AW20_X+,T>^UEPBC/`B"V[H-71ZQXW#GDY$EN?I>)_RC-?D;9L$MG M5--XI2\J%7O5T6X=_[[DH<\V#*D2,91RD%T(JH+)/\?K\743/AZ9:L%%E#S% M(,,W=QB\++ZEQTM<,&UB(TLQ[?U0MB99O?;>L$K"7'F[4SGV*NWOK4++,E73 M4`]X;"[S\OQ5ILXCD>?EFX_EYNGK?9S_*<'W%B&5A=6+-SAU4:BOT),BBP;% M+!K?/H[CIWDUU$S<)-\$P!W^KXBRXW`_8&+8B)&2IX$@XR@YN(8!$ZL#K*XHOC_'V0>1!"@$MCFN*8HW8#4D MT7_LO.JU0266NA,?IK.L>/X8,T]AO87J3OP[L!JB"&?%+!._QTD\F4WNHM>R MX`:^YEY,HC@9BNQV%$(^$(T_AJ#0Y@O^TV'7TRAG5(@LC$=ZB;T&F?>@RR##+[&.,:1^\ M+*!1C[A]O!#3OIQDB.'6/T&(:5]4'NRF)\N1S74YMP!IGU) M2&H&WL<`TSYT"##C[*)25X.*05J,>6\0K,T1ON1MLS8Q"2_1ED]BHU6N:DJ MD+9+V,0D^TQ9L6^I]#/5R+ZFA5B>0SD>'*QW63F-\I,F.$AA^#;V`"SUY5O' MT+5UV[1,G7#7#)AA6K[GS`DIRVE4Z@=6075>`]PADPY96*R)%`&<4!<<0@PH MQ)?XASP,N?XB:^7@SNKAYY/%=+RU^[YIV0$B.L+$TQD$"=UV+**'A'';=2WJ M#C2<^I2VYQ#9.$3B4K->+PJG?;>MAD%,5C@N7Z@8^28H""> MH=N@#KK)7#/D+C)#27@LTZ1ZED-+")&VY]H M26-6Q<3,(W>H:HF)+IL`(&7#^U#@Y]4FR%MPK.8-Y:60JX=^A0.NV6PA&(S$H0-S'=EQ8D=$BVR>V1=GJ"EWMN(`V.PV$ M5A"$`=,MTW5UYH=$=PR"($33T"4V#ESNSAV0?&M=I]E"!2[U1&.4G+S>V8:X MZ1.."Y]B,:2><7P'H9[.3<3MR,O$,)9-",K"GM^C%[FKXZ99EOX$3^-%4[AR M[$G=P^%7,;8QXG@VK+TE:EE5BL%98,A./>:&@6,Y!G?I@E@9\"LU.X>`W"Z> M,\Y^??1$H2)Z'_Y[35J5.-[DX$;YBBWY#F25M?T(*HL M/2>Z1)SPWKG/#>`-N\]EYEIVNJCG/MOJ3U0!_IC^1+5VQ@=)8;<$1W;P5WD2O,7XPKFWS'YPJ- MM:@R\7(M0?!B+<&:R2-PB$,/UG$0`.3:(O!!1A;!.D>>@TV?&S@TYEFD+`"W M3?6479V652UJS;MH&M"26K)81D2LKM*/5Y-V&S09K7M$I_T:YI(QB4**U=-^#9L2:K]?`RDE MQ,S&7L,UU*]APVR:(_@G/>G7T"[$?O5K:!5K`_T:&NEIL,O5-]W3@+3?TZ#& MG!W=TX!\U)X&)X3SNO-:]C2`%=F:9'K=V:U>AJ+2U"(S+8CC#1LTUA6Z#.;\#K99D MW2JW1G?,^1UL2IV%.;\#7)(0AB*S)AUU.\SY'036B\^VM=$$ZQS$^>UCE5O* MG*D3>E;B_`[T>$Z?3BA>^+\#F98,AM39J@=(N#RV:%I[?=&YV>4[4%\3)ACC];RI M%QSS'2QP(25V.^2:YU]O')KG7U8:,?>1>;U\2II0$JO!?_21@[\#D2P)V MI2O>F0C8.T`K"=B1PN?4-@%[^[!DW1E7B;D[)&#O8$4H^;:),0_2QS&P=[!S MU5U-L;7@6S`,UEA#R_:):QJL*Z[+2E$&=LNL?5C^_,0U71=?6U)(O-R%:$J3 M3@MWW?'6D'/SUIS%(/K,6W,6@?!&4J"FF4:J1=$I;PWY`+PU^\74.F\-^0"\ M-?O$U`%O#?D`O#7O8NJ,M\:8\]8HR?MIO#6GL`R\B:`[DI8YD;NA$.?5(VDY M(SR&",;(ARFU?:PSQR:Z[;M,)R0P82%C,.XZ[[P;NUA(VIBW#M@AR)P=@M9E MASB%"V$#WO%<"+7@T87#.H`+H55^@#?'=#Y^`%:63Y`VN(0:%YZ\XBH) MR;B2%1POKM^C\512:<<#<9/DLTPNS7SQ=I"POH3P7$)X23@!N8#U4DJ*;S*, M!=0(0M='.K*Y!;9"7-WQ#:XCRZ>>X=#02(M'6DC^*E<>WS5BI^IEJ0_M5&:3>#[EM^3:_+G MM"C11/ST7&BODDQ]"@-(AYKV*)[B1!;4PB@UL'/C\GVJ]@A<37,7=\#2N(1W M2%G\[ADYPL/5GS54P>50@647L\==*V_M1/D`?(X_(0GGM/B+.72D1R(=/#F@@"FIABJSW,VJAZ(G5T]YB18RFOO M`]3C+DL'0@SS,$LG/JQT\B*6S2)N1^XLAW``BYU#?05YCV\FP\8+Y@8AUG'+ M-\ZI@4C@ZJY/7^BSH/E'21\U-19(%-!;,F]TL#0$;<-QPLY MMVWC@975[#JZQ*M%P-4XE(17%+*@$H3T(QZ*H?OZUURN<]\Z?#N2*ZZL'&X6 M?R.$+G*^*5?:?-9'=,R6^=R,;I)!)J(<@NW\[TYE4VO/W"QI?^3I%;4YS"DX MU8QB>7A+VM;\P-T,)/SV%EJJWD+K2@WLMPG)4\&Z)%)#SZ"H.P]@CH`Z;K`_J=,@,70@9PN>A)?9Y-'V9=H5<+'\P)1B>((5_)A[,,XSI%LLXH#C>OC M>%R*3G4DVWWO%KO;,+BF3*I11\+K.Y)J0$TN_4_/6&K"ED0MARSRU>SD)KF' M[#Z+!R`EF0+V,6.5S)2&NIFQ&T:5,RBI*^29W(,J5;N#* M_IDN^A+>CHX[D]@=0@#(E#.)VX9?48CX+1H+R+9_"/!L74\A)0%R/=?7S=!W M8/W@&;H;VO`O0DP7H'++(6"-\J"`57$\6AEZ!;@]#`^5+%QWT6$O0[OS2F2= MH/]$A,=']O5O`UV3/Y(\!?#`(6\?.A2XZ2)Y'?)$%>`+*BXP@H5^R6K/.2'`L@LD"^:O>9 MCAS#,FV+<=MA(#)Y)$GA8SH"F<+^=T974U=3)'G*_[/WI,V)(UE^GXCY#UIW M3T=WC.32?92W.X*SRKLNNZ)@HK;W2X4``9J2)5J'7=Y?O^]EZ@9CP$@(P\ST M-&`I,]_+=V:^PRA)T[5RYF5[NFU-/=_*:9S>C]`W/1],)--_N@ZM^^"U=0YK MM(SP:$(IW6M6B(.24$^.SK(9&XDD&9!4.@Q7U5Y'ECA-5CH`.:]S;;$-JEJ70*+JAMA2I&_D MOKM4[7$;B)8*:)6UVO:UIFJ4&GCD;4A%_;(&AJ6TN&75LX%V*O%4K8A1-%D2 M6Z+(*1W%`,3@=9"@=CE=TR2#US6E(PI($ZAX-:6H1_8$;]E@)^*YD>*`Z%*A M5.D]67#I^BLVVX=>:_Q79/O6'JJ;[L,3V:0=M(27HFAJ:6HQ8'ISH)9NA)HM MYT5A!=\75KT4!4Z4&KJ<3?0D4;DK6EFW9VO>UO*IMKASC?HOE+,2P/-J9;KKC7;B*@:MRNOA"I\BP$ MN\0J?/7MT+J;3FMV7#8/3\#T4+%<+G8[T$IXR3'UW;2M;$WC%.3"9*[PD:'*/T^2^C"T&-<[H*GU.E06MHVL2R&V9'KAQI5),+T"Q M2D9A2F4P\)QZ'=(--Q4+KO):Z9:ZM.Z5^TCZS(+HO@&7XSAV$X.5!&W5;JZ' MY:5#Y*(2_PRJRX\%/.)QV[S`^HZ31:R?]L)Q\B:P;23A^[8+AE[C)3R&I7!R MR4K;'*22EX(GT\0!)1?)GP%C/KBDOH4'<3&2#^&=;4@?V".R>$VW!4"E>\EH ML7!LO)-JK"^*_<4,O1@^75KV)M?0G^'_4:)0)HF/H%-G;^KY;7."<2*-M%B! M^&51+RJ\5X+YDO!,3C)0G#21"?"4C7]!2.9AV.#B"17,=&J-0U+E;?GOC;QF MPOM642DE8^T"WM^4X@%JJ58V0*87=AJ=?Q9$QE+PS!A8$3C%S';P M9'A8;=)\`E]F#+\!1NE'>])S0(_YGFN/Z2L8G.Y/\-81)L7TT@^F[3;UZEP@ M12KC2C[5@%U)\.$W4DM,4DF9#%Z4]U+&G\QD"+2JP-[ M*I`B(J_N5MEE4]@E*C5*B5B'D!EU@(II#J)H--K6J`$/*!4$0S@JJ5`'>6#. M92F^<7LI\-J8=01:E&52Z`E\`G$O!M5&.9FDP"'F2FE\48^NCFK?'Z`2;TC2 M?GH';`0H*?0E8XN]6L&4!4F7A?K`)*'[V(58T<1Z`55E4=/J`U1&0%&F2:HH MU0JI(NJ&5B.+*DD-4KW427LUH(>H.55?"Q"-.("T@WJI(]O>:E#MT::KAT+4 MN(CAEN=)^V")&@%4T%[7Y4W$6DVQS'63/<8V"_(N?9R?B6T^4&Q!S82C5AUN M<&"16W&K'(UXR_)2:D&3!>[N*-F(K#0D*WWKD[?ZQ5(MI(&5I98SQ'862@?. MHL[*RX*+HBF[":>-+NR%6&W+I7"PO:95'S#4H69,@A>K"-E]]EZ"'YI'DX:H M"+MQ]$:8)&XR)LF60C(K2?5O#%9?4TAZ$ZQ*L;[@A+?.Z;5@$HMTR&^\*1E?J&5GWCJ+970$>C@'1BB[H:C6(%I?[F%6.9!CVGH:?8C0J#6*> M6>[8M@*4'HX71+XU!)2U'6_\?6O\R4E(8+DGM=@R!+DO?6E\^7-]R[;OA M\.[3>X9?A%=,_^YVR`VN_[?WGA&R'_JM3]&Y-&%`*M]Z#A<6=80J) M9?#Q0H\I)YV$@?=,^%L0.2$VF@HLQ['\@)F:M@-T!P_#$$B$%@X;SBT&=)R% M3Y(>53](N4CGB1'E2TUFS+&/K:BFN!2'6<37RS!"7$$&&U!]L!WL7-5!*?_$ M,A\LSY_9)K.(_/$<>0B[7)E,$(T">V*;_A,.!_/"(,B`IOMTR5R[#+)A,(U5 M('TB^7N&(^,*Y`VVZP(89Z;M!F$\4@PE"Q--[0 MA6\#42T`'I-H)I@-1O@9C`R"='@#='L\9XN_`NQVS`"WQ?2_,_$-.]`DR]S< M=%AX\]=L?9VK[-'LU^[5;X!K:RU4*7I@Y$L8=`@/TD7#WZPQ[%R,1[S#GIFS M=/<*&W.96RH,0CK3SDW`!U`$:2,&P-CW]Q9,!$/'4=')NNATTQA'Z4[C`C`I M>8%)G3@`$$CDVSC9-7W8>W1A_R<>4`J,0?:B/,C2RX3'TU=@);DEN,PT@B', M,'O:0\*?6("$_,!,86]8_)N;WZPE^&$0>`7-7,H!.%B*4%Q1:'Z'7VT8`!_, MSW6)6X*$GW$:4LO$#I#&Z.[\V[,!G4%H+[`7.R%D^)_/F",O"O,L+(B4AR^9 M5I%;PSG9[U0*Y.@%GL+P:FM"T&EQ(7@I-C'6\<6?%9XG"&"LN.3K!%G>9QY, M)TI)#XF%O$YA8IG'N3V>XQ933``_P=]&I--EX<5_1Y,961#E(1CCKPC,/&Q8 MY\*2F*XU)K`QDI!`-J3(*W(@]M5#2YI(#B)&W!D'P]R#V"+E6&(>71J/&9D. MZ<87S"TKO%Q2`Y5I,'&-L!]$[HWM?B>4@ST#\TS,8*<%D()F3*U6Q2-#)3H:(8V2I MN,,N2'+P8@(L%H-O3BQ$-KP6[R*0'2$6F,LLC@+Z- M\G[R`$H"6(0D'B82=$KSLREG>(&-X[+,&)L%3!WO$?`+Z*4L2E2AEZ6^%"5Z M(B(2AK42!SB!.T#;AO#:$R$/F_9!GC2$G)=MET%L&GST@H6-Q!O_#\5+AVS3EH19`8+.!B?%DV,`R,J`M-U5LM;-D!-_Z*X)7K4FZU<3-!^["GDUY3$[!/;=0/DY] M,YI$#HFGI4@E#751,X%-1$LO,P#X@M[0XQC!TW@.=JAOC\'BB>E@$=?.(+8N MK`28U4%+!HTH-([\"4CV01!$U!G.*+#;2BNC% M3:1N%G#_W%YDPN)OH)>07:A;9Z+!.?/P[91'81V3:$QU&M#L(QKG)IF(_`R/FM1N M18N$VB8,\!+8%6AW^]:##1(*O4.0M_<++)"*WY(GJ4T*LO0KD:L%!F%@CH!_7<[DQ.@+4 MSLRVUB&%Q6*+(2Y@3,Q3+]<;$,>@-)5CM)P]!Y2;>![9`0"X(#`,<4(>+=0+ M0)8>!D@$[W=',]'O>43R.=)(IUX:GU0L3N;8>_7^BPMR!![9G[^P7F^%K^ M!3-"G]3'IQ*ZPQ.Y-G8H9X9DM:#F)L6#N=#/?YDDPZO&/])!WH63XC,/\;PC M+PR]^W1)ZO.O[.OW4YSZ77&+_!4DI[]$<1?K07&]1]]<_'Y!_YU_>+'+;"E] M)RSGST:_\BS\]S=&6(3H?=B3*^;K=7?X\3VC&)>\LN)L.LFH8281NF?OUQP\ MO[17.=,:.;G(T^5W8X`W`.%B"9'`QL"[+NFY6&3.9-TI`%./G$^1N;Y^O![V MN,'G5@?0F]L$K)#`88D$LE!$QW&9][%R\8@RA)NMD/'$2(PS3DKX8*6M#PU M;%QG2K:$CUS?RO_^,Y`N]%\7<%N;73:\/UI9@W9?L+PY^2J81R$5(M:)KQ;L_;Z3+XJ_D M8)Z\IJOJ1B^NT!RO6>TA(%7T$X%4$\1J(=W`4MF`A9O"L")AV*!VCMWNC17; MK"G'1M"O!5F2I%,#6>,K%EO[8>;FZF/I2-E;8`U%.#5J%WG^U$!6E8I!?EO: M6CY2=E;YDV-F33XUB)6SLGX==RO_/%+VUEE1J=CK:A[0XLE!++$"7[%4VX3% M%S_6'_23V6I`9UDPQ(>?Y'*M!@LUF': M;[QW&SZWXZ&F(+*R?)@#KXH!8V5=>X-P*:RJ-^`<^LA4I02B8N)%(\>J43[M M/FECQ?P9CX<&J9%X7'=WG;N>N9Z#@2&Y=%BL]-#!*?)2U9 M&'/F6U8:L0KC8"[<(FG=L$_QK0)/+ M;)?$_V/TJ>(*<"O^$$(YH19L;9-3XV&@'MXY"D+V:!Y6:S;,8,GB26/HDJ M3^$O1AZG.3ET7>Y388@D>P\CE4BH)`F-]#!&ER1*I2'#BZ3^64#C>%?@M8!/ M$H;L8`PF?+?_CP9CDX%6+S.+@S:3UNI^6B,*`S+?46R4DNABI*(,%!(//+(LC/AKU,Z35. MTYDP/PLJB1_]69)HZ&A&E^E$01P@3UH,D9ANS&N<6S%IW'MN.`]H4MS?_[9F M>C(,S;"(0[B!()RG5:N2!$0MKDO5,.1YFU4%]H]X33!&,55O\S4M2;HTY]JM M)^&Z'#==%+MQ*GN^+>TV"?C%Y/V>27(K:BD0Q M[;]L@2H(`*2D<&U!0Q#Y%M0IB#.,&73\E'Z9_'D)6&"[)@Q\#KV_?O?B@Q,XU;+>5YESME/ ML/H2/DHVSTNK.&Q(NR&^%-*>>G1%BS*)Q-:WCUF7#AOURG+ M@H#5M4'`0R*G/B4&1@\E5(G5]WX14@=<`Y"Z54)U]/2R.L#$Y[\9Z/H\O4; ML%++-8JRW@`&SE3X0HX#VE1OC.A>!%@Z-8#/.URY%#GJ,"#J#9.*$%GU$V9@ MD7I(RQG`E4>-'.JY\YK/:Z[EDG^?K"VM9>VDU$OM3+SC-;;*JOK1Y=GL#*LB MG$HZH""QAGITV42[`ZN*%0-[_#;))H++GM1O?;PZ9E7E3S!05Q%/+OU`90WM MY+),5%:7&Q"2?3P6V,!RIMS"?#HZ02:R_.D),I&5E:,S4UXOO0WCY!)!95;C M*_8TWKR-1JH;3QB,HRAA!/]A[DBYYVLWB'R,USHZ"2BS@FZ<'E\(RM%YI:\% M6@=7_.3L5P!::T#*P/&8'9\4.SE[YD")2P>$V#@YB6TT(/7_&)*=LGO5 MFA(Q7SWA]M1QQM\9?V?\'0O^CM\K7A]-L66P_&[V9$U:5E!913S,&7=]$*K& M85R_FB"4)%:1WCJ$NGSV9+>049^/6";]*K#&[J4.?FLN&?\JLJ*TL[!M,F`R M*PH[^^0-!TS?V1%="]C9_VRJ_7K&WQE_9_P=+_[>NO^Y-IH?Q@Q3#[719IX@ M@]MRF-O7^B"4#Q036Q.$HL%*PIO>0X!04<[Q<%N(IP&6'@()]<1\GIO^O3E^ M.C[9I+.R=)B`J9H`!+X5#W.E6)?L55A=?].'8H+*"FH#+DF/V92B`6Q'(9($ MI=%535\MD-[T)81HO&DC2:BZXN[YL*RISO89?V?\G?%WO/@[-M]S?0#OT`M- MISXW<\?T85%BA69[7[L#INN-]IMW!$Q66.5`N7*5`V;P%=NF;\UXJZ^&^^MG M;*;Z/&/PC,$S!JLRXIK1:6$9J*4BYZ\IWDW+@$\L^WW7&T=XNS!\6EA[*^G= MTU7)Z+4%#O[=XN2>+'*ZU)8XA1?X3J;KK@6O;E4+/H='QDL1&;"` MHK0G`:G2/LYW)8"A?`L;;DRPBXCCN3,NM/Q[9F*-0I;V]<`4<8=42O<6EF^2 M)@^.90:T]0,,8&.M1RL(L4.$%X5!"#_C0S@&[;5!IXSPQW@,;`EB8N..-3TA ML$A]KD3]N;+\II7E=?F5E>6-[2O+JX>KL?Z6IZZ^4/(J!W'-R<^+LZ4$_&P% MV2OFZW5W^/$]HQB7O+*"ZSXGO7>PP9#MOE_#:'LU2:NN@(L?IB`*DXF^?KP> M]KC!YU8'$)M#_PV*X2&(8;)*?",=QF?>Q6ON@G0M(6;O5T:-PMY=HGU*B+@A MNNBD4'&=:=P2,NXR_5LYO;SU*`.!M%NK5N3L[TA05X^NUL"ND"H5A\\T!E)- M.&?/;<&P(NV/6#O'OC8.0]-.KC"*))U<]1N-/T?]O8J]I2-E;X$UE).K1ROR M)U>Y4E4J!OEM:6OY2-E9Y4^.F;63J\&HG)7UZ[A;^>>1LK?.BLKIE=<^.8@E M5N`;D!]X3`%4;R=Z]HR_,_X.B;\Z#/F-=VW#YW;MN22R\H'J_E8,&"M7G3YU M$+@45MV]BM=I*L:W%)-XQN`9@X?&X)'&Q;XJDK$8%/G!\R:/MN.TW,FU&YKN MS(9G6T%@A4$7!G2\(/*KB()4!+VK]GFNTV[U.=D0NUQ+YG6NKRIMH=4Q^(YB MU!T%N3XL+_GEU@LM1KMD8K+"7M-73()%$O:8X1%&HJ@DVY@.N+_0PBKB/`>1 M>V.[WS/XC*M@73]]:](R7<.1[*LB[,[F-B62%:Q6/S501:ZVZ#_-YJG MF7(`693^S=1/!S[VH`W'GEF8W#CZ3^R$#I'@BQ)8\NI2I,-9S2_(?^B$0($_ M1=$,IQFCCG?W4NK8D3-%M_79TUT^EQ9Z>%)=CJQ07D?NC^_!.1-N_8V^C:)HL')FNVDM-T;F- M!)Y42I3J1W#38TO/PYY,QDX)B7V*5KL8>X<4A#]-OK;D?1.E1X(\%V6#/L[O<197X5W7'CLSBXM97&TP M0%I',+.X3F9QE?9QTD* M6F\JUPRV=`S[^^L8'(MMR7&OSINZZ=S^M*J'(7JXJSU M*CBSZ./Y9=&570FWT\AJ4JX'X^!Q-7(ULF5N9AA%-)[AD2OD=P]AH-B;X(`F MS^P'V>#UY7D.)T06O8\[3:@A=VGOMG6QQ\!2*-Z$\@@_+(B'#]U;(7HG:_0H MSCM915,_0"`W,TIY-`LP1G/?BV;D1G(,+)F\=#,X:80<\>%0@$/@6N3\PNXC MES2NB^EYEW>Z0+LA/83.0]K^&UK_[5];[9^0O<;V"9-7#IZ][;38]DFS=3&' M92O'/U;65X3NH&NJ_*!C*KS2'RB\H?04?B#+NMA1H=6N<>IC98>=,")_T&-A MAQXUJO?U].P<4O;O2^NZ]OE-+"N.9<6U(4FL=00WW4%2H:RXJI[.:0^ES+-2 M7;\`XV!>#E;1L[)%5/+_I^WC%VS<'6,XT=[7>$$\&-Y=D7>M]'N*-%`4`^QA MJ[)C6+C\,M61'GGMI6AXUD>V0_1-V_JPW9( M_3^W&TZL'711Z?M6_J9NNGU(AL"M/',K:>'6!?*@I3#Y M.40DSVV"IXZ')Z2:G>W/%[Y'?R''XSQ$H=@B<$*,K%L_CM#]S+%GM(6%!;E3Q MFP!\"4E3<^LG#F#XP>HK'KY*Z+@+_'C!0<_T-UK8;^;?DRMC+!<6!!E?@,.D M`BAUG<&3Q!L9ALG[T!L=LV?C"W05!\^.(NTRZ9#00CD54E*`4T]>@).TA1^P M'1,?'3PW=6R8-S(.'T@.T)P:B(371`Z?:B/$G@.4PPBM.TRF+!EF=.\#861J MMVL?[DYM4O649C,.+=MQGWD\XZ.?-A?M-NZ_+0+3#AD M@?T7KX1U4T;(5(,P;X?^D?2_]QXJ$FWZP]R=`,_.2E#F6R''=J59[$!7C(1)=[#-:4 M;55!7*HGC%[*?!?]&NT-*>8V-F8SZ2AJB*/OB.HZ5O(T33P)\C_`!ZUK-< M9*<'Q$]_)CQK@0R%4^7:'9/-6I.:4^3:7?N0=6);4W];DCE1*KBL>M,ASM73 M[MG3PY28-JFQ`3I].G"@.B#_-#X@-"O9H M],BAA6MY$45Q^)_8691SEVW>S;UVCIC<-HM>NP,+>4ENG9J3Q0I<@E%G`$>Z MV8XJC@X__DX9Q&**;,SM'7.S,%"38HJ2R16^.U2&6%'E#".S,[IFQ$IF6Z95 M43E5J(7?O;H(IRE!19F3]=JM\-PV7/TT>.ZHHLA)6N;H<>WBBK)4<)RE60BM M67%%76J?QT)IGP<^^RW8M269D\2"Y[GIN(V%%NLD[RRTV!JJ66B1A19WED'! M+HKJD:RVSQ276Q=-U>5:F*;5A7"DF^W@XEN.+"8@BH47V9C;.^9FX:`FA1=% MA5.TVMEY&8DU.;GHLVW5H;5V."?[B46#Y;^SX"+59IQDM.Z\BR2U,K@H9?;3 MU2VX6+0J;Q8Z:U9H4=9;YY@5VY?P+A5]*KEZ).M%6QU-QVQU#2P:>;;NNDJ[ M*'*JV#ID*AJ<;K1.LVD&ITH%QU6:!=F:'EBL7\FAW"0+K0LLBDKK9ED1V$UA MI1U;9'%%-N:VC[E9,*A)<47)Y-3LU\K5+`0E:IRHU>YBBJS$UB_"DOW8HBFP MBQE89)'H,TX4:Y9S_$]2*ES8)ES0HHZEKK ML@7DHA.@JT>RTKXT=Y%36:(["RFV1]Y92+$U5+.0(@LI[KC7:N=;RTVR4;MC M"KF57?V2^/.;)R<]DOV!U@E_2C6]N2:]L5&3?KO_$Q6@W]2PV\ILXOPB'S]_ MB$/^SK(6'],Z\==X02Q9[Z[OA+;KAZ`L;_!#U'5]^^=7>!E]GF#GX\"+G.AQ MZ+@XZ%D1OO.#1V3[7@1/7N/IES/LN^,?`U'DZ3^B(@K\?P1!T,>CF_Y8-)0Q MN6-5E&1Q+)PA9_+ES)F,`;GHHF&,!6&HJGU!Y3L=1>45N:/QG7Y?YC73Z`F" M:0P'ICH6Q\K9U]'<!JFCHD?2\\ M&A'#@='3E%Z7'TJ&P"MJK\_#R#O\H"-(NBGKNM:1Q^3%KV0VTLDH6!Y`'+<$ M@D:'O_L11M+%4CY)$/D3ZL:AX^$P1&O.4*%Y.IY'2L/9S(XM//;(= MG)$6?H=^1[%WZ7@_45*N'(T>PPC/0PY]\^P+#D6SP(_O9BB,;T-GXEB!@^$W M_QY$[S8E#8?0ROW,L6?("C`!*;^<"0Y"Y$_1;%4#'84X^.78,$;'0S:@&`O^ M.[>"GV"MP5?01#3#Z&_/B?`$C2*0__!B.;;U7)N?UOTBAXC_?.&'\`;T!>]# M*S`TZ'OF+.A7]_[Z\3!1&.''S&RG;'Q.8SVO+ZE^S@@7T[*_O:O+R\Z/$;P$ M9K=K+4)\!DQT28%?&_3(ES,A^;RP)I/EYWMG$LV^G(F"\![L=3^`.2'?;P'D M[0TJ?4-]_Y9MD.#BY9O2^]5VZ.)IM-F,)$C2X0V);Q_";K\W($Y_KL5O7<@; MI3L'R`\TM2U!Y$B\OURIEDL$VDH%YC@[<"L%RLPL4'*E!(I(!\C+/`8M]8AF M?KAP(A"23=T(;8%>(WHGI#H,^@>E:J&(5-DF,B8:,G)!#WI$YF[Q)#PFOF/2 M55_I`I'QXB`DJ'#FSY^2'$V#MK9DAT/8@FT7?DSV7]@1`?=:9`NU)O]KD7+O M\#[LUP'==0$>DRT2=N@'9TY$..W"]H,`APO?(Y.Q`@3[DOZ)>!R8N#)QC3YU M-J'=--E;'U=22/;5&&3*B]Q':,=-?;*M%Q-NR.\"3(&.RD01R`8*76*P-P3+3@ ML6]>&#E1G"J=E80M18I)"9,2>&R]D^U+"$/73$J2?ONPOQ"^+T'R*LA;'"9^ MLW->.L"GO.D903/KU^8V2MR]^S9$XD)9^VP=S\9($@21!KO).^'^"MIYO+,( M'!=:@=>,"_0*?ES;*6`\)["1#HZZO:&1'CP/&,#"[K87NF>%LWMKW6#B,(<7 MSM?/]3X]]7;_T^^`+]:\>21`8\FQD1TXBRB\?N"@JBMR/A.V'A7;" M1C@BH_V1..8GW<>_`2I_\U9I[1T[!)876C9EUQ.APZ,%UGI=P^QU>S(O#K4AKW2' M!E#9EWA!%B5!U25MV.]5(K!&_G"6?ZQ#;>)NK"UE(J)ON M+L!WP'_2W#LST8KO1-6$-HAGQ84?W76H#9H%0D*\'@SU3D,'T=[MO[_]ZX7R MHK0?,O\<(IY"3!88=A_W!@N-/#]"%_JN,Z$2?VNY%ME?PADF04LK>F40\/Z_8P]O M_"BD/\)6\TX4Y73V1'6;JQSAEC7W8R\B#%U8CQ0,[$_F10EK:U=WO+(WO4'E M;NOJCNOZ]X3=0S_H^_%M-(W=CFU3IEP#VYU?A"D_<.#XH/IMXN/!?9S\]Z3; M6*^K].2^.N"-#FAYQ>@.^*ZL=/B>T)'Z`U/MB,/A6%0%01YK9U\U61:W]K(\ M=&YS#'[UY_C2#\-AX,][P`+'BV$W7,,":*7ON#',QVB6^C2.QZ8Q=#,.2;OA M)L>D/89IIMR3!%F'+5\3>$4T".L&&B^HIM;I#575-+6Q/);TLZ_"A6"N6?5F M`K?Y,[)G>!*[`)1`^!9^:+E_`,A;A(E22#.(DD;Q9-UFTBO-2""`L9LH@1'1 M`1UOT@&;)3'YUQ(='A]%&!VYVU=EDU"QS\[_=$DR1:!6`# MQS\A_A[?_G0BGC"6#Z/`_XEY:GK102UUTS4.8S=*\F939Q[1^.ND%=@#UIO! M9&/JX65_G6"5I+2`VO6B];XQ]="F]@X='(/M2/86X$5$A0%@=O\VKH2Y_"2YZ$95KIVI_QW"O'^IYU?=*N M#SC=8+QE,3UST"%S)O3.&V_+HH9E#`L)OM!V5\JNX4;S<-:M_T6M@O7G`3$/ M=H#QT9.^"R1U12>Y1BDA#IHJ@*I&B5,Z]G1W6&ZWZTT2B;`Y4E/N+.M\/&GL M54K0FL$$)I>[4R*]."7$;&B>&+Y*L]Q"FMD\GT*[O,TD*?@L_"$&W:$7LUVG M%[/MVZN%'ZDKZSDV9C;F`M9\.2MXOL+S_W`20[X=2:X?OJM?5^4W0BFEVJ5[ZK#U,M'
V7'P/J8OO";Z_58\5W>?;18-QD7&1<;&^ M7"S?:CYX9@]\+K/G22FZP'Q)=&DEE6DKEBZ-,\4FTJ5SDE(P@&X@RI)!/T[\ M^-;%)U3*V3NM[-[&^%@V28R/#>9C4UQVKUS+;06>X]V%:1DH=(NG?H#)<0)_ MCE%D/61.L&#/L>=.\ESY9E%12_<$*1+%`N1S13FU:4]$W7GF#*$"D4->HIJ]J9R+FXJK8C.L^S^T88'JSQ M[L&XR+C(N-@D+C;%]_&EDN+A;FL>?8<[F>:ZZ!5IU4J/S6BEFU MZ-DKAE^&%O;))J\F39*KWS)OM?6U4=FLES'KS"BL-H1D7&1<9%QL$A>94;-9;.>L,;E9[P2]H8'QD? M&1^;Q\=MS?LALJ"/S2\FSB_R\?.'..3O+&OQ<63/\"1V\=6T[X2`KRSWC\"/ M%^$WSW9C4L&^OP&X(>HZ_KVSZ\P&/1Y?P`C?$?:NL8+/X#^[KYY4S^8T_ZZC^F/JT80 M&11\N,;3+V?8=\<_!J+(TW]$113X_PB"H(]'-_VQ:"AC$M4"("*.A3/D3+Z< M.9.Q*NJZ:!AC;:CW)%%0>5T2!KPB]%3>["D=WNCJPZ$N2T/5A#;@Q:^$@2G_ M=N7G1\C>,D&^JU%B,^0C5U2)M>&B?ER)B2?%]9DLOQ\[TRBV9GT'>7Y5X[U/>OZI%UGJKN^(\T' M`/N308%7:DQO+OL_L>5&,]L*\,X:/[IG_40$C1;8=H"FQX;0T_,#@`:PS=6% MGMP]-V]Y/ETN_G\$^L\1:L4/89]T`7RF-PM414B*)OO'S`)@9E=KI1=--`&1 M5P`<@U91?>,O3VH=C>)LP8!=M5)L_L=S!M,A88`M9!]3)E(K)+$^4K/C>4.& MLBA^!?P7[<\H[3DV9C;F(VF(JNB#[SA:.C[2\""]Q-NS7&3'(7`!!QDC@SDF M,6,01U0X5:Y=^=V,Q!JD5))YD2IX'N?FPYQKI[VW9X> MIN1,,90XU2SG"O`2B2ZI*&>)%)]KZDD3*4J5:$&J9&6#JJ*S/EX$Q'&9A)G` MQK?F)"#X?_2+VBDT66O=XA;US#G]=259R9SD5E>*U:(WK:8CMDX8XNCT9F9N M?29S1OND790X3SJW93*"Z8-N[68AM0`Y23IR(I'G11!^P M0<$>C1XYM'`M+TH*O_P3.PN21E0[E:?4SA&3VV;1,R>&UY7DUJDY62S8:]QT M`$>ZV8XJCE89C2RFR,;,QLQBBO6,*4HF5_CN4!EB194SC,S.Z)H1*YEMF59% MY52A%G[WZB*QT&*=Y)V%%EM#-0LMLM#BSC(HV$51 M/9+5]IGB\?<+!S4I/"BJ'"* M5CL[+R.Q)B<7?;:M.K36#N=D/[%HL/QW%ERDVHR3C-:==Y&D5@87I6+*7U2/ M6*EH5=XL=-:LT**WV+Z$=ZGH4\G5(UDOVNIH.F:K:V#1R+-UUU7: M19%3Q=8A4]'@=*-UFDTS.%4J.*[2+,C6],"BUCI`(PJM"RR*2NMF61'836&E M'5MD<44VYK:/N5DPJ$EQ1@S3A1KESJ0VZ216^>H.Y14ENC.0HKMD7<64FP-U2RDR$**.^ZUVOG6X4GLXJO_9^])F]O&E?R^5?D/*&^RY52)'E(4=2235,DZ MQIEU8C_+KZ;VDPH2(0DO-*DAR-B>7[_=("F2DBQ+U"TS<\0F@4;?:!"-QB"\ MVOV.C7%]:0^_Q5>\7SZ'+^_9DW=I.?V?7P$@^=UD_%/3Z?OXZI:YW#%;MMG$ MV^?[CNU!VSLV^'+&'*M[V](T1?[12IJJ_$M5U4JW<]_L:M52%ZN@:D5=ZZIG MA)M?SKC9A=BBHE6KW5:UK-=:EYH"?]>54JM45*KZI:X8JJ8V&@V]WFX`C&[Q M["L"4;2BHFN___8B7@':$>U-+L:.H-8?KN./Q3>[;_EXE3H\1O2Y[3,S_(#H MV`*?6HX`CSYAPL:H+&NE:JU5OU0:M;JAE.I&6[EL:&6E7B^UU$NU46DTREWL M^!6%&,KP5969NO!^=H;['PKD?YZ:YX*',]KES6P:_W!`SOI%I&ZX)_R9)'E' M8N9)W9N_1;P+_,O8-359A[>GXZK#LH@S(-Z(D9XON,U@%2*("73X\)-)N"W? MV4AMCUG.(Z$N(ZZT$GA-!<`PDU0[$ZKE+(^=X:7);(0&/\D[7RGV'7";VG@O M-X`0'CQ"?0WB!0I8C4%Q(7*0^BO(B/Y"!)A-J/D?7V!_SP$\!A;K>S`*1T3& M$&\`##G\Q0JLWHQWV84HU06BO&/"MQ(,G!4KES8>2#4I-.B<%!L(..1DK``# MQP+AXU:"=-J?LE-?Q`=3-"W!73GL/-P'*K^^/W/1&7\YJQ0_3]Q*3GN.:S,56J3`^/8V&_2O: MAZ5WWJ,^^LM=-O4\'WJG0V>ZP'Z!9K^P^,L<':X3B\8W>)?GW>"=G$9E,8<8 M^G>9?17_WL(TK*GI<^.!\!9)G=")J64!<;@^WCQ5)Z5.\V^.=X>]<[4`_WQ< MZO+XQ?*8F]EW4(IV&DS(]7):),6%(IE,6M7+^C%H]LVR4RK]F:NRRD7*L=7I'@-6@^R/,(QQ"V+O5I3GJG9GU=; M=X.T=G0VL'8NHW9T1VO6WOA_>^F;AG9T#N\0W=MW]N"XG,JMM[K)CL^_O;WT M]#>7S6B\N42N\\Q!^MKG;!)Y`WM=E4^[P_`KG]Q^3WWB>PH_\Y4--.D:Y* MH5@Z@)NECRS*TL$_FH[?L]@.G7+V00]V;LOYN&^2,!]/Y9/=*T<5J6MS M>RC"TCBDQP:.RS!3WGE@Q*-/F1,L\G9YNYVTV_^R:%NFNX,4B>T&R.>E4N8O MZEG*&6V9&N.DJ*G6,A=P.$!JM()6V@X]IQ((["`U8?5@-).PC3U=EKPC\DK: M07_<6EMZ>[I5:%?2VW:%F+<:[VPFNV!72KZ?>IT[HNX\J*MM9-9_@UMA)I2OD7,RYF'/QE+AXNBO/93?)KE_:)#OH&%#;]D4B^U[: M9,\&.^2X23<.<;MA_7`P^[>1/!X\XMDCYV+.Q9R+I\3%4_GVMSCZPYB/.#;I M4(MM-\S+V^7MUFIWN@NTPTF%6G^UDKVP_I;"^E<6?AD@S)*-70.06/HM\U1[ MO&O47.K[D'J^*#SL$#+G8L[%G(NGQ,5\49@''GG@D4O]34H]#SW+*N9AS M,>?B*7'QK7[R_#9)/B$,KYL5C)SWF,T&W/MXV`%I]N,_AYS58!SB8+'(NYES,N7A*7'Q#7QL'KO/PTEW#6XWX,I=DV,Z) MPWT1D[EP]`%2HV>OQWB`U!CJ=CYVGF`X=V)%VG(^YGS,^7AZ?$Q[WM\\"F/, M0RR,H:+K.N,(;*V03-*I%;%O*B0K?4ARIQ>Y=HX_S$M!Y!/GWYNK!G@AZ&=R M8Y-Y%Q%?P#"XBU4@WHB1AO,PIO9SW+'V61#A]P0W.76?"^2*4Y]SRA M!B"]"U`G0\X0]JH>"DJQO%A3`+O M3/Q":N)/<#KSPD@QQU3$(9WH"\8!0F#CJ@B$5^`<(]R&[K1?M_Q M$5=@!>._T#IDZSYSL05Q8'3)92G@`IY4M'R3VT.)EHR0[\SD?>H&?8-? MN(F-@0_\%P,`8_H<,"4E_M;5':!DFR*M`4CV`Z-X5'+@6\07#!G)+-;W7`?T M`>"-I)8BVHYK$H_U1[9C.4/07\FE&2VU..UQBWN<2:$`]@@DU,I04DB2H,"! MON4(I!&E>T'J7O2@$/-OC`0&4!S?P\$D5WK4`DU@D27<->NPY*(V_OZ^5*B4 M#`!'+)GR`4^TF@;]`[U$-<)UV02)$*%PQ$@`CR/>'X5B`%+>%_4*@!3H1 M*\EET`T;V/,<@D;$)K#C1N$`@"-`L`#+BQEONW?W&%(?\3&Y)]_Q[6MN_YS( M!.6>\%W7UXUI9W,%SU**%GA$DX,6`<]`?P.N7-U\EQ)'%P!PR7NCH*JJ7#V# M*.M#L$7)P,#X`]WY3MW^*#8^K2R-KTC.<819CP?`9FE"U7_DH-44],C^>4'N M8_E/-.F1BDC].((!`[$0S05N!GQ5WWQQ5"@20M<.-VAQ@5`+$8%&\$,"3(!#)GP(@^0G%FG MT"_,T]&@S;26.J0#7@9\'@`.=)PTY+W@.$S'+,$?OB>/K'[D$`4"#L;Y^/T>P"#S_"/?2,6`BI)N$@5++HC`PE)@,?(J4:5%DERO3"W;IAPY..\_?>LY;E0,_7:HQY'?1L:@ MHTTO6_Y@CCODM(#9#1<)[R<=TLJ.?A(PSET\O4QM8%GAVX9CPP*9";0O!!6X MC/.^8Z&-@,7!N$E+BSJFS2QT8$EW#;X(&GK2L]_S@3=Q/2$3T@:,+68L=W8= M52WH!JRC9I'(K6A75B1+!7:2I0);<:E`TF%#9,T*GP?"@#DQD<"P)AO(G\., M'WP)$4.PB+`PW)3KC;[S"Z*:>4Y:>F&4#`.K M@\H#ZO$/SEVNQ_L<;-6+*`LX*,/ZN#]8DPT22S07&##<@F+B!!WF0Z4=55I( MR8\5F$(5CH;+0G>23\5QKAZ@F3-)=+`."[Y&`+<2QA'H.1?X(2'DU@+57W'Q MCQ$:>C_'EC8%(X_3A,X?"V`L.=IDK`*2-X[<&JQ:&<890G[1L"SG,;P*9%IO M5S+*OZZ^W;>4SFV]`69I.^X#M4+CNK^K_^BT;^Z^XW.;0=.;NZ9L^>W'']C[ MZ3-IW%S?W"6_009&_8GTI&*":X60!0UV>?.66%VW[N];=_%@$6*7]<;__G%W M\^\?324Q=-$P"N%_'Z<\@\12>62]G]Q3/`AE%`&!U$^F/'+3&\GW+[N.Q5/K M#)_E5]$-;$2'7W>!P.OZ;0<`X.1&QX*M()B=,A!B9LL28]H'C_KE3`U^'U/3 MC'Z7;;^+G+II[G M0^]TZ"5V@:L;R##)G-^XS@X3FCH8$CPH3UO*M)>ZQ\DEAOY=SBWQ[RV<9*:< MU<93.5?OL0*!'?ZT4_).2J_2&X71C)_*`//"#+`51321S]P`Y@`T[C1(S[5Q M6B3%A2+!P/E4E.]52O4#H'0!]O/6'LMP9,ZH*^=0Y@)=SGDWG:IJ=D9?Y:,]1D*=G3D,^#O*V?#?8VS@OT'H:!U\M M7>;YKDTFF2@[]U$K3NJSN=T[/5:9D[=A\K([XR.A;SO'*-YJ/%5_<%R/_Q,D ML>!&A\L=-TH4@?!V#T'6NBJ2_=C0;N?K=>GS5'T;=):WK++;J MI`[6;DH/<][EO,MYEQ^&WUR0^(-YTQDPV:)">#/`Q,.Y.QV+)PWLM\KLD_5K MR-ZN)%Z>,3MD1_9+7T^2'>6]W3%^D.S(?LWLFXU83^S4\(YCAYQ[.?=R[FTA MGQJ.<)WV3V0>6DY_9]?`3+Y/8(6%#W%:EAMUWF8#P26!S>#>_ITR]Q+*GB_ M,\+3Z_.\TN#-85"%><$9/U.0A6R*P+;D)#LVMHE8I6K7;+-;U1 M5/6*4FJ55:6D55M*M=XJ*ZI1*]<;;<.HU219UVVP'AW;LX=WD3.*$\]E9-L6$8E5M:^U61:E> MUC5@0EL%)E1:B@K/FW75,`R]T<6.7U&%0@U:QO`7+S>G#'6M,ST=_^$!#^%R M>X!6++WH&"&>Z^>(A@Z6S]2GG-;/WR MZMGZ"[ILZOG>ALZ4T3DEUR56,WO(59^;WI8T@$-(%=X6;3,GSC=+U]%KS?P$ MRO]6Y9_C3/P]-8*S?:>>5K+MIC2\%#XLE<8P)RPXMYD\XB[#<=KW?"R'@!$" M%AX2&4OV[R%YM%K0:YF37C:T!;Z[3-E"Q3B`??#7;>%0-/^:"1&KM8R1\8.! MA[5%HF!YYZJ^?I)>H9C]X_)ZB6R[)[9MOGWO/"&C. M-LSF-@.*NJJUBA6EK6L-I52%_]7+K9)2++6KC4I#UUM:>>>;`=6%W]"C)\@: M4KI(%<,C,Z9K8G$;*$:+Z"'#W@6% M"2.6R06O,PXKY@GARP)GB2)K"#2H[>JXLP4*+TA$T0J[L#$][](E%I/T%+6` M'NRT2WJP=MF`SU1=&\X&M`:^+JFJ$YHIU M)\,ZJK>X/V[Z;ER"-9-,4MS&(G4)/-6@F2:Q?1U+#:N.-T-F$VFUY";@10+9 MN:B^6ZJ\XA2R>[#Z:4\\&33X]X79<-E)+)C[3,8_U;'X();I:UMTN+&YK54M MZ[76I:;`WW6EU"H5E:I^J2N&JJF-1D.OMQL`HZN=?1U02[#??YM!)<:P$53^ M;LLZB__'J-NRS2;UUDADF$)65=N&T50-I5XO&4I)KY>5>K.I*^5:M:&JM6J[ M53,`6?WLJZ*H9457`W1?PBO&O.GT_8=4DS8\$;OF,B`.0(P`ZQ=P2@=#?S%< M6#&S_HNY=,A^^&@N-X,FMS!W1D[TXB9Q:<#Z*26S*22*GC6'1"^??:V5*E48 M-3:-%4E*\Z-%72P++6Z9*UO*')/#3J31BV=?U0NU''-@+A&+DHH:09X-](D3 M;8XIE:@L.5![*9/H5?+F\>:>/FUS3:"5F^5B!58"E7H++%HO:4JM6:XK96A? MK-?T-])I58CY^_+)9T,&$RR MU$JU"./D\KOP$IWDR^!6(!Z#C>H5(]ABK0)@]6(U"1:@I`#KVCRHP6T:6)$> M[U])K@+>K5OU]B*4'@9]4WRH50U`&*:=!7PH%F-\8UH6\J&&4"LI+DS>!S'L M>ZV2X$)TR_M\+AQMZ+=41E[=6T!-ZJ8L,J*8[UK0:JJ\T2"QL)`[\8'W@VE< M7NO3IZ[[K``/'ZEK!O6<(W$DI#;VW;$C&&;WT5^46W)C']OBM0E8%=OWP$&2 M9X@OY!4B_\$[/,)\6XL_<"\L%SU9)XU=YQ<7T3-93_8+V;[2(K)2`>E M,KD4"\FM%O%VHX6"Q=K-09%W.00J"`WJ90-X7(M)3)".R5XM'5)N"R^X6X<- MF.N&M;%EY1@BD`P:O$8&3MX`$%3$][A7;ER0X#N"/X9527!#ARQWGO@R(F0W M(625;`F2R]KBTG)=9-1/+&4/;VQB.V$30!XK0P15(;`J^"R&T/\5%:3ABCTFSDK73TSH%6@0RYV(D^3GA8WK'.UPN)A"6 MWFG"R:`V>\RMW#Y?C0KL4710CJNN';LX3US'YJLYVT^ MH&CI>J-9JAE*2Z^WE))1:2N7S9*JM&K-AEXJ-=1JI7W(`45U*IY`;BG(+H+\ M.J:(0F+N(>8F8)Z^50BM(DB2!O/\M`D*EDN.3N\'Y)G0>2;TP>>TYIG0>2;T M6T@,?G,$GWKBT+U+^RR^,W-F:_LP\WZKA9*Z[RJRNZ.U7-QR/O=II3AWKFYO M]Z?1ZZ;W%@M1\>\C4NT-$+WMLLFG[L@;U'W@_1%E%I&Y1D>G^%JA:NR[1.4I M$GU:SOT&+^$]/MVN'%6T\@H>&2#,L@2[)C+3MX3J&TJPE++,4QQJ'-BSK]CC"DV[3BRGT\UMEV\=E^$U;9] M7\:I^<13.EZ9>8$UJ0QU@LD+",:8%\9V8#T^\[CN^-"N3ZND'.L1HC M1PY%L`# M:#)55/@]P4V.M1_#C*4P%;`@"92X,-<.!X.7[MAQH^NKH/^5XPO/L0N85'R1 MQJ!SU;B:'AXKL@;'Z4)$E"40P4P[S*@"^LG[6J%6,BR M(-?0Q!Q88!1"2;/<"#B>1G(B5%QAH-R2"$L6^&-,I821@V-L\X0=#P]0,B$P M!74N,H\:+I'_G1\3.3^B)18OB#:A?&A0!P7H";! MEC^0\_*%^H'016GM'R5U[Z:3*;#0K,PL]#!-71[S[3V3*=W%=&N@RI*9RUY4 MXQFHYF/I#B1'1909#HYOZ%-Y]#1U]O3?%YW_9^])>QLWEOP>8/Z#8$R`"4!. M>!^39`"=66^2L9_MA[??#%IJVD/'9^_59U-T]1LDU9HB@SP""6U&QV M55?7W56?88$XBCY%$02'VITN/WZ75P.`5I_X, M#@_PKO,PN`V=!5Z$[=_?A\$C37R&]WZT!%V2$MY6@A0&3F%%$;LVNXSH+628 M`C?_J9@;GN.,12Q$Q,=>@C0--8,,DVHY-\E]"_]@LMQ5OV%(9F[ M71$]+_BVD"P%NSN#[_ZP*YS.)1>'@+O@5X&`-JDU1C9Q@+^<^(8SEZ!+WA`QI5LP>D- M@C"D^R!W,(^M]LJ0?<\_1F<:@:KJ899Q6B[S(58MTZ!4' M6.4L*=)>+0-71'NE3/UIE?=\J_]#[=%.?A M-)B;!Q;UEQ-.[U;F@,5]-'4)YIBNSI',@.R*K64EW3.9PU!@'4C-GV9%G@V< M;PY3P!#@+44N6DD[Y/$>E*^HA$.%O>AS[S1&7LDOD""^0._Q?=SQD/CD.QXI M?GW&C8"P\BS)0SR$+[BV$V?E`?R@P(-N$E*+&*?B&[8>G'8=YI1?XB40O(D$ MQECH@LY%=04F1N`G.*UX70IK7;A),X'>G!6\H1L!<[M3=LT*'\E=NV(JNP., ME)9P?T!BP&]\98$`=ONG`-G),M2(4; M!]1$?MLG1)&+]1V6(=--<_H\%658=0.>X4HL-2$H?^(.?=:]&RDN^<9SG1L4 M1BX!P%"JH9&0-LIE][T%6/$C+&QZYX2W^:\1[/F2'DTJ$&'>\>#T:M1'O*(> ML\I^BKL$AV'.`'&1'"G/@DF8,*)[PR!RZ:6H5%A5(%!@T]#[5[TI02Y*$4(O MKP$FD)'BU+/0^8X89C(OX>-EF49%WR?*7QGB/TKT=AH^[6]6LRA25G@,3,1T ML!8<5`_7##YF)2G.I*2U1GCDKVJR*((/J1TT"NG^)B4A5JFQU9],X@.7V^(:! MH8BT4#2I\W!76(=H$W#[$$8F]F'V"@_I#RV&-6H79?K9\,WF/TAXS_W;>5IC M_%,5@`XHK)3:KLDO%2;L-]!U[WJ_DR"\=1&>O_A*AQ3'Q;<4QI9\#5XPY==A MW=S=TG3)_*$VD#WPZMR6Y$F@9&PJ;VALKKXQ4(Y>RJ.7FN3"IDYFM.L M473SPTA-5+I-KS12"R8J3/!:([5W1AE9$0ZC]LB0J:K+1:'AEG\`V MSQWL$B-QIDP]6,MX-A[25-BAI*.V:X2]JZA18DUR9X@8E-R5%R=(#++UZA%J4JL*$BM3AHK. MJH:THNULQD=J;@D,YZ5Q"Z"@'N(6(>+>%G:!'78W512YF4!\>@^6.+!U>/6?ZF.D+,?=QMX.&IZE*99\X"!1D'47_I@?[2!X;HY/&::0E,@>4,.N'8 MUH\)];&@`PT1L)IWN34[S)>6'JL>/=F1RRK6+<$*1@472]>15?4E-\\Y'PJS M(!I*&L(J\+*2Q$O0!9*4%,OD2L74=&)6="^OG3&&ROA)@L8[JHOAEXS6ZA'V@=&%+>L72_"O*W5/)T=Q%!JQ@1?*9& M=&6%E6(1EK/PUO'=?ZB].@Q\FMA%/_3]V3D@&TB%?CR;3Q+%[!(U=DI#NRP( MIP^,D61(AF@:8T/45$,6^Q-+%G5;TC5)[IO&9/QL_9:%`[JQ+\;!_1>9WM/G M7[#=75-K]^(OV8ZVU7U&%9,HH%<_GTG>6,S>FA9]Q9E8".J$$ M^)!N/"I5Z=[S\/TSOK1"73;Z#1S'#[P^&X9&W&#VBC)MFA<2C8##-,X]@1`,OQ47=T"0FE2N@V(G( M&NJ'IU/ZSU-_=$=U&%HFS)DQ7[?_]]*G88=,#'+0Z1IR2*_$1!'%I.1^17)] MBF!L5.E+9&/SVRX4%)SO!9U&*&G"P3)<_RC\&*W_=5GXK9<&_PK:53D8CV>G MSW22"X*1>Q36$]A8/+-_I%R#&<0P&9K$G$M4TRM&.3RL'YX@'HXJ4Y$N\0P5 MV8IB\-[5@$ANT8"JPORU64FVK#3\9JZ8HPKN#Z"&?LI6LS`58PC.[.]E%//Q MO!@64ZP\JHNP'N%8?6X9\LKCA4=\8)-1Q()&R`-1QM#ZZK1@7I[&[P-N=#)= M'(8N/:;X!6G=UTQSY[P8D\^H5YAQC>PAU*A6'RLP]BJVOC'623&%9ST!BI;M M8RM`Y37EU,DR**M8.$]X\+"NYC3.E;W$JNTAR;M1D!R!\'#IZ*1/F19;X4MZ ME[^U?I35R![#:N,G=-D#NS\%5#W^09[V7=H;:R7C?[9AVBJKDUVYKJU:L.=+ M31]VY615VK8)>Q[6!]3L4`<,9R+Z.:EW`CM_,"ESS]K$\?R)9P')_])CSOHT M&\+ST-^?SW_)%AK1@!,J[],T=N:&:\45#4LXT1U&X;[#VOH%FZ8X M/R]-D5LIT,J#0SV&KH]\*V0TEMDPF#;'ROBNP_2''];30[[4+I"&ET1/<0-G M+`L(WR(P@N'`L$R_BN[+5'>8X26<'?^Y+K9(@_DU M\H34V7)*\T=916E<=-KYANYCGHI3RBT7I\;H*&P(+HP^S8YKB,>`0GR7._G< M9Y6?VH8O,E1PB].:X[ERT(Q)?/@AT\R84YP?GIHUC%^9 M)']3D1^_7R[_7&H\777KR\>N+9)J;"R2>D59T5^4 M!<%D8V1"I:/^YC48]@'7)3#674+5>GK9OOKNY@TX_%+61X"!C@J[HM!NAW?.10Z\1-SF8ENY6Q'\3BCZY2[)+1K)7U;,F9W7#VUJ7+?F;LVMJZ.W MN?ICXJ#=^R&N66/)$`RK5=5_MX)5EVL7#&P9K+(JV$;K*O77!]90N@K];\"X MW-G^M8_7N5M6-A_V7GIWE?E50=]UVY7#`]H0;+-V9=3V`FUI78.=5S"R2^+- MQ7OGJ76,3!&D]\?(%$'36Z>F;,^];5MZ;T!K@KGKKFA'KZ/1#.-9+U=Z,L$( M_F/M9WJGF$^#F2>MXX":(%O-%#)N%FB]=5;IMD!;8(J_._T5@#:[=EJOX'?M M;*>EO3M]IJ%F,@U";+\[CFUWA?C39\L<\+B;:W3XZ_#7X:^]^&N_5;PYF^*5 M^?#U],D]25G9$'2E&1_W_B`T[&9,OSU!J*J"KAX[A);66;*OX%'G+>9)GV3! MMFKO]B$W6E0$1=U-J\6&`=,$1:YMDQ\X8%9M0[1KCME*_;7#7X>_#G_MQ=^Q MVY\;L_EASCBU4`]:S9,U,%L.NHWL&T"H-903NR<(%5M0Y:/>0X!0U[M\N%>P MI\M[@E4XXJ?>^9T3+ISI4_MXDR5H:C,)4WL"$,ZMTDQ(<5^\5Q'U9403YLZZL^8)9UT'9S3<`T7=`;NBNW<\!L M:<>ZZ;$I;RKP8LRH\,B^N'_]-QZF^.PPV&&PP^"NE+B?:3GBJE7MLV'J%:^T MG5;^YEV1-H0':,U_UJ@DK2V.77,#[.\QC;$%3ZZ]#*O:7TR^O7%8X]PHUSAK M_?NP-U_RNAYMO8T5QP.?U\OG-?EI6QLL$^Y':>>"=9UV_2?FJ\HO=J\;BW*;^]_FPT M6VO;-+:KM8W/OU272>MS-U=U>N>O;GW]UC+B-M>PY,_=X-^'7Q^X/FPKG<_> M%J[64TU7$_;@`3[VT&=%1Z7>IRJ-*^DK$_U42S/>1H^O6Y[/$M2&KOPT`*PA MF+NN:-0V)_%FRO\3&ST]TRYI[Z2^;0CVDRDH9FU'7ITK&$T":PBV5)OFNVL9 MK8Q4=?@[A$C?X2HTYZR]897/@J,%E<1?0,6IQ]QW+,9E0:Y_A>Z`(TRV8.D[ M#@D>&\\^)M=TA\&WY=N'X]QG'F!LSHD>X5[$7, MUOJ60=Z)FH/ MBMIV#7:B.KPKH&F6[-M"?.S.A8'C4>75B7MGTS@H'']^^FN9%@T$#$Q!EINY M2K9_6!6Y=;61:^^JNNL;R\<5!>J#&<1RLT(R#6Y]]Y\D"2PDL^64ID#%09J^ MMO?3O6V,1!6D]C6?VQ;HABX?-+O-NZX-?NRR/0`GX`VS-T4KSM`8(UW$_Q6!5FKK]6!F\[_'7X:Q)_QZ7[YZSY M]=Z\>O)^UU:>I!]CDH#24'/97>_6%BEY7>K#?EAFE_K08?!X,?@B_A"7^,,= M01;VVXELK.<-N3%9V$%K:'P7]>ZBWHW!L_6;&R#GC5'O2_>QBWDW2&M=S+N+ M>1^8E?S?2^^IM0%O0S"TUG7YKFM([[I6^<%`NM45L"[@?7P!;T-0]&:*"'_ M#G]-XN^XE/\NXGU@L>$NXMU%O(\NVMAAL,-@TQBL72[AL7B3'S^7ZB%D7&7] MH/OW^.KNYR&+J>A,7BV?G,#Y/R&-_G5+JNA=6!W60U=5L/;W.17 M:VF]#83`34%]-S?Y-:N9]EM-[*JYZVZQQ^7;//;$!D6P&FH?W"#06NN.^_;; M;&M=8D.7V%!]Y5O3:U=Y:%NT__VD<*B"+M4^\EU>0ROCRAW^.OPUB;_CTOU? MDM=0TY[?K95G"*9QE)VR=QW_;RJO03T`F[Q-$ON88LH=!CL,-HW![B9_%_5N M%T!=U+OIJ/=K;O)W,>_V@=W%O+N8]QO"M"T;[\EJV!=INW7'??IM-><=1_F,7[$<;\#8$6=M-@^\#!-;> M30SX`"$U!$6M?>^Q"WBW,N#8X:_#7Y/X.R[=OPMX'UAHN`MX=P'OHPLV=ACL M,-@T!FM?Y(^+%_E?+G^3>_YQ2?YJ/R;H^`:6=>)6Z[G^U%O.R`S_"(D3D=ZG M&6%__83V]Z>/BFW^U'/\6>^C*BF]>1#"%/$=@7]X&W7!(G,$(W,;JO+0"5"J M"_!T2*)[,HW=!^(]"3@CG2\B<>R1!4%/`(Z>NY[KWT:XB/O0A4%/Q,%W_T5F M+@:8Z2#VP9WUID&$4-T'81Q]7@.B3V)X_@6`ZI*1+/:>D&T#,D5>8P'7C#]WZ\P7>_7&7&_C(+I$O$S@4&. M=TX`)[,)?!C:]G2KG$W M9$65KZ63GCO[[<2=7>NR:#V01_M\7M;&FB)8Z4$5=DJ7A<*CV M)T.8XUH[^?HOY=>?-ZZ)+3N!_-L2J>)L?D%W"$&])+>,H&NO?>F[["D^U4D/ MJ-9=.%[TV\GIM\D*<,9D:.F#\5@<3T:*J!F2)@Y&$X!5LW7;EBQ54<;7./-7 M)=NR]0LO`O@?F@5#9OT'$CJW)'GL\@XH-3I;QE$,Y`K4/'`B=_H&,$=TXCS( MHKH*L:T.%4DU82<-2=1D:RQ:_;$A2KIM](<3'<`VKM5K53_Y:FN:"F_-`'\5 M0$5RC>`V(T"39'-ZW]?CMX&;%D^^2HS,9>!7;'V,G#38$&N MG$<2G0/C07:Z3]BL@:6,[/Y(E`T`2QN;DFA;DXFH3(SQV);'IF'U@8AE"ZC8 M+D%67G@1,&0]`(@+@F%V=@^;CG&FWQW7_S.(HDD8+&#`?1`YWMF\*+LXF_\9^+=7)%R,R,U!T@R2C%JDF77++P))A=BE`^+K@BD6^SX4 MJC*6!L/!2#0G(Q!;UM`0!Q,;_E(4VW\4P4`:Q:>@5PPV!Q'Y([ MXD>@M+"M1NJ`P6=SV/-S$`U`"?TX#MV;)9425\$Y,$I_OWAX(>-3E).O91S4 MA["*/>:.SNJ!22/AW>.?TNB4W\']THH*AJY26)Q9"%H"?8/$@"T%#?4(JLH6+M)2V5S%V?S`;$ MAS_B<\_QQX_H3""S"Q(O0__,Q^_Z443>Q+1\.=3#B6:,AYHJFIH^!-`E2QPH M`U!$+!7T3^\*BRVH0D]?GS*M[<%8RZBVZH934 MEFS-KU7J3JD+'KZJ-+%:I,^!=6V9UBO5N3K0%S'<][Q@"B;"C'HF!TY$9BA4 M0*+0-Z`L]2.R7XQIFJ:,S($XG*`7O:\-1%N=#,6!:DQTU;#`-!HSCJ<475$O M@Z6L$($`G;IT`/SM$8I&?]9?($:9:760]`+:@*RLZ$+/`U/-+AK9YQ=":H!H M,\I.@\*RBS#]Z=P$(4!]03PDA@,&34<2UJ2BA5*]_)((#X,'%^V821".@N5- M/%]Z:;+S`0)J(+$6;=5-(*RRJ.\84Z@8F<7^_A.Z,3F;S_=LM@S0D:,CU$-5 MU*S!&-B4UA>'4E\9C4%_D2>3:SREZC4*/EO75SC6*T`KX25WJL_F<"0<_]:% MX0U8;Z.1K-@3=2*:A@WF^`APT;?ZLC@<6A-9&:F28@X8RS9++'LC#"5[S8GN MX%S@_U"9>W`\5/A8S/24A][_G[VK[6U46=+?5YK_@**[TKF2F06Z>;OGGDB` M86:.YDZRDURM]E/$V.V$NS9X`4_&^^NW"C`8VXD=;//B<'1T3A+CII^GJZNK MJZJKAUG@O96FCW1U3;2-#=P;,&WN7B/8Z-VQ\*6!`,BTH8+K]SK%T*# MF$G+B10AJW5Q$GL]`W[5RR$%GP?9;V%RZ]T'9T%6+$$-=#AL#7=.&9[@L M$%&E-J]2A_+45%1>'\H.KU!1M325P(I%4T?CIG=]#XI=ZOE3$(RCNV!:[U;\ M0(&F2?Z&NDM!Y_W>.8YW,1BFL&I]A=U6-T930OM3VC6:KV/9YSPOFR^WF&67 MK6W(HQ6R<ZAN[L<,Q[8R0 MK7(4;X&R$+;C89*AF;'9RMP_)+KB%_Z)*26=)YGS/][F3(#3=,:;_M-):!^FGF_ZD(V'NTYXK M+P[JDS9.`C#X"-FC)=1)A=9K!:*;:)?*BF(WQ0!"> M&)H$Z'V&(4A+&WKY:=&B<%RE0T#)";'U;@OE4S[E7FZ<<=O7BV8OD%65(R^0 M5=Y^@>PK7SG5WQM[]3NN9[OSJ-^&X+>V%.P>;'\N?+:&2S@QKLY+S;EK@.*R MUBI1ZA[@2R^-=A^Z(\9]'QHZW[> M?;Z];4ZBCRW^)@U6E8DZ)-HG`$W.#/K2%;GEAC-O].2R*9>41NB;'>K2OF>?E1H89L2_&K:)!KMY^KJ.RJL=CFE*'O^VE#* MLTE3A[R^9\VO-CE7\B?7Q)Z_+MH4IU8<%5VPHCB0+[)^ M-0#3J=;\*MXEG7A)Q8-[!D^K%]M1?GD;5%Y"=U_:5)%<94_9*`X#WQNEV;]8 MR#,<8Z4!L%^]G^P[\V8_%F&4Y'T79U1/GX`E"J9C*!+A%6)3G@K&D#<,>\A3 MR;%T4]=MP]'J3L#:+%B+YC'/DLF"3H>V.C) M!_OE<9F4V[9!Q(,9=`I'TIIZT#]WNOJF,8JYW["E]1Y^_G)O6Y\_X(UD<;FK MST_>Z(E[=K$&N(M5JZ"W<-5 M.I\Q8R&6_^.RTKO+I'LP79.3F$DY'^P;/(W?AR^7.#2^?S=*/?M8O/,>>4D0 M)"UD5<\C;K[*^<>NP!]`0T/_H?=Y(73LUP+^#R^%0>)^+#E0X$_<_&D9>2// M]9-Z[/#EIR":>[$[C=;>:K)'S_(1]'5;2V@@W_OBP.QJA3Z#XM#02EO&Y-!#9,`-?\S0U'A0`\KI;G\"8/(;N M+!']]:Z@W):DOY@5$?<#2Z6@O$6+I&N3Q72ZA!&=P=#&:3([-#%C+@X'?+@: M4^B&%W(C!KV;>-`"CG&ET".%C_^!4H#I3#3`MP<9M8T.74&'(R#9__9#5'HW/&_%NG$ MB/#Q%$S.:JY#?N1RZ/E;XX_,EB5`_MB`-MUK%B3=P7F,!7%U1Y,C+&6]5%1Z5 M!9X(*`;KCR7+6IHA_\C\$?K'UKXUV&HS:Z:LL4!KX[#F70/'".KV;HN_SV?A6L2_^1"(VO2 M/5X3;V@JFUXO3:S\S@<7CZB-DHSH>5(R(NDS]NE#>I/&VK4.T/M\2>-\QO#: MBE4[.-M*SV878BRB]8<\F$8,C4E)9/HKG06@AIV?[K>%'O[ MD4-17-,O:6,;"L;+%!/.=1\^9(G0N5R4EL2'+P3)7$]4&`+_F7#/N=#L8T$V MBMH/%C\S=IC>1`9!;DI:UL-.9(]PDS"8P3Q&I01J(_GA8W[IL#O%2SE6G4TO MYLBZBSB*#D/[2>(XMO&RGH.>8U6):/5Z4(W)O1_<+$!E%X?)?(GQ>F,/9^QL MGMX!DG(*#,Z?$MWNI1*1KGG0Y4?D"3JUB*=XH`U7YF1N)+F5J5+8R1.TLBK> MT5X]YV02F]XC@]W?O&HEOVB%6]VODN@&:*30#C@1\&J7X(6Y_Y';^1Y<*`^Z MN89LJJ/LA6YVF\Q?Q($DRKEF>JM>`K,2538+6?+M8ETMONO&,8LR4,)9;5VO)9 M3:)^E24*?]_8LOW:N4%._]W>)A^[`2ZVTJM+/VYS<_>?N,_X!!:]"_.,&3"? MV:EN<%]N234%R"*_;E@[[:L?@=2H)L,UV")5,JE%UF.ZKQ920PV&L M>1&R0ULW?OZM_/DH*6XV"A=>7'N1T8/`4ZR/0,3\X-H;P%0Y^;B[YGT;SS[* M(!,%+<!5R1%YK!_"&ZI)>-66 M'%UP!,>ARH.$Y^1)>5YL][I`]EJ!M_OS^,T$>:B+CB3RIJ;)/)5DAS=E8L)_ M-$ES!$N`L:[=;W;0NIT[TN[73R;EMU8KC;#[HKG;*L[ MSK@N[W,*!T^R-JV)678K5;*VIH;`W1PK:4[A%;=/+MC-HV7^T&2O??'AM:O< M^N.6AQZWU.B1QRVEMQ^WE)L[;GG)K^[\F;WJIR$+C;,QT9H]DU<=4*X:NX+G MZ#)^[<1SN+1;I5TG9NV"NCXUV!+A)\ M3X:X^SG1KV>7FNXT<76[\8XH5SK[M],"SIP+4C$I21V(HGK05UMR7.8(K%+W MSGI6'E5"A/-BO:Q\\54D(2HB5&/TU;OP^W@Q2KRU<9!?0E[[[#XV"9L,!+%R M9? M]N956^_/OZZZ3S]W":Z&1DLZ][&V2UNQ+^GL4L]@SV#3#!ZD'^(- M_?#$4(7]<24J+^N&M6>*L`-MZ/D^ZMU'O1O#<_2;&Q#G5Z/>=]ZO/N;=H*SU M,>\^YMVR7?*?B^GZX=AN!;R5@4*;J2[20,!;;F8CW<2HZD(G:AJW93I?>L!; M&4ARY;)C70W_OK^`MS(@Y,S#?.D+^\4&O.6!5KTL:-?"P*)8>>YW#:H\T*N' M/?J(=R/<1[XN+-O8,]@PVS6#EBK'["MQ( M:UKEY>[V)_DWQ^H$?W^/K^YS&OJ@M\*-WQ;5YZ8H,TT,XM$.T#33LW MW8\?9IWVB0U]8L/N(]]4KO6FR";!OI\4#C*0A?ZFS$/\Q9<35^[YZ_EKDK_+ MLOT/R6NHN)\_[RY/&:A*,[F[Y\5%+_(B5W4@D1;LR;NT8E]23+EGL&>P:0;[ MD_Q]U+M;@/JH=]-1[[>\^YCW"4[R=RC@+6F=JVE=>2/=S+&' M1@+>2B<"7VV9SI<>\)8'2O?R6HX%K7=NNA\_S*IXYBC_I2_L%QOP5@8BK5S= MI6MA8/T\,>`6(E4&$JE\[K$/>'^6A8;[@'3_SU[_\11B)C1=3=C/YXL>N M_^C!8T84L3BR?XVF"SSA_RD(QL_>=%IN@AL%?@R_?&>3/ZY8,'VXM4613_X1 MJ2CP_PG#HS[>,_KKSQ@RRJJJAI#\90-VQ3,WA% MI#I/'4GD->K(/-4=E1)[J(F6^8!?O$;$&>"F1R&/_7CX0T%=A+1$7I1X0.(G MQDT"'!1@<>47@0;<61#&WO^YZ"E-PYY>OI(40:5Y%9Q)O]>1".6DC'*_-^1_ M7R^:+2ZA*D<6EU#>7EQ";:["P]E?_8YS779N738$O[5I(GNP_;GPV1HNX<2X M.B\UY\X/R"O9M464N@?XTL,F>68:M\J@X>[8XPRXK60GU[&//_ESK>YSUWQV MY%5QNP_=,>.^N3-6OW@=&;&1!J"C#OKJ!06F:P#=?0W[NLA;BP@(8B'WG4V3 M;5;TY,V[%X<6!X+V[DHOU`#ZLO3[/]C8P[Q][JL']EG4/2VO*N].R,\.^=+" M&Y<3$.[Y:T-`_:VVRQDW0)44"!EHLM:(UKP<@)=E!ABCT6*V`'.7C3EC+<)0 MS1RH:91_T^5:KQ&J"Y96/2VCSS/LY++4\]?%9;T^IV]Q;K!EF7'20!=:;4E4 MQ]5?!O-^\W=Z!D^KD3N1`54YFZE(B+IE?@16L_UKCKZT,^4\49LZ0]6V>&4X MI#PU["%O&@[A34?05N0XN^0:FDP^XD$5S-HJ]GVRZ''#/+(3F M(F@I3:Z*^ARJ0W.H=*F_H*=_];%_[WP.T(N9+LJ^[*KD(I>B];2Z3?%[4N9F M8_:?W-WP]F^\`>"=]ZM6>)V7I>/3JW:.23X@;RU+Y>Q(9BD!3!? MZ?TKF\&7Z3C!!K0?RHOW2WY!$ED4>*1R M:95NP.M$\F9;]`\ZVD88LPY9O`A]+O`Y-_'8U:Z+C@[Z5BX:=EP=G1[>2>!5 M5[H=P=="#W@#1A-1Q\PZ,CZ>W0*6=.7^-6$ MDS83OJ\=IW)FN;VT=2@)[UGK6>M;:F[[7%J/O&XLWTQFJ67GPR23P MX]V1A=<7`?S>6U:3JMZ*9HRD-Q%3(QVTL2*!K:1#:<;1VE8Z^H32]YL.6:== MT//6\];S=@I+="MMN9PP_%JV[WI.<.@%XYO)[=,R\D:>ZW]:N*'KQXP9CR%C M6+GG9*G!MB6;@N007K"8_`ZE01>(0ZADDDUJD(;#^+5]2WY[Q6(O=TK ML'SQHT6(12+O6!Q/DP^CTR?^ M='V0BB5F5,N#)"_;"F9SUU_B11W,^XEW^'!_$;'VS!K()!P'+8VFKC?C9EA( M:.&/6#$69X'GXH";>9$[GX?!//1R5_L$7A5Q/Y9<_!R@3?4!,[Y#+.NR:BCB M\(V<"[LTM-&X)7-#V+CA=.!^L$?/][%YSP?4@O+Q`V8[C((9P\8SJ,]NZ1HC M>'0K9;V4L/ZAN,.0RS/5TTQW+UHC[F,#HB!J90G/7YK^NZW]7M4%AA;,A^Q$/O0CUA>7',6V==%6%^ M@XB%XPC$#UX*DRWZY'K^UR"JERU%)Y8D$!6(4@2>BD"99M@*+\BZ8EB.+.NZ M\D`>1.GJ.B/J](!3,A<1_^BZ\[_=N5,6?4]O"D.G2T4VH,NJ0(GR"_XO"A+% MWQ6BZ[]$HLA$$*O)EB$)0S*4>-6T))XZ"JYAALF+FB+H="CI*M$>5$$0'Y2K M:TDGHI[(UPO0RK@SX?(?4X5TC"0TC%V]NB9$I27H.]"5X=]FL^\^,$;_N_!" M=@N:GX7Q\G8*=@N(E0U_G1]C5S7,B@B6C4BD$BN'@RZ3-63S$`M&XLR#GZ<, M?X#'2Y'I;M*D75VK2-(:2X>@K5N'J*JL26>E0D(=(LJ:1MNF0^K`#CI$VM"> M[58A=9""*D3>4*P=4R%UT`0JA%"Y?2I$$A3UK-!):G8T;W34@!04!"]*BM)F M%5$##:@2B-@IC5`#*QJNG,<:$=F<.6I"2)2*B%F79>DDAA21;,&TS"&O.D.# MIYJE\*:CPT^2I)JPSY6!)!`*X`!V;"11!6LDK""="R@1=$*$^H!*")1>7>M* MK3"I2#0JU@>3($QR=:W)(JT7J$(E5:T/*$6@R3Y)5TBM2&5)T]4:IZB<*.^K M:T57Q0.`OG:/T_?$68MQBM3K#VM?R-R(#5GZ_V/(.9H,RZ06&32;,$O$'L88AE;6.[\D:H99YV.VAOX;]@\MVEIQ0R MAL$R_.EAM',2A*8[1G]W5P0'M`6T6:;M2.2%4__;`J,Y-Y.L?/KXVR*,8%=A M)<>+338^!TG8[#H[7[XYVY%@5:2:JA'>M@A&@G65U\RAR%N:HUHV(71HJVC] M)<%@45%2C_U>--O`[V(W/HL.21K>!].0!2*80X%W-,7FJ:)37B>6PVN"*5N* M:8,LV#E,J0PR[?DVHCQVXTX-7![.@"UI=Q\VW3)D6X-=BVU()@];(L*;AHFA M%U43+$<6986FV'!G5\:VB6$;93:TGX/964;O'"RSLRD2-[)Z7+V#:)F'KD2;'^G#LVP*]#:159F]U M9^7!ZW_BY=>$SAB]U2DY:&DOO#=OBGO4;QK6(AI@&HIB%=G8L`S/O`YN_?7,<2H5%02;Y@J5[.#9942R9`D7K9D6$!%4^=U41GRFJH2 M7=!4V9+$U,V'VP=UP]5Y&@(*V8&GYT'D3C^%P6(.GZ=E4W>V46?WJFE?H^62R=:S*BB1I^OE8)=FR MN)$^.1O.UF4H]D*H*@*=4TIZ@K0Y4X!B\-186G M5#1X4[5,7E*&LJKI@@Z?Y9L:7M3%_;)9G8F63OPCZ#U(7FGFZN(U73V_/KT- M@Q$CZ[9\LBKUX$8(A:2Y@2\ZBDTSQ6B02;$9%V`A^'H"N19JP%LG"`)1* MA//HPO6,:O2OGHH3^%T3B$2RW\GY1$G*7(Q4W?#/;T(KY,9VP^DR__B6^7BI M]\W_MW>MS6WCR/:ON%([59FJ94*`X"LWFRKJP1G/.+$KSMZI^RG%2+3-.[+H M):4D_O?;#5(/4B]*%$%(QI=4+)$4N_N@T6AT'XQ/6'Z8+:EASR&R14XG213O/`R3:>X;.T%DY#4T81+"5946*[!](4FJ.L8S%R5TB=^%Q:I&NM8 M\$^_IVN>0XEFZEV/V#W3(KZ%#H/R/*1.J*;;FFXN5XUL%*(,=G[,VDV03)Z_ M),$X#0:\P.21K\RO[Y8^JR4],W+IR:&%N#W?IB[3^@0UHL/O>;[9TUS3=#J, M^EVSZV7+(=R&7RD?J2SDFLQM\,./DL>J,\16!(?N`43X`$-D^=>F`Z2 MZ*DF.K:/!4:]KFN9("%S#0WT9L*LT#6T+NOX?<_Q++-C9),G>_4!C_(`:P[" MB[_BY&_LF()7Y0GVJSA`.L:+X#$[K>,)-]*&8$7L>`HNDO![//J.-XQ`<.RJ MNAAPV;&CZ_;W[N\7X7^F\!CX"[NJ1CCM)GC9Z^A7N'VNF8L.IG#GU_)>KN<+ M;.3"[I&+UX[^RZ]X6W\4\2-=+F9)L(M%%NSB-;SG,+R#%YFW<97%R>19]&P. M^6&)?TQ'SQL=>(67WS9M`0JC M]/8)%#N\'O]OD$2(J\_'%7GNM9X@&MWEL8CO]/M^GT$PU^EHK.=3S;.HKKFZ MX7>H2_H=LS/?&M7?`$XV36:;1=NFD"647-\MW\4?UR`.JHH-BZ7,<7WN>=G@ M_A8&"?BKB[M1G/660@#+/5,TX[DN^B3P!<%DX93PHZ@RS^]"G/$V_C:+T M(?,JZ"K_"D:CB]L).!%XV!_Q-(&HZ->+I]$TO2!OS%_^.7ZZQS\'X M/OP8C:/'Z:/TPY3R86KI&V/._>3=ICIL:95@A$)@>4/,_]LD,+YE48K^3QRV M4QAQ^'VVXLIBS@:LN\<2JK+$#$MW]6(LO5FH1>B,[FN6M?@2=\)_IQAG^M$8 M%R&7CQAZ91W:)Z('*>5@L
5%I3IU-JL4YE;[1E^94\RAS M:LNS3,-0RV:9S8D-V2:9VB##2896F63*C@B=D!\GO'4JC8ZS(E\Q;G7G6EUB MAI5E^GKONBJ4B%Q=07K\FQC$X=U0%EGE!W*[O8[3[_I:OX]T%#YU-,XZ]NHDV>]YMNTS#3#C--NNYH.M,HK2W=QV`R37!UCWZV*>$,QX`U0(]J1J\/:P(? M-QQLQ]:HV;'[S+*=7M?+*@-,;CH;3;=9N.5WWB9;5@$7#?*&Q^.)=TAU6V45 M\`K0/X]B%(,%`) MA\C*%8Y3OC[VD@0G8AX>/B\NR?7C_0B2X34/>-+?D.\MO1QGBN MQ7X2PS!QW(<4S/[6/'I6SW,LQ/-PH*K'G%[1M]=Q,1+ M19_'U\$I*-ETB&,UHV2:!T>EG9W&%3VK_)COEEQ!&'+/?V7!-%9'=5EL8;JZ M0P]CPO*\?L?M.[IF4Y]@.T97\^R.H=E]B+QT7_=]9LUCR_)JOI)X2^R12?P8 MI6F:4+4Q#2L_NK4Q#>G.ZL[J[1<6,QQ77B6IEO@?AD\$LNH'900 M'+??[9E=8\EIFY3"@ MY@4E(#PE5S57N]2HH39'#5MH:F_YMJEG/6_AXMA,0<_,G/!*G0R M2:)O4\[:_R6^`3#LLU(49EQ*"\:M*>#AWK'XM,_A$_[(^)Y7)S[+J#>=,_D5 M7<'1!*Y"C7(;W8^CNV@0C"?=!TQXI)?C?CH!R?;BP*BO,5SK.+IG:\1@##36 MQW+4'M-TSW)LUV&FZ\':G_?1Z\5.L`,$.U*GN#B<8!VZ4VJ5W^IC=@][6)D`!1Z01%:"%)JSX^D_\]/IK\?XF:&?&9U>\R0[.9 MV07!=4?KT`Y,T`[V,#LN]4SC*]^%*#6.[2%/41-K)K.9"Y;0V!3+#VE1]BT2 MM-Q?6%\MU;JS>9I,(R4OVD@SX?Y$=,*P@:E"BY`JQ(M-$`;7E[,2$RY$".PK M@846TXNIFD,)@F&L2.W?*5D=\H5WWC<\F'=`K@W43RZVBNX7>UCF'YIF$Y$&#W,_]`5@D9 M=XO2))^V.+3`Q&F7V'?W)\^>(:(-(U>4T^(+BM*H*+QUJ>LB^!8G('2^QRNO M9.#RB6[3X@IQ_=NO]/]GI)AKMLLDE)-3@)9;_#<*((@Q3.B>)^&._9`]SPW< ML*7]_T>H2ZON%KMN42C?5`%9[C$:W;=7Q">X9.[4Z>"RFY MZJTBE)R'0[AEU*YI3=T@-NMK-O,9 MMN3:FMLS?N+A)F4O?I@L5(1;^FM MUQJ1DQ/#)'P%P>1)F)*NG"Y329)=*;2BC[Y)HCC)_1EJ,>L-E3"91E<9V`X2 MK11U90=.@S+YGM$-7)9`@)UD=9?9DUL(-BOJQ,#\0C$(JRY/:0]B^O0TBC`' M+6MDC<1X,B:684[4S`HD=;MD6ULGD/*T9#;"YK&3A*,#,VVZ4?2'VT1H M@7!.&"(`$(:ELWE#XE'(Y3@%6?[)]?CFX3F-!E$P_FT:8`="&*8\Q3%(IM%$ M=%*^WS4[.O4-S>UWD4S*]S2745VS#-]@M,,<9O>^9N>R+=A']Y!%CC/'Q4TT MV"@W.^%%ZH/'"RII[_CDC*T0#WYAK)2_;>X,4*EDYXAQ[/4K;9%'@DJE%4P' M6\6`38XC0J72$JQCC#*/OKA#@ZNJHN'CDS,F-7`AKD$MR3R($-&QR(Q*<.RX M5$KA^TDRGCHNE9;`@9#269XR.)!F3UNFLVVH4EE="^Y"A*"'F#QU?D;FU,\>S&FUF-G-R\P8Y6SARG*RXP?U21T<8#P+EXXD0RVWUK/%6,8\.@)4<^FD< M-=XF;*RF=SS;];8-GV3*58C>ME2J*;&O;?Z,6U[8MU^.3;A'$H(+LA)(U_)' M[?9M"3VOE$_7?!%^%@="MJE(BHITCKM/+1TBFS_WE5<_:*Q!1,JF5`&GE?*9 M0B/G/80KVA)V M'&%>9>F6ENY['D5=#R2/I+S?)9:]-KG^13K M=NDNMRN>YU/LT+`.\B`2\'R*Q8E>TX.T1//9L`>1C^:S3I!246I>@ZWKQ43( M3K+/M0B95:KG$.+K@PU],S57DW7T4BW5QBMD-.)62&8<+O;Q"53K**9:Y0SF MS4BI=4HZ!E4!X^8L&51%Z"UC4%W#I'"*!*IU%%:)0)6?"+)"/=$V@ZH(G"#A M$=EGTU$B!E41\S86P-A.F1)*$(=JWC:/O\!'(SY:J)+LGLF(3S5;9P0U!?.W MU>]I'<_L>K[3,;V^D8V=4@7)NA<_>L&W"/,C/:Q>JN!ME1^V5D*M2O,ZD90? M5H0SAM4^+'U9$C(YY=KW![9VZI8,"H(&EH2;1B_.`:'K8.G)6:EJPD![6 MQ#VHHK5;88<5,>#)ZH"7GAU6Q+2'QWRP(@1%B&ZBG!#.#EM+X"J4HCSC8)5V!$6RPPHP*8,0J=QF)9X= M5H`ID6^I+*>L]+`"5D1>&>EAR_QJNHI1(]+&]&S-W%P?2PLXJZ;OSXB"_Z_'N+'Z M\MZ&]_ACR[)>?O)7A'5[7=IUO)[F.QU'8Y[K:U['(1KI&X;.J,TZ_5XV6QB9 MH)O?62;:6Q$3:%8$=0*$MZQMXLZ,U`))2TRCN(!NFGY.#M%QO6&6&F%:)*.3 M0RGFRNZ,3-1TMN&24P)6Y]*D=C7-D]NR\L2]\NJ"?=(0G`!'LDZA&!> M+G+;)>4)XV3ET[59/FO[Q%D&VU$D."?WR)OLT@&R>6Y;7KJAE5S:.7';KBA5 M`"13$6R#'LAZD4.879F',(M M`14/$\\7_:?$(;RD+6$H(2=_&#PN7'`L\;^C(7YR M%X7)13IX"!_#?[UZF$R>WKU]^^/'CS=I.'AS'W]_V[W\\]4'C$5TU[)=X_W; MQ6V+1Z59I=Z']S^_):-A]"[\^32*!M'D8XB5=A?#Z#$KQ/_7JQW*2#O/R]]X M/Z/TU8?9/1^#<7#/2_>SY[Y_N_;G/@`\\_?))7];$/W]$U\++[W]!'ZK!S_Z M`;6H@6IU`L^8?SJ_,!P/ERZCFD'PT<.EB]Z_77KX^[>Y!>N:LS#(I31GYA-Y M)PYOK0A&N/*\?0A#W+#TAL,(K1N,T#N,XG2:A&#I@@-)MWN0-(,"^AU_.IK$ MXUG-YHN$0A[HO7@HP%O$212,9F"XOO.&XC(TC\O'AT]4&*8O-"YHY"/EA(*"Q!,4QBV:9J/V24+ MWCYA'=!H\GSS$"2/P>#Y90[KPK;=J=HRV_S#!A,_&$0C&.=A^C+-N;6814KS MKM^XS1?ZM_$TP?EW*5#+NH=VF%6!JSEP;:@(.QMP):$"5WO@6E]6>0[@XDFG M83?K@N0-U/QXA3!)%=Y:P]N&8N4SP!M'V,+<&3&^0EIK2-M0_G_B2)L#(AS= MW00*7VW@J]!0(R6>NO$XC4?1,-L?Q<,%BNCIQLE3G(">/L7CEVW#M?/=;.@*]`TJM[.[6U^!2DTX!^"J<=R.A' MWT,\$F'R/#^$#*]_H58T#)=)&D:O6O%V$@_^+EAMR:[]$2["7YP9#6KD=6N& MG&9$XN7+<3I)IGACN<;L\S"XBE_@Z.-F8U1W'4D3$YO,UH5E8S1X",(13(=V M.AY%X[\72T:(I>Y@5MY2ZDE[.ZDS([*Y`V5G(@R@D\A06Q M6%#]<*UQ"$N+"=40UWY#G,SP4!N]HEF$)<2"_/5:NDI"U7DM*> MJBGN3(KA)$:7ZHI3Z&H07:HM3@%.).!47YR"FB"HJ<8X!;"&`*8ZX\[(B*HU M3N5X&D>5Q'./S*A2-5E1]-2=M1E6T>6;V M5`5-+?%[2XL%5=#4&L&WM)A0!4WM%S3)#`]5T"2:XEM"+,B?99,SV26S,25. M;DF;8Y+2GJJ@Z4PRF!*C2Q4T*70UB"Y5T*0`)Q)PJJ!)04T0U%1!DP)80P!3 M!4UG9$15T*1R/(VC2N*Y1V94J3E'PH(F&=3#R;YU6Z=JEU6"75;*$4%WDW[G MES6'"$9I@3C+MBW'?+DDJ$?BR(*%!K[3Y?C/:#R\N?RS8?I5P`G3:!4X99-AF$P MOE3#&%MQ:]9;P]T.PG$`)BKA*__4CY-P$*1'!E@$J@C@Z@PW66@Y^^SXN+$, M7>'F#'%C:8;>'&[8'#^'\1RK M8=A8P$%,0](FD:3L!N'X/_CY/N*$C7E*!= M11!OI"(KT<1LETF%'&HSVY%TN.^%G-E-X!>&(3:WGM\^JV3`T9DI:51V$'"Z MTW02/X8)GTIP5GF(GA2&&L"0G)A1%I*])$*FRH06C-1ZN8%(F0WE.NJATA!O M(>4Z9#623*ZC<9FI;A-UIN+Q0,KK@P@183!UL-ZI'JPG$B^F;LPV^]6FWUEM M^AF\R*"Q.'I!T9:=TFVZND,E*Q)9>TIWMMN73D;A8Y#\G6\?07QR-1HTN*S) M"X4%F$/MP4IO&[4'>[K&4_/AJ1A,[<&>@I'4'NQY;8.TC1RU!ZN`B.MSSF^M.3%R:4714)$,='(;AE%+Z,FX\.@(O'D+#-4 MSCPJL%R=48@"')-:DF9:^S_1]-,H?<`;K^\P*EC8!]9H81*FD^OQ]72"VN*4 M)G#)&5G'<"F3-<^RW3KSD7L5!FF#>_?B;8(U'[JDAYUMMLERK<67O-;BY(TB M4Y58\S+KKBHPK5GV[#9<]ERVD,2AE[01D!@CR>4Z&I99'013N^RY8>>N3GE4(W:#OH'HZSIT%LUMU'8M<@K-;&7# M)]8:Q'FR]PM&I^,H@TR4Q@R'P;]O>W.C/X8!GEGQ(?_N'7SW_NWLP^QA>'_I M22DXA3!=>4CV<87[G^#;E;OQPPKW!H,U]TXGR3O\HL+]2UKX"DK[6I)E&'T' M!"]TC_=]`FS`,B]>(+J*YC*[K+^?/[87CN/':+SIP>NTN7CFZLWOWRZ]^UK1 M\Q!OU6Z(]^R["@J\>7A.`.USYM]6>-*L:6OM@V9?5GA.)QRN`2,\`[^H M<#^/F-=K!;^I\`0O@2O6/H%_4^$)5\&/KWZ4/*Y]R.S+"L]!7Q:,1AOMO/3] MAJ=E7@O^\U]02P,$%`````@`!GE21NSHOD<*$@``=P`L``00E#@``!#D!``#M75MO MX[@5?E]@_X.:!8H6J.,XV=GM!#-;.+?9`)F)865:+Y!0A+V/)Z/3LQ,+>C9VD+?X M>/++;#">7=_?G_SKIV^_^?"7P<":3JT;['G0=>'&^MV&+B3`A]83>,,>7FVL M:^#:@0M\UIKU@+ROSX#"?UC\7\=B7_U^-7VPSD]'EK7T_?7E6KCU=`:#)+N?HT(N[1^.#T_/_T^\\L4!YYS:;W+?'5-8-2QPTBZM,[/1N\& M9^>#T8]/YZ/+=^\O+R[^DRV-UQN"%DO?^IO]=U;X[-V`U;BPIJ?3TPS&OUHS M[%%6>K4&WL8:NZXUY;6H-844DA?HG,:-NC%I$4'PU___PPLY=P!0;(HS[P[%Q%WIBHZNC]^_?# M\->H-$67-&SE`=LAEQ0(M*0E^*=!4FS`OQJ,S@<7H],WZIS\Q#O\0+`+IW!N MA31<^ILU_'A"T6KMPI/XNR6!<_8=W7#&?S\ZCZI_=X/M8`4]AM2Y]7SD;^Z] M.2:KD.@3BS?[R_0^1ST-/-[@$@+77X93R(_GXY`7'Q:V.&Q([I15_&/FLRG' MNWBKV_\&;#?L9!Q5NVD/V!2^0,;/*;3QP@M[&GO.V+;90=&G[%N(7L"S M"^DL6*T`V3S.XPKT"C)RX(3@%\19?H?)#0Z>_7G@)K6;,J-+T@[.P)C(S"`R MLO:+'8AGJM3H8M/CG*D,^)4?V_5-+#5:#K\4.Y$\S3IOCPF?H<..KP2RWJ,_ MD7/KLG,6P1ZR?PYQ(@@+Y`=K`?KS#QT?]"/NX6Z!!I M>=\'84$GBZ%R?^U!?<#>X@F2U0U\]K=B//ME4VSE'1P0#%.A1YT#2O1T..H( MVA,!-IS>C!\PX'M/^/$W3+XB;W$-UL@';OA+%S.U+3(Z&O.?)Y.$H*[1E_;5 M#<1K0%;(7@+H?L%^1WMSY?[:@WKOL7_Y`7(&?=\-34F=0%3NITUHW(CW!-XZ M&K72]MN#C;J"%KE_@X"-360\:^9]/,#X#X^NVBQ M-;?L5HUK=LB/!D2UJ9^Y;/OC9G9_P[8%CS(R.K/H5>NL/9!;_T*F^:O-#"XZ M$UHU>CP0W/B_0V$5=->*0R32`6/>?$$BY M]X]_S+B=TLHIJB?XYE^YV/Y:CST'I*]C?GX!/NON<=[4B5&IAXXQ,3:N,07N M)X*#-;=`N`$/%8)MIWG-O`G-)#Q>F\`EC]1^B=V[ M#YA&D5!L(,M9H-2*%J1;9]4$(#8UXW@1?CK"7FABE($KKZ@%3QS])J8Y&YZF M@ZX2^9`KHX_*,,\D-;T76]Y5(-5J4`=^GBK%M0'V'Q=`+\`-]0,>>T,VC.!? M@1M`"52UNEI0I6NR$,!N,1VT)I'%3!YNHTV+IUA1C;X@^((]NS*(3"4M.-27 M;$QR*<@&+>K@P"W3ZO`&)G$M#P@\(Y=M>F7GO/)Z.M"D,?!"HG?BUP]+FR#$ M_/8MGA\E="M5U8/IA0TU)AM&D93V3!$=-&:F)MNZ]CW*$KI+JVG&4KP\>[(> M,V242DYQ6(^G^F(85^P;O`<4AK:KY*!WDP1_83]DF2F7F ML))*O<(A/T075M&!(1-35VJ\$)?50[4/D`>=6T`\=MRB.?O]'-E(#J&TH@X\ M^UK)]B@YX6X'[(U]GZ#GP`^#]S"7\3Q/![N,E`73*B&!5(:YI<:W?,DX+\>YS)_6UM<8DAY-BQO;8!\N$KJSPE>[1G#D\ZPS`YM8<)@AC<& M_O/L[,1ZA?Q6O/`S^[0F"!.&_^/)^8D54$8<7D=N@;ZB*Q8Q6["CT3&`53DZ MIY!_-`WRCG#-(E3V[CQ+@`OV8)2L.='!#9O:$LQ7AP1QD*W2`KY^R." M7!PADF)^=TR8&_A?4X[\<$0<4=(D4^@&[6"JMO6.0XJ/&&ZE;)L5LD")4Z*61B3WQ:<`@O:`4M;K+ M(L5OD!:@/.I%GKP4N4%*@+IK.V_Q4`F72@\!!@F]>@P1@39(ZM4#719HFK+" MH'-^358TB55-^630EE&/3Y+(DY0#!FT:*JYB);]/[")/C4@&Z4Q5F=!>TEYXM)^(DMJB#%+5NV.02C9>RC*#]/SN M6*82MY*RS*"3<(>SK&IV:\J_.H?J_B;LYU^?ZP.Q^^_+ZKL?RT**%>J6H+,;W1;7W7 M;$UG[^"M\[P-?];F83]NMJ-.=`RG&,:$_0OYI<[A1(N?5]J^23;'Y`HXW.`J MFZ=-6]63II?L=W=L^XWN@0K8!II>+1L]S99QN=R^^02PP60;"]G<,]%-*P6/ M=MEC/SG88N1M1YWIYYOX6N-D%\V#V-[5%%V1I,2J)NWKXPXC+0[]N8(>.\X7 M3XO]TGHHCZ]3Y"+_!1(DW==%)36E7X?+8/OFJ83:?"DM*8S@&1.VR\;>_V*" M)85UT,W66;H<)>3FRVA)E(OD`I>+);2*2FJE^`$""NF4G3/B898G#!77T9:@ M6**%"W>S2(&5X6S8JD9.T-#8'`W*=KB*88JK:,IA*WA?6(A!X=W?0V>#1<\2 M2^C=_JPELPNX?-6&%,A7^6XI+90&Z[6+^/&]:)O:+:75ZJA@^\F:$G?V-2,C M[RI";BRLC0S4.X":G&.RZ"1B9$##@1FW=Y271#?TW$_;K4TAS[`.Q\?(P(I# M\UZ@XTM24GL^:85*7K6YUC"CPZ3TAHK<:F0?,S(?HD`;SZ4%[1Z'CT:.`VRQ M84L2>WHDT(MMM&8&DBIB%_J"C+QCI@1P5P$89B:QJ$T.M9@:249+S]>'Q$B; MC]Q,;,Q&7L*C@+!QE(WDPA[5L=<O0I!`9"DHIXH@W4\L9102(NWL&AD M;2LOD8H-Z/5XUS@3[7C]E66\D6?[CA@DW.2-O+>O(P8)3WD2`U&_&53]&)M7 MC66"T4R+<#UNU)'+9AJ1F\T6E6.!D;<;5->59&R1GO^,O!*Y&5_*K042#[*9 MBZB$*VTH@68ZH0_!KW(Q71X&A+V(NO(A"FY&V>75#X(7)V>0C\@WJ,7DI][I*L4;4$3 M_<"8I!]PYBNCRE72XD*+5DGRD,R$T4&@SU18KJW&A!:G:U9I0>_=H-6A[EPO M7#CB1CIV6N=)T4IO&+UU+"Q2VP2:'7SU;LZS)2`P=U5C;\\1<;@AC[A=>"@) M.-U[:HW.^$PAF\=Y$J49':,+DS/^O,=,XSUFX6)5NQI!6/3/6R9:O66BIQ') MHIAK@QQ?AXVY-LGYI<`9L81H9@TQ8C.+][+,3LQVK_UB.O:O?2K"UPB*'XTO MJ:1#6HY=%[_RN`/!N2`ELP16I3;T[%?"9Y4EFY>HK%8944A^\=.[^5EII.JG MCK[:7#8P1Z>N!'V<%_'&)/6FM_I9G6S)Y"$H[A1)ZI=6ZBT'DK>\&`=VWSG; M/O/5;S)#/TS6ZK%;0,=)XPZQ]0`?V-#OT9MY#T+A.O<:#>G8JPO(C!]\JHHN MJJ;'P^]PJYJ,,,';?Q)'?L5F--U%O,]U=81*E?N`2_QFHQ(J857-WNDJ@Y8/ M1JTZM8T\?-9G4+D<,]*24V4Y%#U]*F.DH7$T]9A29V]O&+/B+`AM.;,=\\ MV2$Z_/@;)E^9HA&_.1S^8L19^N?))$%B`KW7@*R0O030#;?UWM*\O;IR!GW? M#:/_>DSK]G+^WM+('_%&?I@WRV_."(/Y%]"SD9DTISFD_&LF/_P`N(_/+EIL M4Q-VJ\8U]3QI+*!1LC.+R^IY'%A`R4T`QW-V>+Q#1$"]=S)@125B;\R#?+O"@W7ZZ)HXR=X0SC?%]!0&QO81 MV14=7@+ M``$$)0X```0Y`0``[3UK<^.XD=]3E?^@OKZP7&;M;CA8/6EZ/S\VRTOR=X?1K]Z>+]^XL_ M%GZ9H2AP/XT^%C[=8`CB@5V*T:?1^W=7'\_?O3^_^O/3^ZM/'W_X].'#_Q:A MT6:+O>4J'/V'\Y\4^-W'<]KBPVAV,;LHD/COHSD*"(5>;T"P'8U]?S1CKN,U_3JAQ]^N(Q_+4)3/-QP!UY$Z^-E M\F,"3;Q/)![S$3DQ3Q7(&0DAV+_.,[!S]NG\ZOWYAZN+-^*>_84-^"-&/IS! MQ2C&^%.XW<#/9\1;;WQXEGY;8;B@W\B63=,?K]XGS?]PBYQH#0/*%_VR+\ZU' M'!^1",/KB'@!)&2R86<)G5HR=MUXCH'??C?7'D8?8>QOB(J0(()N/BH3YF[D MP\F"_WM;.AN.VC79G-0M3(D]"OT M7L"S#\D\6J\!WDX6:0-R#2DZ<(K1B\=8?H_P+8J>PT7D9ZW;,J-+U([.P!3) MPB12M`[!CL0S56Q,L6FRH`8&>F5*OKF%I8;+\;=B)Y*GW>#ZF/`5NE1]Q9". MGOS5<^]\JF=A%'C.3S$=#$?L4@W,H4*?JHV$VMH08^A^`5Z0M:]LU`D7#6.O M;QJ^(.2^>KY/"7E@)N#2HY,_)@2&)/NI+:]4AC@*0=\@5>S':X1#[U\Q'_NRCL*"3S5![/'VD/J)@^03Q^A8^ASLQ7OS8EK;J`;HAY@D#!\YNQX\( M,`$=__,?"/_J!_=#&=NM#H:)9_FDXSA+JFOG*L;DB\`7CM.2L` M_6\H[.@`JSV>/E(?`OHGT[+F,`S]V-_2"8G*X^@DC7FZGL!;1[-6V;\^4JBU MO?9"QC1"-_Y-;(XO8>!X'9%6>[RCD)I[D=AG*OW""/B39]];[GP2^TW3EAWR MHP52.HT8'X2Q+SK]0;31^3."5_H_GH[A\O.A%:#$8]$;OJ_ M8]'*&4Y+U"`^XI[0;NR=SY],\!($J79.-PU!ON>"U$">8DA8B(S]LQ";R1OG M5#W!M_#:1\ZOS=AS1/PZYN("8HZTIFBH?JF$J.5XQT-H_R MP3JG-'66'4%V2=+.Y&^'0,5]$#K0C+)`Z0W=M424^ MI1GZFXV@OK`*0<`=E29(,B]S[+Z6=+]QY@Y@"4PI!T7 M2=NU\H+PTO76ERG,)NW`!(C^LA]UA\^/@BM;`"QJCFK3N M$M-XA/,U7#]#7!/-4M,.<5S1+K`3/I\,R#$,XU2^KB'&B M6-%CKH2*SRK,$*XXT^F'7[*1F$NM$/NAQ,$'RB"2=> ^C'?50WN>P,K:SJ MW;N+=_0_VC@VF#XQ/0NZG\]"','\(Z(2_2V\2YS(M/N$!V>C#?80IB?1Y[/W M9Z.(4-+0)I%\7;%FS]9LPR0549FQZ>+=%6-2K^F5'V]/BE*>`IC3^N&D M:,U.UYR^/YX4?94:=$[XQY,BO*S\YE3^Z:2HE-@>. M/!4*24[T.^OF6:J.9A.KX!W(:?SO?M)8I1CG!/Y@B,##F`>72!7EN+1XRUPQ MOU@/XB7ZR:2V5&U"3;I+&][.TMY&A"9?Q,XBHQWNK7/((U MRX$B=;=80"<4K.,ZDU_9EYZISDL2Y!4)Z0T>\8T"Z05(/'=FVQX-3:5Z8<8W ML(92'V33WC1,YSU5?APP4PP/CL!)L$H]CE]H1VF4I)GH.`:'W]F^-.KH,"/\[/74$8LHN`=J'L7(,C MU]M:.TGBRC[2X*?)UP/GQ=&9^]@PC:`O'.:E,!Q[=`V'SZ.W@'/'@Q0_Y@>Z M"Y9TWB"F`U=%S%1;:D"2]D2-5N!GA]]D,7:A^*24@NN(#L,PU8(DVC('R(Q[ MLR/#H.ATT&9D[9P55_9%=33IG9DCCJ_UV1P*T MTFLFZXQ'F@[2LPR:H8>K]P@VV@DFCQF>0I$59'/^F04LTVZ*V9P%9XF4J3Y7 MC:?752;K&/)J'5=8VY]$)/?]%#9YN^A=P?"(F8A+BE`N-*"?UR"_,45(>, M1>`]QEU/])5V<$.5ZMN<=P/YV!C=@RS;_%`8L'W@2)$]@ M'.Q2&72OLE\DP\]TA(6-(R.@GAT\D(<.V7(>TV(G5-LD=]5FQQT&N M;IV6)BC:J0F$ZK"'ZH00S&PMD=A+4`H`"2TL\SXKI=A9.S*;U!(9R4FH,(3+ M^3=[BE\?`L7'2;\Q%@:V+?U&T0G;8T949*(92\53$]Y#1L"0:V'3$35D6PS9 M%AU-H9*],*1@5/+QT$H9\B@JF=9ACJI]MQI9D"LD==+WH4S`]'H5AM+[4&)@ M%?/V8OE]J$PPF1=YX#'M0]F":=6&Z[XU7L;0A\P\GEO/N!74!\8=.:7Q?7]O M8+I!ZPT*$H4YW:EINJ+Y*_;G*X!AZ0%2:[(/QW[<.71C'*\!-7\9)RG?8I0R M%O)C)(J-C<2MZ$9A7A=)KD`)Q"2.TBRX%D["4C3==2[:]CX*W*,,0B6 MR6M.U]L<9II8,.-7@%U9C%Y?_T:X4X6S".4#M6B?+>T[[A4_)O%A2+Y00/94 MXA32X]*EIRW1SB#)2#INH&ZV4[^.D5/:U01-C;2#[+_!=?1J_<5@.B MA:[OZ6C)&5H:7(BG>54R/O9DL''M62T^4X\L*X(C"H8H_T#,C&OU MQ=H']Z*TZY%\%:\)4:P,!2H3UDH7?VKC[4G',/KAO>JIEX? MHG,=K2_S`[3Q:KP'>L@=> MX@8DB9Q-,7KQF%R]1_@61<_A(O*SUAINP+;A93P]ED>"U0W%JOBHP93^2?&: M0_SB.=E<['A*&7P-7.9)%5D9;7NUAQ/Y4J/K+T6YX.*LLD=;=FH3'V(LYRC" M[-XIL2]+N;FMM$E]2S4Z.''Z]!37?04!6-)#C@[(WE4)5Q`_!&P38"(NXJAL MHZ6PQ/4@8?G!E%QO)1Q?!FUBM9'5^^I%R^#&L+27U!K MA"M!^###ZZ4)4WK[>JE>]9GOH:FQR4_8%Z.?P_EAU`?_KW[Z^0J$P$5ZT M=@3T(5&T`R$E7CVF\CW5PGQUS?SJM<(W,XW'%=3"@\=A1U_"BO7]"'F=:-F( M[4,V;UMJ2'!_Q[A M0S#SY0GUZ)DL6"+)*ZM#:1WFUU?#(,(G1_\FPA@*KRFNUX<)9Z4:ADGJR4/@ M8`@(O(7)_UL1+>C27A[\@TH.>LHN1"[NK*]Y>P,03#=`?#AC#3 M$&8:PDS:.%Q3*_H^8U'ME*KO,V956PDS'J,:7%:#7V;PRPQ^F;1Z07+Y@DGT MLR`>13J+<%'EQ0DQ"CPGV7*,-.R27<$=N84+2`]PEUUREK6O;&0I_5\0.YX(@2')?C+A7=J-S5?4=S^;L"RRP:OLZT,XLR9SAH^:65R& M'DS?P?0]HNDKW&)\:W9O99^PQ:K$F%QX&M>7&A@!7#'U/2GZZDJP*2U_4(+5 MM:CX#=?Q&N$P-6#W`4RH5S<1"=$:XAGTDXO<5MZ&7X6FTL+\LY95JI@(V@3F M]VP]PD=J$QRL%6HV1>O(9]<%%%>,@*@&'5E&[_7V*_@_A&]\0&2Z29T>+*-0 M=C]593/+:,DY77DO7=U>OAM*#5W1]Q"DYR`?T[NW]+;2"K.[=C=F:.7L)74* ME1K;0!=5+)I2Q6VJL:S[T7/8K3:5U=UE.!W6^\Z*V">9Y_10:3$X/@;'QY&I M>,+`A>S(D&OD!V#'=M)4J.`[<[9J3YZPNT:!1N99:/_VH=BLQ)7\G\=E2U_* M;1M:W47.'.I'YCWB1R%P6]#?4"CV!:JTTN#>8C06V"&(%\H@S4`3>#- M9'K%BBV!&+MJ5V'9'L+IB,(D)WI>ZS'%:$&5J5BCH'^G*G:XG448^+?P!?IH M$XO[*%S%RI(X5J.C6QU/2F'`KM9;QN/^A,C&"X$O')<)+_$34TV[.E:81$'K M$+_6>KJAD9IL*9]QYFTA;8251:'-L9R:A''DI\V!F]KKD4^8?:&9%H1QZI/M MN_.N!7U%E^FNL1?0A4*#*!3VJ8A_"!JH< M47)`V1\M4'!(B/=\LV"`+:[)9&??CMF>'0=N_,]_(/RK%RQO0+S-XU_:O^,^ M^`@M\1%>`^*1^09#X$Z"OP/LL64^`R&\4J)"TMP\;;>0.-B+=]ID440NQEJ) MOHHNS--X3W?H>,V*_97H*8";Q_V!VLL8DI#Q\VZQ@$[\G"X5SO0WL%3S_E;U M83V5[/.,/;7YE63%T)@L&%I222QI8"2&0;6FR>(&0ZK,B2(711`-[N=B?^DE M2MMKA#%ZI8QA[POG(FRRN/.].*Y_[?D^Y-QHPU$+]?9O>E(.**`J./T4;@M* MB<+$*75C"ZUW;QL/Q_:$[*!0:6D+10_,@FM$T7Y+6RCZ"MZ84G&PGFJ0)NQ" MAY"A%NH4(P="ESRA:_@S@>X3NO<"IDP\K#<8O<0!&IY=J=[65-0YS"QU.IC$ MUN2"VH"S5(,2`)O`^RO"X9*>$_(:L'TH,Q=,P8`:IN@>8>@`PB\8K``VB??/ M`6$9F`L/NO**2R&\T5+'#"V5$L<2[!#.'\+Y1X_"28URFZ,S=:.-*IJ8S;&7 M5O-:=`H:C[=T.ZEB9?2$N/QTQNO#"EE-N:V64\DWZUNO*Y=-YD"CV5*YP?+;W.1 MQ3YDD]DG`26/E12I/(A.Y)+'/L-8V>%??ER`']7("35E_=6[C8$7'N#1R6%* M7Y.(YS]-IUD.\9`I/&0*#YG"5LS?D"D\9`H/F<)#IO"0*=P,7P*=BR5ZH4J6 MEZ!*_[*/(?WTRUT0,B<0;_X/?NX>FT>X!'XR)D?AX$%H3L%C#G^JQ(^=WR*/ M>)R<584&1A)\HF?BN1X]R"MRP#B`W\M%)$/*3P]\UBJI(;V-.]7,:^I])$F> M"=+[>%*33)#>!Y6T98*<6")0C4P0^YR>#5,D>-K2R:;Z*.=%&,OT&6*G-6.G MNB]%,93[-,11:Q#)-3.-AT\EBUIDI9?B,ASSSWR"FE0>2@Z?&+4V MUE&1"98FU.S:FJ>J#X&SX0*!7N%MZ+'R/CP2L-O_?_,"=_KP-Z%*KM!@N+3A MN[FT01?VAG:FQDLGAM!M[]SEWT?H5FJGGFPD5QBQ/K&0[H$%H$LNTG@/^1!:@C4[KKEQP%F!=$:D405N" MN3S`((3O-?;%\,@1`@UB`9S9P_M2YT1#"W)&2,\`VP,*:J152F[C`81*.UE\ M2.ZG)W-%I$T*J53YELOX"EK[IGYK(+8OQG+E(2*AMND;L68-#?HKW:AOTD1T MDQC>H/7:"]F11<:!>T-/,R]8PL#QM*3.ZU$]QAB"R6)&B;DCS%;-2H4$FH<0 M7(.%<@,(,Q@!_C7ME?+IT7!T([>9O?_ID!J=*JTZ1$QEX52V^MQLZ M:F!3.^V(.V5W;QMZ9D$R"::K+?$<#P1?(D#UC1!")B&H6HBC9(8XTU>GM0DC MY@OETR,B9`9]ECWRA!ZIA%O&@BUW!0G$BEK;_E_:HBM/-`@Q<&%^:;?(1.=! M:EC(69@^NZ,WO9'YT*=5`:P1E=V>(#_3TQOO=L9XB:'PU;D:C36@FL3Y"Z,= MCL/!4:65#N2H+ND1@G`9<[20`.J:[H<9YO(O'5YV2)^J0J,FJ:FW0=C=% M0X*YHM2XKT(OK:+M;7NN8\,I5=1#;,]_;##)LF/9]JS(%N2J'/VV9TLVV=(J MZH3M29,-Z*YE11E/H51R.RO:\E5W?ECIGI3=^:'@]3&>*UGA5N_\[@^[[S+I M6W:*Q"4[=U;0C7SVS%"L%#IA!/S)LY_J#H33-&VIX\J3P=78M=>$.ZL"OPD? MUAJL;R,X7H00WWN+%F).4MK:'H/@KIZ9!>[9DF$Q.*[`RR4\YE9L8]/42`7Y?@>AV;X`?W M+51QUI<0W!;<*[.G*AJ="!UZ0E99,=HDF$0A"4'@TB'90,*H;%4+4U>"9'?8 M25,Q.8`:F#BA9@U@<_4(`1%<:B^&&SSLI^1AUW'ZG)CKLI[Z=&*.S%IZUHEY M,>O9`B?FRJQKX!GW9!Z1?`OV.6F@/J425=[FC(%FA%8:?GU*%4]3`:8`A]LG#`+"*E508%$6 MMN.PZ\6R2XP*^-*SY";".#EBOJ'`2?XAL%_K]V.FS#,`R]C`DQKC!V`:TP4? MP>N]A]=YDD@6`A( MS!L!L!UX2XUH(7B/<3?D!KA!>(,PE7/?6`'1LM)M)88W\U;2!D,J,.*H(MSX M,#Z'`I?J/?2@_YU:I.?1`KKG?TZT9RYT"-#HPX@8`/J0+Z`H,( MB@_3?2BS[JIT60]W)W!'J=<<>< MFD^R/:E6>"$5W.I5*GB15J%.8-SWH9E0B69O/)S0P,U3^_25+W!+LM*.S8@* M<6[\O0^5FR!YZDGFXU2PMFSV?BO16*56&/=C'\2-FNAL_'A1C<5_@M&BUGS< MM[IL+C=H2RS776%SC4%;@M6<8387&K3E0,$Y;W-!05LRZSB'C)<:U'Q)1F9F MED19^82T/S(7/^/YA'8AKAW%9(*7($CW9TE1I3,YQ9!0F/B?K$SNH'$>/'NB M*%[[R/G55!Q/3.$W]K8GBULG(IG2:!^.E)$;1(#_!:-H0^B9X4=Q4CCE;USZ M$D$W1[\77&]+T5-R8:!U=,U#BMP*^73'$R;IPOC6OUY,R2,"`4E^9O MIG+L[F<\73)L74Y4YW="C`+/28Q']GP)=ME^H;]Z+W`&O?5SA`E,SNJ,1(NG MYPM"[JOG^W1>'NC9$2P]BF^B&_5B>=7#W]9U52P9LYC97#1MY2GG^3UB,6]W MCWCT8MM);H\[0?QM7>*B?,1>3,&^17LJ2%14=7@+``$$)0X```0Y`0``W;U[<^,XEB?Z_T;L=\#F1NQD MQ94S)>I==WHVG$YGE6=<:5_;W3.S%1L=M`C)G*)(-4DYT_WI+P"^28`$*`H' MV?]T9\G`>?'\#EX'!__\O[_O/?2*P\@-_#^]FWP8OT/8WP2.Z^_^].[/CQ>7 MCU]CS\-OZ#\VV,.A'6/T9'\/_&#_AF[M M9^Q%Z-;U_WBV(SQ"]'\=%/CH/SX]W"+KPP2AES@^_/SQX[=OWSZ$H9-1^[`) M]A_1Q47&Z2^)3#^CQ0?+^C`K_>4A./K.SVA>^NDJQ'9,6B.'2/,SLL:3^<78 MNI@LGZS)S_/US]/I_RFW#@YOH;M[B='[S4^D\7A^07I,T<.'AP\E]?X7>@S\ MB+3>'VS_#5UZ'GJ@O2+T@",AR#.?OT=NI<.W:=9\\O$_?KM]W+S@O7WA^E%L^YM*1TJ,UW6R M7J\_LK\FK2/WYXA1N0TVS$H2`B)A"_I?%UFS"_K3Q<2ZF$X^?(^<=_]"&?YS M&'CX`6\1D^'G^.V`__0N&'VG_CS[>D6_I4`YKRF&R MH!S^9_HS\[-WB+;\\\.-4*%UA5;2Z6,BI$?_@_II14S\/<:^@YU,4-J]Q5R, M.K,T(TK)!IL*08_:/`BYBC-:6SMZ9@2/T<7.M@^$\&3V$7MQE/U"G7-V,9ZD M1OZ?Z<]_O=QL"!)B@M3[P',W+HXNGZ,XM#=QQHWI^*=W$AT^YO+3+A4-0AP% MQW"#E4R2?!Y%*?[J/=-.>X]TH>$'^Q=_?GR'7.=/[USGK_/)__WG1)!A=8M)8,*W&A2T^BEX&58]T`XWF:#D MGQT:IBT^;@(2;`[Q1>5#;L-@+^5-&?]`VB@?X?`3W=MO]K.'KXYAB/T.[-0; MZ\=-30)9EUI9ZZ55P4R$4DHCE-("AED5O0X))0/`(?`M#C!XZAL`B@?L MT9'SW@YC`ME4N$O?^4I,H((7"3IP4.H63MH;9TMK(D)9R@:E?(Q`V]"J)T#< M4Q89#%$<(,_^AK9NN.==N@:ND_2"1_(`WV'VEPOX2!E$D-\P).@%@ ME"^)M%(%;=(`$SR*9B$(^0-R0@J/B\`/?21@2!M^.X-/#8WKWMD@G0E7UP8]LC MXNX#_S$.-G^(O*2[HTX0=THC[:;3Z3H[5)1VT@H$Y0P$@CJ/$+G..M$G)9&T.\XM*T-@1A@QRA=)ZE&9-DJ)`V'P#(HS');5W90HDC5$ M_R$K*#9QKW^F"\)F,,:/&(.QIIL^S M[5$F9]3S,;;#&$C3.=7T$]ZYOG\V97F)?_K]>U;L9%2\W,F\W$X908=EY>A5 MC\YJ%C0W2-\S=)`E5XC)*/,9)_]_DNL(2!H7POER2JS'A$]88HRKNA] MQI=[(JUGCJ;'5)455%2:HB&;A`ORW\YQP^:L<4#^XQ7[1W[*D%EAHAT_ZE&C MQ=+F!I%_#]T8WVVWT4E.5E`Q+E3DHLDGIUCYZ8A"=&!\+@+"R.S905][S"JY M$M\(E1C[B.@[0FFZ#@T+KP0#/P+V&VZO#O>J(=40'D5O#+83*P4M^:&5[1/E M^(2_QY^\YLZE8N>!(>H$FR,]R&'+VY,DD_3(V7P]68W_.FTBM#%7_7"6D9D7 ME,ZI:2T6?>'&(L8`_4Y9(,9#\XV2@CLQ7$63J6TH\N-O>D+')W[D$19=1 MA&/A3+>]D\Z);:LD*O.V6>;X!4$:/PN2**$)M(`=4$^KH2<6GY]HFXM*^6%E MZMEM$A!`D:7LW?8!V]YU1"9Z.,OF$7U847.=(!+((!UW)^MIEB%.2%'84&(H MH9:GP`$A9Q#E&&:84H<6;;2!IJU/W$'I!A7ZZ>[J\19>/C]=/CZ`>+`[KP.&;L>^JN%!MI-U;E0L/3!>+ M5=EKX8LIG*!',G\QQ(5;BR,TE81SZ8X\A4H;[0ZM?%EK-;'*_GSF&S1RX;B7 M$DE4I@Q0>K,8V<*!1:]KMYT--Q0&=VRID%UO"^7HZI5CUGD!@JK#&Q+)3]*+ M!?1,GX3>S\:X?W>`Y^D.!X>ON!T"]._:W9XP54B`G*:;D/02!.BF2S_9K?;5 M@5XO+KE#TW,SU0"]-2^H(16_.!+5#K8^4\M/OZ3A=0V1,$.,R0CD?5&:$?3-?3>9*[DI%$A"8J$T6_4[*(T3W/N"G*8!E6RPFP MEJVY*L.J:IVFJH[L%%D09CDI4@8Z7W!@:2_RWRUI;D908++(9CC-9M/YJC,@ M,))&Q((>RG7%@3,JUR<$]-"P"_YB#0&17T%8!^H+FPR`^"L[W+N;%QM[5W;T M\LU^NW\AO]B;MZ]!C'_#^V<<;'T65,9`[?R)KF+[9W%%V$D^NK<5=`2B"%S=J%E0$O>F&% MN=@_2J1'R(Y11ATQ\G"WE,^@_:Q5>T0$HLE2E4B`A^33;M*N%M9ZW!F9 M==\Q[DH".9\E%MEAJ)OIRJI0"2QC'G[E;P\KVW"0)584>WAOAW^DJ;$NCFZ] M3W5P:LK22@5JRJNNPR!/B#_=Z-]\GK'E?L<&>'??J.5=N)BTPOW8&@ M6R39U?EDO5RGYRX%5;935Z$+=_0RN*X3>%W;0\30"ELG*ZPE7,B#,P\:DI8Z M:^@0G<=T]3`F9*ALZT_7LY6UE`D7``TD@BKSLF M]#VJ&6A7()+H5`(W)K6$14EZ]DR/:`]MZ$4K$-)2C]M MB_5N_ZNLS3N,8AB$:+*6%T3'$'=D%JO1,`-F3<&DLW2ML;66`!XJ6(!G)I_1 M$-:`AC``MV*GET2RP)[&8EM4YZLG$=/0K5H$REJL5N/&>K;+J\$*8>FP13?" MC<6\!,'L@1":OT/?B#YC M%H$4SD[4RRKI%=&R_=$(?7/CE^!(7X8.T:M(.YV($CI:'3A\8P#C@[V&$-U$ MT1$[W1^RTAH&(V415(+SBH>2Q]2I$G+@..FO&P\IKE`I`'CP_$P`D(85C(#( MW3&.8IN]K2#[(-*#YW*H'@43;U^3A5DRYP29$9H/9K-9BF: M:%KK9[QA1^EH.ADAZB>L"_G#OQY]C*;CY$=#H"8SBP.?P.4O5Y&%V`..W1#3 M99G*1J0T!;U`E!5+92E13/Z*=]RH`Q;T#=N"/(\1K,&,H!&5JHY>`ZR2):&P M7'NHM>-MX[8>FK$J$$/A(=!9,:%XA"[C.'2?CS&KJQ^S;0ZP6FR#F6#1 M-,&U'=(K`5%J!&@4=KAH'75M5H%!F1\%GNNP4,!2SK*Q5A5"28D5".Z$%-K:=KIBEKI@^I+2Y614D0D.8@8_/P=YVZZE8_M;?4BI2F`R@1EEL,DHX,*0E!3KY-U6M1U"G)"T8B^@ETYQMV8<+>:M(!LA0AO9E#AB MU!$E#S8V#:XZ&ZGN[;<$;\Z173N<_S_HC5`R#VU"M^V$']],)N'QQO]"7*87 M&BM=#+HW#Z.[&DT,=(&PF^GDISL3$[I(R0'5LQI80:NG@OK0V.%\59"UV00&.U%\M_TE")SH,?#$ M=XVJK;3BI,):OFKB:I87EXA8FAJC@2@1*$"#\UDKD6$>G%CK"#HA9% M]/IWW6F:[EU1&,J[Z<7OZ^\TJQIWO5PN;*[9XWDRR#\T.)LO"]]/EOL9,0-N M"@RAG<77#AH2;9Y6!X?0""`P25YI^X+)NL7VGNSOJ62?L(^WKA`M';UT@J9= M%)4)17:6D+[HEY*DF?R9GZ'W*=DSE=+NQ-"0RC(H94K&1$F<*?G/#G83>)%_U%%%?LJER+<`KGWG,UG=U#YI:U,-^&GC M+_]*^3RO59"!IK113U_)H.3T8F4XQ:P^BIT;'S(N1D'1:0;`T>8Q)D*04?"6 M<%(=QP^8"\Y+'QQ#U'[)G%+#ZW($XJA<(J:)S&GU%"%'/1&\5`J6CU5 MU(>M3B>L(JK=+A`X^HR?Y8L9"!IK1`]?`OG+6DLKG?-10B;5(AA",4M=,5U( M:7>S,DA:##%`??\J]=N6YT!$+377\Q>((5O\G:@_2>OX-QSC%NBECT%4XH/X MW"JUUNL?1"\^ACOTTE&?OP,Y65W^-B-`C6\W/@DB#&4MM0@X#36/:U7NTBN0 M\30KNL_,AQ+9SY__%#EV: M1OA`%G@3J<_8TAT,*V*9%-)25GP$C1"CCA+R*/!1Q@`]:-\;/*_ZR8:Z%]@T MOQ;1C!9Z_.SZ1!P<$4-$C(4YT.OV9#$@.VP&#]//.-J$[H%.">^V90&9Y%)^ MT4$"#*[MR"`OAZN\6;V'W%]YAX@Q_;.U']8C4: M8)#J$$QA9V^R%N`L8\&&MA'*N:""C0GX&]02[?-4A/]&K\/$`8I?,"*HM>/D MJLM[]R?VTR%T]SCI]MZ.T.'X[+G1"W:2B[88_;OM>>@Q)G"/T;\2P_BV]Q,Z M>,<(O6;SB"`DU`BYB!Z,&30CED23.#[(?"?C@P;]^8'X47;'90@/;=`T-:C4 M!55(3Q2N@"6"3#*U9HQ'V;VS'R#PG&:MK@6SAZ,(@UXK&P0WO<,%U[IFA0^6 MVN"<,.%H$#`B,-2E4CAS7X[EHD#"PN!YQFDV8-C.56;8/K2J"@]ID2_+X9=K M+@/`&D5'FQCEL_0.=;4''!S+8B@MKQ8(FX-!I9!!X9.0A/BZ&Z+2N2SBEPP":K#:YX,M?GWC?#> MO;!]GY[#E+]U^93F(+:`KE16%2B7ZHT\"K&@0<@JWPK]9&3EF#@8NQ5 M$CG3L[=R8>3;P-]=$//O40U@45HWVHC59P]-&R6@^VD*@ZR*"XIQ5)C%`-00 MR\I]2]H0#C.$N\H](=$&#:5C!#*4]>'F\(T>64+AY%1=DWT'3&\ZI/K2VBLV)08+$+&_52$B,(`I($GKORA\OZP' M,&12,52\:=$+.2.4LC('0KUTMRJZN^PA>7/!5//++DR5+6(*M+X2S9715>H$ M#+!"$H7]JNFZ)\8*;N;`K*\%?BRD-=VT"VPUNP#AS?6QD]8GNR=?Y7(?A+'[ M=SNY-7A/9M!A6N&95K2](BH(Z_;U)*87GSTDE!\?9N/\;(LQ0BDG1%F-4)D9 M13!CEU4M1ZR*^?N$)5"U/QWV8:BN6^+`+)&6/4>;@+_QJ1'>)Z"B!ON^!C4C M'-`"AIL8.P^8+*K].Y^IP`*8M`NUD`"%OE@NA9NO10XR#_`9"Y3PH#4QZ!_2 MD7Q8C*\3&_AX1[/3U5`^F"EFU!:YUF&NM2U4&`[3W:[=CN0.HYF!W^P\@@87 M:7>H=`+%:%D2:5=T>K(FT@D.9SP7;$=6PQ8P M6#J$>.,F#]3B@X?I/RY]ISR`"[^N1%>MN.J61]KGYM.LG&Z9+*TDDQ)FJ15E MTE`0&UIIJZXTT]3NT%0?\.3]M0H_23L-DA;ZG7RW7X/HX,:VQRU`+6RF/=VS M*8-LJM]XO9Q/LM1.2@:]I'1T)V^>JL.DI$-&!ZA>]C`*6:H*Z4FQ%,.B2*<4 MJ`XR-N8U2^^V5\&>UKAG.&*UNK'#WCYZ?+%#_$R?,\M>3NVJEWT:49WCZ4F2 MRN=^K,?9/+:H;LL>`"]8HI0GF_=%(\387C"^Q6/&X.6Z-=K+.KN]M`WH@X"L M,M2?_AV@H@U[ROZ(G;L##IG,O]BN?QM$T1=B,]+@$$2V=[?E-OV$MT&(;]CY MP9/]O<5)A^2B.1X-*+KTK'BRGBZ+`)6113G=$:)"H/=4C)\0]6Z424)Q*>KT MS,1!B3STY`LN:H%9-2VG%T5T]^S1]@9./%'8+`3UK5G9#(0)B^<&;":>)R+5 M8_70=C"=BE309-&CWH`X=K-5%EM^87\X[@G0::&MA^H<+S>>V(0O)UW;H MN_XN0N\]9JW4($5R`NP+M0.CK3,@];3Y$%M)PX@C6).>@X/N#:QAQ9?$RHP^ MKC1-][[*023(Z&=8H?A)@HW#;]>`EN;-,TC[M<3K+/BR6=$7<;!&G^JQ&FP? M`-R*V@6/BBR1)_P]_D3$^D-F!.Y#%FI6U4-6AB#&'VW_1:+.V#1ECIE,C27?IZY[43(T;ZI6EETMK M/.T?+DRHK:W#0-;9#&1D%.DHWGV"Q8=8G*5KETO?N2;LXK<;GZR"]\F"L.4X M7::;[F66A$RR)XW3\7*:K:52LNP8`3/"9$&54]:[1!IUM-N$SH&96'\W.C1(I M-Z/0Z#:$;CS\)[9#.304+4&PD+.7]I?%?#+F(X'2,@,'/;7BHJ!=*_T8:+@6 M'P%5$^CS_P1YU[[#>7%,W$ZS[U>82_O(;+6J3ZC2$'E-,U"TORPVD$:6JD8Z M?9[K3G6/;RJOS]^?"-F6[\+^K-F[*4_IQ[+6JT5]8D/[PWFRNO26E/0ZO;;L M%'5GS?4;8'5_;8?>VP-.'VBXQ[[MQ6]W/JU1S5EJM;76O)9O$47RVR\FE%NR MA&?44)B10X>$'KV&YA"*>H\Y!U-M4JB6DT,I/73GL]<$]*_7!U//:OER4&MR M"3QE2_$N.PR#;I8#3[.^R1#'+GM?)9N&Y.=2,JAX'T^9A/XXH"2?],DVF=DL M\^!0N4E`:**(\D&;G%&1*J$Y)^*\^D\J^K,[*(1)4D8!%6S*N=206X'G-0:+ M-UREP2Z2]`5X*0:I&^Q,@4F0IZX6FCJ(&!":C%@"%6`0D+%F=I@4&AL`@8^N]XQQH[DU\I:`^(@ M%4%ZQW6USBXG\Y"04C,#"[U42^=?0C6@\%!SK#9$E/4>8K7GX4T**\LCL5 MUGHZG:7KPIPE>F$\49@PI;=]$J[DEQ);^O>4K^8EHE;C3&K&27BBE"G*N:(* M6U3P!4S5UV\M%LU^PXZ[H1-YFN&8_(?K(`D;1BA_T(O5AKQ`.2F9WF"KU8$" M5KYV'>*3@4Q.]@,,X+1E[Z]K/KN?&+H[:7\#L[J=SPM(EC/3]X-EBG$U= M4IH785I@N$05^.G+@=5-'O#:;$*ZDW2PWX@0'HL#F>;@5?"DG;0RY9&RTOFS M0)(LW"O",+2]&]_!W_\-OW&2&_CM-.6%<)E+KQ%7D^S9K#2-.B6$&"5$2.G/ M%1E`(TM5(QWY(ZWNE"62B)77YN_!?A_XCS$9V]B"([H[QE%,H@I9A8B_5ELG MO4AHD40E871:A06CBAC9M%1]A$J4P5`RF+;6B=IJ1)"$@];@U&4E7=CB7L%L M_%DK7A3O`$XGV;VCU%=@KCR>)K\E*;\^GVY>,>1JJ,M/O[@>#J_(Y&L7A.(9 M3[655J^ML);^^)/Y9%)Q7D8&972@7/@$92PE9?3Y,]>!JF[=U%J7=S_@G4M/ MU_R87LD5?I9:,ZW^7>6MD#&]K$[G"SKL_C64AY^BCJ6FCCX?Y[M1UXTGZR'M"`#Z7X00]+&D]M.W=<)VFLE'3U'>( M(ZFT1M.=?__R%KD;U_9_.=H40QC3VK@/>!,2OOOF%J=J;]T'3?*BR::5C2>3 MR2H]4TJITXL1AXP^VN4,THW!G(7F=([!0"ND3B<4LO]94(<:*6!-R(Y00!!J:!U(P?0V.0.L0!AN,'0*LP\%S ML8/L"&4WG>P=6;%',8I?Z$64_<'VW_XI0A'VW2!DM]9`Q_5.%ZV,\>V&,P9C MW]UZ.8;.YM#X(C(HS!%G5ANZR)R1D(.:]PZBG=5+.U#4E)RN$S.9/4Q!#+VJ MW%H2L*,3,'H*2>0SQ1?+1?L(18D"%_$;4M<61$GH"HFLIG-VX:MF(PB4?7%] M-\:W[BMV;L@JT-^YSQY."K-?;LC2\,C2&2.E!2",:U:53>-UQ MG*[H$B87C`LJV.1/'I0XH3(KJ,=YSVZ469KK(ZVU+OCV]_HRI'O:SS"8?WK[ MS?ZO(+SR["AJF9&J4#`#V'6QY"^A3+.'R=L1C9[?$&.!&`_0Z>S9[&`-:0<# M\"UR=TE@E8H9>.2))CV.6-/E6@Z>Y5'$@.+T9S6(%(*5 M#&(`JMN`(`ERH64'.*;]F;C M\6HQ24Y8$S(HHX-^3RB=!U"B@]33=9EHUZ7U9/1TA2Q5A72<<[;!(SO0%*H^ M&#P?')L>5G6@L]H*!)P5$50^_[2"34(&L=,Y0&R>H,I$NRH2T#Q!GS(R'SY? M=NNC#YE<9%2!V50<8JI,+^?26C9W_J/MX;OM?4C+A75F\W5VTS@9[I)%_CF# M<9;QPZXL)S5^:,9+\A"/RU[_"+;HSDWN0?YB)WDO3R[]A"CC"YXH.*Q!TIR$ MB*5^/0(_@2OKKN49K)0Y(+&7WD1]"FZ)B^W82/:(X]C#G"1$M;X`*&P52'KG M9#X>$VH.;)T6H4NWNF[]9V0_1J>T=,PP]-^PDQF80> M4DRKD#XZ"6XU26X M-@^ON4+%B$^V:RRG1`/!X*<$4SLJ65A46;!+7/"LK/]$+ M/:,[GR6L(2VA&Y-*;L\#KKQ!C45WU^/=BD1,P[?Z(]/CY7*F#'#P-[C/:0P) MC!N/YM9GMGL8#Q+/MZZ/;V*\%QW]-]L!H#)G+O\DV&12FW"BWRD5Q,@`XZJG M.I:2.KH1TW`D'BBJF@^P^9^4LJ.U_+[8F[1VUB/>T06;\"B@NX_F@X%.@62K M)2[FTW%ZA%?0)$OVC"B*$JIZ;T0.K-ZDIEY!%*54`0\2!M;5.DU7'8<,T@C, MCASD3#18;+@BC.["G>VGV;19[4\R/F=%1+LJ8T;9!I'P@P_*!"3Z#*F!_`MJ MUB1]WBJY:$>W%%U_$V([PNB]@Y-__41^:ZG42OJDI8491(*2$M&'EG[OWUW_ M^O#NI^PJ8X1H;T%5XB@M2XP==/0='+*-SY1>^3WV)[QY\0,OV+TA\B.Z)M@) M]H0UG>=>$<.[]"G>M-_E)D;O*9UWO]X\75_]2G\@XGQ[<3R3!1_A MZ/IQ@#S[&SWT^(*?PZ,=OJ')?J?F*24N;W0AW M??*!XN0M^0UKS7J_?W?Y\'#Y[J$='1)G#F'PZD;LP1KRG^[. M3S:]\\]$F1XCMAM,[$FS>I\#HEU^,SLYEWI)C_[)%_F$=ZY/*WVC;RYIN,7$ MGL0JV^2=XC?Z3C&!LH7>\_[B1NAN$P?TC&M"6(?!HU9T;.\C8#-8H2PYR:KCUQ&1F(3DLA$F]J;#8ZBTE_?O[NZ_)4Y3DA:N`>; MWM&A/DI-P:]23(RX"^U]XF,Y0^HBU>+7N?M%Z)D8UZ&?/#HR`;9'SWLCGV!/ MOD0<)CSWV*:&)'_*/@$1P0W1!A/)MO2J+OTD<>Z4'^AS::]T_/+>1J1M$)6U MCE_L&#D!\H-8Q!1S6%99,`VCX_-_$=A1/ZD^B4@'+GHQ./CF?[-#!]G.?QT3 MKXQHXT3ZW(0Y,I]SER%6%GS).<2D!BYJEF9!B$J!RF*,!&XH4^YZA$K'7%`3 M*#B[6L5!7_*2&3W>0+$8'3+7U'T+RP03)3>T*.SE[*%O%GJ.N5YUVCJX MU2'V?OBJW)/_)1(^XO#5W>`'_(K]([[/1G\R5GVR'7K_5+13="I5C?M*)XHJ M?7JX&E?7J[Q(G7)%*5N4\D4Y8S9-(*S9;6:@:RA:#99D^=`YUZ%B@V=B`UI2 MA$WY6Q?%4'=C]?H5"\-5-W&"XW-,YV9DTDH75*![Z0.%F?(^XA`&-B?B%H]L ML)I.3.SBC"#JVIH_D2AXO)655.&`:6UUA=O2"SK)PCB)MB6^!AP4Z+27=79[ MP<8;59!UAQNE[V!2M&&2/C)W;;NT+]W=@`A2ETG^-MULUCDURYP]I0]Z5?\\ M!N@$OZP!H#$N"SV4$500; MV4P)'=*I[T&M>: M3E==$"]Q0BDK=E:8,3,)Z@-:)7\#/DR\/F)K_RB_JI`<8&U=C[UK'&S1(:3E M6-E)"?]@8!-$E-HA"$W<,I!"3G>,Z/X"$,'BQM\$>TSW@[\04UP%?NSZ1_+A M[@XX3`ZQ/V'R>7'2[HF^B M)/MS;1=VMYN8F_P=T(UP+T<"<_]V87\=$^K M*`;^91R'[O,Q9N\9!P,'RU[,C(J3?320?[]WO5ZIA<@1R@5"J42H+!+-%/G! M8N/Y+:P8%LT.@:?@5RWZ]?XP9@:^>QQ^LB-WPQ[_[.VM52I&A:J*:/*W"V=9 MJ4?Y&$0X(<8J>1869BEY5H.P923K;'8TX#JU&LR;5C(6OY]=[QACYV0$5^B8 MAN&R<`J7H!:]4)PR,Q['_8W"D)QV-Q[+/`=71G/#5O!XID?`B;#8*63]BN.[ M+5E752<6#VRKC2B5/)XIY36GT`?#_PE"J^R)3H1QH2Q`)3+0_=-@2S=@1HW5 MQ3WQ*J@2/D#V*TIKM9O-3\P6V]]-6&MI,\^B:AZG;)[`P%75`,%(')-/M;KI ML5I]%:5"S]!8W&\A,5^NIJJQEQT])74,;8\]TR03HPU!,Z6Q-+?%L8@)-/ M-OD6&_SX@G%\Z3N7CL/*7=M>*Z:F,.A^$P: MJ9PUI$$A'[L9D_1I&L"<>A,-9:D;"BC"G!FF+0'KG!_J'S/^W79<)=0IP3]4 M)+Q5O72W6$^RDJ#UB<0(I0(B)B%;[A0R5J[R-`*0WO-^"W\D\OXY/=,,=#'<)]W^HV,Y4DK],O;*F4'&=2?H/ M&])[?`>@<"[^#O\XD;P29O1&\<(1X"+XD_U=^C6+MA[:(R57#)7MKVH6-R%G MTJL4@^EH]=51+\);W;")2K%A#$%2U\L1K5U@L:3^$,)REA5P%#@:^`L0PZE9 MPY,)EZ_:':\#//`O-Y2N:MW;KO,5=PX_14,(I.3BI41H(AUQ!Y3L3U_ZK*H%Y__?V`_0A_PC[>NIVN7VL-X?]5$:1]9C%; M-4"`4EKH?4I-076KS[2D=-..#[Z[<4'",0804EAE]L]I^?P;_P&3"9]+ M:\E?V=&+^)NV=].+G599%`*O-<]!E#XK\+G\K$!!%U'"4(5#!U9XEA4(V;`Z M%U31#:%"_Q]'!`/?@*$EY9\UC'7;!P9L#@&[[\;XEKX.47_QZ_I[NJ'1\8BK M,AFM8%2337X4R*LC%RPN&`_.`WGO2V!\)BR5UA\358< M&S\6E41%YW+=[:%FS#QAY-^W&H]7]KK6[AL.+&O-^`&G5-6W??Z)0PBA4UCJ=U9UY@O;)F79JMW[PJE=8">R*CY=G=M*F]`$L'[%<5^H@IITMG-T'I;-;UM1O?"/U>6DFH8.EU#%H2>*%^3HDH; M^-IBBM`>0!&%511.,T?$G[322F^<*+.6=ISY;)$7@D@H9.D]<+M&IV@RJZB" M$QHBD&N$!,][:M[?T'J0=61"]LZ_.\81`1B[LX&?X]_P_AF'M4\@TT/[2K-5 M'$GOF*WFUF*>+3U3YPA\%!0TV8/%NK>-!M2MBN$['Y5HL@>IT>\)69"UZH"* M6O6/J*2HG@6M%.B*%6ZW=2#'/)I0W!&K61.`T8[RE7]]85[<^TR]A_8'F]_V MU*#B_R:,:F7_X`UIN8HP3OQ*1I<@?&N[?5%JHM6)"[X*#\K/\UB?=@>]:=%7 M!:NB`JP;-SVDZL8U'2'DSK,ZD?7W(?1BGO]H>S8]$1ZA;S9]"Y-J^)Q<1P#=$FSWLS(L6DS1'R`1 MWGS8!:\?'>PFV"#_J$."_/376[*,])(ZU9R"<;P6&IR?PU8^W6&:):0P"B@A M`5)S[60U+`4USNW7+WZ/;F\M/-[OEP_>O=[>?KA\=_0M?_WY]OGOX3=%20=,W*^"!C+!-QUI&; M+-W=(-PI%]B8KY:3-OR!YR*?1^-DY/K!P=B6?JQD-F!P7AU#^K9/MP-D#6$` MEW*7?Z3&6C6A-4(I&?"!K90-`0L-7\2P**LOQD`D!^/ZAU` M`:%>U&F>G6+P@&'2B'.2AFR,N6JBY&>S8"(YBO!,`0P;^A2P[-!1:@L#ED(` M^8B[G"TY."DH@8\A?94J#2->X.\N"";W!@XD30<3@*-F!V-P(3^B`4]`C" M1&\+#Y!D=^MN\>/&Q<0$=%OEVM^Y/L8AX?Z(=S2Y39AL)]M3<]*=I%B2'CI= M6_.)E23?4)0\%7(=ANG^7JW^6J0 M$J(/AB:DH,;UOLJDV$A4V#`"HTH.\G,0AL$W\B_@Z7K3D:K#;LT`@XRA!23ZWG8N=QL@J,?1T5)%6ZL&Y*^ M]O%X0.%ELZWGB_%TEHW:99=%VU2$PEW1,RW8>9;$+92*@7`;Z:CI&A12T<28'2@1!F22E.DD0$P1C:)-#3U$:6ES9!_)3_/:95KYU#YQ8V)L,T%1'1C;YU^^LQ;@4 M2()&(!F5(DG&:(1*K."G2\,;A!L/O,#VD=.N.,1D2L7E11,N:1.:@N_K[P]!^`>-2!O[ MX-*3/5RHZ@A4A82FP%N[T,BSDRD`O/'=V.T%P'I/8`#6Q%$9*-8=`"Q(&P;` MDW1.GB@G_:C.;%"T=R$&+Z"HX*1=N..9QQ3<_69_=_?'?6.@5OCZ0A+`2!3) MI;(=-NF`9,J#,ZDU!YW#V($[AR5K-8\J;>_IXLTTN';Y=A=N6PTWQ'8B"7;W M8;#!V(F>@D_XSQ%VGH(OKD\KR=WL#V'PFE1NY.UN2/?5O0TH*YCLELIBLEBG M53$H;71(B:,X0,\8'0E]^L]MP@&Y)1::M^[.H_DDUSPCCIX"]`DC2I_^,^6` MRBP`MMO.H[W5Y[N#;:ZI`CK?.%,RWL"AAS+[$H27F[\=W0\6*Y*(Q;Z0`M,NM)9PWF89!^P*_8/R8/7^Q\YO_,/)PC1MAT MA%.P45F(]#8L6$BXM]\X"0W<)KH!G/*5O_0^F4]+N$1I?T",]=(@@<[G2T1) M@,.BYA\-;R^K"./$_H[>1*#E[(2?HM1$JQ,7?.7W:];31DX:)0#EQ7U5L%I+ M!9\N>>=ML=Z2FU'DF.?75?#5](,&7\<=%$Y+("BJWGX@07G"0V1Q<_@W.SZ& MPCM0>E':2[O*W8Y]KDURJ)/I[`P>A>1+-I_^_69)S:@HR@L([%N_&@3.VRZB M"`P`C7KNQ9.6AD"85[IG0)8PUGC!@SS058JA-*K=W00O9=SM4"((0%^$*(G2 M70V`WQ@("3VNSD\7XQE_`"P>\S!Q*.RKJE55=?AQ+U7F%8?/P?G5F113<535 M:H1P_@&;H^((Q29-@CN*(H@-!1T@NG=3>6V!PH/Z=M]RGBO,,N:"):*E!1(L=WA]+)ZZ*43 M%R('J\.":P434/$YV-NN\$8*OS$@,A()I'UHO)[.V["1D#,$'7UT:\%'BVY0 M"*DZ6QM&2K88)'DE&9CNGCUWQU)$6A\6;VVN/7%%+(ML"0-KOIPLL[05,NUF MKA(4!'5GJ@RE40YLQ.9))8+`KXH/IV+RK,)QO[?#-[HS"C\KE,53D9K280N( M4?`WVSO0HEON!NF@Y2%4QE`#C*6_V;Z]P\Z5'>:I)HP=^8["@E#=?32/JIT" MR>823J:KV2096E.::$.(LHRC@"5DN2E=O8/LP`I.R@I2HJSN4Y)QEM$%+/DT ML+960]O_9>\/_V]97Q8^H"L^24,Q&XOE[`0S(%/)A%7EA,VT#KE5WO*7%J>3 M"H(`ZZ,-HXNEH(N^`9/O0-41DJ/U$$,B=MR-[3KB\:_:0/=@5^$N^:GGUFJ] M3,L;9@0T#V$GB#TIBPTY,)V@@R6M@Y:QANOC^<#2U',P7(7XEDQI_0AWP*O> M#@1E-2%D%_OCR7RZ+H.-S#F\A!`$Z$[28E+1(B4$CL&35+*45=('20$\JLCD M:3\@0#N1"0M)M37`8F8MEU4LPF"PC]A5\,&#KH\.EK0..E'6#J^A<;4/0M?V M?@TB5E[H;GOI8*\%92W-M6-.+(OL_&=A6:M\-$S(H9>4'MT$IQ1U0W(HK285 MK3)ZM"8FI0B*V*%4M/@J!A(JZ@%T-[@*>'<8!62O)`CC'7U?NWVKI-9*YTY) ME;7"YL(LK0694X#>)SE%$TM>$VV[)'S7J6R2<%2&\/*O-"<4WVWSYRU$R5N< MAAI]OTN(T`A9D#$@E?%4W1@`/ATCUZ=78`HJD`@0NU49!`+- M07"`XRL[>KD/@U?7PC$C;14THGG MR_DZW6YARII`>KQ7R^EH)WSL34(?MD*RP& MM`(PLEL<70+1(DN:C>1^`W@;(2.1K3Q.S=!NZ@">[@;T'\!Y!.!ASI%*81JZFDK!.V=R]@&\)Z9/MH(UH!6`D=WB MZ!*(%ED2",DW_B;8X]L@:@%KJ8U>/!:,Y>N%S;)S?NIL"0'TGI+X"5W&<>@^ M'V-:'8_6NKZWS_=0N,1$N:]V^5SXV@Y]^FYHJA\P5)J>5$-#3=\!,@$(T;2@ MJ6""*6BD^=2_*8%L@M5TM9RG[W'2#QXF5/2>[I\J?0[&K/8LU+1U"&6LFC(P M4\]VW\^.YP6Z@@PT@1]DXUX2!JZ_'VC&7=?"L+.?S@&I2QCYE]*FBVS95Z*9 MCU8IV9_@%WC#:LS`DUP32NG`+MQDG;(RCDF9!`AC,2UQ72IM+?ZLC99Z<51G M+ST!6BTFTQPYC$I7Q7(M*#E-'X8+LD[8NU$4A&_(#V),EDBNOW$/MF?`:U`M MKE7#!M<0,&B(<4PYNGUIOH7K+4^,O.DM=DG,\6+(P$ M3=MZIL_'1(2*YH7+23I,2CK<;1$E@B@5@#7+27I8C6^!MNF#?.R;@*U?!"#( M5R\\K0<$WU6PWQ]]8H4L>YGW+&!+8R!`-B61O3XR7ZRM91V:FXQUH&=WPC:YO1@@'VJ7C5@YQ=F"GIPP#Y5-ZOSFT$#6PRF.K`%MA@0 MV+?VMR]NN(\>L$_0UM*5D4)G3I M\19.*C#)<(!A(64OAJT)'ADXTU@-$NXV&C!/) M97Z'KAPNX\:$H^TS=O2$BAGM8DE/)L=+:]6('"GM9)%NQYS9)5#\&%+I>A3) ME&:K^LN8LUP`C"5#*EZ/*-U?&SRNR*&W$5TDK':&&//U&$:NO[LB*,8AY2WQ M89M]@.-*0R#I^B_SR7HLC"A^0A9M&%WF/$W7M MBAO5;VM*S!"B410M^%8:,$ZD#'X-]JW+E$HSH&A0ED%VD!FOYVNK'@`RWW@A ME&``WU^5&L8S:#-*<*#NKX\E_C3@*P@>-NI`;6@^(#;SZ^LV41O;;?AL-`7" M:%T.:6=8C,<-G`8%,613:C!@/4VG&F!+Q!"C!@?:T_2R.KX5-'A%X*D#F&N% M`4%\__(6N1O7]J,_^PX.?SG:H4T&- MTX%#3AX=*7VTRQ@@.^<`$PZ&UKP6(`KRB-%'.0-4<(`+&D-K;_7X[M"A11[2 M]6`C:3V0?+14Q`=\"$)V`^41[WCQ2:*#SEPUH132>5_CU7I>02'QPX(]Q=!R`Y374N,0 MQ&$O_]KVQ$HOVMPU;MD([TR>?]0Y626KJM(A#+9NC-Y[YU.IZS[KR2HMJBK= MIRJ!WVQMP4EY_!3I/\#`F9.^)>MG05U;<3O-PRA7".E8;LU6Z7MAA2=XC)#> MT70`+6I1)R$$6,%Z`)4L995TC+:M\,@&7;'VH&-O(LT#P5-ZB_`K%EV%;>\# M,1[S!%&HZK448&2$*,GLAN@($:K`H_3IBC+D,+7HTXV[_Z=+7VN`C\*/-=A_W'I._?$ M&[)ET=TVK;MK>VR3A\G>4>ED&-HZ,3B$P-)NO1A;:0)>F>\(53BSR569-]T* MS+FC@CUX814`XUF:C*S;_'`QZK,;;USE'`[, M8_.C1"Z.[-(X7"[FUH!!K!#%@-=P8(V:O*5C1VY$K57F]\.&J!8L#A:M1'8' M"5RT+MAE%&$RS2-B88]\=QP0%NH4>5YW1YW!I5,:^;=J%I,L7+": M:0G5$:K0':&",M#)S\`:LX.@)\H5^3D)9#,&H&B6=M`*/N6L`XPX%9"!XZJ' M8ZT6DQ4/2N?&3N>H>;I6I:**IL)%&B&F@.(JV!]"_(+]R'W%Q8'N5QS?;9_L M[_=!R$;84CGIIR`I)MWVG4^@JAMH_465=E[+LA9E2%985I,TV!D0G=@1UB.4 M,M=:S5L*Q[J,5D+\IF(TE_$$!_WIZ&F$AQ--"QA(HIA,Q-,SLGP_L]V+^%WT MAP"N'-*NNI[,YE5\1\GI9WZPF],$Q>P`6I8`69Q1I<>[\&-PAP]RL"8VR1#9 M3)3'K]CVXI<-02@K`O(FSFEJ::T[LTDLBO3=ZO5TFMZ73]SE)2>7U'5YTYSF M-)1*)9P7Y)*Z/&^0.4]#Z5=".'BZ4S=^\J2G#O7!AL5;UWY.BX1==2\[.:UU M#X9-$:1'B,DR*R:;^$^)U`A=@2\^3]6LA`Q[LPF/V#%GY!.[66/0$YC!!(3( M[\+A_C-^ M;L=,N9UVJ)28JX3/*!E(8/36IL`#O.-S_*;I[W5-P=S\T?9H M"BY[X:DE;YS75+>SU_@K['=ES[TD_IZ2@$P*/UD=JZ$.?,@7N%+#^7F*0_C_ MO?U&E^HW_K^YOG-_\V_TE8[6I-66#AJQ()9"(=UAE6ZKI<20ZR-*#KTG!']B M#ZH`I[`.I:5U@I:ZT-/MB&4,=5@&$$G14W"Y^=O1#?%]2/68`W&8`S1A5<'$.9F6-.,`.N3S'J\"/7?_H^KN\ MS!:OL,:)!#7OLY\FK:PGK^?S95H6JPQG.X5SJS./T";G7%1FTWQ%6:>9JE'O MJ1GUDJ"'+LLQ#Q5\B[)\`]]%6R<-T)ZH!AF/"3 MG4$,8'NM(96FQ":"8&>@H"H@:6Q8Y@=6I\3[!PBM0YBJ7W`M M<_YAPNL@YNH38`5N97Z(;0]'ZD&VY0N`K#YI1A>[J\"VE^Z#*`YQ3!2@LG[" M/MZZ68$!T1I'@8+.]:>\6`K9\=-U&BT2ZLS)DYW$*@.4')EE:EH*T"PTGD:2[/D3(Q:F^J'7X6__#'M.%_RI/Y5H0.T MEW.R1LG3VZ7^=%J6(8@.F@;`A^M;')PTS3#$(B&AG<+LB641"Z[!=C;7/;EO MD4722^:3R6*6OA%P7XVKFF??@^E2P7!*#S&"@!=FAU4Q!?7^$/AL^4!OOU85 M!IOC2J`IG[]VV6,0=(=NX)1JA#>K@W._5'BNCU[H76R:X4S7 M9O8F=C>8$29_LHN7;GW`=*5TGC'+D4JN M^H3X8!.FGH=8\T-Z(X@X/YD\E40.\0:[K]C1'<`&_D!I'$M,47K"@/=V`40P M&UC=6BWG-VR']`54MK!UF(=D3I;4OI5U+KA(*!UYBH`H9U.090#YAE_M/;[\ M[@JG_^4F.J?]);[R]?O7B^Q.CI(T`?#KA+)U!4US+*3E$0@/8K_LH4O?L%D5T^W;5;7C>75(8 MQ+\)+1R2H?,Q)M/IQQ9OB)\C-&??3>*C@:![02]!7`[MJ@("#:NCW;`K6D< M>,#]Q?:.PF-!3DLP6#'V\I<$)G/12,4(C="-,<#IH5D-*X^-H8F=:F;0&2%K M-!Z/4TB9`Z2*[XFQ4]@'""X'V\TJ.61GBTFII?9[US(]]<*I2QSY]Q@FUC2' M%Z6:GPP4I^E9>3#0Z]F#*VV5E<8EI8/D^C9XR3`%?ZU!3LI0,!`,-A@[T1>B MZ&?W%45L[B[<&-_J`5+?@39>ENNI,#)&22/8VUUO3ILFGJ M63G9O%;)&PHIX5&ICHGF@_;!E9TTE,WI(D:8EJ&!61:<1^'DK+U9A^8M2ZH7 M?G:PTW0%L.;'Z;)V&R:8[-TH"L(W>KN;ABK^AZPWTA\H:A+(7L-8S:W).@\+ M*1$2`V*,Z&BC/02>XRDE$H$]>O:NUB`L)4"D#-%UG1^PY\G:V^5>>EK<'47'1BZ\+G M:PD.*T$)K$[;`$'JU:53VR]!^#DX/L?;HW>YV01'/VX9ML1=]$)**(?"T<:L M&+(2[MS5OV\"LP MQCK=LX:Q=GM!8.R!W2.@MP^ZGG'EM=2(*`Y[^6JLP4,U#U:\>7>)K/=UGL1G(9: M05[G+I\F/9O/,X0S(HA1`;XC<:I"EII"^E`@Q9?[K:EWR2^9!<%(,1TB"7_#.4RRZBK>EZ)U@BE'-@K?L7O\"@;U`@,?K=X M9WLHPN&KNTGN1,CBV"*(REC,(N]TKMXYN\"A57@$M M%]9XU0%-$Y9X0VK+&0(5M`7&8<=:4,).)B'NTUOY+RWWQ14(&(#"IE0*D[3I MA#OK!+QO?BXU>7-1\!OIZJXJ@T"!J4S"(BW\Z`71,136M.I#P0`TX>'@L&@%6CSFZ%CF'31,RVN+0,:$4F@T'M(2WA>K=M2=MN--.*ORIO^5M_ M\W6^EYJ1H,M`N.3KTU2Q*JI038)C',6V[]!R1%X`6TA1Y$E51'#TAW9[B5L+ MPN9`,.B5KF]-LL(L53B<\U9"=QWO@=6;56J:!W[M,@+WP0-34--U+Z'51`,D M$(OH2[],H$A`<^*QFG22?K>86./I,DE*KL**.A[*'<^,]P7.:8)Z9+E+(@O+ M:6:1Q:27`\YJB*X89-B;`/U@GV52][`DS(!/RS9BY]H.:?'&Z')#@L61S<\_ MXZV[<<5#?V='K9.`+FD42G-;^8Y00A1E5-'[$EV4$OX):LH\K,9616.<4H6= M`LBZ9G4R(&47&*PEC\L*OVCZ9ZVX27C*/S9'B^*G^YBM&VEDIAOW1]NCQ8R#;_2*:W0>A$O4`^CY=:SRYT'/>!LDSSR5 M\E2=+!?7;LG%U0?T*BZJ<"Z9``*T)^E@98_/ MA&>-2%VY6-\##=\D,,AYP<[1PW?;[#87O?(?W0:V'UWZSA?7)XL?LDHJ\N"[ M\A1.H:@5?;W%5$A\6ZPS?";[`INSA45;-'OR=-8X#D. MVBR6(/ZXW]OA&[KQR4IUS_9'V9HUXUVR$"S\3\9/-4"<9F/8$/+9C0Y!9'N_ MA,'Q$-WX&^](#]_YF]WDSV01\!C;Y+QW%C5ABHR`>) MY$.//DE`0I8V]:2!.UN,Y\U0E\F)$D%'*!=5=-S%FA!Q42[O"*42(R8RBY.% MT*4TL,C`2&GHA[(X'TKV\%%_9-4>5O@16>^WA(WDOP2!\\WU/`:H3B^OM@:) MB!419,&P6"_FG`E:1BN-)^!!Y`3=&D"7T4T_PKGNQD=ATQB&($5Z;M+L`8L8 MY2%D8LUGG:@Q:10^454&HHR&88"1&[KX!A@@*:Y@<>/'Q)0N^?))A?_K[^GX M6`%LV\/=_6EI3I7K+:AL#=CQ8K8<)UES982Y.;?T40B$,WYHES+4FS&GR1+5 M6'.W106W]$T0E/,KXI`)+XIK,E!^XD:WE_;TV>6_)SLF#4-!I=&='"BRC+K3 M+'K6D,>;+,OT,"9\J4PPIV1DG-2#%!>:YYQ%JP>F'CI*A!^0E<+@BEHG*0H; M1AI+!UGK#!H2V!-'HIMMMZZ/;V*\YUT.4"8!%C3DY)-UO/5D.>=,=9+WOMK* M!5!.B+&"BBSG,$1C505O",GP>LL%6$/B47IWH\8F!P_)`\-NII]$%W5.@E#/*_Q^?( M=5SR<03E(B4[@>V:B"22?4N,K(C'R^9N*R7+_C\G?.ZRD=W[(L.HVMATU:^J MY,[',/HV]EZ5]=6[M]&%R^9N1JN=8&YE8D\ M)9`YA[1X"OF$\TESJI&20CFCIYB6Z/U`0D%M9J-L0.!B\ MD&7/)SO"SE6P/V`_8J)>AB'YJ"S!.R)BYVW2ZE:7W^S0D9PVG$@?)F"<)K1" M$N9RP0DAE/+%,R6-ROQ160`624H-4R$0D\*8N8=..S9G)&>U(T"4&@:J@K@U MP*<"B61)2&V_%%]IHS.BE!G+OR(XR?,EDOX1]'WW_FI8TFIHPQ//82J8:&@+ MZ-?Y/*+C,1EA<_W>WI!!_A6'^6Q5(=BLZ1Z+3">M$T,G2*B03K3/82>RK=6RKP8]TF@UGZ3&Y.=3W-7"Q(==.>@MDHC>R%SN9ROK#3_-".(#BE% MS45'!E1H4E4HHUADGX`LF8;6TCI!2RU9I5((RS-*NRT#,K?):_T=(S+1BJ+L M/*_E@?7V/CKG&VV"R%?OG:[7]2-9P!?4!U3*DE1*VZ@LXVR5\;73%J"8N=M> MV='+%R_X%G4=X;9U@4`,1P[YPW\K+^"?D:,I.90@8A3A#W0'4]/JKZ9V5+6X M(Q=4(N,`8RH_V;L/(E9O5AY;XJXP&!/*HW#@N9ARL%:L M-@`&.]U7@,5VHX%B,GL`1&9.6&D+@;JR`/+GF=-I[4T:,^:`_96Q))71CA"> M,W$AT=`=!@/!YH^7P'/()[O^V]&-15=Y)3IH18-("OD5Q&R2CSP%L7]""3ET M&<>A^WR,V3V7.*`%:]BB''P4&D;Q8JNSIC@LAKJ>QY`OR^7$DC[Q>Q$%1VD=B^07-?#T7([K\S$G*O0'R MJ@`HDP#HT5(`Z[&W3I^H9,C\X'`*MMH#26]#FQ%TZ.M4"CG$TOU!0X=`*)5A M;]8RWE/RAN45G\<$/\C(W^'#[?AM,]009X^4(8D19$+HON)[8O6G;\'32W", M;-^Y]FA]'O$QI'1?W2>2LH+)GG)-I^M9>CA)**$X)84PHX4<-\0;8F\44<;I MX3HZ$)J:#R[/HW<1:5!.'%'JB!HCHX\2!I`GFN=1GT49`IP)B:GI=TZ,D60& M))8`/^%4Q7%^V*ED-)!)P?$YPG\[$@&O7T59$>UM=0[V/`$4MH/R*Z=6GZZ6I:R6MA&[S<$JH[/0"@;@XHGP:]OU%;2&PT8F@L))PW(E0`>E!;L- M/(1N?(ATZ`:$DKJ[M>"D8@Q#D-)>J$#8'A8MBJ_;+V9YF4.^3\%6,QA&OS;, MF%#FH,OU.G`#7?X@*Z;HXJASXE5KJ!DK5>[R][\6D]*4*R-BP'3K%'TL)7UT M8H'O3'40<'0?8J_CZ-,F29GAC1WB^S#8XBAB[R23?Q]P&+\]'$/;^TR6/5YP M8#G@1[+:#]V8?W=S,+*Z=T@&D%FV_.QX.EO,TLSN7^_OTUFLRJ.1>2O;5.(*1$4EC.Y5?<2I2+A-1JY07H1(QS*&]5 ME2^?1Y4S<\N&^!EV[A, M`A13$1`]-W%3(73/AR!,)AL2V:^4/R("H$0"Q$1`1(8\FP7V@080"[*X6ICG M_0/>8/<5.S]1YP*)H.>(2<4L:4`;@\V4R$KV^CN]VSCM] MU6,>J^H%1FSGG0KY;')ZD@5!ANS0=O!7>]]QEM=HIG/`KO&6KWJT7$UR,#H8 M,1K`QWBG*6-5E3'B"$_D096AFJ=U?W>/\.;#+GC]Z&`W\73RC[J#DY\86]?? M/;[MGX/Z!VG^78-+-YC*ERI=H\)9[=W*FEUP-.#L^B?)I)/Y[WT%?+Q%`1M?E$4,5:$!._ M?\?N[B7&SN4K#NT=_GJDTMQM/[O>D?S*;E!%=\B/4,H99MYY5FLP$+>HIVLJVM.GRS/5/G8R M"+X-`3MV8I7)P`-8*)O\4FIES4Y!,/B>[WDM8Y4MZ3D+#0+0SP13*/LSGO:#.V)B-[AZ68-`6JF8::"M^ MW`>QA8421TZ5OB7TR'^3_R+_H*70R7_\_U!+`P04````"``&>5)&("T$CU2TR,#$T,3(S,5]P&UL550)``,K\>14*_'D5'5X M"P`!!"4.```$.0$``.U]67/KMI;N>U?U?]#=777KWJK>8Y+N3BKI+H\[KN-M MJ63GG-/]DJ))2.(-12@`:5OGUU^`@TA*&$E0H""^9#LVAK4^8E@S?OZOMW4T M>0$(AS#^Y=WG#Y_>34#LPR",E[^\^^WQ_<7CU=W=N__ZSW_^IY__U_OWD_E\ M<@WC&$01V$[^[H,(("\!DR?O#<9PO9W,$,`@3KR$##>Y#^,_GCT,_G5"_QM, MR*_^?CF_GWSY\'DR627)YJ>/'U]?7S\@%)1C?O#A^N/D_?MROK_FE/TT^;88Q)Z_7&B[>3 MBRB:S&DO/)D35M$+"#X4@T8%NQ,":8Q_>5?C\.T911\@6GXDTWSWL6SX[I__ M:9(W_ND-AXT.K]^5S3]__/NW^T=_!=;>^S#&B1?[C8YT,%;7SS_^^./'[*]Y M:QS^A+-1[J&?H:1`X(3;@O[?^[+9>_JK]Y^_O/_N\X%;];(;`@O\-;"OSWG[_DW?_E&OKIFBZB.+B)DS#9 MWL4+B-89T>\F=-C?YG<-ZG$:TP%7P(N25;:$DF)!?J3-/PI'_-B1W#GI^/LC M6?*`3C%=W(8Q^4:A%\T@#ND,5Y&'<;@(0=".>L6QC\C'S$.@Y:?0F"!9@23T MO<@X9W?D@%N#BR@!*"9KX`5T9N5P1-,T7WEX=1O!5WP7!R$"?M*9YL,1N])\ M'6(_@CA%X#+%80PPGF[H_4`^+;X(@NP;>U'WW:P]C3G&Z$^0'"%Q"H)J5GH\ M!VD$I@OVW[ORV7+6OMGNY9OJ3-4W@_32AS'9+7BZF(&82B(W;QOR0\L3H\-\ MYEA]7)'#=06C@(A6-W^FY#;LY3NJ3F..L3EX`03/.?#A,LYFNHB#"]\G@F*" MR6]!^.(]1P`_INNUA[;31=$!7P)"#I@A^!)2R&\ANH;I<[)(H[)W5S#Z).WH M`!9$UCXB(>NPV9$P4Z7&%DS3!5$9X"L5V^TM+#5:CK\5>SEYNDUN#H1O("#B M*P)D]OS',+B)B)R%8!SZOV9\4!I10"0PGQSZ1&S$UV`!$`+!5R^,R_[23KV@ M:)EZ`UM?@.=D=X_5?=N5-/D$_S#PASP?S MZXM[Z-$#.OO?OT'T1Q@OK[Q-F'A1]I<^/JB!YCT=(%ISV>.U;N8_)=*68\@2:+,WM(+B\KSF&2-6KJ>O+>>OIIT M?'.L$&U['284-$PV_E6FCB]![(<]L:8]WU%8K:Q(]-?D]$M2+YH^1^%R9Y/8 M[UKT[!&/#D295&(B+\ELTL;SP4O(=--%5TN_U@P]\T1@W$#L15\13#=438]2 M&@S`-E@?84UTIF?@>#UEMJBAH590U3-VCPF9JN$CH&V/L*C4)^X9`:IXX?S/ MR`NHL6V:K`"J62F/@$8[(H:(3#^;J0LI/:,DLZ[.0;A^3A'.6E<$][:4.M/3 M,UX"0]X1-IKF[(/"HI^MU8J&WD^>FG6POS.7-8D-SOHZ,_E3]_N. MXLEZY[0PEAWA[!+.U3.?`DO1$3C7G'U06/2SN5O1T#,N/`/:$1:(SM1]:U2Y M36D.-M0/FRM\?>M2"E/:Y[J?C:`^<8'`IF;%NB=S-J`@74`YX]#V1805D97_NGYI\U5\!ZO^+[LBY^/87 ML&60Q6YW-/J(*`3CS)Z813SC:9K0)"UJ;>43*^IT+,IOPPB@*[*REA#Q<6VV M.A9M<[`,Z1$7)P_>FK46FMRNGV'$(*OY]QT]]5O_`C5I\Y!? M#D1^/+CRFVEW18N/FRP_ZKV_"J.=M+!`<*UQ=91$0,;FGD`4`)2E@W[^].G= MA-"?!W;>YZQRZX80$0I^>??EW23%A#>XR?V[)X7.GFA3P?-E MA(=_L54P?3?")))1*J"^'X$2"YT55#^,4!W>2!4\_S;"PQ4G*I3^?42)+VI7 M,/W'")/0H%`A]>.(%$_#V(%$9,H1)#4%LL*L;T'\YX_[MLEC6"Q5ZV84DX8) M'?\S%9,^3=Y/=KT;/\/%9#?6I!SL7R>UX5KKB0L//V<@I_C]TO,VN;((H@27 MO]G7&HM?_U[F'\Z\+34(%T?)G@HI:=Q>O^U.=Q6K\0`2->J972SQ@%(0U%(+ MI`QPVENB/EVGF8?I&I#=2)8U7=#DYPB4R:VUK+L9@AN`DNTL\O+CZ,\TW*R% MS)H9WC(V64@6+:"`P(J63G@I4DGN(!\3,O)$NSR$VK MW1X\YN0=K?!3I*.R::[GB]J@B^.7X32R1Z?D'&NTL4ZE$JC[;>U1_0!C7X-P M1G-[M&E#<2;1-1C*!Q4!Y0& M$[5.5OA0/W3V3V$>DQU&M('`S7H3P2TH\T/O0^\YC(A`)]-AY/UL<%,57&$2 MO5J9W+P5ZT-"MU)7.SR]D$\-T990Q*6]UL0&C;6E26ZJP\PL#MW2 M;D/D12))*G>WS)OXZ!G(67-(ACKZ0]!":N1(;S5VV\%0K0[\0+2H&D4&5:FN MHUI!HEY%1\P=HZ5MBN4;A]W8!MV9Z3&7'[Z150"BR(L!3.6;7Z&C97YT6!@" MUL]&U*C02LEI8HWM"RF'F)YC(M7,4RJ]+30.K!#,$% MP#BS_ICL/\1_T6[,I5.YF!W".\XEN_2*G6TUN(TXJ9(%MHN5 M1D4U6QQH[:YF):@#([L`74U,T%@ZQJ)E7,U>,+#:,C&E6]("I(653QP??IR` MJUD*NMAT34@XE57",3#7`5$,3*@"?MV*N=?&BZ-?5/BX%6FOC4_3M;>#Y8M; ML?7:L`AC-RJ47!8@%5`21W57,+DL1:K`U"&8K@+19?%1`40E*VF%EEL9L"V7 M'`.7-H+DJ8A/?$]Q\\93"="I$',K`[8-8BQ4W,IX;8.*+#BRPLIE$5P1JRX! MF!60+LOJ:D!RO.$[B+YS66[7AH@;`%'AU4:"'_Y]J!M`6,=/%/#F:L4#P[B) M;7EN7@==H!/FI;A:%,$$<*+6KM9),+Q7.<'BW2HFG-0-H6'HV2\[4-VC;IIX M]%!B!KE6$+EIP-"$/J0+,31N.]L[C%9VH@'+3.ZBY^;K&VE=PNFGQT8.3 M&\!
2\"J"WZA@(M9'T3TIT4-/(>:D4%5#.2_9BH-2#K'>0?>^\4*]A[>&D M*U1@N>FGU=^(,IS:2/'#/[!THIL/G6@,C?I[-T7YMCBI:^(5@F[*]GI6"&:J M4F5X<%.EUK<,-NN]5/BXN@EU\%&IYU8A-FXZM=2="C$W-6O--:9;';&"STU- MNJN-OET>3X5J&\5;1TH;<@W?6?9U5B`)?4*OW0ID#Y!0HUB&K-;6$R?L8_"[`#A MITY+NCF=\GI"BIQLG;J>.6D0M[U]X7I&95OD.+>IZTF3!N!J7N.N/OUD'##V MLQB]YU=:%ZES/>TB(E3'9+:7G`7D)?4!6ZT<@6G=3:7.0#R4KMEYF27^^")WBPMQJB)[*941^ZA$L&L5+2N2"S M)%&R`[C-AT#[I8=#7Y'PO.T0J+X.HS3AZN^\U@:6^:_9A7]%!IVBI1<7^_X; M"$*??MDXR'\,@YL(^`F"<>CG7>;`)S(/)CF%\?UCTK*=);'PT M-ALS\E]"77&%S<$+(#M[AN!+2",P%A!=>@$-5^'=@%U'M5/%NS35WQ+9FG44 M7P)"(ZC%&MZ\D3."?$PBT)O1'L([&PH$OFY03&0EV^!#%8<&N:\EK;H1RGR(NI\.7# M%X#X+UNQ6EIZ+R:[F`OPN-0V6UFIB.\]0T3D_B)W1TPPI[$-NLF94!T=''*; M;:Q0"6.8'V-46*.DE*5NQ.>&O)^5*O)-D@3(LUI:I?@>>!C@.3F#"R#YU;3% M?:Q5[Y<$:#&UA3RNAL=GQU$M(H&3RNJ[^UQB-ME=+!5XSTT'MQ!=P_0Y6:11 MF8K+C;40=+%3*CVS@O#HW?W92@R(%]%=FU'`W^7[K:Q0FFXV44C-(Z)+=[^5 M#4K_!L+EBMSX%T2F\I;@(5T_`T0S,BMI7"&$2W>4`7%Z0)SD`M<>9LB\B@SY M>F/8C#:0.1>;$09[KEW7@Z1TP.&I#*Z'0^E@)+[D78^$TD'JX!)T/>I)_QRJ M`C=?4JN2&-;K^H)_1M=BQ>E&KQP`=7(9&HN9=?QU0Y\II1GEV>PG0 MJ?76.2:PV^N!3JTR82F";F\&.K'FVAF177]6L`-P,FNFZZ\,:NQ-OAG.]1<$ M-4#2#UIT_6U!Y<2+O4=DFUD[[7MU&\)7HK$&(0`W`HNC5#U0;%16]HB-,LB&L%+XBL],'$2#)(7ZY_0W3Q^N*FHWD)O.3\"5[*83#@<8`P^9/EK:K/]"`^+V+ M7\@JZ_`]60,,F[]VWU,TT(#XW?DSVWY/U@`&"IW-O&WV*O03O/#)?8AH:`.9 M*=G.(B_.HOG);S>T""@0&/RA+;]-.)*2[9(D16"Z MN$QQ&`.,N4M0I:=MCFA=9IH;,%W4'S]48(C3T4[F]J986$I<<)L;V#2\L96W MB.8`EA\DV.FMZ@\1'':QEJ:>4>1%)45W-`QMG9M5).PH]C:PH"1395<`'H&9[H\M0$4V[\:U>' MPH$C4Q%)$SIXNPH6(\9Z1H%VI3#.!^4V!LUN)32&?V6I:)P*V#&-AZZFG1O& M3KAZ7<^;-(2A4&AU/:U2%T,])W6WQ];=.P$50Q. MF:HY?#?QP*497?"4+:O./[ZN9V(N)6QS!E]7TV#[,(NS0F;S\)5NR;+GC.)A M`-;Q4FGM1'12G3>".$6@M(+5,B&"(,Q)K"&L%ZO)=!"5,Y'/4J^W0)@#6;HM MP_$C[6+`;\69XXDF;*F3E#AVZ_EAE,G>CV!)E_XW0`.1&33)^Q@@ MK`R#IN__IC%9TK]"O`G)?F1].$%C@Z3O9`Y$.* MR,I97@%Z)-%Y%<@[[&.0L&+P7\GA)Z*ET)6ZV,1&=L:%U+:-D.UMYY$KWM[([1=+!:CA/ M>0>7^^GB+>1M0G$?6^*LJBC4,-4)SA]7"^3K8B6^7UPMD=\%)98TYVJ!_"XX ME=>LJ_7QNV`C%<-=+9S?!;2F].UJP7P3RXJA.+E:-%_5'M$P8XNEHA*J3Q\^ MN>4VUL%*;1GNH'(.JUX4,@FPQ4>HMJJ;D#*UN>:+#4)CGNMAL4)\9%IIMPC7 M$P!'1:-M'/9--(^WN6R[*=A!>H_^"@1I!&AQ#F807W?#R35E`I6R+-=6854S/,ABD%"I)=D"HQ>@&;'^&2!$D:)F> M83#+@0HUY5+^BF"ZD9FE=4<9#*>TAN]B`?R$LV-U^)6.96915WCN"N@RIZO* MTD\790UV]B+N-**E3UE;56*B\8.W!D*O0]O1#'S.VS1*8"R]9IG-;`!?WG73 MF+Y\,%V4V062XT':S5X%(B/5DYE,FQO?'CJ5I.Y%-+OQ<04`S2*I@F4J615? M;K5VDL!]=:3)W<3UP,)X='#O6P8JG0K"K""I8\]NX/*Y#Q?@T0\!H2][IR5> MDN\&$)E8YB57[6F`2#(24=&]J+S\IHN+`/!O2F%S$_$G("FD((%>P&ADRU3< MDQ+4>#W4E$+I>H9-2U7K,&CW"&>;Z_;KCAI$:LL-@\>V,;KJ-3<, MGOA>=-6Q;AA$90G(5<^[KEXOO?>[F-Q=]PD:`UENM'3=@]@&RCY>RVI5DV#X MVCT`N(VK[*X&@%O^5NIWD:N1Y98L MKL3WH6W_#^'*)=Q>;IVNW2+8#@>+6DAAE\9Z!.@*$@"/"DQ/KLQ+YS1[V.9#'Q/": MFXAA&F-+54/*7(@M=368T(T(M!L/1=M=@?@9B&E>PC1F/,\A:WU2X7""Z>>! M=P^]6#)[LY6;<2YCA-88H76:"#L2H36TX*J&DXJK2[GNA9)I MD?)#ANB)JC;Q(<)\+4T5#I,0#E##^)T,O> M_WMFXS>0?8-#B7X,+>D5\!Y#;%U]0LUBX);0E.YZ3HCMG<)U+KN>3S(HX/<\ MXZZGH=@,RCVPQ;J>HV);`&4:E5W/6;$8%LBRQ8YAF*<$/OA,9&"4%(5I:6("`?D1 MH)?0!U<0)U?D2X7\\,M6@]D);=PGE7X$^C;['"0IBJ=Q1C[&@/MHC=80P^"Q M?..-@J_,5:/3&"%XA"`$6AXZ60$T(X@CD(0H/YCS3U(>%L+8!*413MSO*5O> MKAMV>X%0=`JV,]R>DB&P%TC5+E37\_T,0*MU.G:SG>JDV]L6,Q]7!/P5C`B_ MF#YMG6P'DVYT$66#@R"C\=+#(*#B+_E"&4GBJTRQLRV))`<_>Q9J1],<1)1@ MNJ]Q1O4SI7I6.,`4!)0.@UJ15\CQ1OW9@J#O1A.;-`J3*?8:67FR;U>@G[W> M+Q#RXF7^OLCEMFI3+(2+5P\%HA!F<^-;04=&,X_D`_OL/BS=!SXI/*;9Y86_ MDH8)OHMG@%QO`;E[L7&`!#.9>*4S@?X?=[%/9@M?`-V_3Z_P:053[,7!3433 MD/D/=BKW-4!H;>A;,EM^0SC*YCKZKF MNVZ1[0?=7D3]XP7AVC:/%16)YL"'RS@SBU&OMN_32#],?@O"%WJFX,=TO?;0 MEKX:GW7`>2#L#,&7D)H=;R&ZANESLDBCLK>!-_,4GKT\4`OD?6QHI#E55X2J M:>UITQGY+Z&K,'@7T.XP)0!?>@$-VN%IGUU''0X2U5(CZZ\@N192(;-3=!QT M2#AD5#["%-$*VGS+H7+WH?(FM#AJ#&"B*(`7>TMR@9#I2O?)74R7",+\R@#2 M/D:J%02A[X6!H#Y!HX&Q*1&03+EK8&#*#+SJV+[)2D)SYQ>UMK'6,WIHG5)< M5??CK&IF4SN%!'87N\3MPFIIA^)<[."26?S9BK59Z>,/X;M7.F;S*&4?MVK^ M$O61K'#,>C5\GY=&&SM41@NBFS#//'8;$SX"R9OIAXX!<0[X/I+"/ M30W9C&CL M6S=3!W45:OD*92NLKGL)]97WJCQ-4W=T/7^R*U*58N]ZTF,[I#CBL>M5SSHL M*[DAR_5*6^W!$YJA7*^M);`(L8./-`P(KE^8':PJ#6S%NNP9!4!T@E%=#'0^ M;;IG1%5UDS,('&%9&'G4_?UT1-\X>ZI;T<$HITWK7['0A M6FBV\JK=OYR.SN7O7P;,9QZ^?1?["'@87(/\WTYLCV\:XL3.- M&VNM.[20C3?9/4O010P-&1W#HV-X=`R?B,4:#Z;T)_M0?`P)]8O0]^+D M:D7K5^"[^`8G(:&3F_G89J03]J4.UVW4ZI,>[WRWO47+W`"R,CGV-'MBP*\*ZV%KPLTZ/M\97]II\'L\48]&BI0EL68*U`D.T%G!&/&^OT5 MW.;#E0\J==&U M`]RBU78^I:>^0AB\AE%$P+LCT\7+D&K>V6L*Y9]L'-N[N=EG\N[/-H0H`63* MEXK>&#:YE'E/#]O9=8B6]*@Y/9NM1^_AZ#VT=)&U.E38EK^]'>"Z=8][4-71 MJ>X3Y^U5XI-P]&.T@HJQR-QU/QBV"[NI>8QV80,JQ@-(IHOZXV/[#:R8C%*< MP#5`V>L0A":\"C?L$I0J/>R\JEE_8EHFP?-:VZ#\-B2:.+@/7\#!6KGP_72= M9@]VU%<,AZD6`PV,W\OM-^__0705>5@DTNJ,,#`.14_Z2+L-C)<*:>E#7KJC MC#:.OKB$S?<@O\U;MZ*)\,EUBCM8>SPRMA%ZAPJ=1X"7T2D:,L5LZO!:L[W MH4\?F9`6=6ZV,QIMO\\RRTJFTF.TE(V6LB-S\82\`-!K42R+'S2S^O"<6!"O MJX?Z=U&[L.C3T;`UP),+F:[7W=1::6J20+?"D3JYUH.'K(U:VJZ:Y"EE+718 M&ON!;:ON(J9*N?KKM^6NKC=4P/I0K7#=<&0!-:2%UWL'7`3Z`, MNOZ::VO_MI+^ZNI!IZ&\*UX4A_>,LV[>EN`I>L7'M281`D?_N*)_W,V\\=$_ M;L`_/I@TBKIJ>W@X<$QQDDYGYM7KUZNZOC`29\KY%*+UM!*,I[BM/8@`.G.?*!D:H&)*^E M_0@>@9^&T=`^O=(0"&YS^[2+\@98+6U0?`^]&,^\K8#41A,[--;.1AZ-M28G M0*.EVIMU$L251%DM;5/\`&-?F>A:8QMTTQM3LJ\:3:R]=*VP<`_;F8B&R.6E MJF;*#,$%T>TR28W\O`$HVRK9#3TTQ8-Z9+EMA)6)D'9OF[>RJG4<3E.;1ZFKH MBB8HC+/D9FLRD]6>VE8M=#:501-*,VN1Y8HXJFDIG<]7@:@=&2 M?[HY'O"AB(WP`CUFU,*0?%KY(7]]08_OBSC(_O=O$/T1QLLK+SOQL[\,Q1\] M.I?.UKETZ>$0/Y(]X@73^*\>"NG^GA-Y_;,2%X+N]GF[!MA'X29WM]>)RZA6 MXD\RA'T>;\G)(`3BN?-8@%\6FYQ!A`MO.@MU=R& MLC$&SR7]]9Q6T?T6QN$Z79O@^F#,`:"`<4H?T+A6/EJ:/>QS,+KACTHQD:34 M"*8-;=![\Y80<2X-\8J2,5U0LH0GL:"#%; M\3[$]A(B!%$,.1&K1UAT\5-%&;1<9=A%`%&Y7N&6&AV?-L?Y8`#HCJ07R7; MFE"B\.&4AAD*KS=OFQ!E>I#HHE#I.12.[NCC#:TXVN\Y%(Z^>6]4J#A83QJL M<8I9>J=[75B!04EH8 MR&0"79/9=`@T"R4H3F,;='^#*%F2>T)<'F._E9UBS2`FBBF\A0CX'F;74I$T MMDGW;S&FR3V+$`3B8C3<]E:KP)1DJ51_:;0=(ZS&"*M!^+2%BKJK3D==O[^* M9.>J2['3>JH;*%UU(QI83'RA>@QYY)J'QL!'38_.&`]IPD#?+8#R/%$GCU8[GW<%VEG*\SUX(2I$SUKJ;[J3*E!&25_FXJBP M.FL!7]_U50'GEO@_AMP/+N3^LUN2_ACW;`P;ME/.V;IVFNAPW"0E/%_.%)[! M!,W;04?DR!;MK7.YV,1.\SI"!V[JZL9RR\*G[#5NON+*=HU7(+EEBE)R3K,` M8J!Y/A4C&\7H?IW-RKR=,3MGS,X9LW/&[)PQ.V?,SAFS<\;LG#$[Y^C9.1CX M'Y;PY6,`PIQ4\L,^A>17O]_$"34.L[[_P9_[I^8>++THGY,A<+!:&`Y[ITY3 MHO-<^'^F(0X9>2(*':P$U:;/.`Q"8[+@0!J'/ M9D:MS^"X*`^6-MSL^MKGZA2""\;"9N.KC'4:=[OH+V$@H]6/`Q!@PTN$C'$C8YV0H^/#C[(1651= MC;91MFKJE0QQRWRD9#P=2X;L12N1(SM%U`KT")(DRG#K*TII-]6!TE/S%3,: MV;#`[\BHZJ.2??3-BS;4EAWZLK`D]?ZVN8,O@`8L*O!1MC003+`;EN73932P M\FY2];%VU,C?JY/ULI6,#/Y,R=:^>:&&*5D^\F';`5`M\:;S6@^$ MEI&*?U37+U#F,>*R=TH-%NG!X:HWJO7E62J(^]>"JUH/_PK-B#&X!+$8,%]VUO6RX8(6-"4V2(NXN">S*3+CZ2OG7C*UM4#[=`/H^2+R\AQA?>0AM MR?'RZJ&`I\4).M@5:*5KJ*D7<3Z8J[I12YRDQ[W[BE(;O&27BJN!?"U1$QU" MKD;SM82*?;\?+[K/MDQ\!=?K,,D>Y2/[ZPK&=-F`V`\')"-?(.!-%W/"S`VF M!T%9Z81SHW*;&[#B7WF8NHP\]$>B]B8(VGV__<\G&*=<Y$(K[&D_CV6J+0S_TXJ^IA[PX`8`",@<^ M2G-\&(M"I[>-!?*5H$1OVCF(:!;&$[PGY^8R.RXK%S-G8:CU/?VRQZ;R'V.R M0X*:E9VG5K%:&EC(90AW^1!=\=;AH3=9TM@@*;L]@7\C,@':[8R+)0+E:[M< MTA0Z&R`UC^.NS78X#X-&E5XFB"/B8X@Q1%E0,*,X.J>1+6^!QHU?%W3Y0I2K M*GH'L)CGC*NJ>0N<>/O&53V\PU)2%`Y<5MRZET'J%3D`)=3\MH< M82IRB2TPTU+E7,W3TS!N2,NJ.A?"H0F.\CIT/^BEE:5)CJ'CH66B0K4* M-EM7TS_'>K5MG!Z/_@H$:02FBZM,!_23U(NFSU$ALF-&UZ*GB:*VHS%_-.:; MX9*Q=KG@^'H-DW(^50\!57D%F-"[!Q0.2"@MH1;@/;P./FC1[5:8A7E+;I@N9>"S*LN,V'0KLTSTK2R4A>8UZ49QI/TP0G M7AR0">DTW)@(60];!6'+%PR$R8*,A@9`K`*V@([]D?+N09N=;%V-)\K`[>OYYRG]5P?NJXV/)AXT2DBQ4VC MY8NYH]-A=#J,3@>#Z,DT2MFV/*=L934-=K\VW+Y:YFJXFCY*`LW1U5BU=B!) M;13GDP-?A*'-/)1LGY`78UJ>!,8#2O;Q??KF0UEIO48ON52*=$!RUSS`V,__ MAV.HT1_'3L6MV%MF@49"J]-!,X/QX_?>ZVV(UE6`8N85%D>T\_O8`+&^IH76 M4$9#V_36]F#^V`F>+FJ_4V!$-L*`.,02QZJTVY!XN=S6_R+P(F@,8&!;5P$, MTV0%$&_R`RV[MLNUA[#SW%5)I!J^HJ?TVHUE4_[A'WG-LFS[MXNK=G/=@Z=9 M%+?52G)=6],_]^J@LA:HJXAU.79YF$GE`E?58%-@MM`C7%6:NT*JJ"VXFOQE M1.)0V.?,D]59@[TQ5-NM[F/:]6W;?&[#V(O]L&':N=P^@J6ATO>&0Y-6&\E.BZW.96-Z.$AT:.M.!['4\X&?3>*OZQ M;5&5U*VT6ZSRBIS+,`J##)[L:UM4%Z&O3[!"__/-$2[&BVSR,N4 MU1ORVXV@F)3&`%8D)"\"1'%\`7$*^-?1?BN[QN5]B8AUS:N9EM5'LBB]BA]M M:;1Q0L:V2'OM^_.<,5I=3?B.Z*-PY!;:/9,KN[,D':S`7+Z%=YEB@@TN[U"1 M6"GN8SN"Z_[##Q2_>C&=G MS>V$G^00=_[A;5,P*HD<[H>X,X7;TG>@H*N[ZFM5PDA8EKI7$U9[0J6FOW8U;S5KN@Q7TEQ*S^U*T0Z M=EQ7J\]IF6,8,NNY%*6CM;/)0MFYD7=XX2E:>G%Q'#7T2;*`9C6::&&,@\Z5 M@_J)D'@90?\/B\D\9._,"/G9HT)BBZV@@Q5?DNEOP'%"F9[&YHZ7?_.&Y&(< M8==C3_@GQH-':^A,%X4T2-`<]WR+.+1#%-ET,QJ>SKYC<7F^.X<<)!N(O>@K M@ND&$R4J2K,487*^9#4-4A!40`WD;F431X[-)C.2S:<[BI6`GZY?A\MZMV%M M[O:67[^A!W>&=3PPVF+WE+\I-!X;.H^(Q9A,4KP_D0'(V^'2YG9CBK063V[1 MJ]1H+R)K$3RN`*"6A"IZOUID6';PV:#DQ,]**Q_/=;=3A^\B/Q".YY8:VMWT MF!``5C`B_&-J:4RR!]H&(K7F!$ENE[U&=L+(5$'DA92I]K=:1HGY-9J1&,HX MG*\T>`^]&.=_IJ]&DA.L2$/80I\@'.(^.NR"E5]]((5ZB1 M(4_@Q.T&F>N*G3:(+7:>ZV&'$@QU[Q'7*YSR[_J;"/@)@G'HYYN3`$O`H*89 M\M?P!/8G< M^?.>KR3^%<+@-8PBGC94B0R6,,!Z(S*U$H6=!Z8]C8FIK?H0.;PY#S M6GW5NO"B"]BXQ=60LN<9/8^-7@G=):WJNMQA#Z,%B_<1NWDKG&N[>6524?NQ M3OHL$GY3UY7-UNAU7'SGZV"LO\IB-P2.$*!\-',:VWYM5.YF8;6UZK87HLY[ MOF<4A7@[QV(LV-'W#U,"*%&I7O3CAC!)FP][8\BY/=^]<1<3U++P*)`D4?X[ MDT8X\?B'RTS\(&CWXY+T-Q!+&H$>R$D4];.P@(:+*+`SC MME'X&G593,SZ^6XRI>=/K6Z[5@^T'E3PU1G#3DUBK>_0@1%]]OX;34PEJZNTS"F%&W4;\\2/@4YPGN^IP'LD M9B"W_CD\H:E^L>N,,,1'\T0[6`N=\]VO^]68!K)/72I)KI'>I-!S2*6[A-Y3 M%13&?2>`QY[(K%EP4SG206^T(>Q=UY\;:_VE+>_'-D550) M``,K\>14*_'D5'5X"P`!!"4.```$.0$``.U=W6_;.!)_7V#_!YX?[EI@'==) MT[T&S2Z[>XEP4MT391F?225!+?7W\D]45+-"W)3J+B])+(XLQP MAO,3/T9#\=/O3XL`/"#&,26GG?[!NPY`Q*,^)K/3SK?[[N#^_/JZ\_MO/__T MZ6_=+AB-P`4E!`4!6H$_/!0@!@4"8_A$"5VLP+TW1POX"YA`CGQ`"?CC;'0# M#@_Z`,R%6)[T>H^/CP>,^8F0`X\N>J#;32KX5Z3*"?AP<'AX\-XH&=&0^"?@ MV+AUSA`4DAKX4HD3>&\E M\;OCKN0X`J.#T8%AU=_!/25<4B^6D*S`(`C`2'%Q,$(KZ/?^^'H3-4KGYY]`1'OR-&$!7N-0=Q*>HQXF7$#B(8,E MP.2[@T,5JS8W*RFPQ&KU/W[\V-.E!G7(NS,(ERG]%/*)IHX+9#7]]]UW_>Y1 M?YU+K):(6]ETB9V/\]6:9CPD2I\Y@H&8:T@HMO[A&A.1+@H7]D;P!>NI^GJ2 MJ"NI$,.>R;J=K\"C:'R1LIGM?=R+"@UJ3Z)3L-4Z.4?>P8P^].)"9=11H2V\ MD#'YR&UBC4OM[>@C;&>3!78.].3-[2RJQ,Z#R0/BPLX5E=DM(Q![W,ZFBQ17 MOX@-[-EY9,$&#K%D&UAD29Y'0#9#XA8N$%]"#U7!H>SN%HB(*\H6%V@*PT`V MRE\A#/`4([\#H!`,3T*!U@A"DI'\IJ1\@H10H3LN_5O=62XQF=+XI[RAM#AA M-$!C"4Z@+KZ-KK>H*N).N*?(>Q?4"Y6RD/B71&"QNI85L(6NM@.P?]IQ4J2J M),KX:(H)UDKWW_5!%R3LYJ44!2)9P!#VJ9>7D!<>RM'BCORFKST8>&&@&6_D M[Y@YIG`Q+IGLGXFHP9EIMIDOOIOX9)^NNI0`Y MC_&EG#:2#'^69'#[\$@Z+A4$U/!(?$34L"VO.`VP&E1]<`8#-12!^SE"@K>N MW(?,"S0(!&)$&O*` M[%XMDKG=>%S.C2D)!W0*[I9J4H[5)%;UQVHBR]!X/==RM*@&ZEM:9Y9UY M2P7B8YIVLUF;WK$9)/B_VJ2LV>6/`?&'AKE&'YTQ7V#N!92'#(W1DS@+J/?= M@,8+5NH&VJ]JTI9RR1]GD&.-)K.R%D-U,70+A6S7NVG6%9="@87-[<=_%OP8 M%07IK3[_UW>;_?S^7U^DW%!(>%3/H(SE*W\EE$QLA#^$'.`E0[?Z@GF0W&/IY,(S0`Y(= M@/SOT5E$IM<*`T^'*E6H.ZVN!4E=D%P&%\VL6IOYJH^7I7(Q-D)X M,0D9U]19BU?#R\Z5N*%SF(?.5^1C3W8E&B_1#^R#3`L0J0%B/4"J"`<7:(H8 MD\/.9XB)*:H,=PO#NC#\3*G_B(-`=B77*MH[P]+_`\Y1_>5*19%NB!WE(99( MUQ#+Y(.H@A8(]0S9UN"6ZW'N?=F@H#/)76.K>^`R?ZG;-3@%NUWXHNE;) M4MD=[?A;WZ7G=+'`0E_*\?)<+[YG2!+57R14%.EV>R$8:$B/WR`8\EL2XW5V("::UF%D;8+("<5VMTU\KA#S6(9@7"23'53FA3+AA@KX&47^6Z0[!1N;)'SP@&?"I"I)=B-E4)\T1W\:='Q/%&@2OW& M9GZWKPN!OO6(4.O;%UYJ5G!Z+<%N-!3B@\YE9PN.EUB`5$!$>6EN&!3BB=L6 M(RT2RNX`2%LUR0K*YN<#W]>*P:"X+:`RF]O!A:BB)4=)WLU$K_G]S042$+>Y MR.6=;5_PJ3UH?AB@NZF]/._[FE+<4"A$&C>M'KL@J4GE)&Y<8[;8V`LV2G4& M55C=*"A$&S>CH.T4GM7Q:FL`)3K_>#I4&P0HN7Q:JHSSGWHU)9B>USOS]OQY$W(_`FEV]) MV,V(NMV'BP5DJ[MIS,#/D&QV-&3T`:L'[HJR"QI.Q#0,$NX\0IZS*C>J=HLW M2A!&&JG^)=$)1$J!5"L@?X)$KTQ0B\AG0F3L$^/IE[@HDM4$85GI;MP58I<5 M<&?`SNSA%,ILU"W.GA=G=]-!$-!'E<:TOZZNG&PWQ@HQTWH8DUU;JD3;E;WP MX%IJ@K6;,#>("J'6B@-D.QW;$V*2C'?IVB1U?EO^/D^RYE72?,*_E:D4Y%Y9 M&S=F"W'AU]IXT.)_?_AWO$!.BO(@+84H-897XW,`K!Z:W` M:`>'/2'!3"Q)ET[FS;SKMS.X?5V(0N?R4=:63_E+_JN#9RNM&2"$(G4>(DI\"I$7`,R'@'+(%]N80!3IU MJ3(*2O&[D5`("^>1D-4!="4M&/8(!LO>UE(@*,WG=GXA7FO;'MOZ>Y_^CO>[ MEGS8M]*[_5L(I9I[9%N_[L^OCHSC4GZNS._V>R$H]WV/OOS?[H;P6C&LU6\%:$4"&I(<".A$*+#2'S5PN!98]7)-]Y1OW+46K+VW8X_WA:.+!.Y M!F]2'4'__\'UZH\Z(VF$ID`??W2B3OXY[7"\6*I,PN@>9)[B=Q^>9 M&*#DR.D?#().K[F&KWMQN]V2WF+W12KE!S$[@!,4E+-8DEHLOE$"?A!C\\_X M=ILEA\5F\U/T-M,_]"@1/974S M6=6;PWJ46ZE6,3EO(T;5+!]5L_0_[*))/2WJJ6`]:*XL*A(&5>EQ92#D#_K; M`0?J3E48;#LSSZF.C2_YT/&BRE@<$67^\$A\+)A:64R+BBRVXFH+H*N8,02RF0\*B+ MW2K/':E8KO:$25]MJ#\^75$K<-IQ[9D86SZ3+B<4?U;AB:9'T9FB)R*Y?RW0 M0BT=.@!.N`ZPGG:F,-`3('5HZXF<&&'JCS6S'[)XD4]P$"CYIQW!0C6&AY(; MBU"5ZN^QG78B=BSEV^U-OHJ@OL-E'`8DYSU(*<4S*[=31K9%-4HK,)G9[(I4 M?1VSQMGF+8=),=4+F^.+D[GD9%XXT0UJ-RQ[B:\.X'J$J^%/J_C*UI, M$,OL*T6\ADB?+B`FK^8VJ:9Z5PW9]V&Z&+@)O*)=3K)&692^%\F_X+$\8J6( M&_24;=8W]Z!M)6SDLZ;B5D8`K>BOC00-\I'2\5JN%YD^*E>N3^0CHDZ$E"O( M(%"WAG"E_JU;58[#-!,3@6:(O=Y(=B$'4\2^4*X3'O-=AKVT23V%]5L749J' M.C/SBM&%E23:,I[FEPQBK0W3]RVX2>@VOS[K_OALO/E0;^&(O^/!UQII-T%F MHRPH04)M]*[W,$1ED^B0W-..QY"/Q7Z:*SXQ>V`Y>]L"G%+4#4+#)63!:H26 M4?\T1`0&8G5'LB1^9963Z/F\Z*/)GIR8G*6K'MXA8OI;)M&8&LK;QD>2"@ZM MSMDLYQ:4W_!UJ%*&;^-MDNE[.=%+-\3.DIJV@$UZX#LRG*\X]C`DGT/(H)R. M(+6PDT:P,)I[&LU0A>E'Z!.NPD!0LFGR8R]MTN0GTG#D0[5+P:Y^KK!)VD?/ MDMK:?04]'&"U'HT3'O*VE"!MGF7G4ETS0%)G![_:`Z^ZWWQ3[%?V#S$+2W/S M+4M*6UF#1J(2AX"M66$G:]H8DJJ;"UOD[S.NN)1X/5F>4 M,?HH]3Z#',G)JNKDX$R27098[P$_D_4BRS=ZS+;8J]BXQ61S+2.^2D]JE*RP MGYY330"&C'H(^7Q,S]`WCOSD,^'H>K%D]"'J;(RV*,^RQ\%CS[8JI?6GXOX* M,<=9AF?>0!O=CS!]3?(0C2T%EE'%3=6T0>4K)/+Y\L^CN8P^Y$:/)XCQ?-]5 M@K1)O58R+RN8D;O?/)U5D-Y3*S^[ZH7B)EJP2?5FZKR@#,,@67K>30<^*BQ/ MW51-LN<6B3CZ6XPQV."K9V,@ M"O"R&+B-H=%FWH:,JZ_6(+545"9L-M!"VDC38CV_T(4-C^NEC30@?3^G6\O+M4 M)+:WMYG!N\KY(:+IY8UT'4%5K;DV2?HQ&FSMR)Q-2%$<* MT[02Q*8K$U5?T3Y&IXAS/<;?8#C1(=T1YM_Y+27G>H^':6`IZIW!FD9VGQ&K MC"XPYY3IE&45_%NSLE#6+*^E649\?:OUMHZH*M\/T>UD'[3)?S#W\BE.MTL^ M>KNI3]I!1-,ZK,VFY-Y!;B5LY$O)3.OX='?[%VDL+\"KPVNB;-L^^%Z@.2-!(URQL_TO&Y(UAA<2!,"JF>Y@U#,*;,LI/8CK5GM MLUQ&-Z#>*W45T$@D MIKG1T;92TR M,#$T,3(S,2YX;6Q55`4``ROQY%1U>`L``00E#@``!#D!``!02P$"'@,4```` M"``&>5)&[.B^1PH2``!W!P$`%``8```````!````I($[K@```L``00E#@``!#D!``!02P$"'@,4```` M"``&>5)&`:\AEQP=``!%\@$`%``8```````!````I(&3P````L``00E#@``!#D!``!02P$"'@,4```` M"``&>5)&\"G?>>)7```2I@0`%``8```````!````I(']W0```L``00E#@``!#D!``!02P$"'@,4```` M"``&>5)&("T$CU`L``00E#@``!#D!``!02P$"'@,4```` M"``&>5)&O9H$U&<0``"BL0``$``8```````!````I('29`$` XML 59 R41.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt (Carmichael Notes) - Additional Information (Detail) (Carmichael Notes [Member], USD $)
In Thousands, unless otherwise specified
0 Months Ended 6 Months Ended 0 Months Ended

Oct. 22, 2014

Dec. 31, 2014

Installment

Oct. 22, 2012

Apr. 22, 2012

Jun. 30, 2014

Apr. 22, 2008

Debt Disclosure [Line Items]

Loan agreement amount $ 3,000us-gaap_DebtInstrumentFaceAmount

Interest rate percentage 8.00% 8.00%

Date of loan agreement Apr. 22, 2008

Principal and interest payment 185us-gaap_DebtInstrumentPeriodicPayment

Carmichael Notes 1,852us-gaap_NotesPayable 1,852us-gaap_NotesPayable

Note due date Oct. 22, 2017

Number of semi-annual installment of interest payment 5

Interest payment 75

Scenario, Forecast [Member]

Debt Disclosure [Line Items]

Carmichael Notes 1,255

Payment in Kind (PIK) Note [Member]

Debt Disclosure [Line Items]

Principal and interest payment $ 252 $ 247

X

- Details

Name: ssy_DebtDisclosureLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Debt instrument number of installment payment.

+ References

No definition available.

+ Details

Name: ssy_DebtInstrumentNumberOfInstallmentPayment

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of the required periodic payments including both interest and principal payments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

+ Details

Name: us-gaap_DebtInstrumentPeriodicPayment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the required periodic payments applied to interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 60 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Statement of Cash Flows [Abstract]

Net Cash Provided by (Used in) Operating Activities $ (52) $ 3,545

Cash Flows from Investing Activities:

Proceeds from sale of Fulton 6,090

Net change in cash in escrow (160)

Expenditures for property, plant and equipment-continuing operations (737) (768)

Expenditures for property, plant and equipment-discontinued operations (11) (83)

Net Cash Provided by (Used in) Investing Activities 5,342 (1,011)

Cash Flows from Financing Activities:

Payments on long-term debt-continuing operation (239)us-gaap_RepaymentsOfLongTermDebt (409)us-gaap_RepaymentsOfLongTermDebt

Payments on long-term debt-discontinued operations (4,842) (61)

Proceeds from long-term debt 175

Net Cash Used in Financing Activities (4,906) (470)

Net increase in Cash and Cash Equivalents 384 2,064

Cash and Cash Equivalents Beginning of Period 3,587 2,497

Cash and Cash Equivalents End of Period 3,971 4,561

Cash Paid (Received) for:

Interest 562us-gaap_InterestPaid 575us-gaap_InterestPaid

Income taxes $ 29us-gaap_IncomeTaxesPaidNet $ (1,629)us-gaap_IncomeTaxesPaidNet

X

- Definition

Payments to acquire property, plant and equipment, continuing operations.

+ References

No definition available.

+ Details

Name: ssy_PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Payments to acquire property, plant and equipment, discontinued operations.

+ References

No definition available.

+ Details

Name: ssy_PaymentsToAcquirePropertyPlantAndEquipmentDiscontinuedOperations

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Repayments of long term debt discontinued operations.

+ References

No definition available.

+ Details

Name: ssy_RepaymentsOfLongTermDebtDiscontinuedOperations

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: ssy_SupplementalCashFlowInformationCashPaidForIncomeTaxesAndInterestAbstract

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_StatementOfCashFlowsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables
6 Months Ended

Dec. 31, 2014

Receivables [Abstract]

Revenue Recognition and Accounts Receivables

Note 5. – Revenue Recognition and Accounts Receivables

The Company’s subsidiaries recognize revenues in the period in which services are performed. Accounts receivable primarily consist of amounts due from third-party payors and patients. The Company’s subsidiaries’ ability to collect outstanding receivables is critical to their results of operations and cash flows. Amounts the Company’s subsidiaries receive for treatment of patients covered by governmental programs such as Medicare and Medicaid and other third-party payors such as health maintenance organizations (“HMOs”), preferred provider organizations (“PPOs”) and other private insurers are generally less than the Company’s subsidiaries’ established billing rates. Additionally, to provide for accounts receivable that could become uncollectible in the future an allowance for doubtful accounts is established to reduce the carrying value of such receivables to their estimated net realizable value. Accordingly, the revenues and accounts receivable reported in the accompanying unaudited condensed consolidated financial statements are recorded at the net amount expected to be received.

Revenues before provision for doubtful accounts by payor were as follows for the three and six months ended December 31, 2014 and 2013:

 Three Months Ended Six Months Ended

 December 31, December 31,

 2014 2013 2014 2013

Healthcare Facilities Segment:


Medicare
 $ 6,685 $ 6,516 $ 13,963 $ 13,623

Medicaid
 3,602 3,524 6,971 6,844

Self-pay
 2,002 2,453 3,990 4,705

Managed Care & Other Insurance
 4,189 4,156 8,514 8,572

Other
 43 45 96 98









Revenues before provision for doubtful accounts
16,521 16,694 33,534 33,842

Provision for doubtful accounts
(1,982 ) (2,231 ) (4,215 ) (4,288 )









Healthcare Facilities Segment Net Revenues
14,539 14,463 29,319 29,554

Specialty Pharmacy Segment Net Revenues
8,430 9,326 15,884 16,168

Other Revenues
157 91 299 187









Total Net Revenues
$ 23,126 $ 23,880 $ 45,502 $ 45,909









The net revenues of the Specialty Pharmacy Segment are presented net of contractual adjustments. The provision for bad debts of the Specialty Pharmacy Segment is presented as a component of operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Summary information for accounts receivable is as follows:

 December 31, June 30,

 2014 2014

Accounts receivable (net of contractual allowances)
 $ 18,394 $ 16,753

Less allowance for doubtful accounts
 (7,279 ) (6,903 )





Patient accounts receivable—net
$ 11,115 $ 9,850





The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and six months ended December 31, 2014:

 Healthcare Specialty

Three Months Ended December 31, 2014: Facilities Pharmacy Total

Balance at October 1, 2014
 $ 7,117 $ 213 $ 7,330

Additions recognized as a reduction to revenues
 3,016 80 3,096

Accounts written off, net of recoveries
 (3,078 ) (69 ) (3,147 )







Balance at December 31, 2014
$ 7,055 $ 224 $ 7,279







 Healthcare Specialty

Six Months Ended December 31, 2014: Facilities Pharmacy Total

Balance at July 1, 2014
 $ 6,649 $ 254 $ 6,903

Additions recognized as a reduction to revenues
 6,251 80 6,331

Accounts written off, net of recoveries
 (5,845 ) (110 ) (5,955 )







Balance at December 31, 2014
$ 7,055 $ 224 $ 7,279







 Healthcare Specialty

Three Months Ended December 31, 2013: Facilities Pharmacy Total

Balance at October 1, 2013
 $ 7,317 $ 482 $ 7,799

Additions recognized as a reduction to revenues
 2,899 42 2,941

Accounts written off, net of recoveries
 (3,456 ) (45 ) (3,501 )







Balance at December 31, 2013
$ 6,760 $ 479 $ 7,239







 Healthcare Specialty

Six Months Ended December 31, 2013: Facilities Pharmacy Total

Balance at July 1, 2013
 $ 7,286 $ 475 $ 7,761

Additions recognized as a reduction to revenues
 5,617 95 5,712

Accounts written off, net of recoveries
 (6,143 ) (91 ) (6,234 )







Balance at December 31, 2013
$ 6,760 $ 479 $ 7,239







Net revenues included increase (decrease) of ($297) and $302 for the three months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports. Net revenues included net increase (decrease) of ($297) and $506 for the six months ended December 31, 2014 and 2013, respectively, for the settlements and filings of prior year Medicare and Medicaid cost reports.

X

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5066-111524

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5162-111524

+ Details

Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9

Discontinued Operations - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 1 Months Ended 0 Months Ended

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2012

Beds

Jul. 02, 2012

Mar. 16, 2012

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from sale $ 6,090

Loss on sale of assets 191 191

Contribution to pension plan 56us-gaap_PensionContributions 56us-gaap_PensionContributions

Dexter Hospital [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Number of bed facility sold 50

Memorial Hospital of Adel [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from sale 8,350

Fulton Hospital [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from sale 6,090

Loss on sale of assets 191 191

Fulton RDA Loan [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Loan agreement amount 5,000

Date of loan agreement Mar. 16, 2012

Fulton RDA Loan [Member] | Fulton Hospital [Member]

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Repayment of outstanding loan 4,745

Early repayment penalty $ 237

X

- Definition

Early repayment penalty on debt.

+ References

No definition available.

+ Details

Name: ssy_EarlyRepaymentPenaltyOnDebt

Namespace Prefix: ssy_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of beds sold.

+ References

No definition available.

+ Details

Name: ssy_NumberOfBedsSold

Namespace Prefix: ssy_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Date the debt instrument was issued, in CCYY-MM-DD format.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentIssuanceDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of gain (loss), before tax expense or benefit and not previously recognized, resulting from the sale of a business component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash or cash equivalents contributed by the entity to fund its pension plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_PensionContributions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromDivestitureOfBusinesses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.

+ References

No definition available.

+ Details

Name: us-gaap_RepaymentsOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_FultonRdaLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_DexterHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_FultonHospitalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ssy_MemorialHospitalOfAdelMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 134 200 1 false 32 0 false 13 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.sunlinkhealth.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) false false R5.htm 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sunlinkhealth.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 107 - Disclosure - Basis of Presentation Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Basis of Presentation false false R7.htm 108 - Disclosure - Business Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations Business Operations false false R8.htm 109 - Disclosure - Discontinued Operations Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Discontinued Operations false false R9.htm 110 - Disclosure - Shareholders' Equity Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Shareholders' Equity false false R10.htm 111 - Disclosure - Revenue Recognition and Accounts Receivables Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlock Revenue Recognition and Accounts Receivables false false R11.htm 112 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsElectronicHealthRecordsIncentiveReimbursementReceivableTextBlock Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives false false R12.htm 113 - Disclosure - Goodwill and Intangible Assets Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Goodwill and Intangible Assets false false R13.htm 114 - Disclosure - Long-Term Debt Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock Long-Term Debt false false R14.htm 115 - Disclosure - Insurance settlement Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsInsuranceSettlementsTextBlock Insurance settlement false false R15.htm 116 - Disclosure - Income Taxes Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R16.htm 117 - Disclosure - Commitments and Contingencies Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R17.htm 118 - Disclosure - Related Party Transactions Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock Related Party Transactions false false R18.htm 119 - Disclosure - Financial Information by Segment Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Financial Information by Segment false false R19.htm 120 - Disclosure - Discontinued Operations (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsDisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlockTables Discontinued Operations (Tables) false false R20.htm 121 - Disclosure - Revenue Recognition and Accounts Receivables (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLoansNotesTradeAndOtherReceivablesDisclosureTextBlockTables Revenue Recognition and Accounts Receivables (Tables) false false R21.htm 122 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill and Intangible Assets (Tables) false false R22.htm 123 - Disclosure - Long-Term Debt (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlockTables Long-Term Debt (Tables) false false R23.htm 124 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables Commitments and Contingencies (Tables) false false R24.htm 125 - Disclosure - Financial Information by Segment (Tables) Sheet http://www.sunlinkhealth.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Financial Information by Segment (Tables) false false R25.htm 126 - Disclosure - Business Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureBusinessOperationsAdditionalInformation Business Operations - Additional Information (Detail) false false R26.htm 127 - Disclosure - Discontinued Operations - Schedule of Discontinued Operations (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperations Discontinued Operations - Schedule of Discontinued Operations (Detail) false false R27.htm 128 - Disclosure - Discontinued Operations - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsAdditionalInformation Discontinued Operations - Additional Information (Detail) false false R28.htm 129 - Disclosure - Discontinued Operations - Components of Pension Expense (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureDiscontinuedOperationsComponentsOfPensionExpense Discontinued Operations - Components of Pension Expense (Detail) false false R29.htm 130 - Disclosure - Shareholders' Equity - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureShareholdersEquityAdditionalInformation Shareholders' Equity - Additional Information (Detail) false false R30.htm 131 - Disclosure - Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesSummaryOfRevenuesBeforeProvisionForDoubtfulAccounts Revenue Recognition and Accounts Receivables - Summary of Revenues Before Provision for Doubtful Accounts (Detail) false false R31.htm 132 - Disclosure - Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryInformationForAccountsReceivable Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) false false R32.htm 133 - Disclosure - Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivableSummaryOfAllowanceForDoubtfulAccounts Revenue Recognition and Accounts Receivable - Summary of Allowance for Doubtful Accounts (Detail) false false R33.htm 134 - Disclosure - Revenue Recognition and Accounts Receivables - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRevenueRecognitionAndAccountsReceivablesAdditionalInformation Revenue Recognition and Accounts Receivables - Additional Information (Detail) false false R34.htm 135 - Disclosure - Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureMedicareAndMedicaidElectronicHealthRecordsIncentivesDeferredGainMedicareElectronicHealthRecordsIncentivesAdditionalInformation Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives - Additional Information (Detail) false false R35.htm 136 - Disclosure - Goodwill and Intangible Assets - Goodwill (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsGoodwill Goodwill and Intangible Assets - Goodwill (Detail) false false R36.htm 137 - Disclosure - Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsNetOfAmortizationIntangibleAssets Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) false false R37.htm 138 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation Goodwill and Intangible Assets - Additional Information (Detail) false false R38.htm 139 - Disclosure - Long-Term Debt - Summary of Long-Term Debt (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSummaryOfLongTermDebt Long-Term Debt - Summary of Long-Term Debt (Detail) false false R39.htm 140 - Disclosure - Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtTraceRDALoanAndTraceWorkingCapitalLoanAdditionalInformation Long-Term Debt (Trace RDA Loan and Trace Working Capital Loan) - Additional Information (Detail) false false R40.htm 141 - Disclosure - Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtSHPPRDALoanAdditionalInformation Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) false false R41.htm 142 - Disclosure - Long-Term Debt (Carmichael Notes) - Additional Information (Detail) Notes http://www.sunlinkhealth.com/taxonomy/role/DisclosureLongTermDebtCarmichaelNotesAdditionalInformation Long-Term Debt (Carmichael Notes) - Additional Information (Detail) false false R42.htm 143 - Disclosure - Insurance settlement - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureInsuranceSettlementAdditionalInformation Insurance settlement - Additional Information (Detail) false false R43.htm 144 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R44.htm 145 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation Commitments and Contingencies - Additional Information (Detail) false false R45.htm 146 - Disclosure - Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfContractualObligationsCommitmentsAndContigencies Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) false false R46.htm 147 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation Related Party Transactions - Additional Information (Detail) false false R47.htm 148 - Disclosure - Financial Information by Segment - Additional Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentAdditionalInformation Financial Information by Segment - Additional Information (Detail) false false R48.htm 149 - Disclosure - Financial Information by Segment - Segment Information (Detail) Sheet http://www.sunlinkhealth.com/taxonomy/role/DisclosureFinancialInformationBySegmentSegmentInformation Financial Information by Segment - Segment Information (Detail) false false All Reports Book All Reports Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) (Unaudited) Process Flow-Through: 106 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) ssy-20141231.xml ssy-20141231.xsd ssy-20141231_cal.xml ssy-20141231_def.xml ssy-20141231_lab.xml ssy-20141231_pre.xml true true XML 64 R38.htm IDEA: XBRL DOCUMENT v2.4.1.9

Long-Term Debt - Summary of Long-Term Debt (Detail) (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2014

Jun. 30, 2014

Debt Disclosure [Line Items]

Other $ 175us-gaap_OtherLongTermDebt

Total 12,445us-gaap_LongTermDebt 12,509us-gaap_LongTermDebt

Total 12,445us-gaap_LongTermDebt 12,509us-gaap_LongTermDebt

Less current maturities (866)us-gaap_LongTermDebtCurrent (561)us-gaap_LongTermDebtCurrent

Total Long-term debt, excluding current maturities, total 11,579us-gaap_LongTermDebtNoncurrent 11,948us-gaap_LongTermDebtNoncurrent

Trace RDA Loan [Member]

Debt Disclosure [Line Items]

RDA Loan 8,405 8,624

SHPP RDA Loan [Member]

Debt Disclosure [Line Items]

RDA Loan 2,013 2,033

Carmichael Notes [Member]

Debt Disclosure [Line Items]

Carmichael Notes $ 1,852 $ 1,852

X

- Details

Name: ssy_DebtDisclosureLineItems

Namespace Prefix: ssy_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LoansPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Including both current and noncurrent portions, carrying amount as of the balance sheet date of other forms of debt not elsewhere specified in the taxonomy with initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_OtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_CarmichaelCashwayPharmacyNoteMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_SunlinkHealthcareProfessionalPropertyRuralDevelopmentAuthorityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=ssy_TraceRegionalHospitalRuralDevelopmentAuthorityLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9

Revenue Recognition and Accounts Receivables (Tables)
6 Months Ended

Dec. 31, 2014

Receivables [Abstract]

Summary of Revenues Before Provision for Doubtful Accounts

Revenues before provision for doubtful accounts by payor were as follows for the three and six months ended December 31, 2014 and 2013:

 Three Months Ended Six Months Ended

 December 31, December 31,

 2014 2013 2014 2013

Healthcare Facilities Segment:


Medicare
 $ 6,685 $ 6,516 $ 13,963 $ 13,623

Medicaid
 3,602 3,524 6,971 6,844

Self-pay
 2,002 2,453 3,990 4,705

Managed Care & Other Insurance
 4,189 4,156 8,514 8,572

Other
 43 45 96 98









Revenues before provision for doubtful accounts
16,521 16,694 33,534 33,842

Provision for doubtful accounts
(1,982 ) (2,231 ) (4,215 ) (4,288 )









Healthcare Facilities Segment Net Revenues
14,539 14,463 29,319 29,554

Specialty Pharmacy Segment Net Revenues
8,430 9,326 15,884 16,168

Other Revenues
157 91 299 187









Total Net Revenues
$ 23,126 $ 23,880 $ 45,502 $ 45,909









Summary Information for Accounts Receivable

Summary information for accounts receivable is as follows:

 December 31, June 30,

 2014 2014

Accounts receivable (net of contractual allowances)
 $ 18,394 $ 16,753

Less allowance for doubtful accounts
 (7,279 ) (6,903 )





Patient accounts receivable—net
$ 11,115 $ 9,850





Summary of Allowance for Doubtful Accounts

The following is a summary of the activity in the allowance for doubtful accounts for the Healthcare Facilities Segment and the Specialty Pharmacy Segment for the three and six months ended December 31, 2014:

 Healthcare Specialty

Three Months Ended December 31, 2014: Facilities Pharmacy Total

Balance at October 1, 2014
 $ 7,117 $ 213 $ 7,330

Additions recognized as a reduction to revenues
 3,016 80 3,096

Accounts written off, net of recoveries
 (3,078 ) (69 ) (3,147 )







Balance at December 31, 2014
$ 7,055 $ 224 $ 7,279







 Healthcare Specialty

Six Months Ended December 31, 2014: Facilities Pharmacy Total

Balance at July 1, 2014
 $ 6,649 $ 254 $ 6,903

Additions recognized as a reduction to revenues
 6,251 80 6,331

Accounts written off, net of recoveries
 (5,845 ) (110 ) (5,955 )







Balance at December 31, 2014
$ 7,055 $ 224 $ 7,279







 Healthcare Specialty

Three Months Ended December 31, 2013: Facilities Pharmacy Total

Balance at October 1, 2013
 $ 7,317 $ 482 $ 7,799

Additions recognized as a reduction to revenues
 2,899 42 2,941

Accounts written off, net of recoveries
 (3,456 ) (45 ) (3,501 )







Balance at December 31, 2013
$ 6,760 $ 479 $ 7,239







 Healthcare Specialty

Six Months Ended December 31, 2013: Facilities Pharmacy Total

Balance at July 1, 2013
 $ 7,286 $ 475 $ 7,761

Additions recognized as a reduction to revenues
 5,617 95 5,712

Accounts written off, net of recoveries
 (6,143 ) (91 ) (6,234 )







Balance at December 31, 2013
$ 6,760 $ 479 $ 7,239







X

- Definition

Allowance for doubtful accounts.

+ References

No definition available.

+ Details

Name: ssy_AllowanceForDoubtfulAccountsTableTextBlock

Namespace Prefix: ssy_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3, 4

-Article 5

+ Details

Name: us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of patient service revenue (net of contractual allowances and discounts), by major payor source of revenue for health care organizations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 50

-Paragraph 4

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=35755915&loc=SL9156464-115641

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 605

-Section 55

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35755955&loc=SL9156489-173031

+ Details

Name: us-gaap_ScheduleOfRevenueSourcesHealthCareOrganizationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Related Party Transactions - Additional Information (Detail) (Management [Member], USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014 Law_Firm	Dec. 31, 2013	Jun. 30, 2014
Management [Member]
Schedule of Other Related Party Transactions [Line Items]
Legal services to these law firms	$ 91	$ 159	$ 190	$ 319
Amount payable to law firms	$ 113		$ 113		$ 115
Number of law firms related to entities			2

Business Operations - Additional Information (Detail)	3 Months Ended	6 Months Ended
Business Operations - Additional Information (Detail)	Dec. 31, 2014 Segment	Dec. 31, 2014 Segment
Business And Organization [Line Items]
Number of segments		2us-gaap_NumberOfReportableSegments
Number of community hospitals	3ssy_NumberOfCommunityHospitals
Healthcare Facilities Segment [Member]
Business And Organization [Line Items]
Number of operational areas		3
Number of community hospitals		3
Number of states		2
Number of licensed beds at community hospital		183
Number of nursing homes		2
Number of licensed beds at nursing center		166
Specialty Pharmacy Segment [Member]
Business And Organization [Line Items]
Number of operational areas		4

Financial Information by Segment - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2014 Segment
Segment Reporting [Abstract]
Number of segments	2us-gaap_NumberOfReportableSegments

Shareholders' Equity	6 Months Ended
Shareholders' Equity	Dec. 31, 2014
Equity [Abstract]
Shareholders' Equity	Note 4. – Shareholders’ Equity *Stock-Based Compensation* For the three months ended December 31, 2014 and 2013, the Company recognized $48 and $15, respectively, in stock based compensation for options issued to employees and directors of the Company. For the six months ended December 31, 2014 and 2013, the Company recognized $21 and $31, respectively, in stock based compensation for options issued to employees and directors of the Company. The fair value of the share options granted was estimated using the Black-Scholes option pricing model. There were 90,000 and 0 share options granted under the 2005 Equity Incentive Plan during the six months ended December 31, 2014 and 2013, respectively. There were 0 and 21,000 share options granted under the 2011 Director Stock Option Plan during the six months ended December 31, 2014 and 2013, respectively.

Commitments and Contingencies - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Dec. 31, 2014 acre	Dec. 31, 2013	Dec. 31, 2014 Physician Hospital acre	Dec. 31, 2013
Commitment And Contingencies [Line Items]
Real property	24.74us-gaap_AreaOfRealEstateProperty		24.74us-gaap_AreaOfRealEstateProperty
Number of hospital facilities			3ssy_NumberOfHospitalFacilities
Number of physicians under guarantee agreements			1
Number of years required for maintaining practice within a hospital geographic area			3 years
Expenditure on physician guarantees and recruitment	$ 16	$ 33	$ 31	$ 67
Castlemark Properties, LLC [Member]
Commitment And Contingencies [Line Items]
Promissory note Principal amount	600		600
Promissory note term			5 years
Estimated fair value of the real property			$ 500

Revenue Recognition and Accounts Receivable - Summary Information for Accounts Receivable (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013
Receivables [Abstract]
Accounts receivable (net of contractual allowances)	$ 18,394us-gaap_AccountsReceivableGrossCurrent		$ 16,753us-gaap_AccountsReceivableGrossCurrent
Less allowance for doubtful accounts	(7,279)	(7,330)	(6,903)	(7,239)	(7,799)	(7,761)
Patient accounts receivable-net	$ 11,115us-gaap_ReceivablesNetCurrent		$ 9,850us-gaap_ReceivablesNetCurrent

Long-Term Debt (SHPP RDA Loan) - Additional Information (Detail) (SHPP RDA Loan [Member], USD $) In Thousands, unless otherwise specified	6 Months Ended
	Dec. 31, 2014	Oct. 31, 2012
Debt Disclosure [Line Items]
Debt instrument maturity period	25 years
Floating rate of interest, spread	2.00%
Floating rate of interest, lesser	5.00%
Floating rate of interest equal to the greater of (i) the prime rate (as published in The Wall Street Journal) plus variable or (ii) stated	5.25%
Loan proceeds used for acquisition	1,800ssy_LoanProceedsUsedForAcquisition
Debt instrument description	The prime rate (as published in The Wall Street Journal) plus 2.0%, or (ii) 5%
Subsidiaries [Member]
Debt Disclosure [Line Items]
Loan agreement amount		$ 2,100
Date of loan agreement	Oct. 31, 2012

Condensed Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014
Current Assets:
Cash and cash equivalents	$ 3,971	$ 3,587
Receivables-net	11,115us-gaap_ReceivablesNetCurrent	9,850us-gaap_ReceivablesNetCurrent
Inventory	4,047us-gaap_InventoryNet	3,757us-gaap_InventoryNet
Deferred income tax asset	2,319us-gaap_DeferredTaxAssetsNetCurrent	2,978us-gaap_DeferredTaxAssetsNetCurrent
Due from third party payors	2,672us-gaap_AccountsReceivableNetCurrent	2,786us-gaap_AccountsReceivableNetCurrent
Current assets held for sale	0	270
Prepaid expense and other assets	3,536	2,547
Total current assets	27,660us-gaap_AssetsCurrent	25,775us-gaap_AssetsCurrent
Property, plant and equipment, at cost	54,307us-gaap_PropertyPlantAndEquipmentGross	53,466us-gaap_PropertyPlantAndEquipmentGross
Less accumulated depreciation	31,484	30,389
Property, plant and equipment-net	22,823us-gaap_PropertyPlantAndEquipmentNet	23,077us-gaap_PropertyPlantAndEquipmentNet
Noncurrent Assets:
Intangible assets-net	2,908	2,979
Goodwill	461us-gaap_Goodwill	461us-gaap_Goodwill
Deferred income tax asset	4,436us-gaap_DeferredTaxAssetsNetNoncurrent	4,432us-gaap_DeferredTaxAssetsNetNoncurrent
Noncurrent assets held for sale	0	6,111
Other noncurrent assets	1,550us-gaap_OtherAssetsNoncurrent	1,012us-gaap_OtherAssetsNoncurrent
Total noncurrent assets	9,355	14,995
TOTAL ASSETS	59,838us-gaap_Assets	63,847us-gaap_Assets
Current liabilities:
Accounts payable	5,433us-gaap_AccountsPayableCurrent	4,530us-gaap_AccountsPayableCurrent
Current maturities of long-term debt	866us-gaap_LongTermDebtCurrent	561us-gaap_LongTermDebtCurrent
Accrued payroll and related taxes	4,097	4,186
Income tax payable	139us-gaap_AccruedIncomeTaxesCurrent	73us-gaap_AccruedIncomeTaxesCurrent
Current liabilities held for sale	0	4,842
Other accrued expenses	2,072us-gaap_OtherLiabilitiesCurrent	2,314us-gaap_OtherLiabilitiesCurrent
Total current liabilities	12,607us-gaap_LiabilitiesCurrent	16,506us-gaap_LiabilitiesCurrent
Long-Term Liabilities
Long-term debt	11,579us-gaap_LongTermDebtNoncurrent	11,948us-gaap_LongTermDebtNoncurrent
Noncurrent liability for professional liability risks	964	1,268
Other noncurrent liabilities	786us-gaap_OtherLiabilitiesNoncurrent	807us-gaap_OtherLiabilitiesNoncurrent
Total long-term liabilities	13,329us-gaap_LiabilitiesNoncurrent	14,023us-gaap_LiabilitiesNoncurrent
Commitment and Contingencies
Shareholders' Equity
Preferred Shares, authorized and unissued, 2,000 shares	0us-gaap_PreferredStockValue	0us-gaap_PreferredStockValue
Common Shares, without par value: Issued and outstanding, 9,444 shares at December 31, 2014 and at June 30, 2014	4,722us-gaap_CommonStockValue	4,722us-gaap_CommonStockValue
Additional paid-in capital	13,464	13,444
Retained earnings	16,050	15,486
Accumulated other comprehensive loss	(334)	(334)
Total Shareholders' Equity	33,902	33,318
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 59,838	$ 63,847

Commitments and Contingencies - Schedule of Contractual Obligations, Commitments and Contigencies (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014
Long-Term Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	$ 866
Payments due in 2 years	775
Payments due in 3 years	1,951
Payments due in 4 years	601
Payments due in 5+ years	8,252
Contractual obligations, commitments and contingencies	12,445
Operating Leases [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	858
Payments due in 2 years	333
Payments due in 3 years	200
Payments due in 4 years	74
Payments due in 5+ years	22
Contractual obligations, commitments and contingencies	1,487
Interest on Outstanding Debt [Member]
Commitment And Contingencies [Line Items]
Payments due in 1 year	712
Payments due in 2 years	708
Payments due in 3 years	650
Payments due in 4 years	508
Payments due in 5+ years	3,104
Contractual obligations, commitments and contingencies	$ 5,682

Basis of Presentation	6 Months Ended
Basis of Presentation	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Presentation	Note 1. –Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements as of December 31, 2014 and for the three and six month periods ended December 31, 2014 and 2013 have been prepared in accordance with Rule 10-01 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and, as such, do not include all information required by accounting principles generally accepted in the United States of America (“GAAP”). The condensed consolidated June 30, 2014 balance sheet included in this interim filing has been derived from the audited financial statements at that date but does not include all of the information and related notes required by GAAP for complete financial statements. These Condensed Consolidated Financial Statements should be read in conjunction with the audited consolidated financial statements included in the SunLink Health Systems, Inc. (“SunLink”, “we”, “our”, “ours”, “us” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2014, filed with the SEC on September 26, 2014. In the opinion of management, the Condensed Consolidated Financial Statements, which are unaudited, include all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the financial position and results of operations for the periods indicated. The results of operations for the three and six month periods ended December 31, 2014 are not necessarily indicative of the results that may be expected for the entire fiscal year or any other interim period.

Goodwill and Intangible Assets - Goodwill (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014
Goodwill [Line Items]
Goodwill	$ 461us-gaap_Goodwill	$ 461us-gaap_Goodwill
Specialty Pharmacy Segment [Member]
Goodwill [Line Items]
Goodwill	$ 461	$ 461

Goodwill and Intangible Assets - Net of Amortization Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014
Debt Instrument [Line Items]
Total	$ 2,908	$ 2,979
Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Finite and Indefinite-Lived Intangible Assets, Gross	3,858	3,858
Accumulated Amortization	(950)	(879)
Total	2,908	2,979
Trade Name [Member] \| Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Indefinite-Lived Intangible Assets	2,000	2,000
Customer Relationships [Member] \| Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Finite-Lived Intangible Assets, Gross	1,089	1,089
Medicare License [Member] \| Specialty Pharmacy Segment [Member]
Debt Instrument [Line Items]
Finite-Lived Intangible Assets, Gross	$ 769	$ 769

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Jun. 30, 2014
Statement of Financial Position [Abstract]
Preferred shares, authorized	2,000,000us-gaap_PreferredStockSharesAuthorized	2,000,000us-gaap_PreferredStockSharesAuthorized
Preferred shares, unissued	2,000,000	2,000,000
Common shares, without par value
Common shares, issued	9,444,000us-gaap_CommonStockSharesIssued	9,444,000us-gaap_CommonStockSharesIssued
Common shares, outstanding	9,444,000us-gaap_CommonStockSharesOutstanding	9,444,000us-gaap_CommonStockSharesOutstanding

Related Party Transactions	6 Months Ended
Related Party Transactions	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions	Note 12. – Related Party Transactions A director of the Company and the Company’s secretary are members of two different law firms, each of which provides services to SunLink. The Company has expensed an aggregate of $91 and $159 for legal services to these law firms in the three months ended December 31, 2014 and 2013, respectively. The Company has expensed an aggregate of $190 and $319 for legal services to these law firms in the six months ended December 31, 2014 and 2013, respectively. Included in the Company’s condensed consolidated balance sheets at December 31, 2014 and June 30, 2014 is $113 and $115, respectively, of amounts payable to these law firms.

Document and Entity Information	6 Months Ended
Document and Entity Information	Dec. 31, 2014	Feb. 17, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	SSY
Entity Registrant Name	SUNLINK HEALTH SYSTEMS INC
Entity Central Index Key	0000096793
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		9,443,408dei_EntityCommonStockSharesOutstanding

Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives	6 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Medicare and Medicaid Electronic Health Records Incentives Deferred Gain - Medicare Electronic Health Records Incentives	Note 6. – Medicare and Medicaid Electronic Health Records Incentives Deferred Gain – Medicare Electronic Health Records Incentives Electronic Health Records (“EHR”) payments are incentive reimbursements received under the Health Information Technology for Economic and Clinical Health Act (the “HITECH Act”) which was enacted into law on February 17, 2009 as part of the American Recovery and Reinvestment Act of 2009 (“ARRA”). The HITECH Act includes provisions designed to increase the use of EHR by both physicians and hospitals. Beginning with federal fiscal year 2012 (federal fiscal year is October 1 through September 30) and extending through federal fiscal year 2016, eligible hospitals and critical access hospitals (“CAH”) participating in the Medicare and Medicaid programs are eligible for reimbursement incentives based on successfully demonstrating meaningful use of their certified EHR technology. Conversely, those hospitals that do not successfully demonstrate meaningful use of EHR technology are subject to payment penalties or downward adjustments to their Medicare payments beginning in federal fiscal year 2015. The Company accounts for EHR incentive payments in accordance with Accounting Standards Codification (“ASC”) 450-30, “Gain Contingencies”, (“ASC 450-30”). In accordance with ASC 450-30, the Company recognizes a gain for Medicare and Medicaid EHR incentive payments when its subsidiaries’ eligible hospitals have demonstrated meaningful use of certified EHR technology for the applicable period and when the cost report information needed for the full cost report year used for the final calculation of the EHR incentive reimbursement payment is available. The demonstration of meaningful use is based on meeting a series of objectives and varies among hospitals, between the Medicare and Medicaid programs and within the Medicaid program from state to state. Additionally, meeting the series of objectives in order to demonstrate meaningful use becomes progressively more stringent as its implementation is phased in through stages as outlined by the Centers for Medicare and Medicaid Services. For the three and six months ended December 31, 2014, the Company reported no EHR incentive payments. For the three and six months ended December 31, 2013, the Company reported a net $1,215 gain for Medicare and Medicaid EHR incentive payments which were for successful Medicaid attestation by the three hospitals and also adjustments calculated at the time of filing Medicare cost reports for the preceding fiscal year.

Income Taxes	6 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	Note 10. – Income Taxes Income tax expense of $799 ($643 federal tax expense and $156 state tax expense) and income tax benefit of $297 ($328 federal tax expense and $31 state tax expense) was recorded for the three months ended December 31, 2014 and 2013, respectively. Income tax expense of $985 ($863 federal tax expense and $122 state tax expense) and income tax benefit of $95 ($78 federal tax benefit and $17 state tax benefit) was recorded for the six months ended December 31, 2014 and 2013, respectively. At December 31, 2014, the Company had $5,190 of estimated net operating loss carry-forwards for federal income tax purposes available for use in future years subject to the limitations of the provisions of Internal Revenue Code Section 382. At December 31, 2014, we have provided a partial valuation allowance against the deferred tax asset so that the net tax asset was $6,755. Based upon management’s assessment that it was more likely than not that a portion of its deferred tax asset (primarily its net operating losses subject to limitation) would not be recovered, the Company established a valuation allowance for the portion of the tax asset which management estimates will not be utilized.

Insurance settlement	6 Months Ended
Insurance settlement	Dec. 31, 2014
Text Block [Abstract]
Insurance settlement	Note 9. – Insurance settlement In January 2015, the Company received a $1,000 settlement on a claim made under its insurance policy covering, among other things, employee theft relating to misappropriation of funds by two now former employees over an eight year period beginning in 2006. Income of $1,000 was recognized in the three and six months ended December 31, 2014 for this settlement.

Long-Term Debt (Carmichael Notes) - Additional Information (Detail) (Carmichael Notes [Member], USD $) In Thousands, unless otherwise specified	0 Months Ended	6 Months Ended	0 Months Ended
	Oct. 22, 2014	Dec. 31, 2014 Installment	Oct. 22, 2012	Apr. 22, 2012	Jun. 30, 2014	Apr. 22, 2008
Debt Disclosure [Line Items]
Loan agreement amount						$ 3,000us-gaap_DebtInstrumentFaceAmount
Interest rate percentage		8.00%				8.00%
Date of loan agreement		Apr. 22, 2008
Principal and interest payment		185us-gaap_DebtInstrumentPeriodicPayment
Carmichael Notes		1,852us-gaap_NotesPayable			1,852us-gaap_NotesPayable
Note due date		Oct. 22, 2017
Number of semi-annual installment of interest payment		5
Interest payment	75
Scenario, Forecast [Member]
Debt Disclosure [Line Items]
Carmichael Notes		1,255
Payment in Kind (PIK) Note [Member]
Debt Disclosure [Line Items]
Principal and interest payment			$ 252	$ 247

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Statement of Cash Flows [Abstract]
Net Cash Provided by (Used in) Operating Activities	$ (52)	$ 3,545
Cash Flows from Investing Activities:
Proceeds from sale of Fulton	6,090
Net change in cash in escrow		(160)
Expenditures for property, plant and equipment-continuing operations	(737)	(768)
Expenditures for property, plant and equipment-discontinued operations	(11)	(83)
Net Cash Provided by (Used in) Investing Activities	5,342	(1,011)
Cash Flows from Financing Activities:
Payments on long-term debt-continuing operation	(239)us-gaap_RepaymentsOfLongTermDebt	(409)us-gaap_RepaymentsOfLongTermDebt
Payments on long-term debt-discontinued operations	(4,842)	(61)
Proceeds from long-term debt	175
Net Cash Used in Financing Activities	(4,906)	(470)
Net increase in Cash and Cash Equivalents	384	2,064
Cash and Cash Equivalents Beginning of Period	3,587	2,497
Cash and Cash Equivalents End of Period	3,971	4,561
Cash Paid (Received) for:
Interest	562us-gaap_InterestPaid	575us-gaap_InterestPaid
Income taxes	$ 29us-gaap_IncomeTaxesPaidNet	$ (1,629)us-gaap_IncomeTaxesPaidNet

Discontinued Operations - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	6 Months Ended	1 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2012 Beds	Jul. 02, 2012	Mar. 16, 2012
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale		$ 6,090
Loss on sale of assets	191	191
Contribution to pension plan	56us-gaap_PensionContributions	56us-gaap_PensionContributions
Dexter Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of bed facility sold			50
Memorial Hospital of Adel [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale				8,350
Fulton Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale		6,090
Loss on sale of assets	191	191
Fulton RDA Loan [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loan agreement amount					5,000
Date of loan agreement		Mar. 16, 2012
Fulton RDA Loan [Member] \| Fulton Hospital [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayment of outstanding loan		4,745
Early repayment penalty		$ 237

Long-Term Debt - Summary of Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014
Debt Disclosure [Line Items]
Other	$ 175us-gaap_OtherLongTermDebt
Total	12,445us-gaap_LongTermDebt	12,509us-gaap_LongTermDebt
Total	12,445us-gaap_LongTermDebt	12,509us-gaap_LongTermDebt
Less current maturities	(866)us-gaap_LongTermDebtCurrent	(561)us-gaap_LongTermDebtCurrent
Total Long-term debt, excluding current maturities, total	11,579us-gaap_LongTermDebtNoncurrent	11,948us-gaap_LongTermDebtNoncurrent
Trace RDA Loan [Member]
Debt Disclosure [Line Items]
RDA Loan	8,405	8,624
SHPP RDA Loan [Member]
Debt Disclosure [Line Items]
RDA Loan	2,013	2,033
Carmichael Notes [Member]
Debt Disclosure [Line Items]
Carmichael Notes	$ 1,852	$ 1,852